
<html lang="en"     class="pb-page"  data-request-id="215e0b74-a89a-4f49-a19d-8c3d5b66b5ef"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b01679;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2019.62.issue-4;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)" /></meta><meta name="dc.Creator" content="Miguel  Guerrero" /></meta><meta name="dc.Creator" content="Mariangela  Urbano" /></meta><meta name="dc.Creator" content="Eun-Kyong  Kim" /></meta><meta name="dc.Creator" content="Ana M.  Gamo" /></meta><meta name="dc.Creator" content="Sean  Riley" /></meta><meta name="dc.Creator" content="Lusine  Abgaryan" /></meta><meta name="dc.Creator" content="Nora  Leaf" /></meta><meta name="dc.Creator" content="Lori Jean  Van Orden" /></meta><meta name="dc.Creator" content="Steven J.  Brown" /></meta><meta name="dc.Creator" content="Jennifer Y.  Xie" /></meta><meta name="dc.Creator" content="Frank  Porreca" /></meta><meta name="dc.Creator" content="Michael D.  Cameron" /></meta><meta name="dc.Creator" content="Hugh  Rosen" /></meta><meta name="dc.Creator" content="Edward  Roberts" /></meta><meta name="dc.Description" content="κ opioid receptor (KOR) antagonists are potential pharmacotherapies for the treatment of migraine and stress-related mood disorders including depression, anxiety, and drug abuse, thus the developme..." /></meta><meta name="Description" content="κ opioid receptor (KOR) antagonists are potential pharmacotherapies for the treatment of migraine and stress-related mood disorders including depression, anxiety, and drug abuse, thus the developme..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 1, 2019" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01679" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01679" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01679" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01679" /></link>
        
    
    

<title>Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01679" /></meta><meta property="og:title" content="Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0014.jpeg" /></meta><meta property="og:description" content="κ opioid receptor (KOR) antagonists are potential pharmacotherapies for the treatment of migraine and stress-related mood disorders including depression, anxiety, and drug abuse, thus the development of novel KOR antagonists with an improved potency/selectivity profile and medication-like duration of action has attracted the interest of the medicinal chemistry community. In this paper, we describe the discovery of 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4 amine (CYM-53093, BTRX-335140) as a potent and selective KOR antagonist, endowed with favorable in vitro ADMET and in vivo pharmacokinetic profiles and medication-like duration of action in rat pharmacodynamic experiments. Orally administered CYM-53093 showed robust efficacy in antagonizing KOR agonist-induced prolactin secretion and in tail-flick analgesia in mice. CYM-53093 exhibited a broad selectivity over a panel of off-target proteins. This compound is in phase 1 clinical trials for the treatment of neuropsychiatric disorders wherein dynorphin is thought to contribute to the underlying pathophysiology." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01679"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01679">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01679&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01679&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01679&amp;href=/doi/10.1021/acs.jmedchem.8b01679" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1761-1780</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01092" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.8b01725" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Miguel Guerrero</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Miguel Guerrero</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Miguel++Guerrero">Miguel Guerrero</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6137-8072" title="Orcid link">http://orcid.org/0000-0001-6137-8072</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mariangela Urbano</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mariangela Urbano</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mariangela++Urbano">Mariangela Urbano</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eun-Kyong Kim</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eun-Kyong Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eun-Kyong++Kim">Eun-Kyong Kim</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ana M. Gamo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ana M. Gamo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ana+M.++Gamo">Ana M. Gamo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sean Riley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sean Riley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sean++Riley">Sean Riley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lusine Abgaryan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lusine Abgaryan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lusine++Abgaryan">Lusine Abgaryan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nora Leaf</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nora Leaf</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nora++Leaf">Nora Leaf</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lori Jean Van Orden</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lori Jean Van Orden</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">BlackThorn Therapeutics, Inc. 780 Brannan Street, San Francisco, California 94103, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lori+Jean++Van+Orden">Lori Jean Van Orden</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steven J. Brown</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven J. Brown</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven+J.++Brown">Steven J. Brown</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7354-1612" title="Orcid link">http://orcid.org/0000-0002-7354-1612</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jennifer Y. Xie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jennifer Y. Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, University of Arizona, Tucson, Arizona 85724, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer+Y.++Xie">Jennifer Y. Xie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Frank Porreca</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Frank Porreca</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, University of Arizona, Tucson, Arizona 85724, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Frank++Porreca">Frank Porreca</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael D. Cameron</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael D. Cameron</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+D.++Cameron">Michael D. Cameron</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hugh Rosen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hugh Rosen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hugh++Rosen">Hugh Rosen</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Edward Roberts</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Edward Roberts</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: (858)784-7770. E-mail: <a href="/cdn-cgi/l/email-protection#a1c4d3cec3c4d3d5d2e1d2c2d3c8d1d1d28fc4c5d4"><span class="__cf_email__" data-cfemail="6005120f020512141320130312091010134e050415">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Edward++Roberts">Edward Roberts</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5587-8174" title="Orcid link">http://orcid.org/0000-0002-5587-8174</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01679&amp;href=/doi/10.1021%2Facs.jmedchem.8b01679" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1761–1780</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 1, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 October 2018</li><li><span class="item_label"><b>Published</b> online</span>1 February 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 February 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01679" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01679</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1761%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMiguel%2BGuerrero%252C%2BMariangela%2BUrbano%252C%2BEun-Kyong%2BKim%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D4%26contentID%3Dacs.jmedchem.8b01679%26title%3DDesign%2Band%2BSynthesis%2Bof%2Ba%2BNovel%2Band%2BSelective%2BKappa%2BOpioid%2BReceptor%2B%2528KOR%2529%2BAntagonist%2B%2528BTRX-335140%2529%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1780%26publicationDate%3DFebruary%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01679"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5113</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01679" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Miguel&quot;,&quot;last_name&quot;:&quot;Guerrero&quot;},{&quot;first_name&quot;:&quot;Mariangela&quot;,&quot;last_name&quot;:&quot;Urbano&quot;},{&quot;first_name&quot;:&quot;Eun-Kyong&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Ana&quot;,&quot;last_name&quot;:&quot;M. Gamo&quot;},{&quot;first_name&quot;:&quot;Sean&quot;,&quot;last_name&quot;:&quot;Riley&quot;},{&quot;first_name&quot;:&quot;Lusine&quot;,&quot;last_name&quot;:&quot;Abgaryan&quot;},{&quot;first_name&quot;:&quot;Nora&quot;,&quot;last_name&quot;:&quot;Leaf&quot;},{&quot;first_name&quot;:&quot;Lori&quot;,&quot;last_name&quot;:&quot;Jean Van Orden&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;J. Brown&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Y. Xie&quot;},{&quot;first_name&quot;:&quot;Frank&quot;,&quot;last_name&quot;:&quot;Porreca&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;D. Cameron&quot;},{&quot;first_name&quot;:&quot;Hugh&quot;,&quot;last_name&quot;:&quot;Rosen&quot;},{&quot;first_name&quot;:&quot;Edward&quot;,&quot;last_name&quot;:&quot;Roberts&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;1761-1780&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01679&quot;},&quot;abstract&quot;:&quot;κ opioid receptor (KOR) antagonists are potential pharmacotherapies for the treatment of migraine and stress-related mood disorders including depression, anxiety, and drug abuse, thus the development of novel KOR antagonists with an improved potency/selectivity profile and medication-like duration of action has attracted the interest of the medicinal chemistry community. In this paper, we describe the discovery of 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4 amine (CYM-53093, BTRX-335140) as a potent and selective KOR antagonist, endowed with favorable in vitro ADMET and in vivo pharmacokinetic profiles and medication-like duration of action in rat pharmacodynamic experiments. Orally administered CYM-53093 showed robust efficacy in antagonizing KOR agonist-induced prolactin secretion and in tail-flick analgesia in mice. CYM-53093 exhibited a broad selectivity over a panel of off-target proteins. This compound is in phase 1 clinical trials&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01679&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01679" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01679&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01679" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01679&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01679" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01679&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01679&amp;href=/doi/10.1021/acs.jmedchem.8b01679" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01679" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01679" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01679%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DGuerrero%26date%3D2019%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2Ba%2BNovel%2Band%2BSelective%2BKappa%2BOpioid%2BReceptor%2B%2528KOR%2529%2BAntagonist%2B%2528BTRX-335140%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D4%26spage%3D1761%26epage%3D1780%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291089" title="Plasma">Plasma</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/jmcmar.2019.62.issue-4/20190228/jmcmar.2019.62.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">κ opioid receptor (KOR) antagonists are potential pharmacotherapies for the treatment of migraine and stress-related mood disorders including depression, anxiety, and drug abuse, thus the development of novel KOR antagonists with an improved potency/selectivity profile and medication-like duration of action has attracted the interest of the medicinal chemistry community. In this paper, we describe the discovery of 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-yl)piperidin-4 amine (<b>CYM-53093</b>, <b>BTRX-335140</b>) as a potent and selective KOR antagonist, endowed with favorable in vitro ADMET and in vivo pharmacokinetic profiles and medication-like duration of action in rat pharmacodynamic experiments. Orally administered <b>CYM-53093</b> showed robust efficacy in antagonizing KOR agonist-induced prolactin secretion and in tail-flick analgesia in mice. <b>CYM-53093</b> exhibited a broad selectivity over a panel of off-target proteins. This compound is in phase 1 clinical trials for the treatment of neuropsychiatric disorders wherein dynorphin is thought to contribute to the underlying pathophysiology.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The opioid receptors belong to the superfamily of G-protein coupled receptors and are generally classified into four subtypes: μ opioid receptor (MOR), δ opioid receptor (DOR), κ opioid receptor (KOR), and the nociceptin/orphanin FQ (N/OFQ) receptor. The opioid receptors show a high degree of sequence homology, however, activation of these receptors by selective endogenous and exogenous ligands has been shown to produce striking differences in pharmacological and physiological effects.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> The KOR is a Gα<sub>i/o</sub>-coupled receptor primarily activated by endogenous dynorphin opioid peptides.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> The KOR is distributed throughout the spinal cord, brain stem, and human brain.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In the brain, KORs are particularly expressed in the anterior cingulate cortex, amygdala, insula, putamen, neocortical region, caudate, thalamus, globus pallidus, pons, substantia nigra, and hippocampus.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9">(5−9)</a> Numerous lines of evidence from preclinical and clinical studies have suggested the KOR as a central player in a variety of neuropsychiatric and neurological disorders such as depression, epilepsy, Alzheimer’s disease, substance and alcohol abuse, and schizophrenia.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19">(10−19)</a> Studies suggest that the KOR may play a role in post-traumatic stress disorder (consistent with the modulatory effects of dynorphin on reward, mood, and stress) and in migraine prophylaxis.<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20−22)</a> As a consequence of these findings, the development of selective KOR antagonists has stimulated great interest in both academia and the pharmaceutical industry. Archetypical KOR antagonists nor-BNI (<b>1</b>), GNTI (<b>2</b>), and nonmorphinan JDTic (<b>3</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) exhibit a delay in the onset of action of hours or days, and their antagonism effects are measurable even for several weeks at minimally effective doses; in contrast, these compounds show a rapid decline in plasma levels.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Concerns about the feasibility of developing medications with archetypical KOR antagonists have centered on their abnormal long duration of action. These concerns have led to the development of KOR antagonists with medication-like duration of action from which JNJ-67953964 (<b>4</b>) (formerly known as LY-2456302 and CERC-501) and PF-04455242 (<b>5</b>) have been evaluated in clinical trials (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><b>5</b> showed single-digit nanomolar activity at the KOR and good selectivity against the DOR but poor selectivity against the MOR.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Phase 1 clinical trials of <b>5</b> were terminated due to toxicology findings in animals exposed to the compound for three months.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a><b>4</b> displayed in vitro subnanomolar KOR antagonism with a selectivity of approximately 21-fold over the MOR and 135-fold over the DOR and efficacy in animal models of substance abuse and depression.<a onclick="showRef(event, 'ref24 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref24 ref27 ref28 ref29">(24,27−29)</a><b>4</b> was until recently the only KOR antagonist undergoing clinical development as monotherapy and has been shown to be safe in humans, with mild to moderate side effects at daily doses of 10 mg (po).<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> Remarkably, <b>4</b> has shown clinically meaningful results in a phase II proof of concept study for treating patients with treatment-resistant depression,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> but dose escalation may be limited as effects of MOR antagonism begin to emerge.<a onclick="showRef(event, 'ref31 ref33'); return false;" href="javascript:void(0);" class="ref ref31 ref33">(31,33)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Prototypical and clinical stage KOR antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The compound ALKS-5461 is a combination of buprenorphine (<b>6</b>) (partial MOR agonist and KOR antagonist) and samidorphan (<b>7</b>) (MOR antagonist) that has been postulated to act primarily as a KOR antagonist.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> ALKS-5461 is well tolerated in humans with limited concerns for abuse potential. The compound has been studied as adjunctive therapy for patients with treatment-resistant depression and showed clinically meaningful antidepressant effects in a few randomized double-blind placebo-controlled trials.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> As a result of this work, a new drug application (NDA) has recently been filed for ALKS-5461 for the adjunctive treatment of major depressive disorder (MDD) in patients with inadequate response to standard antidepressant therapy.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26544" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26544" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In an effort to identify novel selective KOR antagonists with desirable pharmacokinetic and pharmacodynamic properties, a high-throughput screening (HTS) campaign of the Molecular Libraries–Small Molecule Repository (MLSMR) was carried out by our laboratories and identified the hit 3-ethyl-5-methyl-2-(4-((2-hydroxycyclohexyl)amino)piperidin-1-yl)-6-methylpyridine-3,5-dicarboxylate <b>8</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) as a weak KOR antagonist (IC<sub>50</sub> = 410 nM) with poor selectivity against the MOR (11-fold).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The initial structure–activity relationship (SAR) investigations of the hit were focused on increasing the potency while trying to improve the selectivity against the MOR. Iterative SAR led to the discovery of the pyridine <b>CYM-50202</b> (<b>9</b>) as a potent KOR antagonist (IC<sub>50</sub> = 12.6 nM) with good and moderate selectivity against the DOR and MOR (278- and 27-fold), respectively (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). <b>9</b> displayed high solubility, an encouraging pharmacokinetic (PK) profile in rat, and excellent CNS penetration. Perhaps more importantly, <b>9</b> did not display long lasting pharmacodynamic effects observed with prototypical KOR antagonists.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> From a panel of 52 pharmacologically relevant off-target proteins, <b>9</b> exhibited >50% inhibition at only the sodium channel site 2 (IC<sub>50</sub> = 1.8 μM) and ORL-1 (IC<sub>50</sub> = 3 μM).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Unfortunately, we identified a number of issues with this molecule. First, <b>9</b> showed significant inhibition of CYP2D6 at 10 μM, raising concerns of potential drug–drug interaction liabilities. In addition, the activity at sodium channel site 2 raised concerns of potential cardiovascular liabilities. Moreover, the methyl ester and bromide group were identified as undesirable structural motifs of this chemotype due to the likely ester cleavage in vivo and a structural alert in the case of the bromide. Consequently, additional efforts to develop KOR antagonists with improved potency (single-digit nanomolar), selectivity (>100-fold against MOR), and safety profile were undertaken, and the results of the SAR studies are reported in this article. For the purpose of exploring the SAR of <b>9</b>, the molecule was divided into three fragments: the pyridine headgroup <b>A</b>, the piperidine linker <b>B</b>, and the amine tail <b>C</b>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Early KOR antagonist HTS hit <b>8</b> and <b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We started our iterative SAR studies by replacing the ester group with an oxadiazole isostere and by changing the bromine for small alkyl groups while exploring single diastereomers in the piperidine-region <b>B</b>. These efforts culminated in the discovery of single-digit nanomolar KOR antagonist <b>16</b> (IC<sub>50</sub> = 1.3 nM) with modest and high selectivity against the MOR and DOR (24- and >100-fold), respectively (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). All synthesized compounds were evaluated for antagonist activity at the MOR, DOR, and KOR using our established assays.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a><b>16</b> is endowed with physicochemical properties that are consistent with CNS-penetrant compounds<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> (cLogP = 2.2, tPSA = 81.8,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> MW = 371) and devoid of the structural liabilities of <b>9</b>. Unfortunately selectivity over the MOR remained suboptimal (optimal >100-fold). The synthesis of <b>16</b> is depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Amine <b>12</b> was synthesized through reductive amination of diastereomerically pure amine <b>10</b> with cyclohexanone followed by Cbz hydrogenolysis. The oxadiazole intermediate <b>15</b> was synthesized from the carboxylic acid <b>13</b> via coupling cyclization with acetamidoxime <b>14</b> in the presence of EDCI and HOBt. The final compound <b>16</b> was obtained via microwave-assisted nucleophilic aromatic substitution (S<sub>N</sub>Ar) of chloride <b>15</b> with amine <b>12</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. KOR, MOR, DOR Antagonist Activity of Compounds <b>16</b>, <b>27</b>–<b>39</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0010.gif" alt="" id="gr5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0011.gif" alt="" id="gr6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Values are reported as mean of <i>n</i> = 3 determinations.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">This assay uses Tango OPRK1-bla U2OS cells which express KOR linked to a GAL4-VP16 transcription factor via a TEV protease site. Stimulation of the KOR by U-50488 causes migration of the β-arrestin fusion protein to the GPCR and through proteolysis liberates GAL4-VP16 from the receptor. Assay protocols are described in ref <a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a>.</p></div></div><div></div></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <b>10</b> (1.0 equiv), <b>11</b> (1.0 equiv), NaBH(OAc)<sub>3</sub> (1.5 equiv), AcOH (1.5 equiv), 1,2-dichloroethane, rt, 24 h, 76%; (ii) Pd/c 10%, EtOH, 2 h, rt, 97%; (iii) <b>13</b> (1.0 equiv), <b>14</b> (1.1 equiv), EDCI (1.3 equiv), HOBt (1.3 equiv), DMF, 110 °C, mw, 1 h, 71%; (iv) <b>15</b> (1.0 equiv), <b>12</b> (2.0 equiv), DIPEA (2.0 equiv), EtOH, mw, 135 °C, 4 h, 62%.</p></p></figure><div class="NLM_p">Encouraged by these data, we sought to improve the selectivity of <b>16</b> by undertaking a multiparameter SAR optimization of the three molecular regions of <b>16</b> (<b>A</b>, <b>B</b>, and <b>C</b>). For the optimization process, we outlined specific tactics for each molecular region: (1) in region <b>A</b> to replace the pyridine for a quinoline ring while keeping the oxadiazole fixed in position 3 (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>), (2) in region <b>B</b> to simplify the piperidine ring by removing the 3-hydroxy group to rapidly prepare a variety of analogues in the quinoline ring and tail amine in a parallel chemistry format, (3) in region <b>C</b> to explore a variety of structurally diverse amines with the goal of optimizing the physicochemical properties (p<i>K</i><sub>a</sub>,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> tPSA, MW, cLogP,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> and hydrogen bond donors) for good oral bioavailability and brain penetration.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>27</b>–<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) (a) <b>17</b> or <b>18</b> (1.0 equiv), SOCl<sub>2</sub> (3.0 equiv), DMF (cat.), CH<sub>2</sub>Cl<sub>2</sub>, 60 °C, 2 h, (b) <b>14</b> (1.3 equiv), DIPEA (2.0 equiv), 1,4-dioxane, 110 °C, 3 h, 39–42%; (ii) <b>19</b> or <b>20</b> (1.0 equiv), <b>21</b> (2.0 equiv), DIPEA (2.0 equiv), EtOH, mw, 130 °C, 3 h, 82–86%; (iii) 10% aq H<sub>2</sub>SO<sub>4</sub>, THF, rt, 3 h, 87–91%; (iv) <b>24</b> or <b>25</b> (1.0 equiv), <b>26</b> (1.1–2.0 equiv), NaBH(OAc)<sub>3</sub> (2.0 equiv), AcOH (2.0 equiv), 1,2-dichloroethane, rt, overnight, 75–92%.</p></p></figure><div class="NLM_p">The synthesis of these compounds is depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> and their biological activities are listed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Oxadiazole intermediates <b>19</b> and <b>20</b> were synthesized from the corresponding commercially available carboxylic acids <b>17</b> and <b>18</b> via acyl chloride formation followed by coupling cyclization with acetamidoxime <b>14</b>. Ketones <b>24</b> and <b>25</b> were synthesized via microwave-assisted S<sub>N</sub>Ar of <b>19</b> and <b>20</b> with amine <b>21</b> followed by ketal deprotection. Finally, reductive amination of ketones <b>24</b> and <b>25</b> with a variety of amines <b>26</b> furnished the final compounds <b>27</b>–<b>39</b>.</div><div class="NLM_p">On the basis of iterative SAR optimization cycles, the 6-position of the quinoline ring was found to be an essential structural feature to enhance selectivity against the MOR and DOR. For example, the 6-ethyl analogues <b>30</b> and <b>31</b> showed similar potency at the KOR and enhanced selectivity against the DOR and MOR (>1700-fold) as compared to the 6-methyl counterparts <b>27</b> and <b>28</b>. This SAR analysis also revealed that the location of a hydrogen bond acceptor in the amine tail was important for selectivity. For instance, both 6-methylquinoline 4-THP derivative <b>29</b> (<b>CYM-51317</b>) and 6-ethylquinoline 4-THP analogue <b>32</b> showed single-digit nanomolar activity at the KOR but modest selectivity against the MOR (26-fold). Further modifications at the tail region were carried out while keeping the ethyl group at the 6-position. The enantiomeric pair of 3-THP-analogues <b>36</b> and <b>37</b> showed similar activity at KOR, but (<i>R</i>)-3-THP <b>36</b> was more selective against the MOR. The 5-membered ring analogues (<i>R</i>)-3-THF <b>38</b> and (<i>S</i>)-3-THP <b>39</b> were ∼12- and ∼7-fold less potent than their corresponding 6-membered ring enantiomers <b>36</b> and <b>37</b> and showed good selectivity against the MOR. Interestingly, the bulkier and lipophilic analogue <b>33</b> as well as the polar aminoalcohol <b>34</b> showed subnanomolar potency at the KOR and exquisite selectivity against the MOR (4382- and 988-fold, respectively). Furthermore, the oxetane <b>35</b> showed nanomolar potency at the KOR and remarkable selectivity against the MOR. This diverse set of molecules highlighted the potential of the amine tail to tune in the desired pharmacokinetic properties while maintaining potency and selectivity.</div><div class="NLM_p">A set of selected compounds, <b>27</b>, <b>29</b>, <b>33</b>, <b>34</b>, <b>35</b>, and <b>36</b>, were assayed for stability in rat, mouse, and human liver microsomes (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The tested compounds showed relatively high intrinsic clearance in human hepatic microsomes and, in general, compounds with lower cLogP values (e.g., <b>29</b>, <b>35</b>) displayed lower intrinsic clearance in hepatic microsomes than compounds with higher cLogP values (e.g., <b>27</b>, <b>33</b>). Representative compounds <b>29</b>, <b>34</b>, <b>35</b>, and <b>36</b> were further profiled in additional pharmacokinetic and off-target assays (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The compounds were moderately bound by plasma proteins (64.0–98.1% bound) across species, and a correlation was observed between cLogP values and plasma protein binding. Remarkably, many compounds (at 10 μM concentration) showed both low cytochrome P450 inhibition and a hERG inhibition profile. Specifically, <b>29</b> was tested in a panel of four relevant cardiac ion channels in a patch clamp assay and found devoid of activity at 10 μM (<50% inhibition). Additionally, <b>29</b> showed high membrane permeability (A–B) in a Caco-2 cell line with low efflux (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). On the basis of these results we decided to examine the in vivo pharmacokinetic profile of <b>29</b> in rats (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). <b>29</b> distributed well into tissues (<i>V</i><sub>ss</sub> = 13 L/kg) and had a high clearance (CL) after 1 mg kg<sup>–1</sup> intravenous dosing (iv) and exhibited plasma exposures out to 6 h (110.16 ng mL<sup>–1</sup> at <i>C</i><sub>max</sub> and 1705 min·ng mL<sup>–1</sup> AUC<sub>0–∞</sub>), after a dose of 2 mg kg<sup>–1</sup> po. The absolute oral bioavailability (<i>F</i>) was 20% (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Additionally, <b>29</b> displayed a brain to plasma ratio of 2.9 in mice at 30 min and of 3.8 at 120 min post intraperitoneal (ip) administration of a 10 mg kg<sup>–1</sup> dose (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Although <b>29</b> was only moderately selective against the MOR, it showed promising overall pharmacokinetic properties and off-target profile thus it was selected as a tool compound for further in vivo studies.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Intrinsic Clearance (Cl<sub>int</sub>) in Hepatic Microsomes of Compounds <b>27</b>, <b>29</b>, <b>33</b>, <b>34</b>, <b>35</b>, and <b>36</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">calculated physicochemical properties</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">microsomal Cl<sub>int</sub> (mL/min/kg)<a class="ref internalNav" href="#t2fn2" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">MW</th><th class="colsep0 rowsep0" align="center" char=".">tPSA</th><th class="colsep0 rowsep0" align="center" char=".">cLogP</th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">mouse</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="char" char=".">379</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">49.5</td><td class="colsep0 rowsep0" align="center">49.5</td><td class="colsep0 rowsep0" align="center">ND<a class="ref internalNav" href="#t2fn1" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="char" char=".">407</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">15.1</td><td class="colsep0 rowsep0" align="center">7.1</td><td class="colsep0 rowsep0" align="center">14.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">407</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">46.5</td><td class="colsep0 rowsep0" align="center">ND<a class="ref internalNav" href="#t2fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">58.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">435</td><td class="colsep0 rowsep0" align="char" char=".">82</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">36.1</td><td class="colsep0 rowsep0" align="center">ND<a class="ref internalNav" href="#t2fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">34.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="char" char=".">421</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">23.1</td><td class="colsep0 rowsep0" align="center">35.4</td><td class="colsep0 rowsep0" align="center">17.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char=".">421</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">40.3</td><td class="colsep0 rowsep0" align="center">51.3</td><td class="colsep0 rowsep0" align="center">58.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn2"><div class="footnote" id="t2fn2"><sup><sup>a</sup></sup><p class="last">Test compounds (1 μM) were incubated with 0.2 mg mL<sup>–1</sup> pooled human, rat, and mouse hepatic microsomes at 37 °C with continuous shaking. Further details for the assays can be found in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and ref <a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a>.</p></div><div class="footnote" id="t2fn1"><sup><sup>b</sup></sup><p class="last">ND = no data.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. ADMET Properties of <b>29</b>, <b>34</b>, <b>35</b>, and <b>36</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>29</b></th><th class="colsep0 rowsep0" align="center"><b>34</b></th><th class="colsep0 rowsep0" align="center"><b>35</b></th><th class="colsep0 rowsep0" align="center"><b>36</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein plasma binding (% bound) at 1 μM<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="center">71</td><td class="colsep0 rowsep0" align="center">98.1</td><td class="colsep0 rowsep0" align="center">91.7</td><td class="colsep0 rowsep0" align="center">96.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="center">64</td><td class="colsep0 rowsep0" align="center">95.5</td><td class="colsep0 rowsep0" align="center">89</td><td class="colsep0 rowsep0" align="center">91.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="center">78</td><td class="colsep0 rowsep0" align="center">97</td><td class="colsep0 rowsep0" align="center">92.4</td><td class="colsep0 rowsep0" align="center">96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human cytochrome P450 inhibition at 10 μM (%)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">CYP3A4</td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center">–28</td><td class="colsep0 rowsep0" align="center">–13</td><td class="colsep0 rowsep0" align="center">–22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CYP2D6</td><td class="colsep0 rowsep0" align="center">20</td><td class="colsep0 rowsep0" align="center">9</td><td class="colsep0 rowsep0" align="center">–40</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CYP2C9</td><td class="colsep0 rowsep0" align="center">–6</td><td class="colsep0 rowsep0" align="center">–13</td><td class="colsep0 rowsep0" align="center">–11</td><td class="colsep0 rowsep0" align="center">–18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CYP1A2</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ion channel % inhibition at 10 μM<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">voltage-gated sodium (Nav1.5)</td><td class="colsep0 rowsep0" align="center">32</td><td class="colsep0 rowsep0" align="center">72</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">hERG</td><td class="colsep0 rowsep0" align="center">35</td><td class="colsep0 rowsep0" align="center">77</td><td class="colsep0 rowsep0" align="center">19</td><td class="colsep0 rowsep0" align="center">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">voltage-gated calcium (Cav1.2)</td><td class="colsep0 rowsep0" align="center"><25</td><td class="colsep0 rowsep0" align="center">28</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">inward-rectifying voltage-gated potassium (Kir2.1)</td><td class="colsep0 rowsep0" align="center"><25</td><td class="colsep0 rowsep0" align="center"><25</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">hyperpolarization-activated cyclic nucleotide-gated potassium (HCN4)</td><td class="colsep0 rowsep0" align="center"><25</td><td class="colsep0 rowsep0" align="center"><25</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 cells</td><td class="colsep0 rowsep0" align="left">A–B (10<sup>–6</sup> cm/s)</td><td class="colsep0 rowsep0" align="center">26.2</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">efflux ratio</td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">ND = no data. A–B = movement of the compound from the apical to the basal side of the membrane; a surrogate for permeability.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Further details for the assays can be found in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and ref <a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a>.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Compounds were profiled in the Eurofin cardiac profiler panel. Further details can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Plasma Pharmacokinetic Profile of Compound <b>29</b> in Rodents<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="8" align="center">rat (<i>n</i> = 3, mean values)</th></tr><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="4" align="center">iv (1 mg·kg<sup>–1</sup>)</th><th class="rowsep1 colsep0" colspan="4" align="center">po (2 mg kg<sup>–1</sup>)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">CL (mL·min<sup>–1</sup>·kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>∞</sub> (min·ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L·kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–∞</sub> (min·ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">83</td><td class="colsep0 rowsep0" align="center">1.98</td><td class="colsep0 rowsep0" align="center">12740</td><td class="colsep0 rowsep0" align="center">12.95</td><td class="colsep0 rowsep0" align="center">1.56</td><td class="colsep0 rowsep0" align="center">110.16</td><td class="colsep0 rowsep0" align="center">1705</td><td class="colsep0 rowsep0" align="center">20</td></tr></tbody></table><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="center" char=".">brain:plasma ratio in mice (ip administration) 10 mg kg<sup>–1</sup>, mean values)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">time (min)</th><th class="colsep0 rowsep0" align="center" char=".">mean values (mg kg<sup>–1</sup>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last"><b>29</b> was dosed as the monotartrate salt.</p></div></div></div><div class="NLM_p">In a mouse tail-flick assay, <b>29</b> did not show a long duration of action in blocking the antinociceptive effect of the KOR-agonist, U69,593.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Perhaps most importantly, in an injury-free rat model of cephalic pain with features of migraine and medication overuse headache, oral administration of <b>29</b> showed preventive benefits on blocking stress induced allodynia, thus suggesting that KOR antagonists could provide a new therapeutic strategy in preventing migraine.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In parallel, the potential mutagenic activity of this compound class was tested on selected compounds <b>33</b>, <b>34</b>, <b>35</b>, and <b>36</b> in a bacterial reverse mutation assay (Ames assay). Four <i>Salmonella typhimurium</i> strains TA100, TA1535, TA1537, and TA98 as well as the <i>Escherichia coli</i> strain WP2uvrA were used in the presence and absence of an exogenous metabolic activation system (S9). Both <b>34</b> and <b>35</b> exhibited mutagenicity in the TA1537 strain in the presence and absence of S9; <b>33</b> and <b>36</b> also showed a mutagenic response in the TA1537 strain but only in the absence of S9. Positive mutagenic activity in the TA1537 strain often reflects intercalation of the tested molecules with DNA, and this intercalation is commonly associated with the planarity, π-stacking, and hydrogen bonding interaction capabilities of molecules.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> On the basis of the hypothesis that the quinoline <b>A</b> was the portion of the molecule involved in the intercalation with the DNA, two strategies were evolved to address the genotoxicity liability: (1) reduce the basicity of the quinoline-nitrogen to disrupt hydrogen-bond interactions between DNA and the quinoline ring and (2) disrupt the planarity of the quinoline–oxadiazole axis to hinder π-stacking interactions. To implement these strategies, a fluorine atom was introduced at the 8-position of the quinoline ring to substantially reduce the p<i>K</i><sub>a</sub> of the quinoline nitrogen (up to 2.5 p<i>K</i><sub>a</sub> units).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> In addition, a methyl group was installed in the 4-position of the quinoline ring in an attempt to disrupt the planarity.</div><div class="NLM_p">For the construction of poly substituted quinoline rings, we decided to use the Friedländer methodology because it is one of the most robust strategies for the modification and manipulation of quinoline rings.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The synthesis of these compounds is described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> (without a 4-methyl group) and <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> (with a 4-methyl group) and their biological activity reported in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. The aldehyde <b>41</b> was synthesized from carboxylic acid <b>40</b> via reduction with BH<sub>3</sub>–THF complex followed by oxidation with manganese dioxide in dichloromethane. The quinoline intermediate <b>43</b> was synthesized by condensation of acetic acid <b>42</b> with aldehyde <b>41</b> in phosphorus oxychloride. A S<sub>N</sub>Ar reaction of <b>43</b> with amine <b>21</b>, followed by Suzuki–Miyaura coupling with Et<sub>3</sub>B and ketal deprotection, afforded the key ketone intermediate <b>45</b>. Finally, reductive amination of ketone <b>45</b> with a series of amines <b>26</b> furnished the final compounds <b>46</b>–<b>50</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Preparation of ketone <b>54</b> was accomplished via iodination of aniline <b>51</b> followed by Heck coupling with ethylene glycol vinyl ether <b>53</b>.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Condensation of acetic acid <b>42</b> with ketone <b>54</b> in phosphorus oxychloride afforded the poly substituted quinoline <b>55</b>. A S<sub>N</sub>Ar reaction of amine <b>21</b> with <b>55</b> followed by ketal deprotection afforded the ketone intermediate <b>57</b>. The final compounds <b>58</b>–<b>62</b> were synthesized via reductive amination of <b>57</b> with amines <b>26</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>46</b>–<b>50</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <b>40</b> (1.0 equiv), BH<sub>3</sub>–THF (3.0 equiv), THF, 0 °C to rt, 18 h, 76%; (ii) MnO<sub>2</sub> (6.0 equiv), CH<sub>2</sub>Cl<sub>2,</sub> rt, 8 h, quantitative; (iii) <b>41</b> (1.0 equiv), POCl<sub>3,</sub> 80 °C, 1 h, 14%; (iv) <b>43</b> (1.0 equiv), <b>21</b> (1.5 equiv), DIPEA (1.5 equiv), EtOH, 130 °C, mw, 2 h, 45%; (v) (a) <b>44</b> (1.0 equiv), Cs<sub>2</sub>CO<sub>3</sub> (3.0 equiv), Pd(dppf)Cl<sub>2</sub>·DCM (0.1 equiv), THF, 70 °C, 1 h, 74%, (b) 10% aq H<sub>2</sub>SO<sub>4</sub>, 45 °C, 2h, 94%; (vi) <b>45</b> (1.0 equiv), 26 (2.0 equiv), NaBH(OAc)<sub>3</sub> (3.0 equiv), AcOH (3.0 equiv), DIPEA (2.0 equiv), 1,2-dichloroethane, rt, overnight, 77–87%.</p></p></figure><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>58</b>–<b>62</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <b>51</b> (1.0 equiv), NIS (1.05 equiv), AcOH, rt, 1 h, 94%; (ii) <b>52</b> (1.0 equiv), <b>53</b> (6.0 equiv), K<sub>2</sub>CO<sub>3</sub> (1.2 equiv), DPPP (0.05 equiv), <b>42</b> (1.1 equiv), POCl<sub>3</sub>, 80 °C, 1 h, 40%; (iv) <b>55</b> (1.0 equiv), <b>21</b> (1.3 equiv), DIPEA (2.0 equiv), EtOH, 110 °C, overnight, 93%; (v) <b>56</b> (1.0 equiv), 10% aq H<sub>2</sub>SO<sub>4</sub>, THF, 45 °C, 2 h, 84%; (vi) <b>57</b> (1.0 equiv), <b>26</b> (2.0 equiv), NaBH(OAc)<sub>3</sub> (2.0 equiv), AcOH (2.0 equiv), 1,2-dicholoroethane, rt, overnight, 73–84%.</p></p></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. KOR, MOR, and DOR Antagonist Activity of Compounds <b>29</b>, <b>46</b>–<b>50</b>, <b>58</b>–<b>62</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0012.gif" alt="" id="gr10" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0013.gif" alt="" id="GRAPHIC-d7e1999-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Values are reported as mean of <i>n</i> = 3 determinations.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">This assay uses Tango OPRK1-bla U2OS cells which express KOR linked to a GAL4-VP16 transcription factor via a TEV protease site. Stimulation of the KOR by U-50488 causes migration of the β-arrestin fusion protein to the GPCR, and through proteolysis liberates GAL4-VP16 from the receptor. Assay protocols are described in ref <a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a>.</p></div></div><div></div></div><div class="NLM_p">For the selection of tail amines, we sought to modulate the physicochemical properties in a range compatible with oral bioavailability and CNS penetration utilizing the SARs gleaned from the previous series. The THP analogues <b>47</b> (<b>CYM-53052</b>), <b>48</b>, and <b>46</b> were approximately equipotent to the nonfluorinated analogues <b>36</b>, <b>37</b>, and <b>32</b>, with higher selectivity against the MOR in the case of <b>46</b> and <b>48</b> and lower in the case of <b>47</b>. Furthermore, the 3-amino-THF enantiomers <b>49</b> and <b>50</b> were ∼4-fold more potent than the nonfluorinated analogues <b>38</b> and <b>39</b>, and both enantiomers (<b>49</b> and <b>50</b>) retained excellent selectivity against the MOR. The introduction of a methyl group in the 4-position of the quinoline ring generally increased potency at the KOR while decreasing the selectivity against the MOR. For example, the 4-amino-THP <b>58</b> (<b>CYM-53093</b>, <b>BTRX-335140</b>) and the 3-amino-THP enantiomers <b>59</b> and <b>60</b> were ∼4-fold more potent than the demethylated analogues <b>46</b>–<b>48</b> but less selective against the MOR. The 5-membered ring analogues <b>61</b> and <b>62</b> were ∼3-fold more potent than <b>49</b> and <b>50</b> at the KOR and moderately less selective against the MOR. From these analogues, compounds <b>58</b> and <b>47</b> were selected as representative molecules of the 4-methyl- and nonmethylated series for Ames assays. Neither analogue showed mutagenicity in the Ames assays, with or without the addition of S9, highlighting the success of the aforementioned stereoelectronic design principles.</div><div class="NLM_p">In a variety of in vitro pharmacokinetic assays, <b>47</b> and <b>58</b> exhibited low intrinsic clearance in human hepatic microsomes and hepatocytes and moderate to high clearance in other species (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). In vivo pharmacokinetic studies in rats (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>) indicated that <b>58</b> distributed well into tissues (high apparent <i>V</i><sub>ss</sub> of 13.8 L kg<sup>–1</sup>) and had a high plasma clearance rate (105 mL min <sup>–1</sup> kg<sup>–1</sup>) after a 1 mg kg<sup>–1</sup> iv dose. After a 5 mg kg<sup>–1</sup> po dose, <b>58</b> exhibited plasma exposure levels out to 8 h (39.1 ng mL<sup>–1</sup> at <i>C</i><sub>max</sub> and 232 h·ng mL<sup>–1</sup> AUC<sub>0–<i>t</i></sub>). The absolute oral bioavailability was 30%. The pharmacokinetic parameters observed in mice were similar. In rats, <b>58</b> distributed well into the CNS with a high brain to plasma ratio of 2:1 and adequate CSF exposure (∼4-fold its IC<sub>50</sub>) 1 h after an oral administration of 5 mg kg<sup>–1</sup> (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Intrinsic Clearance (Cl<sub>int</sub>) in Hepatic Microsomes and Hepatocytes for <b>47</b>, <b>49</b>, <b>58</b>, <b>59</b>, <b>61</b>, and <b>62</b><a class="ref internalNav" href="#t6fn2" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">physicochemical properties</th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">microsomal Cl<sub>int</sub> (mL/min/kg)</th><th class="rowsep1 colsep0" colspan="4" align="center">hepatocytes Cl<sub>int</sub> (mL/min/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">MW</th><th class="colsep0 rowsep0" align="center" char=".">tPSA</th><th class="colsep0 rowsep0" align="center" char=".">cLogP</th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char=".">rat</th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">dog</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="char" char=".">439</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">12.0</td><td class="colsep0 rowsep0" align="char" char=".">22.7</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">54.4</td><td class="colsep0 rowsep0" align="center">14.8</td><td class="colsep0 rowsep0" align="center">209</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="char" char=".">425</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">6.69</td><td class="colsep0 rowsep0" align="char" char=".">83.0</td><td class="colsep0 rowsep0" align="center">112.0</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="char" char=".">453</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">1.95</td><td class="colsep0 rowsep0" align="char" char=".">17.5</td><td class="colsep0 rowsep0" align="center">49.1</td><td class="colsep0 rowsep0" align="center">55.2</td><td class="colsep0 rowsep0" align="center">8.3</td><td class="colsep0 rowsep0" align="center">118</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">84.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="char" char=".">453</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">36.2</td><td class="colsep0 rowsep0" align="char" char=".">57.5</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="char" char=".">439</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">21.0</td><td class="colsep0 rowsep0" align="char" char=".">54.6</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="char" char=".">439</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">22.0</td><td class="colsep0 rowsep0" align="char" char=".">89.5</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">39.5</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn2"><div class="footnote" id="t6fn2"><sup><sup>a</sup></sup><p class="last">Details for the assays can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf" class="ext-link">Supporting Information</a>. Compounds were profiled by Agilux. ND = no data.</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Profile of Compound <b>58</b> in Rodents<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">iv (rat, 1 mg·kg<sup>–1</sup>; mice, 3 mg·kg<sup>–1</sup>)</th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">po (rat, 5 mg kg<sup>–1</sup>; mice, 10 mg·kg<sup>–1</sup>)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">CL (mL·min<sup>–1</sup>·kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–<i>t</i></sub> (h·ng mL<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L·kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng mL<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–<i>t</i></sub> (h·ng mL<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mice</td><td class="colsep0 rowsep0" align="char" char=".">66.5</td><td class="colsep0 rowsep0" align="char" char=".">1.91</td><td class="colsep0 rowsep0" align="char" char=".">725</td><td class="colsep0 rowsep0" align="char" char=".">7.72</td><td class="colsep0 rowsep0" align="char" char=".">2.57</td><td class="colsep0 rowsep0" align="char" char=".">80.9</td><td class="colsep0 rowsep0" align="char" char=".">265</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rats (fed)</td><td class="colsep0 rowsep0" align="char" char=".">105</td><td class="colsep0 rowsep0" align="char" char=".">1.81</td><td class="colsep0 rowsep0" align="char" char=".">153</td><td class="colsep0 rowsep0" align="char" char=".">13.8</td><td class="colsep0 rowsep0" align="char" char=".">6.19</td><td class="colsep0 rowsep0" align="char" char=".">39.1</td><td class="colsep0 rowsep0" align="char" char=".">232</td><td class="colsep0 rowsep0" align="char" char=".">30.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last"><b>58</b> was dosed as the monotartrate salt.</p></div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. CNS Exposure of <b>58</b> in Male Rats (<i>n</i> = 2, Mean Values)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="4" align="center" char="."><b>58</b> (fasted) po 5 mg kg<sup>–1</sup>, 1h</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">plasma (μM)</th><th class="colsep0 rowsep0" align="center" char=".">brain (μM)</th><th class="colsep0 rowsep0" align="center" char=".">CSF (μM)</th><th class="colsep0 rowsep0" align="center" char=".">brain:plasma</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">0.276</td><td class="colsep0 rowsep0" align="char" char=".">0.54</td><td class="colsep0 rowsep0" align="char" char=".">0.0031</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last"><b>58</b> was dosed as the monotartrate salt.</p></div></div></div><div class="NLM_p">Having a few compounds in the series with promising in vitro and in vivo attributes in hand, we sought to assess the potential for our KOR antagonists to elicit an on-target pharmacodynamic response in an in vivo model. Prolactin (PRL) is a hormone involved in many biological processes that is mainly secreted by lactotroph cells of the anterior pituitary gland. Prolactin is primarily regulated via tonic inhibition by dopamine released from the tuberoinfundibular dopaminergic (TIDA) neurons.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> Activation of the opioid system, particularly of the KOR believed to be localized on dopaminergic neurons within TIDA and in the mesolimbic–mesocortical system, modulates dopamine release.<a onclick="showRef(event, 'ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46">(44−46)</a> PRL overproduction by KOR agonists has been investigated in clinical and preclinical models, and its modulation has been postulated as a KOR-mediated translatable biomarker,<a onclick="showRef(event, 'ref44 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref44 ref46 ref47 ref48">(44,46−48)</a> thus reduction of KOR agonist-induced plasma PRL in rats by KOR antagonists may be used as an estimation of KOR antagonist target engagement. We selected this preclinical pharmacodynamic model as a screen to guide the decision-making process for the further advancement of our KOR antagonists. For practical reasons, the rat PRL model was adapted to mice and leveraged to rapidly screen KOR antagonist compounds. U69,593 was chosen as a reference KOR agonist and administered via intraperitoneal injection. KOR antagonist compounds were initially assessed via intraperitoneal (ip) dosing at a single concentration, typically at 10 or 30 mg kg<sup>–1</sup>, and those demonstrating inhibition of PRL release were further evaluated at lower concentrations. Compounds that showed robust ip PRL inhibition were tested orally (po). Each KOR antagonist was injected 1 h prior to U69,593 in the ip experiments, while in the po experiments, the KOR antagonists were administered by oral gavage 2 h before U69,593. From these po studies, we found that at 30 and 10 mg kg<sup>–1</sup><b>47</b> and <b>49</b> were effective in reducing plasma prolactin to basal levels but were ineffective at lower doses; at 3 mg kg<sup>–1</sup>, <b>58</b> and <b>62</b> were effective in reducing U69,593-stimulated plasma prolactin secretion to basal levels (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Furthermore, <b>58</b> showed effective PRL reduction at 0.1 mg kg<sup>–1</sup> after oral administration (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of KOR agonist stimulated prolactin via po administration of <b>47</b>, <b>49</b>, and <b>62</b>. KOR antagonists were dosed as the monotartrate salts. Three mice per dose group where two samples were collected per mouse.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibition of KOR agonist stimulated prolactin via po administration of <b>58</b>. <b>58</b> was dosed as the monotartrate salt. Four mice per dose group where two samples were collected per mouse.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From this set, <b>47</b>, <b>49</b>, <b>58</b>, and <b>62</b> were tested in further pharmacokinetic and off-target assays (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). <b>58</b> was 93.4% bound to human plasma proteins and 98.4% bound to rat brain homogenate. The other tested compounds were protein bound to a similar extent in human plasma and in plasma across other species. Moderate solubility was observed for this series of compounds (70–85 μM), and permeability was moderate to high for <b>58</b> with low efflux ratio (7.1 and 20.9 × 10<sup>–6</sup> cm/s in Caco-2 cells and MDCK-MDR1 cells, respectively; ER < 2.3). Furthermore, <b>58</b> showed minimal inhibition of CYP450 enzymes 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4 with IC<sub>50</sub> values of >30 μM, and there was no change in the potency of <b>58</b> upon preincubation for any of the CYP enzymes. <b>58</b> also was profiled in a very comprehensive panel of over 500 off-targets including ion channels, kinases, GPCRs, and other receptors and transporters, and there were no hits identified with IC<sub>50</sub> values <1 μM. Few off-target hits were identified with IC<sub>50</sub> values between 10 and 1 μM; in a patch clamp assay conducted at physiological temperature, the compound inhibited the hERG channel with an IC<sub>50</sub> of 1 μM.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Additional ADMET Properties of <b>47</b>, <b>49</b>, <b>58</b>, and <b>62</b><a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>47</b></th><th class="colsep0 rowsep0" align="center"><b>49</b></th><th class="colsep0 rowsep0" align="center"><b>58</b></th><th class="colsep0 rowsep0" align="center"><b>62</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding (% bound)</td><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="center">92.4</td><td class="colsep0 rowsep0" align="center">94.8</td><td class="colsep0 rowsep0" align="center">93.4</td><td class="colsep0 rowsep0" align="center">97.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0">rat</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">94.3</td><td class="colsep0 rowsep0" align="center">91.5</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0">dog</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">96.3</td><td class="colsep0 rowsep0" align="center">91.5</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">binding in rat brain homogenate (2 μM) (% bound)</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">98.4</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDCK-MDR1 cell line (P-gp)</td><td class="colsep0 rowsep0">A–B (10<sup>–6</sup> cm/s)</td><td class="colsep0 rowsep0" align="center">8.76</td><td class="colsep0 rowsep0" align="center">13.5</td><td class="colsep0 rowsep0" align="center">7.1</td><td class="colsep0 rowsep0" align="center">4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0">efflux ratio</td><td class="colsep0 rowsep0" align="center">1.5</td><td class="colsep0 rowsep0" align="center">0.896</td><td class="colsep0 rowsep0" align="center">2.3</td><td class="colsep0 rowsep0" align="center">5.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 cell line</td><td class="colsep0 rowsep0">A–B (10<sup>–6</sup> cm/s)</td><td class="colsep0 rowsep0" align="center">19.2</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">20.9</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0">efflux ratio</td><td class="colsep0 rowsep0" align="center">0.493</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">0.38</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility (μM) at pH 7.4</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="center">75</td><td class="colsep0 rowsep0" align="center">84</td><td class="colsep0 rowsep0" align="center">74</td><td class="colsep0 rowsep0" align="center">70</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">KOR-antagonists were used as monotartrate salts. ND = no data. A–B = movement of the compound from the apical to the basal side of the membrane, a surrogate for permeability.</p></div></div></div><div class="NLM_p">In a radioligand binding assay using [<sup>3</sup>H]diprenorphine, <b>58</b> exhibited a <i>K</i><sub>i</sub> of 1.5 nM at the human KOR and 300-fold selectivity over the human MOR (<i>K</i><sub>i</sub> = 450 nM).</div><div class="NLM_p">On the basis of these results, we decided to evaluate in vivo the duration of action of <b>58</b> in a hot water (50 °C) tail-flick test in male mice by assessing its ability to antagonize the antinociceptive effect of U-50488. <b>58</b> or vehicle were administered to mice at 1 and 24 h prior to the administration of U-50488 (15 mg kg<sup>–1</sup>, ip), and latencies for tail-flick were measured at baseline, 30 and 60 min after agonist injection (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Baseline tail-flick latency of naïve mice was 5.76 ± 0.16 s. Injection of U-50488 produced antinociception indicated by a significant increase in tail-flick latency, which peaked at 30 min postdose. Unlike nor-BNI,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a><b>58</b> (1 mg kg<sup>–1</sup>, ip) blocked the U-50488-induced antinociception at 1 h, but not at 24 h pretreatment time, indicating a medication-like duration of action in blocking the KOR in vivo (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A–D). There was no observable change in the rat tail-flick latency response induced by ip <b>58</b> (1 mg kg<sup>–1</sup>) alone at 1 h postdose (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E,F). Remarkably, oral administration of <b>58</b> (3, 10, and 30 mg kg<sup>–1</sup>) also blocked U-50488-induced antinociception in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>G,H).</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0005.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. KOR nlockade of antinociceptive response by <b>58</b> in the mouse tail-flick assay. (A,B) Systemic injection of U50488 (15 mg kg<sup>–1</sup>, ip) induced robust antinociception within 30 min in the mouse tail-flick test (50 °C water bath), which was blocked by <b>58</b> (1 mg kg<sup>–1</sup>, ip) given at 1 h prior to U50488. (C,D) <b>58</b> (1 mg kg<sup>–1</sup>, ip) given at 24 h prior to U50488 (15 mg kg<sup>–1</sup>, ip) failed to block U50488-induced antinociception assessed at 30 min post-U50,488. (E,F) <b>58</b> (1 mg kg<sup>–1</sup>, ip) alone did not alter tail flick latency at 60 min postdose. (G,H) Oral <b>58</b> (3, 10, 30 mg kg<sup>–1</sup>, po) given at 1 h prior to U50488 (15 mg kg<sup>–1</sup>, ip) dose-dependently blocked U50488-induced antinociception assessed at 30 min post-U50488. Data represent mean ± SEM %maximum possible effect (MPE) = (post-dose latency – pre-dose latency)/(cutoff – pre-dose latency) × 100. Cutoff = 15 s to prevent tissue damage. Statistics performed using two-way ANOVA followed by Sidak’s multiple comparisons posthoc test (A–F) or linear regression (G,H). *<i>P</i> < 0.05 vs baseline (BL) of the corresponding treatment group. Group sizes are shown in the figure. <b>58</b> was dosed as the monotartrate salt.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34071" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34071" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have developed a novel chemical class of potent and selective KOR antagonists via multiparametric optimization approach originating from a submicromolar HTS-hit <b>8</b>. <b>29</b> showed favorable pharmacokinetic properties including good CNS penetration. Remarkably, <b>29</b> was tested in a novel injury-free rat model of migraine and was found to ameliorate stress-induced allodynia, thus providing support for the hypothesis that KOR antagonists could have a therapeutic role in the preventive treatment of migraine. <b>29</b> and <b>58</b> displayed reversibility of analgesic effects induced by a KOR agonist within 24 h in a tail-flick assay in mice, indicating medication-like duration of action of their KOR antagonist activity in vivo. The pharmacokinetic attributes of <b>58</b>, including its CNS exposure, provide confidence in the drug-like properties and developability of the compound. A low oral dose of <b>58</b> to mice effectively reduced the elevation of U69,593-induced plasma PRL. <b>58</b> did not exhibit significant inhibition of the major cytochrome P450 isoforms and was highly selective for KOR against a broad off-target panel. <b>58</b> was advanced into phase 1 clinical trials<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> based on its overall in vitro and in vivo properties across nonclinical species as well as its safety profile.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16172" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16172" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Methods and Materials</h3><div id="sec4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Plasma Protein Binding</h4><div class="NLM_p">Plasma protein binding of compounds <b>29</b>, <b>34</b>, <b>35</b>, and <b>36</b> to human, mouse, and rat plasma was evaluated using equilibrium dialysis (Pierce RED system). Compound (1.0 μM) was added to the plasma compartment, and after 8 h the concentration of drug was measured in the plasma and buffer compartments by LC-MS/MS. The concentration in the buffer compartment is considered to be the free fraction of compound.</div><div class="NLM_p last">Plasma protein binding of compounds <b>47</b>, <b>49</b>, <b>58</b> and <b>62</b> were performed by Agilux Laboratories (now Charles River Laboratories) (Worcester, MA) (assay protocols are described in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Hepatic Microsome Stability</h4><div class="NLM_p">Test compounds (<b>27</b>, <b>29</b>, <b>33</b>, <b>34</b>, <b>35</b>, and <b>36</b>) (1 μM) were incubated (separately) with 0.2 mg mL<sup>–1</sup> pooled human, mouse, and rat hepatic microsomes at 37 °C with continuous shaking to determine the rate of metabolism. Samples were collected at 0, 5, 10, 20, 40, and 60 min, and acetonitrile was added to quench the reactions and precipitate the proteins. Samples were then centrifuged, and the concentration of test compound was determined using HPLC coupled to a triple quadrupole mass spectrometer (LC/MS-MS).</div><div class="NLM_p last">Microsomal hepatic stability of compounds <b>47</b>, <b>49</b>, <b>58</b>, <b>59</b>, <b>61</b>, and <b>62</b> and hepatic stability of <b>47</b> and <b>58</b> were performed by Agilux Laboratories (now Charles River Laboratories) (Worcester, MA) (assay protocols are described in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Cytochrome P450 Inhibition</h4><div class="NLM_p last">The metabolism by CYP1A2 (phenaceten demethylated to acetaminophen), CYP2C9 (tolbutamide hydroxylated to hydroxytolbutamide), CYP2D6 (bufuralol hydroxylated to 4′-hydroxybufuralol), and CYP3A4 (midazolam hydroxylated to 1′-hydroxymidazolam) in the presence or absence of 10 μM test compound (<b>29</b>, <b>34</b>, <b>35</b>, and <b>36</b>) were evaluated. The concentration of each marker substrate is approximately its <i>K</i><sub>m</sub>. Specific inhibitors for each isoform were used to validate the system. Compound concentrations were determined by LC-MS/MS. CYP inhibition of <b>58</b> was performed by Cyprotex (assay protocols are described in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf" class="ext-link">Supporting Information</a>)</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Bidirectional Permeability Assays</h4><div class="NLM_p">The MDCK-MDR1 permeability assays of <b>47</b>, <b>49</b>, <b>58</b>, and <b>62</b> were performed by AMRI and Agilux Laboratories (detailed methods in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_p last">The Caco-2 permeability assays of <b>47</b> and <b>58</b> were performed by Agilux Laboratories (now Charles River Laboratories) (Worcester, MA) (assay protocols are described in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Solubility Assay</h4><div class="NLM_p last">The solubility assays were performed by AMRI (assay protocols are described in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Brain Homogenate Assay</h4><div class="NLM_p last">The purpose of this assay is to asses brain tissue binding. The rat brain homogenate assay was performed by Agilux Laboratories (assay protocols are described in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Electrophysiological Assays</h4><div class="NLM_p last">The electrophysiological assays for <b>29</b>, <b>34</b>, <b>35</b>, and <b>36</b> were performed by Eurofins Pharma Bioanalytics Services US Inc. The electrophysiological assays profiled the activity of these compounds at 10 μM on the ion channel targets described in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> using the IonWorks Quattro electrophysiological platform (assay protocols are described in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Procedure for Pharmacokinetic Studies</h4><div class="NLM_p">Pharmacokinetics of <b>29</b> monotartrate salt was assessed in Sprague–Dawley male rats (350–400 g). The compound was prepared as a solution in 10:10:80 dimethyl sulfoxide/Tween 80/water (v/v/v) at a concentration of 1 mg mL<sup>–1</sup> for ip and po administration of 1 and 2 mg kg<sup>–1</sup>, respectively. Compound concentrations were determined using peripheral whole blood. Blood was obtained at 5, 15, and 30 min and 1, 2, 4, 6, and 8 h postdose for both iv and po experiments. All procedures and handling were according to standard operating procedures approved by the Institutional Animal Care and Use Committee (IACUC).</div><div class="NLM_p">Brain levels of <b>29</b>. <b>29</b> monotartrate salt was dosed ip at 10 mg kg<sup>–1</sup> in a 1 mg mL<sup>–1</sup> solution containing 1 part DMSO, 1 part Tween 80, and 8 parts water into C57Bl6 mice (<i>n</i> = 6). Blood and brain were taken at 30 and 120 min. Blood was collected into EDTA-containing tubes, and plasma was generated using standard centrifugation techniques. Brain was homogenized, and proteins were precipitated with acetonitrile and compound concentrations were determined by LC-MS/MS. Data were fit by WinNonLin using a noncompartmental model and compound concentration in plasma and brain is calculated.</div><div class="NLM_p">The pharmacokinetic studies and CNS exposure of <b>58</b> monotartrate salt were conducted at BioDuro Inc. (Shanghai, China).</div><div class="NLM_p">Pharmacokinetics of <b>58</b> monotartrate salt was assessed in Sprague–Dawley male rats (241–287 g). The compound was prepared as a solution in PBS at a concentration of 0.25 mg mL<sup>–1</sup> for iv and po administration of 1 and 5 mg kg<sup>–1</sup>, respectively. Compound concentrations were determined using peripheral whole blood. For iv route, aliquots of 250 μL of blood were taken via a jugular vein cannula (<i>n</i> = 3) at 5, 15, and 30 min and 1, 2, 4, 8, and 24 h postdose. For oral route, aliquots of 250 μL of blood were taken via a jugular vein cannula (<i>n</i> = 3) at 15 and 30 min and 1, 2, 4, 8, and 24 h postdose. LC–MS/MS was used as the analytical method for the establishment of compound concentration in blood. Summary statistics were calculated using Microsoft Excel 2013, and graphs were prepared with GraphPad Prism Version 7.</div><div class="NLM_p">Pharmacokinetics of <b>58</b> monotartrate salt was assessed in CD-1 male mice (26–27 g). The compound was prepared as a solution in 0.5% MC at a concentration of 1 mg mL<sup>–1</sup>.</div><div class="NLM_p last">All procedures and handling were according to standard operating procedures approved by the Institutional Animal Care and Use Committee (IACUC).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Prolactin Assay</h4><div class="NLM_p">The assay to measure KOR antagonist inhibition of KOR agonist stimulated prolactin release was conducted at The Scripps Research Institute (TSRI, La Jolla, California) and was approved through the TSRI Institutional Animal Use and Care Committee. Eight to ten week old C57BL/6J male mice from the colony maintained by the Department of Animal Resources were used in this study (<i>n</i> = 3–4/group). Animals were maintained on a 12 h light/dark cycle and had access to food and water ad libitum.</div><div class="NLM_p last">For oral administration, KOR antagonist monotartrate salts were solubilized in water at a concentration of 0.5 mg mL<sup>–1</sup> and administer by gavage. The KOR agonist, U69,593 (Sigma), was solubilized in 45% 2-hydroxypropyl-cyclodextrin at a concentration of 10 mg mL<sup>–1</sup> and was administered (0.3 mg kg<sup>–1</sup>) subcutaneously in the nape of the neck. The KOR antagonists were administered 2 h before U69,593 administration. Sample collection and prolactin determination: Thirty minutes post agonist treatment, mice were euthanized with carbon dioxide and cardiac puncture was performed. Blood was collected and placed into a microtainer coated with K<sub>2</sub>EDTA and kept cold. Blood was spun at 4 °C, 1000<i>g</i>, for 10 min. Plasma was removed and prolactin levels determined using the Milliplex Mouse Pituitary Magnetic Bead Panel (MPTMAG-49K) on a Milliplex Analyzer Luminex 200, and pg/mL of prolactin was quantitatively determined using Milliplex Analyst 5.1 software.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Tail-Flick Test</h4><div class="NLM_p">Tail flick test of <b>58</b> monotartrate salt was conducted in the University of Arizona. Adult male ICR mice (weight 25–30 g) were purchased from Envigo (Indianapolis, IN, USA). All procedures were performed in accordance with the guidelines of the Committee for Research and Ethical Issues of IASP under protocols approved by the University of Arizona Institutional Animal Care and Use Committee. Animals were housed three per cage on a 12 h light–dark cycle with food and water ad libitum.</div><div class="NLM_p last">Mice were held gently and <sup>1</sup>/<sub>2</sub> to <sup>2</sup>/<sub>3</sub> of the tail was dipped into 50 °C hot water. The latency to a rapid flick of the tail was recorded by an investigator blinded to the treatment groups. The cutoff time was set at 15 s to prevent tissue damage. U50488 (KOR agonist, Tocris, Bristol, BS, UK) was dissolved in saline. The dose volume was 10 mL/kg for ip injections in mice.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Bacterial Reverse Mutation Assay (Ames Assay)</h4><div class="NLM_p">The potential mutagenic activity of compounds <b>33</b>, <b>34</b>, <b>35</b>, and <b>36</b> was conducted by BioReliance Corporation in Rockville Maryland. The monotartaric salts of <b>33</b>, <b>34</b>, <b>35</b>, and <b>36</b> were evaluated for their ability to induce reverse mutations at the histidine locus of strains of <i>Salmonella typhimurium</i> (TA98, TA100, TA1535, TA1537) and <i>Escherichia coli</i> (WP2 uvrA) in the presence and absence of rat liver S9. Positive controls were employed for each strain and metabolic activation system. The compounds were tested at eight concentrations ranging from 1.5 to 5000 μg/plate.</div><div class="NLM_p last">The Ames assay of <b>47</b> and <b>58</b> were conducted by Charles River Laboratories Montreal ULC. The monotartaric salts of <b>47</b> and <b>58</b> were tested at concentrations between 0.075 and 250 μg/well in the micro Ames duplicate with tester strains TA98, TA100, TA1535, TA97a, and WP2 uvrA. Both monotartaric salts were also tested at concentrations between 1.58 and 5000 μg/plate in the standard Ames in triplicate with tester strain TA1537 (assay protocols are described in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Chemistry</h3><div id="sec4_13_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> General Methods</h4><div class="NLM_p last">Unless otherwise stated, commercially available reagents and solvents were used without purification. Solvents for extraction: ACS grade. Solvents for reaction: reagent grade. Reagents: unless otherwise noted, from Alfa Aesar, Fisher, and Aldrich, highest quality available. TLC: silica gel 60 F254 aluminum plates, (Whatman, type Al Sil G/UV, 250 μm layer); visualization by UV absorption. Flash chromatography was performed on silica gel 60 (0.40–0.63 mm, 230–440 mesh, EM Science). Biotage Flash+ systems were used for medium-pressure column chromatography. NMR: <sup>1</sup>H and <sup>13</sup>C spectra were obtained using a Bruker DRX-500 MHz spectrometer. <sup>1</sup>H and <sup>13</sup>C NMR data are reported with chemical shifts (δ) in parts-per-million (ppm) relative to the residual signal of the deuterated solvent as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qn = quintet, m = multiplet, and br = broad), coupling constant in Hz. Reactions were monitored by LC/MS using Shimadzu LC/MS2020. Purity was determined by LCMS using a luna C-18 column (5 μm, 4.6 mm × 50 mm, Phenomenex), and detection was performed with a UV DAD at 254 and 230 nm wavelengths. Elution was carried out with a 10–95% gradient over 5 min of CH<sub>3</sub>CN in water containing 0.1% AcOH at a flow rate of 1.0 mL/min at 25 °C. The purity of all test compounds is higher than 95%. High resolution mass spectra were obtained on an Agilent 6230 TOF LC/MS system using electrospray ionization (ESI) in positive mode.</div></div><div id="sec4_13_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Synthesis of (3<i>S</i>,4<i>S</i>)-4-(Cyclohexylamino)piperidin-3-ol (<b>12</b>)</h4><div class="NLM_p">A mixture of amine <b>10</b> (500 mg, 2 mmol), cyclohexanone <b>11</b> (207 μL, 2 mmol), NaBH(OAc)<sub>3</sub> (635 mg, 3 mmol), and AcOH (171 μL, 3 mmol) in 1,2-dichloroethane (5 mL) was stirred at room temperature (rt) for 24 h. The mixture was filtered through Celite, concentrated under reduced pressure, and purified by column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–12% MeOH) to give (3<i>S</i>,4<i>S</i>)-benzyl 4-(cyclohexylamino)-3-hydroxypiperidine-1-carboxylate as a white solid in 76% yield (510 mg, 1.53 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.37–7.30 (m, 5H), 6.58 (br s, 2H), 5.17–5.04 (m, 2H), 4.46–4.12 (m, 2H), 3.66–3.57 (m, 1H), 2.90–2.59 (m, 4H), 2.05–1.96 (m, 3H), 1.82–1.74 (m, 2H), 1.66–1.59 (m, 2H), 1.44–1.36 (m, 1H), 1.31–1.13 (m, 4H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 155.1, 136.5, 128.6, 128.2, 128.1, 67.6, 59.3, 54.6, 48.9, 42.7, 31.9, 30.3, 28.0, 25.4, 24.9, 24.6, 24.1. LCMS: (M + 1) <i>m</i>/<i>z</i> = 333.</div><div class="NLM_p last">A solution of (3<i>S</i>,4<i>S</i>)-benzyl 4-(cyclohexylamino)-3-hydroxypiperidine-1-carboxylate (500 mg, 1.5 mmol) in 12 mL of EtOH was added Pd/C (10 wt %, 5 mg). The reaction mixture was purged three times with hydrogen and stirred under hydrogen atmosphere for 2 h. The reaction mixture was filtered through Celite and condensed to give 97% yield (290 mg, 1.46 mmol) of <b>12</b> as a pale-brown solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 3.29–3.22 (m, 1H), 3.18–3.14 (m, 1H), 3.05–2.98 (m, 1H), 2.61–2.52 (m, 2H), 2.46–2.37 (m, 2H), 2.06–1.99 (m, 1H), 1.93–1.86 (m, 1H), 1.76–1.66 (m, 3H), 1.62–1.54 (m, 1H), 1.31–1.08 (m, 6H), 1.02–0.94 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 72.3, 59.3, 53.2, 51.9, 45.9, 35.3, 33.6, 32.6, 26.2, 25.3, 24.8. LCMS: (M + 1) <i>m</i>/<i>z</i> = 199.</div></div><div id="sec4_13_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Synthesis of 5-(2-Chloro-5-methylpyridin-3-yl)-3-methyl-1,2,4-oxadiazole (<b>15</b>)</h4><div class="NLM_p last">To a solution of carboxylic acid <b>13</b> (600 mg, 3.49 mmol) in 10 mL of DMF were added EDCI (870 mg, 4.54 mmol) and HOBt (694 mg, 4.54 mmol), and the mixture was stirred at rt for 10 min. Acetamidoxime <b>14</b> (284 mg, 3.84 mmol) was added, and the mixture was stirred 30 min at rt. The solution was heated at 110 °C under microwave irradiation (mw) for 1 h. The mixture was quenched with brine (100 mL) and extracted with EtOAc (3 × 60 mL). The combined organic phases were washed with brine (3 × 100 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. Then <b>15</b> was purified by column chromatography using hexanes/EtOAc (0–30% EtOAc) to give the product as a pale-brown solid in 71% yield (519 mg, 2.46 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.40 (d, <i>J</i> = 2.4 Hz, 1H), 8.18 (d, <i>J</i> = 2.4 Hz, 1H), 2.51 (s, 3H), 2.42 (s, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 172.8, 167.9, 152.9, 147.0, 140.9, 132.8, 120.2, 17.7, 11.8. LCMS: (M + 1) <i>m</i>/<i>z</i> = 210.</div></div><div id="sec4_13_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Synthesis of (3<i>S</i>,4<i>S</i>)-4-(Cyclohexylamino)-1-(5-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)pyridin-2-yl)piperidin-3-ol (<b>16</b>)</h4><div class="NLM_p last">A mixture of chloropyridine <b>15</b> (20 mg, 0.095 mmol), <b>12</b> (38 mg, 0.19 mmol), and DIPEA (33 μL, 0.19 mmol) in EtOH (250 μL) was heated at 135 °C under microwave irradiation for 4 h. After cooling to room temperature, the mixture was concentrated under reduced pressure and purified by column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give pyridine <b>16</b> as a pale-yellow solid in 62% yield (22 mg, 0.059 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.19 (d, <i>J</i> = 2.3 Hz, 1H), 8.00 (d, <i>J</i> = 2.3 Hz, 1H), 3.70–3.66 (m, 1H), 3.58–3.53 (m, 1H), (td, <i>J</i> = 8.2, 4.0 Hz, 1H), 2.97–2.91 (m, 2H), 2.62–2.55 (m, 2H), 2.46 (s, 3H), 2.28 (s, 3H), 2.09–2.04 (m, 1H), 1.94–187 (m, 1H), 1.78–1.67 (m, 3H), 1.62–1.56 (m, 1H), 1.48–1.40 (m, 1H), 1.31–1.10 (m, 5H), 1.04–0.96 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.0, 167.6, 158.3, 151.6, 141.0, 125.5, 109.1, 70.5, 57.8, 54.4, 53.6, 49.0, 35.1, 33.7, 29.7, 26.2, 25.3, 24.9, 17.3, 11.8. HRMS (ESI-TOF) calcd for C<sub>20</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 372.2394, found 372.2399.</div></div><div id="sec4_13_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Synthesis of 5-(2-Chloro-6-methylquinolin-3-yl)-3-methyl-1,2,4-oxadiazole (<b>19</b>)</h4><div class="NLM_p last">A mixture of acid <b>17</b> (2.0 g, 9.0 mmol), SOCl<sub>2</sub> (2.0 mL, 27.0 mmol), and DMF (cat.) in CH<sub>2</sub>Cl<sub>2</sub> was heated at 60 °C for 2 h. After cooling to rt, the mixture was concentrated under reduced pressure. The solid residue was dissolved in 1,4-dioxane (12 mL), and <i>N</i>-hydroxyacetamidine <b>14</b> (866 mg, 11.7 mmol) and DIPEA (3.14 mL, 18 mmol) were added. The resulting mixture was stirred at rt for 30 min and 3 h at 110 °C. After cooling to rt, the mixture was concentrated under reduced pressure. The crude was dissolved in EtOAc (200 mL) and washed with brine (3 × 100 mL). The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography using hexanes/EtOAc (0–25% EtOAc) to give quinoline <b>19</b> as a yellow solid in 42% yield (981 mg, 3.77 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.79 (s, 1H), 7.98 (d, <i>J</i> = 8.4 Hz, 1H), 7.70 (d, <i>J</i> = 8.4 Hz, 1H), 7.69 (s, 1H), 2.57 (s, 3H), 2.55 (s, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 173.1, 168.0, 147.2, 146.1, 141.3, 138.7, 135.6, 128.4, 127.3, 126.0, 118.2, 21.8, 11.9. LCMS: (M + 1) <i>m</i>/<i>z</i> = 260.</div></div><div id="sec4_13_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Synthesis 5-(2-Chloro-6-ethylquinolin-3-yl)-3-methyl-1,2,4-oxadiazole (<b>20</b>)</h4><div class="NLM_p last">A mixture of acid <b>18</b> (1.76 g, 7.5 mmol), SOCl<sub>2</sub> (1.6 mL, 27.0 mmol), and DMF (cat.) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was heated at 60 °C for 2 h. After cooling to room temperature, the mixture was concentrated under reduced pressure. The solid residue was dissolved in 1,4-dioxane (12 mL), and <i>N</i>-hydroxyacetamidine <b>14</b> (719 mg, 9.7 mmol) and DIPEA (2.6 mL, 14.93 mmol) were added. The resulting mixture was stirred at rt for 30 min and 3 h at 110 °C. After cooling to rt, the mixture was concentrated under reduced pressure. The crude was dissolved in EtOAc (200 mL) and washed with brine (3 × 100 mL). The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography using hexanes/EtOAc (0–25% EtOAc) to give quinoline <b>20</b> as a yellow solid in 39% yield (800 mg, 2.92 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.81 (s, 1H), 8.00 (d, <i>J</i> = 8.6 Hz, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.70 (s, 1H), 2.87 (q, <i>J</i> = 7.6 Hz, 2H), 2.55 (s, 3H), 1.35 (t, <i>J</i> = 7.6, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 173.1, 168.0, 147.5, 146.2, 144.8, 141.5, 134.6, 128.6, 126.2, 126.0, 118.2, 29.0, 15.2, 11.9. LCMS: (M + 1) <i>m</i>/<i>z</i> = 274.</div></div><div id="sec4_13_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Synthesis of 8-(6-Methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane (<b>22</b>)</h4><div class="NLM_p last">A mixture of <b>19</b> (1.0 g, 3.8 mmol), <b>21</b> (1.1 g, 7.7 mmol), and DIPEA (1.34 mL, 7.7 mmol) in EtOH (15 mL) was heated at 130 °C under microwave irradiation for 3 h. The mixture was concentrated under reduce pressure and purified by column chromatography using hexanes/EtOAc (0–30% EtOAc) to give quinoline <b>22</b> as a yellow solid in 86% yield (1.205 g, 3.28 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.52 (s, 1H), 7.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.50 (d, <i>J</i> = 8.5 Hz, 1H), 7.49 (s, 1H), 3.99 (s, 4H), 3.45–3.40 (m, 4H), 2.51 (s, 3H), 2.48 (s, 3H), 1.91–186 (m, 4H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.5, 167.9, 156.7, 147.2, 141.7, 134.4, 134.3, 127.4, 127.2, 123.5, 111.5, 107.6, 64.5, 48.2, 34.8, 21.4, 11.9. LCMS: (M + 1) <i>m</i>/<i>z</i> = 367.</div></div><div id="sec4_13_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Synthesis of 8-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane (<b>23</b>)</h4><div class="NLM_p last">A mixture of <b>20</b> (500 mg, 1.82 mmol), <b>21</b> (523 mg, 3.65 mmol), and DIPEA (636 μL, 3.65 mmol) in EtOH (8 mL) was heated at 130 °C under microwave irradiation for 3 h. The mixture was concentrated under reduce pressure and purified by column chromatography using hexanes/EtOAc (0–30% EtOAc) to give quinoline <b>23</b> as a yellow solid in 82% yield (569 mg, 1.49 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.54 (s, 1H), 7.74 (d, <i>J</i> = 8.6 Hz, 1H), 7.54 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.50 (s, 1H), 3.98 (s, 4H), 3.45–3.41 (m, 4H), 2.77 (q, <i>J</i> = 7.6 Hz, 2H), 2.50 (s, 3H), 1.91–1.86 (m, 4H), 1.30 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.5, 167.9, 156.7, 147.4, 141.8, 140.7, 133.3, 127.5, 125.9, 123.5, 111.4, 107.6, 64.5, 48.2, 34.8, 28.7, 15.5, 11.9. LCMS: (M + 1) <i>m</i>/<i>z</i> = 381.</div></div><div id="sec4_13_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Synthesis of 1-(6-Methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)piperidin-4-one (<b>24</b>)</h4><div class="NLM_p last">To a solution of <b>22</b> (1.5 g, 4.09 mmol) in THF (7 mL) was added 10% aq H<sub>2</sub>SO<sub>4</sub> (120 mL) at rt. The mixture was stirred at rt for 3 h. The mixture was neutralized with satd aq NaOH and the product extracted with EtOAc (×3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by column chromatography using hexanes/EtOAc (0–30% EtOAc) to give quinoline <b>24</b> as a yellow solid in 91% yield (1.20 g, 3.72 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.63 (s, 1H), 7.75 (d, <i>J</i> = 8.4 Hz, 1H), 7.55 (d, <i>J</i> = 8.4 Hz, 1H), 7.54 (s, 1H), 3.66 (t, <i>J</i> = 6.0 Hz, 4 H), 2.66 (t, <i>J</i> = 6.0 Hz, 4H), 2.52 (s, 3H), 2.50 (s, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 208.8, 175.1, 168.0, 156.0, 146.9, 142.0, 135.1, 134.7, 127.5, 127.3, 123.9, 111.3, 49.8, 41.4, 21.5, 11.9. LCMS: (M + 1) <i>m</i>/<i>z</i> = 323.</div></div><div id="sec4_13_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Synthesis of 1-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)piperidin-4-one (<b>25</b>)</h4><div class="NLM_p last">To a solution of <b>23</b> (580 mg, 1.52 mmol) in THF (4 mL) was added 10% aq H<sub>2</sub>SO<sub>4</sub> (50 mL) at rt. The mixture was stirred at rt for 3 h. The mixture was neutralized with satd aq NaOH and the product extracted with EtOAc (×3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by column chromatography using hexanes/EtOAc (0–30% EtOAc) to give quinoline <b>25</b> as a yellow solid in 87% yield (447 mg, 1.32 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.67 (s, 1H), 7.77 (d, <i>J</i> = 8.6 Hz, 1H), 7.59 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.56 (s, 1H), 3.66 (t, <i>J</i> = 6.0 Hz, 4 H), 2.80 (q, <i>J</i> = 7.6 Hz, 2H), 2.66 (t, <i>J</i> = 6.0 Hz, 4H), 2.52 (s, 3H), 1.32 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 208.8, 175.1, 168.0, 156.0, 147.2, 142.2, 141.5, 133.6, 127.6, 126.0, 123.9, 111.3, 49.8, 41.4, 28.8, 15.5, 11.9. LCMS: (M + 1) <i>m</i>/<i>z</i> = 337.</div></div><div id="sec4_13_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> General Procedure for the Synthesis of Final Compounds</h4><div class="NLM_p">Procedure 1: A mixture of ketone (1.0 equiv), amine (1.1–2.0 equiv), NaBH(OAc)<sub>3</sub> (2.0 equiv), and AcOH (2.0 equiv) in 1,2-dichloroethane was stirred at rt overnight. After filtration through Celite, the filtrate was concentrated under reduced pressure and purified.</div><div class="NLM_p last">Procedure 2: A mixture of ketone (1.0 equiv), amine-HCl salt (1.1–2.0 equiv), DIPEA (1.1–2.0 equiv), NaBH(OAc)<sub>3</sub> (2.0 equiv), and AcOH (2.0 equiv) in 1,2-dichloroethane was stirred at rt overnight. After filtration through Celite, the filtrate was concentrated under reduced pressure and purified.</div></div><div id="sec4_13_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Synthesis of <i>N</i>-Isobutyl-1-(6-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)piperidin-4-amine (<b>27</b>)</h4><div class="NLM_p last">Prepared according to procedure 1 using <b>24</b> (30 mg, 0.093 mmol) and isobutylamine (18.6 μL, 0.186 mmol) with purification by prep-HPLC (10–95% ACN in H<sub>2</sub>O with 0.1% TFA for 12 min) to give <b>27</b> as a pale-yellow solid in 81% yield (28.5 mg, 0.075 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.50 (s, 1H), 7.71 (d, <i>J</i> = 8.6 Hz, 1H), 7.50 (dd, <i>J</i> = 8.6, 1.9 Hz, 1H), 7.47 (s, 1H), 3.70–3.64 (m, 2H), 2.99–2.92 (m, 2H), 2.66–2.59 (m, 1H), 2.51 (s, 3H), 2.47 (s, 3H), 2.46 (d, <i>J</i> = 6.7 Hz, 2H), 1.97–1.90 (m, 2H), 1.76–1.68 (m, 1H), 1.63–1.54 (m, 2H), 1.44 (br s, 1H), 0.91 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.7, 167.8, 157.2, 147.2, 141.6, 134.3, 134.2, 127.3, 127.2, 123.5, 111.7, 55.3, 55.0, 49.3, 32.6, 28.8, 21.4, 20.9, 11.9. HRMS (ESI-TOF) calcd for C<sub>22</sub>H<sub>29</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 380.2445, found 380.2449.</div></div><div id="sec4_13_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-(Cyclopropylmethyl)-1-(6-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)piperidin-4-amine (<b>28</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 1 using <b>24</b> (40 mg, 0.119 mmol) and cyclopropylmethylamine (21 μL, 0.248 mmol) with purification by prep-HPLC (10–95% ACN in H<sub>2</sub>O for 12 min) to give <b>28</b> as a yellow solid in 88% yield (41 mg, 0.108 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.50 (s, 1H), 7.70 (d, <i>J</i> = 8.5 Hz, 1H), 7.49 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.47 (s, 1H), 3.70–3.63 (m, 2H), 2.94 (t, <i>J</i> = 13.6 Hz, 2H), 2.70–2.64 (m, 1H), 2.51 (d, <i>J</i> = 6.9 Hz, 2H), 2.50 (s, 3H), 2.46 (s, 3H), 1.96–1.90 (m, 2H), 1.63–1.55 (m, 2H), 1.00–0.92 (m, 1H), 0.50–0.46 (m, 2H), 0.13–0.09 (m, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.6, 167.8, 157.1, 147.1, 141.6, 134.3, 134.2, 127.3, 127.2, 123.5, 111.7, 55.0, 52.0, 49.3, 32.5, 21.4, 11.9, 11.6, 3.6. HRMS (ESI-TOF) calcd for C<sub>22</sub>H<sub>27</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 378.2288, found 378.2293.</div></div><div id="sec4_13_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 1-(6-Methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-yl)piperidin-4-amine (<b>29</b>)</h4><div class="NLM_p last">Prepared according to the general procedure1 using <b>24</b> (1.0 g, 3.1 mmol) and 4-aminotetrahydropyran (352 μL, 3.41 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>29</b> as a yellow solid in 89% yield (1.125 g, 2.76 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.50 (s, 1H), 7.70 (d, <i>J</i> = 8.6 Hz, 1H), 7.49 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.47 (s, 1H), 4.00–3.94 (m, 2H), 3.70–3.64 (m, 2H), 3.39 (td, <i>J</i> = 11.7, 2.0 Hz, 2H), 2.98–2.91 (m, 2H), 2.89–2.80 (m, 2H), 2.50 (s, 3H), 2.46 (s, 3H), 1.95–1.89 (m, 2H), 1.83–1.77 (m, 2H), 1.61–1.53 (m, 2H), 1.44–1.35 (m, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.7, 167.8, 157.1, 147.1, 141.7, 134.4, 134.3, 127.3, 127.2, 123.5, 111.7, 67.0, 51.0, 50.3, 49.3, 34.4, 33.0, 21.4, 11.9. HRMS (ESI-TOF) calcd for C<sub>23</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 408.2394, found 408.2399.</div></div><div id="sec4_13_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Synthesis of 1-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-isobutylpiperidin-4-amine (<b>30</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 1 using <b>25</b> (30 mg, 0.089 mmol) and isobutylamine (17.8 μL, 0.178 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>30</b> as a yellow solid in 80% yield (28 mg, 0.071 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.53 (s, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.53 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.49 (s, 1H), 3.71–3.64 (m, 2H), 3.00–2.92 (m, 2H), 2.77 (q, <i>J</i> = 7.6 Hz, 2H), 2.66–2.60 (m, 1H), 2.51 (s, 3H), 2.46 (d, <i>J</i> = 6.8 Hz, 2H), 1.97–1.92 (m, 2H), 1.76–1.68 (m, 1H), 1.62–1.54 (m, 2H), 1.39 (br s, 1H), 1.30 (t, <i>J</i> = 7.6 Hz, 3H), 0.91 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.7, 167.8, 157.2, 147.4, 141.8, 140.6, 133.2, 127.4, 126.0, 123.5, 111.6, 53.3, 55.0, 49.3, 32.6, 28.8, 28.7, 20.9, 15.5, 11.9. HRMS (ESI-TOF) calcd for C<sub>23</sub>H<sub>31</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 394.2601, found 394.2607.</div></div><div id="sec4_13_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Synthesis of <i>N</i>-(Cyclopropylmethyl)-1-(6-ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)piperidin-4-amine (<b>31</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 1 using <b>25</b> (40 mg, 0.119 mmol) and cyclopropylmethylamine (20 μL, 0.238 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>31</b> as a yellow solid in 90% yield (42.1 mg, 0.107 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.52 (s, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.53 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.49 (s, 1H), 3.70–3.64 (m, 2H), 2.98–2.90 (m, 2H), 2.77 (q, <i>J</i> = 7.6 Hz, 2H), 2.70–2.63 (m, 1H),2.51 (d, <i>J</i> = 6.8 Hz, 2H), 2.50 (s, 3H), 1.96–1.91 (m, 2H), 1.63–1.55 (m, 2H), 1.29 (t, <i>J</i> = 7.6 Hz, 3H),0.98–0.91 (m, 1H), 0.50–0.46 (m, 2H), 0.13–0.09 (m, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.7, 167.8, 157.2, 147.4, 141.8, 140.6, 133.2, 127.4, 125.9, 123.5, 111.6, 55.1, 52.1, 49.3, 32.6, 28.7, 15.5, 11.9, 11.7, 3.5. HRMS (ESI-TOF) calcd for C<sub>23</sub>H<sub>29</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 392.2445, found 392.2450.</div></div><div id="sec4_13_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Synthesis of 1-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-yl)piperidin-4-amine (<b>32</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 1 using <b>25</b> (40 mg, 0.119 mmol) and 4-aminotetrahydropyran (24.6 μL, 0.238 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>32</b> as a yellow solid in 87% yield (43.8 mg, 0.104 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.53 (s, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.53 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.49 (s, 1H), 3.99–3.93 (m, 2H), 3.70–3.64 (m, 2H), 3.39 (td, <i>J</i> = 11.7, 2.3 Hz, 2H), 2.98–2.92 (m, 2H), 2.89–2.80 (m, 2H), 2.76 (q, <i>J</i> = 7.6 Hz, 2H), 2.50 (s, 3H), 1.95–1.89 (m, 2H), 1.83–1.77 (m, 2H), 1.62–1.53 (m, 2H), 1.44–1.35 (m, 2H), 1.29 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.6, 167.8, 157.1, 147.3, 141.8, 140.7, 133.2, 127.4, 125.9, 123.5, 111.6, 67.0, 51.0, 50.3, 49.3, 34.4, 33.0, 28.7, 15.5, 11.9. HRMS (ESI-TOF) calcd for C<sub>24</sub>H<sub>31</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 422.255, found 422.2556.</div></div><div id="sec4_13_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Synthesis of (<i>S</i>)-1-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(3-methylbutan-2-yl)piperidin-4-amine (<b>33</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 1 using <b>25</b> (200 mg, 0.59 mmol) and (<i>S</i>)-2-amino-3-methylbutane (91 μL, 0.77 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>33</b> as a yellow solid in 92% yield (222 mg, 0.545 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.52 (s, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.53 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.48 (s, 1H), 3.70–3.63 (m, 2H), 3.00–2.90 (m, 2H), 2.79–2.69 (m, 3H), 2.64–2.59 (m, 1H), 2.50 (s, 3H), 1.96–1.87 (m, 2H), 1.68–1.46 (m, 3H), 1.29 (t, <i>J</i> = 7.6 Hz, 3H), 1.23 (br s, 1H), 0.96 (d, <i>J</i> = 7.6 Hz, 3H), 0.89 (d, <i>J</i> = 6.8 Hz, 3H), 0.86 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.7, 167.8, 157.2, 147.4, 141.8, 140.6, 133.2, 127.4, 125.9, 123.4, 111.6, 54.5, 52.1, 49.4, 49.3, 33.4, 32.7, 28.7, 19.5, 17.4, 16.9, 15.5, 11.9. HRMS (ESI-TOF) calcd for C<sub>24</sub>H<sub>33</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 408.2758, found 408.2763.</div></div><div id="sec4_13_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Synthesis of (1<i>S</i>,2<i>S</i>)-2-((1-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)piperidin-4-yl)amino)cyclohexanol (<b>34</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 2 using <b>25</b> (1.16 g, 3.46 mmol) and (1<i>S</i>,2<i>S</i>)-2-aminocyclohexanol HCl (530 mg, 3.46 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>34</b> as a yellow gum in 78% yield (1200 mg, 2.75 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.53 (s, 1H), 7.74 (d, <i>J</i> = 8.6 Hz, 1H), 7.54 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.49 (s, 1H), 3.68–3.60 (m, 2H), 3.11–3.06 (m, 1H), 3.03–2.91 (m, 2H), 2.85–2.73 (m, 3H), 2.50 (s, 3H), 2.33–2.28 (m, 1H), 2.10–2.02 (m, 2H), 1.98–1.92 (m, 1H), 1.87–1.79 (m, 1H), 1.74–1.61 (m, 3H), 1.56–1.48 (m, 1H), 1.30–1.21 (m, 7H), 0.98–0.89 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.7, 167.8, 157.1, 147.4, 141.8, 140.7, 133.2, 127.4, 126.0, 123.5, 111.6, 74.2, 60.6, 51.9, 49.0, 48.9, 34.0, 33.1, 32.5, 31.8, 28.7, 25.5, 24.4, 15.5, 11.9. HRMS (ESI-TOF) calcd for C<sub>25</sub>H<sub>33</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 436.2707, found 436.2713.</div></div><div id="sec4_13_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Synthesis of 1-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-((3-methyloxetan-3-yl)methyl)piperidin-4-amine (<b>35</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 1 using <b>25</b> (1.59 g, 4.73 mmol) and (3-methyloxetan-3-yl)methanamine (0.65 mL, 6.15 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>35</b> as a yellow solid in 91% yield (1.81 g, 4.29 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.54 (s, 1H), 7.74 (d, <i>J</i> = 8.6 Hz, 1H), 7.54 (d, <i>J</i> = 8.6 Hz, 1H), 7.50 (s, 1H), 4.45 (d, <i>J</i> = 5.7 Hz, 2H), 4.37 (d, <i>J</i> = 5.7 Hz, 2H), 3.70–3.65 (m, 2H), 3.01–2.94 (m, 2H), 2.86 (s, 2H), 2.78 (q, <i>J</i> = 7.6 Hz, 2H), 2.69–2.62 (m, 1H), 2.51 (s, 3H), 2.00–1.94 (m, 2H), 1.64–1.55 (m, 2H), 1.32–1.28 (m, 6H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.7, 167.8, 157.2, 147.4, 141.9, 140.7, 133.2, 127.4, 126.0, 123.5, 111.6, 81.4, 55.6, 54.4, 49.2, 39.8, 32.6, 28.7, 22.2, 15.5, 11.9. HRMS (ESI-TOF) calcd for C<sub>24</sub>H<sub>31</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 422.255, found 422.2556.</div></div><div id="sec4_13_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Synthesis of (<i>R</i>)-1-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-3-yl)piperidin-4-amine (<b>36</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 2 using <b>25</b> (150 mg, 0.446 mmol) (<i>R</i>)-3-aminotetrahydropyran HCl (73.6 mg, 0.535 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>36</b> as a yellow solid in 87% yield (164 mg, 0.389 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.52 (s, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.53 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.48 (s, 1H), 3.90–3.86 (m, 1H), 3.80–3.76 (m, 1H), 3.69–3.63 (m, 2H), 3.42–3.36 (m, 1H), 3.14 (dd, <i>J</i> = 11.0, 8.5 Hz, 1H), 3.00–2.91 (m, 2H), 2.82–2.72 (m, 4H), 2.50 (s, 3H), 1.96–1.84 (m, 3H), 1.70–1.52 (m, 4H), 1.38–1.31 (m, 2H), 1.29 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.6, 167.8, 157.1, 147.3, 141.8, 140.6, 133.2, 127.4, 125.9, 123.5, 111.6, 73.1, 68.3, 52.0, 50.1, 49.20, 49.18, 33.1, 33.0, 31.0, 28.6, 24.8, 15.5, 11.9. HRMS (ESI-TOF) calcd for C<sub>24</sub>H<sub>31</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 422.255, found 422.2560.</div></div><div id="sec4_13_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Synthesis of (<i>S</i>)-1-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-3-yl)piperidin-4-amine (<b>37</b>)</h4><div class="NLM_p last">Prepared according to procedure 2 using <b>25</b> (30 mg, 0.089 mmol) and (<i>S</i>)-3-aminotetrahydropyran HCl (24.5 mg, 0.178 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>37</b> as a yellow solid in 75% yield (28 mg, 0.066 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.52 (s, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.53 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.49 (s, 1H), 3.90–3.86 (m, 1H), 3.80–3.76 (m, 1H), 3.69–3.64 (m, 2H), 3.42–3.37 (m, 1H), 3.15 (dd, <i>J</i> = 11.0, 8.5 Hz, 1H), 2.98–2.92 (m, 2H), 2.82–2.72 (m, 4H), 2.50 (s, 3H), 1.96–1.84 (m, 3H), 1.70–1.52 (m, 4H), 1.38–1.31 (m, 2H), 1.29 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.7, 167.8, 157.1, 147.4, 141.8, 140.7, 133.2, 127.4, 125.9, 123.5, 111.6, 73.1, 68.3, 52.1, 50.1, 49.21, 49.20, 33.1, 33.0, 31.0, 28.7, 24.8, 15.5, 11.9. HRMS (ESI-TOF) calcd for C<sub>24</sub>H<sub>31</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 422.255, found 422.2556.</div></div><div id="sec4_13_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Synthesis of (<i>R</i>)-1-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydrofuran-3-yl)piperidin-4-amine (<b>38</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 2 using <b>25</b> (30 mg, 0.089 mmol) and (<i>R</i>)-3-aminotetrahydrofuran HCl (22 mg, 0.178 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>38</b> as a yellow solid in 91% yield (33 mg, 0.0809 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.54 (s, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.54 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.49 (s, 1H), 3.95–3.90 (m, 1H), 3.85 (dd, <i>J</i> = 8.4, 5.5 Hz, 1H), 3.80–3.75 (m, 1H), 3.71–3.65 (m, 2H), 3.59–3.51 (m, 2H), 3.00–2.92 (m, 2H), 2.77 (q, <i>J</i> = 7.6 Hz, 2H), 2.72–2.66 (m, 1H), 2.50 (s, 3H), 2.16–2.09 (m, 1H), 1.97–1.89 (m, 2H), 1.73–1.67 (m, 1H), 1.64–1.55 (m, 2H), 1.48 (br s, 1H), 1.30 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.6, 167.8, 157.1, 147.4, 141.8, 140.7, 133.2, 127.4, 126.0, 123.5, 111.6, 74.0, 67.3, 55.4, 53.6, 49.2, 33.8, 32.83, 32.81, 28.7, 15.5, 11.9. HRMS (ESI-TOF) calcd for C<sub>23</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 408.2394, found 408.2401.</div></div><div id="sec4_13_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Synthesis of (<i>S</i>)-1-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydrofuran-3-yl)piperidin-4-amine (<b>39</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 2 using <b>25</b> (30 mg, 0.089 mmol) and (<i>S</i>)-3-aminotetrahydrofuran p-toluenesulfonate (46 mg, 0.178 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>39</b> as a yellow solid in 85% yield (31 mg, 0.076 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.54 (s, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.54 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.49 (s, 1H), 3.95–3.90 (m, 1H), 3.85 (dd, <i>J</i> = 8.4, 5.5 Hz, 1H), 3.80–3.75 (m, 1H), 3.70–3.65 (m, 2H), 3.58–3.51 (m, 2H), 2.99–2.92 (m, 2H), 2.77 (q, <i>J</i> = 7.6 Hz, 2H), 2.72–2.65 (m, 1H), 2.50 (s, 3H), 2.16–2.09 (m, 1H), 1.97–1.89 (m, 2H), 1.73–1.67 (m, 1H), 1.64–1.55 (m, 2H), 1.30 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.6, 167.8, 157.1, 147.4, 141.8, 140.7, 133.2, 127.4, 126.0, 123.5, 111.6, 74.0, 67.3, 55.4, 53.6, 49.2, 33.8, 32.83, 32.81, 28.7, 15.5, 11.9. HRMS (ESI-TOF) calcd for C<sub>23</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 408.2394, found 408.2401.</div></div><div id="sec4_13_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Synthesis of 2-Amino-5-bromo-3-fluorobenzaldehyde (<b>41</b>)</h4><div class="NLM_p">To a solution of <b>40</b> (8.0 g, 34 mmol) in anhydrous THF (50 mL) was added a 1 M solution of BH<sub>3</sub><b>·</b>THF complex in THF (102.5 mL, 102.5 mmol) dropwise at 0 °C. The mixture was then stirred at rt for 18 h. The reaction was quenched by slow addition of ∼20 mL of MeOH at 0 °C. The mixture was concentrated under reduced pressure, and the residue was partitioned between EtOAc and brine. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude (2-amino-5-bromo-3-fluorophenyl)methanol was obtained as a brown solid in 76% yield (5.65 g, 25.68 mmol) and was used in the next reaction without further purification. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ (ppm) 7.10 (s, 1H), 7.09 (dd, <i>J</i> = 11.7, 2.2 Hz, 1H), 4.86 (s, 1H), 4.56 (s, 2H). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ (ppm) 152.7 (<i>J</i> = 240.1 Hz), 134.6 (<i>J</i> = 13.1 Hz), 130.8 (<i>J</i> = 4.2 Hz), 127.3 (<i>J</i> = 2.9 Hz), 118.1 (<i>J</i> = 22.6 Hz), 108.1 (<i>J</i> = 9.6 Hz), 62.2. LCMS: (M + 1) <i>m</i>/<i>z</i> = 419, 421.</div><div class="NLM_p last">A mixture of crude (2-amino-5-bromo-3-fluorophenyl)methanol (5.6 g, 25.45 mmol) and activated MnO<sub>2</sub> (13.27 g, 152.7 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (120 mL) was stirred at rt for 8 h. The filtrate was concentrated after filtration through Celite. The residue was purified with a short silica gel path using hexanes/EtOAc (0–30% EtOAc) to give <b>41</b> as a pale-yellow solid in quantitative yield (5.55 g, 25.4 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 9.81 (s, 1H), 7.43 (s, 1H), 7.28 (d, <i>J</i> = 8.7 Hz), 6.19 (br s, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 192.3, 150.8 (<i>J</i> = 245.1 Hz), 138.1 (<i>J</i> = 13.5 Hz), 132.6 (<i>J</i> = 3.4 Hz), 122.8 (<i>J</i> = 21.1 Hz), 121.1 (<i>J</i> = 4.6 Hz), 105.4 (<i>J</i> = 8.7 Hz).</div></div><div id="sec4_13_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Synthesis of 5-(6-Bromo-2-chloro-8-fluoroquinolin-3-yl)-3-methyl-1,2,4-oxadiazole (<b>43</b>)</h4><div class="NLM_p last">A mixture of aldehyde <b>41</b> (1.50 g, 6.88 mmol), oxadiazole acid <b>42</b> (1.173 g, 8.25 mmol), and POCl<sub>3</sub> (8 mL) was stirred at 80 °C for 1 h. After cooling to rt, excess POCl<sub>3</sub> was removed under reduced pressure. The crude was quenched with ice/H<sub>2</sub>O, and the mixture was stirred at 0 °C for 10 min. The precipitate was filtered, washed with H<sub>2</sub>O, and dried under reduced pressure. The product was purified by column chromatography using hexanes/EtOAc (0–30% EtOAc) to give <b>43</b> as a yellow solid in 14% yield (330 mg, 0.963 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.82 (d, <i>J</i> = 1.4 Hz, 1H), 7.92 (s, 1H), 7.70 (dd, <i>J</i> = 9.2, 2.0 Hz, 1H), 2.56 (s, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 172.1, 168.2, 156.7 (<i>J</i> = 264.2 Hz), 148.2, 140.5 (<i>J</i> = 2.8 Hz), 137.5 (<i>J</i> = 11.9 Hz), 128.1 (<i>J</i> = 2.2 Hz), 126.3 (<i>J</i> = 5.0 Hz), 121.4 (<i>J</i> = 21.6 Hz), 121.4, 120.6. 11.9. LCMS: (M + 1) <i>m</i>/<i>z</i> = 341, 343.</div></div><div id="sec4_13_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Synthesis of 8-(6-Bromo-8-fluoro-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane (<b>44</b>)</h4><div class="NLM_p last">A suspension of <b>43</b> (300 mg, 0.875 mmol), <b>21</b> (168 μL, 1.31 mmol), and DIPEA (229 μL, 1.31 mmol) in EtOH (70 mL) was heated at 130 °C under microwave irradiation for 2 h. After cooling to rt, the mixture was concentrated under reduced pressure and purified by column chromatography using hexanes/EtOAc (0–50% EtOAc) to give quinoline <b>44</b> in 45% yield as a yellow solid (200 mg, 0.445 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.46 (s, 1H), 7.65 (s, 1H), 7.48 (dd, <i>J</i> = 9.7, 1.6 Hz, 1H), 3.98 (s, 4H), 3.51–3.46 (m, 4H), 2.51 (s, 3H), 1.89–1.84 (m, 4H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 174.7, 168.1, 156.7, 156.5 (<i>J</i> = 259.1 Hz), 141.0 (<i>J</i> = 2.2 Hz), 137.6 (<i>J</i> = 11.5 Hz), 126.0 (<i>J</i> = 4.7 Hz), 125.4 (<i>J</i> = 3.2 Hz), 120.1 (<i>J</i> = 21.9 Hz), 115.6 (<i>J</i> = 8.7 Hz), 112.9, 107.3, 64.5, 47.8, 34.7, 11.9. LCMS: (M + 1) <i>m</i>/<i>z</i> = 449, 451.</div></div><div id="sec4_13_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Synthesis of 1-(6-Ethyl-8-fluoro-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)piperidin-4-one (<b>45</b>)</h4><div class="NLM_p">To a mixture of <b>44</b> (110 mg, 0.24 mmol), Cs<sub>2</sub>CO<sub>3</sub> (239 mg, 0.73 mmol), and Pd(dppf)Cl<sub>2</sub>.CH<sub>2</sub>Cl<sub>2</sub> (19.6 mg, 0.024 mmol) in THF (4 mL) was added 1 M solution of Et<sub>3</sub>B in THF (730 μL, 0.73 mmol) at rt. The mixture was heated at 70 °C for 1 h. After cooling to rt, the mixture was partitioned between brine (30 mL) and EtOAc (30 mL). The aqueous layer was extracted with EtOAc (2 × 30 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by column chromatography using hexanes/EtOAc (0–70% EtOAc) to give 8-(6-ethyl-8-fluoro-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane in 74% yield as a yellow solid (71 mg, 0.178 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.52 (d, <i>J</i> = 1.5 Hz, 1H), 7.29 (s, 1H), 7.25 (dd, <i>J</i> = 11.5, 2.0 Hz, 1H), 3.98 (s, 4H), 3.49–3.43 (m, 4H), 2.75 (q, <i>J</i> = 7.6 Hz, 2H), 2.50 (s, 3H), 1.90–1.85 (m, 4H), 1.29 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.2, 167.9, 156.6 (<i>J</i> = 253.7 Hz), 156.5, 141.6 (<i>J</i> = 3.1 Hz), 140.7 (<i>J</i> = 6.4 Hz), 137.1 (<i>J</i> = 11.9 Hz), 124.9 (<i>J</i> = 2.9 Hz), 121.5 (<i>J</i> = 4.1 Hz), 117.1 (<i>J</i> = 18.1 Hz), 112.1, 107.5, 64.5, 48.0, 34.7, 28.7, 15.3, 11.9. LCMS: (M + 1) <i>m</i>/<i>z</i> = 399.</div><div class="NLM_p last">To a solution of 8-(6-ethyl-8-fluoro-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane (60 mg, 0.15 mmol) in THF (1 mL) was added 10% aq H<sub>2</sub>SO<sub>4</sub> (5 mL), and the mixture was stirred at 45 °C for 2 h. After cooling to rt, the mixture was neutralized with satd aq NaOH and extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The ketone <b>45</b> was obtained as a yellow solid in 94% yield (50 mg, 0.144 mmol) and was used for the next reaction without further purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.65 (d, <i>J</i> = 1.6 Hz, 1H), 7.36 (s, 1H), 7.30 (dd, <i>J</i> = 11.5, 1.7 Hz, 1H), 3.70 (t, <i>J</i> = 6.0 Hz, 4H), 2.78 (q, <i>J</i> = 7.6 Hz, 2H), 2.66 (t, <i>J</i> = 6.1 Hz, 4H), 2.52 (s, 3H), 1.31 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 208.5, 174.7, 168.1, 156.6 (<i>J</i> = 254.4 Hz), 155.9, 142.0 (<i>J</i> = 3.1 Hz), 141.6 (<i>J</i> = 6.3 Hz), 136.9 (<i>J</i> = 11.9 Hz), 125.3 (<i>J</i> = 2.8 Hz), 121.6 (<i>J</i> = 4.1 Hz), 117.5 (<i>J</i> = 18.0 Hz), 112.1, 49.5, 41.2, 28.8, 15.3, 11.9. LCMS: (M + 1) <i>m</i>/<i>z</i> = 355.</div></div><div id="sec4_13_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Synthesis of 1-(6-Ethyl-8-fluoro-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-yl)piperidin-4-amine (<b>46</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 1 using <b>45</b> (53 mg, 0.149 mmol) and 4-aminotetrahydropyran (23 μL, 0.224 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>46</b> as a yellow solid in 82% yield (54 mg, 123 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.52 (d, <i>J</i> = 1.5 Hz, 1H), 7.29 (s, 1H), 7.25 (dd, <i>J</i> = 11.6, 1.8 Hz, 1H), 4.00–3.94 (m, 2H), 3.75–3.68 (m, 2H), 3.40 (td, <i>J</i> = 11.8, 2.1 Hz, 2H), 3.03–2.96 (m, 2H), 2.90–2.82 (m, 2H), 2.75 (q, <i>J</i> = 7.6 Hz, 2H), 2.51 (s, 3H), 1.97–1.89 (m, 2H), 1.84–1.77 (m, 2H), 1.62–1.52 (m, 2H), 1.45–1.35 (m, 3H), 1.29 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 174.4, 167.9, 156.9, 156.6 (<i>J</i> = 253.3 Hz), 141.7 (<i>J</i> = 3.0 Hz), 140.7 (<i>J</i> = 6.4 Hz), 137.1 (<i>J</i> = 11.8 Hz), 124.9 (<i>J</i> = 2.9 Hz), 121.5 (<i>J</i> = 4.0 Hz), 117.1 (<i>J</i> = 18.1 Hz), 112.4, 67.1, 51.0, 50.4, 49.1, 34.5, 32.9, 28.7, 15.3, 11.9. HRMS (ESI-TOF) calcd for C<sub>24</sub>H<sub>30</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 440.2456, found 440.2464.</div></div><div id="sec4_13_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Synthesis of (<i>R</i>)-1-(6-Ethyl-8-fluoro-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-3-yl)piperidin-4-amine (<b>47</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 2 using <b>45</b> (29 mg, 0.082 mmol) and (<i>R</i>)-3-aminotetrahydropyran HCl (15 mg, 0.11 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>47</b> as a yellow solid in 87% yield (32 mg, 0.073 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.50 (d, <i>J</i> = 1.5 Hz, 1H), 7.28 (s, 1H), 7.24 (dd, <i>J</i> = 11.6, 1.7 Hz, 1H), 3.90–3.84 (m, 1H), 3.80–3.75 (m, 1H), 3.74–3.66 (m, 2H), 3.42–3.36 (m, 1H), 3.14 (dd, <i>J</i> = 11.0, 8.5 Hz, 1H), 3.01–2.93 (m, 2H), 2.82–2.71 (m, 4H), 2.50 (s, 3H), 1.96–1.84 (m, 3H), 1.70–1.51 (m, 4H), 1.38–1.29 (m, 2H), 1.28 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.3, 167.9, 156.8, 156.5 (<i>J</i> = 254.4 Hz), 141.6 (<i>J</i> = 3.0 Hz), 140.6 (<i>J</i> = 6.4 Hz), 137.1 (<i>J</i> = 11.7 Hz), 124.9 (<i>J</i> = 3.0 Hz), 121.5 (<i>J</i> = 4.0 Hz), 117.0 (<i>J</i> = 18.1 Hz), 112.4, 73.1, 68.3, 51.9, 50.1, 48.97, 48.93, 33.0, 32.9, 30.9, 28.7, 24.8, 15.3, 11.9. HRMS (ESI-TOF) calcd for C<sub>24</sub>H<sub>30</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 440.2456, found 440.2464.</div></div><div id="sec4_13_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Synthesis of (<i>S</i>)-1-(6-Ethyl-8-fluoro-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-3-yl)piperidin-4-amine (<b>48</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 2 using <b>45</b> (25 mg, 0.0705 mmol) and (<i>S</i>)-3-aminotetrahydropyran.HCl (19.4 mg, 0.141 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>48</b> as a yellow solid in 84% yield (26 mg, 0.059 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.51 (d, <i>J</i> = 1.5 Hz, 1H), 7.28 (s, 1H), 7.25 (dd, <i>J</i> = 11.5, 1.8 Hz, 1H), 3.90–3.86 (m, 1H), 3.80–3.75 (m, 1H), 3.74–3.67 (m, 2H), 3.43–3.37 (m, 1H), 3.15 (dd, <i>J</i> = 10.9, 8.5 Hz, 1H), 3.02–2.94 (m, 2H), 2.82–2.71 (m, 4H), 2.51 (s, 3H), 1.97–1.85 (m, 3H), 1.71–1.50 (m, 4H), 1.39–1.31 (m, 2H), 1.29 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.4, 167.9, 156.9, 156.6 (<i>J</i> = 253.4 Hz), 141.6 (<i>J</i> = 3.1 Hz), 140.7 (<i>J</i> = 6.4 Hz), 137.1 (<i>J</i> = 11.7 Hz), 124.9 (<i>J</i> = 3.0 Hz), 121.5 (<i>J</i> = 3.9 Hz), 117.1 (<i>J</i> = 18.1 Hz), 112.4, 73.1, 68.3, 52.0, 50.1, 49.00, 48.96, 33.0, 32.9, 31.0, 28.7, 24.8, 15.3, 11.9. HRMS (ESI-TOF) calcd for C<sub>24</sub>H<sub>30</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 440.2456, found 440.2463.</div></div><div id="sec4_13_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Synthesis of (<i>R</i>)-1-(6-Ethyl-8-fluoro-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydrofuran-3-yl)piperidin-4-amine (<b>49</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 2 using <b>45</b> (25 mg, 0.0705 mmol) and (<i>R</i>)-3-aminotetrahydrofuran HCl (17 mg, 0.141 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>49</b> as a yellow solid in 77% yield (23 mg, 0.054 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.52 (d, <i>J</i> = 1.5 Hz, 1H), 7.29 (s, 1H), 7.26 (dd, <i>J</i> = 11.6, 1.8 Hz, 1H), 3.95–3.90 (m, 1H), 3.85 (dd, <i>J</i> = 8.4, 5.5 Hz, 1H), 3.80–3.69 (m, 3H), 3.59–3.51 (m, 2H), 3.03–2.95 (m, 2H), 2.78–2.67 (m, 3H), 2.51 (s, 3H), 2.16–2.09 (m, 1H), 1.98–1.89 (m, 2H), 1.74–1.67 (m, 1H), 1.64–1.50 (m, 3H), 1.29 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.3, 167.9, 156.9, 156.6 (<i>J</i> = 253.4 Hz), 141.7 (<i>J</i> = 2.9 Hz), 140.7 (<i>J</i> = 6.4 Hz), 137.1 (<i>J</i> = 11.7 Hz), 124.9 (<i>J</i> = 2.8 Hz), 121.5 (<i>J</i> = 3.9 Hz), 117.1 (<i>J</i> = 18.1 Hz), 112.4, 74.0, 67.3, 55.4, 53.5, 49.02, 49.00, 33.8, 32.71, 32.69, 28.7, 15.3, 11.9. HRMS (ESI-TOF) calcd for C<sub>23</sub>H<sub>28</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 426.23, found 426.2310.</div></div><div id="sec4_13_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Synthesis of (<i>S</i>)-1-(6-Ethyl-8-fluoro-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydrofuran-3-yl)piperidin-4-amine (<b>50</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 2 using <b>45</b> (25 mg, 0.075 mmol) and (<i>S</i>)-3-aminotetrahydrofuran p-toluenesulfonate (36.6 mg, 0.141 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–10% MeOH) to give <b>50</b> as a yellow solid in 78% yield (25 mg, 0.0587 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.52 (d, <i>J</i> = 1.4 Hz, 1H), 7.29 (s, 1H), 7.25 (dd, <i>J</i> = 11.6, 1.6 Hz, 1H) 3.95–3.89 (m, 1H), 3.85 (dd, <i>J</i> = 8.5, 5.7 Hz, 1H), 3.80–3.69 (m, 3H), 3.58–3.51 (m, 2H), 3.02–2.95 (m, 2H), 2.78–2.67 (m, 3H), 2.51 (s, 3H), 2.16–2.08 (m, 1H), 1.98–1.89 (m, 2H), 1.74–1.66 (m, 1H), 1.64–1.53 (m, 2H), 1.46 (br s, 1H), 1.29 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.3, 167.9, 156.9, 156.6 (<i>J</i> = 253.5 Hz), 141.7 (<i>J</i> = 3.0 Hz), 140.7 (<i>J</i> = 6.3 Hz), 137.1 (<i>J</i> = 11.6 Hz), 124.9 (<i>J</i> = 2.9 Hz), 121.5 (<i>J</i> = 3.9 Hz), 117.1 (<i>J</i> = 18.1 Hz), 112.4, 74.0, 67.3, 55.4, 53.5, 49.01, 48.99, 33.8, 32.71, 32.69, 28.7, 15.3, 11.9. HRMS (ESI-TOF) calcd for C<sub>23</sub>H<sub>28</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 426.23, found 426.2307.</div></div><div id="sec4_13_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Synthesis of 4-Ethyl-2-fluoro-6-iodoaniline (<b>52</b>)</h4><div class="NLM_p last">To a mixture of <b>51</b> (9.8 g, 70.4 mmol) in acetic acid (110 mL) was added in a single portion NIS (16.63 g, 73.93 mmol), and the mixture was stirred at rt for 1 h. The mixture was diluted with EtOAc (800 mL) and washed with brine (×3) and satd aq NaHCO<sub>3</sub> solution (× 2). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The product was purified by column chromatography using hexanes/EtOAc (0–20% EtOAc) as mobile phase. <b>52</b> was obtained as reddish oil in 94% yield (17.5 g, 66.04 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.25 (s, 1H), 6.82 (dd, <i>J</i> = 11.6, 1.8 Hz, 1H), 3.98 (br s, 2H), 2.51 (q, <i>J</i> = 7.6 Hz, 2H), 1.17 (t, <i>J</i> = 7.6 Hz, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 149.9 (<i>J</i> = 241.7 Hz), 136.1 (<i>J</i> = 6.3 Hz), 133.7 (<i>J</i> = 14.1 Hz), 132.9 (<i>J</i> = 3.0 Hz), 114.8 (<i>J</i> = 18.7 Hz), 84.1, 27.5, 15.5. LCMS: (M + 1) <i>m</i>/<i>z</i> = 265.</div></div><div id="sec4_13_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Synthesis of 1-(2-Amino-5-ethyl-3-fluorophenyl)ethanone (<b>54</b>)</h4><div class="NLM_p last">A mixture of <b>52</b> (17.5 g, 66.02 mmol), <b>53</b> (35.5 mL, 396 mmol), K<sub>2</sub>CO<sub>3</sub> (10.95 g, 79.2 mmol), DPPP (1.31 g, 3.3 mmol), and Pd(OAc)<sub>2</sub> (161 mg, 0.66 mmol) in H<sub>2</sub>O/toluene (9:1, 200 mL) was heated at 90 °C for 32 h. After the mixture was cooled to rt, concentrated HCl (33 mL) was slowly added, and the mixture was stirred at rt for 1 h. The mixture was neutralized with satd aq NaHCO<sub>3</sub> solution. The product was extracted with EtOAc (3 × 200 mL). The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The product was purified by column chromatography using hexanes/EtOAc (0–20% EtOAc) and obtained as a pale-yellow solid in 16% yield (1.91 g, 10.5 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.30 (s, 1H), 6.99 (dd, <i>J</i> = 12.0, 1.5 Hz, 1H), 6.14 (br s, 2H), 2.58 (s, 3H), 2.56 (q, <i>J</i> = 7.6 Hz, 2H), 1.21 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 200.5 (<i>J</i> = 2.5 Hz), 151.7 (<i>J</i> = 238.8 Hz), 137.4 (<i>J</i> = 13.4 Hz), 130.6 (<i>J</i> = 6.0 Hz), 125.5 (<i>J</i> = 2.7 Hz), 119.9 (<i>J</i> = 4.1 Hz), 118.6 (<i>J</i> = 17.7 Hz), 28.3, 28.1, 15.8. LCMS: (M + 1) <i>m</i>/<i>z</i> = 182.</div></div><div id="sec4_13_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Synthesis of 5-(2-Chloro-6-ethyl-8-fluoro-4-methylquinolin-3-yl)-3-methyl-1,2,4-oxadiazole (<b>55</b>)</h4><div class="NLM_p last">A mixture of <b>54</b> (400 mg, 2.2 mmol) and <b>42</b> (344 mg, 2.42 mmol) in POCl<sub>3</sub> (5 mL) was stirred at 80 °C for 1 h. The mixture was concentrated under reduced pressure and quenched with ice/H<sub>2</sub>O. The mixture was stirred at rt for 30 min and the solid was collected by filtration. The solid was purified by column chromatography using hexanes/EtOAc (0–30% EtOAc), and the product was obtained as a pale-yellow solid in 40% yield (271 mg, 0.886 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.60 (s, 1H), 7.42 (d, <i>J</i> = 10.8 Hz, 1H), 2.87 (q, <i>J</i> = 7.6 Hz, 2H), 2.58 (s, 3H), 2.57 (s, 3H), 1.35 (t, <i>J</i> = 7.6 Hz, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 172.9, 167.9, 157.3 (<i>J</i> = 255.9 Hz), 149.2 (<i>J</i> = 2.5 Hz), 147.7, 145.0 (<i>J</i> = 6.8 Hz), 136.7 (<i>J</i> = 12.4 Hz), 127.6, 120.2, 118.1 (<i>J</i> = 4.1 Hz), 117.3 (<i>J</i> = 17.8 Hz), 29.5, 17.2, 15.3, 12.0. LCMS: (M + 1) <i>m</i>/<i>z</i> = 306.</div></div><div id="sec4_13_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Synthesis of 8-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane (<b>56</b>)</h4><div class="NLM_p last">To a mixture of <b>55</b> (600 mg, 1.97 mmol), <b>21</b> (366 mg, 12.56 mmol), and DIPEA (687 μL, 3.94 mmol) in EtOH (10 mL) was heated at 110 °C overnight. After cooling to rt, the mixture was concentrated under reduced pressure and purified by column chromatography using hexanes/EtOAc (0–60% EtOAc) to give ketal <b>56</b> as a yellow solid in 93% yield (750 mg, 1.82 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.45 (s, 1H), 7.25 (dd, <i>J</i> = 11.3, 1.7 Hz, 1H), 3.94 (s, 4H), 3.35–3.30 (m, 4H), 2.78 (q, <i>J</i> = 7.6 Hz, 2H), 2.54 (s, 3H), 2.50 (s, 3H), 1.72–1.67 (m, 4H), 1.30 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.4, 167.9, 157.3, 157.2 (<i>J</i> = 252.5 Hz), 147.8 (<i>J</i> = 2.7 Hz), 140.3 (<i>J</i> = 6.7 Hz), 136.4 (<i>J</i> = 11.6 Hz), 125.2 (<i>J</i> = 2.5 Hz), 117.9 (<i>J</i> = 4.0 Hz), 116.1 (<i>J</i> = 18.2 Hz), 113.0, 107.4, 64.4, 47.5, 34.8, 29.2, 16.6, 15.6, 11.9. LCMS: (M + 1) <i>m</i>/<i>z</i> = 413.</div></div><div id="sec4_13_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Synthesis of 1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)piperidin-4-one (<b>57</b>)</h4><div class="NLM_p last">To a solution of ketal <b>56</b> (800 mg, 1.94 mmol) in THF (3 mL), 10% aq H<sub>2</sub>SO<sub>4</sub> (15 mL) was added. The mixture was stirred at 45 °C for 2 h. After cooling to rt, the mixture was neutralized with satd aq Na<sub>2</sub>CO<sub>3</sub> and extracted with EtOAc (3 × 100 mL). The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The product was purified by column chromatography using hexanes/EtOAc (0–60% EtOAc) to give ketone <b>57</b> as a yellow solid in 84% yield (601 mg, 1.63 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.50 (s, 1H), 7.29 (dd, <i>J</i> = 11.2, 1.7 Hz, 1H), 3.55 (t, <i>J</i> = 6.0 Hz, 4H), 2.80 (q, <i>J</i> = 7.6 Hz, 2H), 2.56 (s, 3H), 2.54 (s, 3H), 2.48 (t, <i>J</i> = 5.8 Hz, 4H), 1.31 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 208.3, 175.1, 168.0, 157.2 (<i>J</i> = 253.2 Hz), 156.5, 148.5 (<i>J</i> = 2.7 Hz), 141.1 (<i>J</i> = 6.7 Hz), 136.1 (<i>J</i> = 11.5 Hz), 125.5 (<i>J</i> = 2.4 Hz), 118.0 (<i>J</i> = 4.0 Hz), 116.4 (<i>J</i> = 18.2 Hz), 112.8, 48.9, 41.2, 29.3, 16.7, 15.6, 12.0. LCMS: (M + 1) <i>m</i>/<i>z</i> = 369.</div></div><div id="sec4_13_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Synthesis of 1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-yl)piperidin-4-amine (<b>58</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 1 using <b>57</b> (800 mg, 2.17 mmol) and 4-aminotetrahydropyran (337 μL, 3.26 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–8% MeOH) to give <b>58</b> as a yellow solid in 75% yield (740 mg, 1.63 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.45 (s, 1H), 7.25 (dd, <i>J</i> = 11.3, 1.7 Hz, 1H), 3.98–3.93 (m, 2H), 3.60–3.54 (m, 2H), 3.41–3.34 (m, 2H), 2.91–2.72 (m, 6H), 2.54 (s, 3H), 2.49 (s, 3H), 1.85–1.75 (m, 4H), 1.46 (br s, 1H), 1.41–1.25 (m, 8H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.4, 167.8, 157.8, 157.1 (<i>J</i> = 252.3 Hz), 147.8 (<i>J</i> = 2.6 Hz), 140.4 (<i>J</i> = 6.8 Hz), 136.4 (<i>J</i> = 11.5 Hz), 125.3 (<i>J</i> = 2.5 Hz), 118.0 (<i>J</i> = 4.0 Hz), 116.1 (<i>J</i> = 18.3 Hz), 113.3, 67.1, 51.0, 50.3, 48.6, 34.4, 33.0, 29.2, 16.6, 15.6, 12.0. HRMS (ESI-TOF) calcd for C<sub>25</sub>H<sub>32</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 454.2613, found 454.2623.</div></div><div id="sec4_13_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Synthesis of (<i>R</i>)-1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-3-yl)piperidin-4-amine (<b>59</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 2 using <b>57</b> (30 mg, 0.081 mmol) and (<i>R</i>)-3-aminotetrahydropyran HCl (22.4 mg, 0.162 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–8% MeOH) to give <b>59</b> as a yellow solid in 84% yield (31 mg, 0.068 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.45 (s, 1H), 7.25 (dd, <i>J</i> = 11.2, 1.7 Hz, 1H), 3.87–3.82 (m, 1H), 3.79–3.74 (m, 1H), 3.60–3.52 (m, 2H), 3.42–3.36 (m, 1H), 3.12 (dd, <i>J</i> = 11.0, 8.4 Hz, 1H), 2.91–2.83 (m, 2H), 2.80–2.71 (m, 3H), 2.71–2.64 (m, 1H), 2.54 (s, 3H), 2.49 (s, 3H), 1.94–1.88 (m, 1H), 1.86–1.74 (m, 2H), 1.70–1.54 (m, 2H), 1.35–1.26 (m, 7H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.4, 167.8, 157.8, 157.1 (<i>J</i> = 252.3 Hz), 147.7 (<i>J</i> = 2.7 Hz), 140.4 (<i>J</i> = 6.6 Hz), 136.4 (<i>J</i> = 11.4 Hz), 125.2 (<i>J</i> = 2.5 Hz), 118.0 (<i>J</i> = 3.9 Hz), 116.1 (<i>J</i> = 18.3 Hz), 113.3, 73.1, 68.3, 52.0, 50.1, 48.57, 48.50, 33.1, 33.0, 30.9, 29.2, 24.8, 16.6, 15.6, 12.0. HRMS (ESI-TOF) calcd for C<sub>25</sub>H<sub>32</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 454.2613, found 454.2625.</div></div><div id="sec4_13_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Synthesis of (<i>S</i>)-1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-3-yl)piperidin-4-amine (<b>60</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 2 using <b>57</b> (30 mg, 0.081 mmol) and (<i>S</i>)-3-aminotetrahydropyran·HCl (22.4 mg, 0.162 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–8% MeOH) to give <b>60</b> as a yellow solid in 79% yield (29 mg, 0.063 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.45 (s, 1H), 7.25 (dd, <i>J</i> = 11.4, 1.7 Hz, 1H), 3.87–3.82 (m, 1H), 3.80–3.74 (m, 1H), 3.61–3.52 (m, 2H), 3.42–3.36 (m, 1H), 3.12 (dd, <i>J</i> = 11.0, 8.4 Hz, 1H), 2.91–2.83 (m, 2H), 2.80–2.64 (m, 4H), 2.54 (s, 3H), 2.49 (s, 3H), 1.94–1.88 (m, 1H), 1.86–1.74 (m, 2H), 1.70–1.54 (m, 2H), 1.36–1.25 (m, 7H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.4, 167.8, 157.8, 157.1 (<i>J</i> = 252.5 Hz), 147.7 (<i>J</i> = 2.5 Hz), 140.4 (<i>J</i> = 6.7 Hz), 136.4 (<i>J</i> = 11.3 Hz), 125.2 (<i>J</i> = 2.5 Hz), 118.0 (<i>J</i> = 3.8 Hz), 116.1 (<i>J</i> = 18.3 Hz), 113.3, 73.1, 68.3, 52.0, 50.1, 48.57, 48.50, 33.1, 33.0, 30.9, 29.2, 24.8, 16.6, 15.6, 12.0. HRMS (ESI-TOF) calcd for C<sub>25</sub>H<sub>32</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 454.2613, found 454.2623.</div></div><div id="sec4_13_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Synthesis of (<i>R</i>)-1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydrofuran-3-yl)piperidin-4-amine (<b>61</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 2 using <b>57</b> (30 mg, 0.081 mmol) and (<i>R</i>)-3-aminotetrahydrofuran HCl (20 mg, 0.162 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–8% MeOH) to give <b>61</b> as a yellow solid in 73% yield (26 mg, 0.059 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.45 (s, 1H), 7.25 (dd, <i>J</i> = 11.3, 1.7 Hz, 1H), 3.93–3.87 (m, 1H), 3.84–3.79 (m, 1H), 3.78–3.72 (m, 1H), 3.61–3.54 (m, 2H), 3.54–3.47 (m, 2H), 2.91–2.84 (m, 2H), 2.77 (q, <i>J</i> = 7.6 Hz, 2H), 2.64–2.58 (m, 1H), 2.54 (s, 3H), 2.49 (s, 3H), 2.13–2.05 (m, 1H), 1.86–1.78 (m, 2H), 1.70–1.63 (m, 1H), 1.37–1.25 (m, 6H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.4, 167.8, 157.8, 157.1 (<i>J</i> = 252.3 Hz), 147.8 (<i>J</i> = 2.6 Hz), 140.4 (<i>J</i> = 6.7 Hz), 136.4 (<i>J</i> = 11.4 Hz), 125.2 (<i>J</i> = 2.4 Hz), 118.0 (<i>J</i> = 3.9 Hz), 116.1 (<i>J</i> = 18.3 Hz), 113.3, 74.0, 67.3, 55.4, 53.5, 48.56, 48.55, 33.7, 32.8, 29.2, 16.6, 15.6, 12.0. HRMS (ESI-TOF) calcd for C<sub>24</sub>H<sub>30</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 440.2456, found 440.2467.</div></div><div id="sec4_13_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Synthesis of (<i>S</i>)-1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-<i>N</i>-(tetrahydrofuran-3-yl)piperidin-4-amine (<b>62</b>)</h4><div class="NLM_p last">Prepared according to the general procedure 2 using <b>57</b> (20 mg, 0.054 mmol) and (<i>S</i>)-3-aminotetrahydrofuran <i>p</i>-toluenesulfonate (21 mg, 0.081 mmol) with purification on silica gel column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (0–8% MeOH) to give <b>62</b> as a yellow solid in 73% yield (17.5 mg, 0.0398 mmol). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.45 (s, 1H), 7.25 (dd, <i>J</i> = 11.3, 1.6 Hz, 1H), 3.92–3.87 (m, 1H), 3.83–3.79 (m, 1H), 3.77–3.71 (m, 1H), 3.60–3.53 (m, 2H), 3.52–3.46 (m, 2H), 2.90–2.83 (m, 2H), 2.76 (q, <i>J</i> = 7.6 Hz, 2H), 2.64–2.57 (m, 1H), 2.54 (s, 3H), 2.49 (s, 3H), 2.13–2.05 (m, 1H), 1.86–1.76 (m, 2H), 1.70–1.62 (m, 1H), 1.37–1.25 (m, 6H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 175.4, 167.7, 157.8, 157.1 (<i>J</i> = 252.2 Hz), 147.7 (<i>J</i> = 2.7 Hz), 140.4 (<i>J</i> = 6.8 Hz), 136.4 (<i>J</i> = 11.4 Hz), 125.2 (<i>J</i> = 2.5 Hz), 118.0 (<i>J</i> = 3.8 Hz), 116.1 (<i>J</i> = 18.4 Hz), 113.3, 74.0, 67.3, 55.4, 53.5, 48.55, 48.53, 33.7, 32.8, 29.2, 16.6, 15.6, 11.9. HRMS (ESI-TOF) calcd for C<sub>24</sub>H<sub>30</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 440.2456, found 440.2465.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> General Method for the Preparation of Monotartrate Salts</h4><div class="NLM_p last">To a solution of <span class="smallcaps smallerCapital">l</span>-(+)-tartaric acid (342 mg, 2.27 mmol) in DI water (3 mL) was added a solution <b>58</b> (1.032g, 2.27 mmol) in EtOH (3 mL). The mixture was stirred at rt for 1 h and concentrated under reduced pressure. The solid was dried under reduced pressure overnight.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01679" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48877" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48877" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01679" class="ext-link">10.1021/acs.jmedchem.8b01679</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental details of the ADME/PK and off-target studies; plasma protein and brain tissue binding; microsomal stability; hepatocyte stability; MDCK-MDR1 or Caco-2 cell permeability and efflux assay; kinetic solubility; off-target selectivity; safety off-target panels; ion channel inhibition and functional hERG; cytochrome P450 (Cyp) inhibition; screening bacterial reverse mutation tests in <i>Salmonella typhimurium</i> and <i>Escherichia coli</i> (Ames); pharmacokinetic analysis (brain and plasma) (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf">jm8b01679_si_001.pdf (165.97 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_002.csv">jm8b01679_si_002.csv (2.77 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01679" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78102" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78102" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edward Roberts</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Medicine, The Scripps Research
Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5587-8174" title="Orcid link">http://orcid.org/0000-0002-5587-8174</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6c091e030e091e181f2c1f0f1e051c1c1f42090819"><span class="__cf_email__" data-cfemail="7a1f0815181f080e093a091908130a0a09541f1e0f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Miguel Guerrero</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Medicine, The Scripps Research
Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6137-8072" title="Orcid link">http://orcid.org/0000-0001-6137-8072</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mariangela Urbano</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Medicine, The Scripps Research
Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eun-Kyong Kim</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Medicine, The Scripps Research
Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ana M. Gamo</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Medicine, The Scripps Research
Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sean Riley</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Medicine, The Scripps Research
Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lusine Abgaryan</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Medicine, The Scripps Research
Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nora Leaf</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Medicine, The Scripps Research
Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lori Jean Van Orden</span> - <span class="hlFld-Affiliation affiliation">BlackThorn
Therapeutics, Inc. 780 Brannan Street, San Francisco, California 94103, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven J. Brown</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Medicine, The Scripps Research
Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7354-1612" title="Orcid link">http://orcid.org/0000-0002-7354-1612</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Y. Xie</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, University of Arizona, Tucson, Arizona 85724, United States</span>; 
    <span>Present Address:
                        For J.Y.X.: Department of Basic Sciences, New York Institute of Technology College of Osteopathic Medicine at Arkansas State University, Jonesboro, Arkansas 72446, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frank Porreca</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, University of Arizona, Tucson, Arizona 85724, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael D. Cameron</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Medicine, The Scripps Research
Institute, Jupiter, Florida 33458, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hugh Rosen</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Medicine, The Scripps Research
Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): ER and HR are advisors to Blackthorn therapeutics and may receive compensation in stock and/or monetary payment.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00783" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00783" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Ronald B. Franklin and Paul C. Anderson for insightful scientific consultation during the course of the project and for their help in preparing the manuscript. This work was supported by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) and BlackThorn Therapeutics. The grant is funded as part of the Blueprint Neurotherapeutics Network (BPN) of the NIH Blueprint for Neuroscience Research grant 1UH2 NS093030-01 (Edward Roberts, Hugh Rosen, Frank Porreca).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">ADMET</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, excretion, and toxicity</p></td></tr><tr><td class="NLM_term">AUC<sub>0–<i>t</i></sub></td><td class="NLM_def"><p class="first last">area under the plasma concentration–time curve from time zero to time <i>t</i></p></td></tr><tr><td class="NLM_term">AUC<sub>0–∞</sub></td><td class="NLM_def"><p class="first last">area under the plasma concentration–time curve from time 0 extrapolated to infinite time</p></td></tr><tr><td class="NLM_term">BH<sub>3</sub>-THF</td><td class="NLM_def"><p class="first last">borane–tetrahydrofuran</p></td></tr><tr><td class="NLM_term">Cav1.2</td><td class="NLM_def"><p class="first last">L-type voltage-gated calcium channel 1.2</p></td></tr><tr><td class="NLM_term">Cbz</td><td class="NLM_def"><p class="first last">carboxybenzyl</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">Cl<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">cLogP</td><td class="NLM_def"><p class="first last">calculated logarithm of the partition coefficient between <i>n</i>-octanol and water</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum observed plasma concentration</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">cp<i>K</i><sub>a</sub></td><td class="NLM_def"><p class="first last">calculated p<i>K</i><sub>a</sub></p></td></tr><tr><td class="NLM_term">CSF</td><td class="NLM_def"><p class="first last">cerebrospinal fluid</p></td></tr><tr><td class="NLM_term">CYP1A2</td><td class="NLM_def"><p class="first last">cytochrome P450 1A2</p></td></tr><tr><td class="NLM_term">CYP3A4</td><td class="NLM_def"><p class="first last">cytochrome P450 3A4</p></td></tr><tr><td class="NLM_term">CYP2C9</td><td class="NLM_def"><p class="first last">cytochrome P450 2C9</p></td></tr><tr><td class="NLM_term">CYP2D6</td><td class="NLM_def"><p class="first last">cytochrome P450 2D6</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DNA</td><td class="NLM_def"><p class="first last">deoxyribonucleic acid</p></td></tr><tr><td class="NLM_term">DOR</td><td class="NLM_def"><p class="first last">delta opioid receptor</p></td></tr><tr><td class="NLM_term">DPPP</td><td class="NLM_def"><p class="first last">1,3-bis(diphenylphosphino)propane</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">3-(ethyliminomethyleneamino)-<i>N</i>,<i>N</i>-dimethylpropan-1-amine</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">GPCRs</td><td class="NLM_def"><p class="first last">G protein-coupled receptors</p></td></tr><tr><td class="NLM_term">HCN4</td><td class="NLM_def"><p class="first last">potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high-resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">ip</td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous dosing</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">50% inhibitory concentration</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>i</sub></td><td class="NLM_def"><p class="first last">binding affinity</p></td></tr><tr><td class="NLM_term">Kir2.1</td><td class="NLM_def"><p class="first last">inward-rectifying voltage-gated potassium 2.1</p></td></tr><tr><td class="NLM_term">KOR</td><td class="NLM_def"><p class="first last">kappa opioid receptor</p></td></tr><tr><td class="NLM_term">MDD</td><td class="NLM_def"><p class="first last">major depressive disorder</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">MHz</td><td class="NLM_def"><p class="first last">megahertz</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsomes</p></td></tr><tr><td class="NLM_term">MLSMR</td><td class="NLM_def"><p class="first last">Molecular Libraries–Small Molecule Repository</p></td></tr><tr><td class="NLM_term">MOR</td><td class="NLM_def"><p class="first last">mu opioid receptor</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">mw</td><td class="NLM_def"><p class="first last">microwave</p></td></tr><tr><td class="NLM_term">Nav1.5</td><td class="NLM_def"><p class="first last">voltage-gated sodium channel type 5</p></td></tr><tr><td class="NLM_term">NDA</td><td class="NLM_def"><p class="first last">new drug application</p></td></tr><tr><td class="NLM_term">nM</td><td class="NLM_def"><p class="first last">nanomolar</p></td></tr><tr><td class="NLM_term">ORL-1</td><td class="NLM_def"><p class="first last">opioid receptor like</p></td></tr><tr><td class="NLM_term">p<i>K</i><sub>a</sub></td><td class="NLM_def"><p class="first last">negative base-10 logarithm of the acid dissociation constant</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">oral administration</p></td></tr><tr><td class="NLM_term">Pd(dppf)Cl<sub>2</sub> DCM</td><td class="NLM_def"><p class="first last">[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane</p></td></tr><tr><td class="NLM_term">ppm</td><td class="NLM_def"><p class="first last">parts per million</p></td></tr><tr><td class="NLM_term">PRL</td><td class="NLM_def"><p class="first last">prolactin</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsomes</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">S<sub>N</sub>Ar</td><td class="NLM_def"><p class="first last">nucleophilic aromatic substitution</p></td></tr><tr><td class="NLM_term">S9</td><td class="NLM_def"><p class="first last">rat hepatic S9 fractions</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyran</p></td></tr><tr><td class="NLM_term">TIDA</td><td class="NLM_def"><p class="first last">tuberoinfundibular dopaminergic</p></td></tr><tr><td class="NLM_term">tPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">steady-state volume of distribution</p></td></tr><tr><td class="NLM_term">μM</td><td class="NLM_def"><p class="first last">micromolar</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55116" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55116" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagerström, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundin, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiöth, H. B.</span></span> <span> </span><span class="NLM_article-title">The G-protein-coupled receptors in the human genome form five main families. phylogenetic analysis, paralogon groups, and fingerprints</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1272</span>, <span class="refDoi"> DOI: 10.1124/mol.63.6.1256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1124%2Fmol.63.6.1256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=12761335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Shu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=1256-1272&author=R.+Fredrikssonauthor=M.+C.+Lagerstr%C3%B6mauthor=L.+G.+Lundinauthor=H.+B.+Schi%C3%B6th&title=The+G-protein-coupled+receptors+in+the+human+genome+form+five+main+families.+phylogenetic+analysis%2C+paralogon+groups%2C+and+fingerprints&doi=10.1124%2Fmol.63.6.1256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints</span></div><div class="casAuthors">Fredriksson, Robert; Lagerstrom, Malin C.; Lundin, Lars-Gustav; Schioth, Helgi B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1256-1272</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The superfamily of G-protein-coupled receptors (GPCRs) is very diverse in structure and function and its members are among the most pursued targets for drug development.  We identified more than 800 human GPCR sequences and simultaneously analyzed 342 unique functional nonolfactory human GPCR sequences with phylogenetic analyses.  Our results show, with high bootstrap support, five main families, named glutamate, rhodopsin, adhesion, frizzled/taste2, and secretin, forming the GRAFS classification system.  The rhodopsin family is the largest and forms four main groups with 13 subbranches.  Positions of the GPCRs in chromosomal paralogons regions indicate the importance of tetraploidizations or local gene duplication events for their creation.  We also searched for "fingerprint" motifs using Hidden Markov Models delineating the putative inter-relationship of the GRAFS families.  We show several common structural features indicating that the human GPCRs in the GRAFS families share a common ancestor.  This study represents the first overall map of the GPCRs in a single mammalian genome.  Our novel approach of analyzing such large and diverse sequence sets may be useful for studies on GPCRs in other genomes and divergent protein families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdX4VhTsaDzrVg90H21EOLACvtfcHk0lgSzgvbiaETjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Shu7k%253D&md5=504ea873ee8469cd0b6016bc94943836</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fmol.63.6.1256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.63.6.1256%26sid%3Dliteratum%253Aachs%26aulast%3DFredriksson%26aufirst%3DR.%26aulast%3DLagerstr%25C3%25B6m%26aufirst%3DM.%2BC.%26aulast%3DLundin%26aufirst%3DL.%2BG.%26aulast%3DSchi%25C3%25B6th%26aufirst%3DH.%2BB.%26atitle%3DThe%2520G-protein-coupled%2520receptors%2520in%2520the%2520human%2520genome%2520form%2520five%2520main%2520families.%2520phylogenetic%2520analysis%252C%2520paralogon%2520groups%252C%2520and%2520fingerprints%26jtitle%3DMol.%2520Pharmacol.%26date%3D2003%26volume%3D63%26spage%3D1256%26epage%3D1272%26doi%3D10.1124%2Fmol.63.6.1256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldhoer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whistler, J. L.</span></span> <span> </span><span class="NLM_article-title">Opioid receptors</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">990</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.73.011303.073940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1146%2Fannurev.biochem.73.011303.073940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=15189164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslagsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2004&pages=953-990&author=M.+Waldhoerauthor=S.+E.+Bartlettauthor=J.+L.+Whistler&title=Opioid+receptors&doi=10.1146%2Fannurev.biochem.73.011303.073940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid receptors</span></div><div class="casAuthors">Waldhoer, Maria; Bartlett, Selena E.; Whistler, Jennifer L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">953-990</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Opioid receptors belong to the large superfamily of 7 transmembrane-spanning (7TM) G protein-coupled receptors (GPCRs).  As a class, GPCRs are of fundamental physiol. importance mediating the actions of the majority of known neurotransmitters and hormones.  Opioid receptors are particularly intriguing members of this receptor family.  They are activated both by endogenously produced opioid peptides and by exogenously administered opiate compds., some of which are not only among the most effective analgesics known but also highly addictive drugs of abuse.  A fundamental question in addiction biol. is why exogenous opioid drugs, such as morphine and heroin, have a high liability for inducing tolerance, dependence, and addiction.  This review focuses on many aspects of opioid receptors with the aim of gaining a greater insight into mechanisms of opioid tolerance and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSV3Nl3WDHrVg90H21EOLACvtfcHk0lgTke9o36askg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslagsbs%253D&md5=9f865544116a6dac76c80432587180a3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.73.011303.073940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.73.011303.073940%26sid%3Dliteratum%253Aachs%26aulast%3DWaldhoer%26aufirst%3DM.%26aulast%3DBartlett%26aufirst%3DS.%2BE.%26aulast%3DWhistler%26aufirst%3DJ.%2BL.%26atitle%3DOpioid%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2004%26volume%3D73%26spage%3D953%26epage%3D990%26doi%3D10.1146%2Fannurev.biochem.73.011303.073940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, A.</span></span> <span> </span><span class="NLM_article-title">Dynorphin is a specific endogenous ligand of the kappa opioid receptor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1126/science.6120570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1126%2Fscience.6120570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=6120570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaL38XhtFKntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=1982&pages=413-415&author=C.+Chavkinauthor=I.+F.+Jamesauthor=A.+Goldstein&title=Dynorphin+is+a+specific+endogenous+ligand+of+the+kappa+opioid+receptor&doi=10.1126%2Fscience.6120570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Dynorphin is a specific endogenous ligand of the κ opioid receptor</span></div><div class="casAuthors">Chavkin, Charles; James, Iain F.; Goldstein, Avram</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue">4531</span>),
    <span class="NLM_cas:pages">413-15</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">In the guinea pig ileum myenteric plexus-longitudinal muscle prepn., dynorphin-(1-13)  [72957-38-1] and the prototypical κ agonist ethylketocyclazocine had equally poor sensitivity to naloxone antagonism and showed selective cross protection in receptor inactivation expts. with the alkylating antagonist β-chlornaltrexamine.  In binding assays with membranes from guinea pig brain, ethylketocyclazocine and dynorphin-(1-13) amide  [79515-34-7] were more potent in displacing tritium labeled ethylketocyclazocine than in displacing typical μ and δ opioid receptor ligands.  In the two prepns. studied, the dynorphin receptor appears to be the same as the κ opioid receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0CJdDpQ9ourVg90H21EOLACvtfcHk0lgTke9o36askg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XhtFKntbc%253D&md5=90f2695917a67dba88463f0673eb16c5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.6120570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.6120570%26sid%3Dliteratum%253Aachs%26aulast%3DChavkin%26aufirst%3DC.%26aulast%3DJames%26aufirst%3DI.%2BF.%26aulast%3DGoldstein%26aufirst%3DA.%26atitle%3DDynorphin%2520is%2520a%2520specific%2520endogenous%2520ligand%2520of%2520the%2520kappa%2520opioid%2520receptor%26jtitle%3DScience%26date%3D1982%26volume%3D215%26spage%3D413%26epage%3D415%26doi%3D10.1126%2Fscience.6120570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruchas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Land, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span> <span> </span><span class="NLM_article-title">The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1314</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2009.08.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2Fj.brainres.2009.08.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=19716811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlelsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1314&publication_year=2010&pages=44-55&author=M.+R.+Bruchasauthor=B.+B.+Landauthor=C.+Chavkin&title=The+dynorphin%2Fkappa+opioid+system+as+a+modulator+of+stress-induced+and+pro-addictive+behaviors&doi=10.1016%2Fj.brainres.2009.08.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors</span></div><div class="casAuthors">Bruchas, M. R.; Land, B. B.; Chavkin, C.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1314</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">44-55</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Stress is a complex experience that carries both aversive and motivating properties.  Chronic stress causes an increase in the risk of depression, is well known to increase relapse of drug seeking behavior, and can adversely impact health.  Several brain systems have been demonstrated to be crit. in mediating the neg. affect assocd. with stress, and recent evidence directly links the actions of the endogenous opioid neuropeptide dynorphin in modulating mood and increasing the rewarding effects of abused drugs.  These results suggest that activation of the dynorphin/kappa opioid receptor (KOR) system is likely to play a major role in the pro-addictive effects of stress.  This review explores the relationship between dynorphin and corticotropin-releasing factor (CRF) in the induction of dysphoria, the potentiation of drug seeking, and stress-induced reinstatement.  We also provide an overview of the signal transduction events responsible for CRF and dynorphin/KOR-dependent behaviors.  Understanding the recent work linking activation of CRF and dynorphin/KOR systems and their specific roles in brain stress systems and behavioral models of addiction provides novel insight to neuropeptide systems that regulate affective state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWddx4_zzq3LVg90H21EOLACvtfcHk0lgTke9o36askg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlelsL8%253D&md5=bfe759208b7a72a43fe30ddc806758a1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2009.08.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2009.08.062%26sid%3Dliteratum%253Aachs%26aulast%3DBruchas%26aufirst%3DM.%2BR.%26aulast%3DLand%26aufirst%3DB.%2BB.%26aulast%3DChavkin%26aufirst%3DC.%26atitle%3DThe%2520dynorphin%252Fkappa%2520opioid%2520system%2520as%2520a%2520modulator%2520of%2520stress-induced%2520and%2520pro-addictive%2520behaviors%26jtitle%3DBrain%2520Res.%26date%3D2010%26volume%3D1314%26spage%3D44%26epage%3D55%26doi%3D10.1016%2Fj.brainres.2009.08.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simonin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavériaux-Ruff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Befort, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micheletti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattéi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, B.</span></span> <span> </span><span class="NLM_article-title">Kappa-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">7006</span>– <span class="NLM_lpage">7010</span>, <span class="refDoi"> DOI: 10.1073/pnas.92.15.7006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1073%2Fpnas.92.15.7006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=7006-7010&author=F.+Simoninauthor=C.+Gav%C3%A9riaux-Ruffauthor=K.+Befortauthor=H.+Matthesauthor=B.+Lannesauthor=G.+Michelettiauthor=M.+G.+Matt%C3%A9iauthor=G.+Charronauthor=B.+Blochauthor=B.+Kieffer&title=Kappa-opioid+receptor+in+humans%3A+cDNA+and+genomic+cloning%2C+chromosomal+assignment%2C+functional+expression%2C+pharmacology%2C+and+expression+pattern+in+the+central+nervous+system&doi=10.1073%2Fpnas.92.15.7006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1073%2Fpnas.92.15.7006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.92.15.7006%26sid%3Dliteratum%253Aachs%26aulast%3DSimonin%26aufirst%3DF.%26aulast%3DGav%25C3%25A9riaux-Ruff%26aufirst%3DC.%26aulast%3DBefort%26aufirst%3DK.%26aulast%3DMatthes%26aufirst%3DH.%26aulast%3DLannes%26aufirst%3DB.%26aulast%3DMicheletti%26aufirst%3DG.%26aulast%3DMatt%25C3%25A9i%26aufirst%3DM.%2BG.%26aulast%3DCharron%26aufirst%3DG.%26aulast%3DBloch%26aufirst%3DB.%26aulast%3DKieffer%26aufirst%3DB.%26atitle%3DKappa-opioid%2520receptor%2520in%2520humans%253A%2520cDNA%2520and%2520genomic%2520cloning%252C%2520chromosomal%2520assignment%252C%2520functional%2520expression%252C%2520pharmacology%252C%2520and%2520expression%2520pattern%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1995%26volume%3D92%26spage%3D7006%26epage%3D7010%26doi%3D10.1073%2Fpnas.92.15.7006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hille, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, P.</span></span> <span> </span><span class="NLM_article-title">Subtraction autoradiography of opiate receptor subtypes in human brain</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>418</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(87)90101-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2F0006-8993%2887%2990101-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=2823963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaL2sXlt1Omtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=418&publication_year=1987&pages=343-348&author=A.+J.+Crossauthor=C.+Hilleauthor=P.+Slater&title=Subtraction+autoradiography+of+opiate+receptor+subtypes+in+human+brain&doi=10.1016%2F0006-8993%2887%2990101-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Subtraction autoradiography of opiate receptor subtypes in human brain</span></div><div class="casAuthors">Cross, Alan J.; Hille, Christopher; Slater, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">418</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">343-8</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">Opiate-binding sites in sections of human brain were labeled with [3H]etorphine.  Many brain areas contained high levels of [3H]etorphine-binding sites, although the globus pallidus was an exception.  Subtraction autoradiog. was performed using selective displacement of [3H]etorphine with opioid agonists to visualize μ-, δ-, and κ-opiate receptor subtypes.  μ-Receptors were most abundant the thalamus, caudate nucleus, putamen, and the superficial layers of the cerebral cortex.  Kappa receptors were concd. in the high concns. of endogenous opioid peptides have many receptors, but in other areas, for example the globus pallidus, there is a mismatch between peptide concn. and receptor d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSK2XSEJMouLVg90H21EOLACvtfcHk0lhoJ1NPP5oeyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXlt1Omtbw%253D&md5=befc9ea332b946f9eb3754c30116f85f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2887%2990101-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252887%252990101-6%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DA.%2BJ.%26aulast%3DHille%26aufirst%3DC.%26aulast%3DSlater%26aufirst%3DP.%26atitle%3DSubtraction%2520autoradiography%2520of%2520opiate%2520receptor%2520subtypes%2520in%2520human%2520brain%26jtitle%3DBrain%2520Res.%26date%3D1987%26volume%3D418%26spage%3D343%26epage%3D348%26doi%3D10.1016%2F0006-8993%2887%2990101-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belcheva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coscia, C. J.</span></span> <span> </span><span class="NLM_article-title">Opioid receptor density changes in Alzheimer amygdala and putamen</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>632</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(93)91155-L</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2F0006-8993%2893%2991155-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=8149229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVeru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=632&publication_year=1993&pages=209-215&author=J.+Bargauthor=M.+Belchevaauthor=J.+Rowinskiauthor=A.+Hoauthor=W.+J.+Burkeauthor=H.+D.+Chungauthor=C.+A.+Schmidtauthor=C.+J.+Coscia&title=Opioid+receptor+density+changes+in+Alzheimer+amygdala+and+putamen&doi=10.1016%2F0006-8993%2893%2991155-L"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid receptor density changes in Alzheimer amygdala and putamen</span></div><div class="casAuthors">Barg, Jacob; Belcheva, Mariana; Rowinski, Jan; Ho, Andrew; Burke, William J.; Chung, Hyung. D.; Schmidt, Catherine A.; Coscia, Carmine J.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">632</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">209-15</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">Since opioids can influence the release of acetylcholine, substance P and a no. of other neurotransmitters that have been implicated in the pathogenesis of Alzheimer's disease (AD), it is of interest to assess opioid receptor levels in AD.  The authors have examd. μ, δ and κ opioid receptor binding parameters, binding sensitivity to a GTP analog and distribution in amygdala, frontal cortex and putamen of AD brain.  Control brains were matched according to age, sex, post-mortem interval and storage time.  Kd values and GTP analog binding sensitivity did not differ in AD and control brains.  Bmax values for μ ([3H]DAMGE) sites also appeared unaffected by in vitro binding assays.  In contrast, κ ([3H]U69593) and δ ([3H]DSLET) opioid receptor levels, were significantly changed.  In AD amygdala κ Bmax values increased from control levels of 123±12 to 168±13 fmol/mg protein, whereas densities of κ and δ sites were decreased from 94±8 to 48±8 and 102±3.6 to 69±8.5 fmol/mg protein, resp., in putamen.  Autoradiog. revealed corresponding differences in the distribution of κ opioid receptors.  The findings indicate that the κ binding site, which is quant. the major opioid receptor class in human brain, undergoes marked changes in AD amygdala and putamen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXJPEM61tjN7Vg90H21EOLACvtfcHk0lhoJ1NPP5oeyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVeru7g%253D&md5=27e37d823057e6ddb57d440d326f4e89</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2893%2991155-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252893%252991155-L%26sid%3Dliteratum%253Aachs%26aulast%3DBarg%26aufirst%3DJ.%26aulast%3DBelcheva%26aufirst%3DM.%26aulast%3DRowinski%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DW.%2BJ.%26aulast%3DChung%26aufirst%3DH.%2BD.%26aulast%3DSchmidt%26aufirst%3DC.%2BA.%26aulast%3DCoscia%26aufirst%3DC.%2BJ.%26atitle%3DOpioid%2520receptor%2520density%2520changes%2520in%2520Alzheimer%2520amygdala%2520and%2520putamen%26jtitle%3DBrain%2520Res.%26date%3D1993%26volume%3D632%26spage%3D209%26epage%3D215%26doi%3D10.1016%2F0006-8993%2893%2991155-L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehraein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herz, A.</span></span> <span> </span><span class="NLM_article-title">Opiate receptor binding sites in human brain</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>248</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(82)91150-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2F0006-8993%2882%2991150-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=6289997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaL38XlsFOht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1982&pages=87-96&author=A.+Pfeifferauthor=A.+Pasiauthor=P.+Mehraeinauthor=A.+Herz&title=Opiate+receptor+binding+sites+in+human+brain&doi=10.1016%2F0006-8993%2882%2991150-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Opiate receptor binding sites in human brain</span></div><div class="casAuthors">Pfeiffer, Andreas; Pasi, Aurelio; Mehraein, Parviz; Herz, Albert</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">248</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-96</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">Subclasses of opiate receptor binding sites in human brain membranes were investigated by means of competitive binding techniques.  The exptl. data were analyzed by use of a computerized nonlinear regression curve fitting program.  The μ-, δ-, and κ-types of opiate binding were found in 5 different regions of the brain.  A more extensive anal. of the regional distribution of subclasses of opiate-binding sites was performed using a simple sequential inhibition technique.  This method gave results which were comparable with those obtained by computer anal. of multiple tracer displacement curves.  The κ- and μ-sites represented the major component of binding in most brain areas, whereas δ-sites were fewer in no.  The 3 types of binding showed different distribution patterns, suggesting that they are independent from each other.  The distribution pattern obsd. in human brain resembled the one obsd. in rat brain, although κ-sites appear to represent a more important, and δ-sites appear to represent a less important, fraction of binding in human as compared with rat brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiBdlykH_Ad7Vg90H21EOLACvtfcHk0lgq4nbPXinG0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlsFOht7s%253D&md5=35bb4a70a626234c46fb1df25b07e273</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2882%2991150-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252882%252991150-7%26sid%3Dliteratum%253Aachs%26aulast%3DPfeiffer%26aufirst%3DA.%26aulast%3DPasi%26aufirst%3DA.%26aulast%3DMehraein%26aufirst%3DP.%26aulast%3DHerz%26aufirst%3DA.%26atitle%3DOpiate%2520receptor%2520binding%2520sites%2520in%2520human%2520brain%26jtitle%3DBrain%2520Res.%26date%3D1982%26volume%3D248%26spage%3D87%26epage%3D96%26doi%3D10.1016%2F0006-8993%2882%2991150-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delay-Goyet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javoy-Agid, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agid, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span> <span> </span><span class="NLM_article-title">Regional distribution of μ, δ and κ opioid receptors in human brains from controls and parkinsonian subjects</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>414</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(87)91321-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2F0006-8993%2887%2991321-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=3040166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaL2sXltFeltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=1987&pages=8-14&author=P.+Delay-Goyetauthor=J.+M.+Zajacauthor=F.+Javoy-Agidauthor=Y.+Agidauthor=B.+P.+Roques&title=Regional+distribution+of+%CE%BC%2C+%CE%B4+and+%CE%BA+opioid+receptors+in+human+brains+from+controls+and+parkinsonian+subjects&doi=10.1016%2F0006-8993%2887%2991321-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Regional distribution of μ, δ and κ opioid receptors in human brains from controls and parkinsonian subjects</span></div><div class="casAuthors">Delay-Goyet, P.; Zajac, J. M.; Javoy-Agid, F.; Roques, B. P.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-14</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">The binding properties of μ and δ opioid receptors were investigated in several areas of human brain by using [3H]Tyr-D-Ala-Gly(Me)Phe-Gly-ol and [3H]Tyr-D-Thr-Gly-Phe-Leu-Thr as resp. selective ligands, while the totality of opioid receptors was measured by using [3H]etorphine as a non-selective agonist.  Receptor densities were highest in cerebral cortex, amygdala and striatum, and lowest in the substantia nigra (pars compacta).  In the different brain areas of patients with Parkinson's disease, the d. and the proportion of the various opioid receptors were not significantly different from control subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU5K19hx_b_rVg90H21EOLACvtfcHk0lgq4nbPXinG0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXltFeltb4%253D&md5=0eaa9db177a7cd18996ce0d4efe3d4b0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2887%2991321-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252887%252991321-7%26sid%3Dliteratum%253Aachs%26aulast%3DDelay-Goyet%26aufirst%3DP.%26aulast%3DZajac%26aufirst%3DJ.%2BM.%26aulast%3DJavoy-Agid%26aufirst%3DF.%26aulast%3DAgid%26aufirst%3DY.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26atitle%3DRegional%2520distribution%2520of%2520%25CE%25BC%252C%2520%25CE%25B4%2520and%2520%25CE%25BA%2520opioid%2520receptors%2520in%2520human%2520brains%2520from%2520controls%2520and%2520parkinsonian%2520subjects%26jtitle%3DBrain%2520Res.%26date%3D1987%26volume%3D414%26spage%3D8%26epage%3D14%26doi%3D10.1016%2F0006-8993%2887%2991321-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlezon, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Béguin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNieri, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todtenkopf, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, B. M.</span></span> <span> </span><span class="NLM_article-title">Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">440</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.092304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1124%2Fjpet.105.092304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=16223871" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2005&pages=440-447&author=W.+A.+Carlezonauthor=C.+B%C3%A9guinauthor=J.+A.+DiNieriauthor=M.+H.+Baumannauthor=M.+R.+Richardsauthor=M.+S.+Todtenkopfauthor=R.+B.+Rothmanauthor=Z.+Maauthor=D.+Y.+Leeauthor=B.+M.+Cohen&title=Depressive-like+effects+of+the+kappa-opioid+receptor+agonist+salvinorin+A+on+behavior+and+neurochemistry+in+rats&doi=10.1124%2Fjpet.105.092304"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.092304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.092304%26sid%3Dliteratum%253Aachs%26aulast%3DCarlezon%26aufirst%3DW.%2BA.%26aulast%3DB%25C3%25A9guin%26aufirst%3DC.%26aulast%3DDiNieri%26aufirst%3DJ.%2BA.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DRichards%26aufirst%3DM.%2BR.%26aulast%3DTodtenkopf%26aufirst%3DM.%2BS.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DD.%2BY.%26aulast%3DCohen%26aufirst%3DB.%2BM.%26atitle%3DDepressive-like%2520effects%2520of%2520the%2520kappa-opioid%2520receptor%2520agonist%2520salvinorin%2520A%2520on%2520behavior%2520and%2520neurochemistry%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D316%26spage%3D440%26epage%3D447%26doi%3D10.1124%2Fjpet.105.092304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mague, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pliakas, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todtenkopf, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasiewicz, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlezon, W. A.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>305</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1124/jpet.102.046433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1124%2Fjpet.102.046433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=12649385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1amsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2003&pages=323-330&author=S.+D.+Magueauthor=A.+M.+Pliakasauthor=M.+S.+Todtenkopfauthor=H.+C.+Tomasiewiczauthor=Y.+Zhangauthor=W.+C.+Stevensauthor=R.+M.+Jonesauthor=P.+S.+Portogheseauthor=W.+A.+Carlezon&title=Antidepressant-like+effects+of+kappa-opioid+receptor+antagonists+in+the+forced+swim+test+in+rats&doi=10.1124%2Fjpet.102.046433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats</span></div><div class="casAuthors">Mague, Stephen D.; Pliakas, Andrea M.; Todtenkopf, Mark S.; Tomasiewicz, Hilarie C.; Zhang, Yan; Stevens, William C., Jr.; Jones, Robert M.; Portoghese, Philip S.; Carlezon, William A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">323-330</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We showed previously that cAMP response element-binding protein (CREB) within the nucleus accumbens (NAc) of rats regulates immobility in the forced swim test (FST), an assay used to study depression.  Because CREB regulates expression of dynorphin (which acts at κ-opioid receptors) in NAc neurons, these findings raised the possibility that κ-receptors mediate immobility behaviors in the FST.  Here, we report that i.c.v. administration of the κ-antagonist nor-binaltorphimine dose dependently decreased immobility in the FST, suggesting that it has antidepressant-like effects.  VImplicating a specific effect at κ-receptors, similar antidepressant-like effects were seen after treatment with either of two novel, structurally dissimilar κ-antagonists: 5'-guanidinonaltrindole, which was effective after i.c.v. but not systemic treatment, and 5'-acetamidinoethylnaltrindole (ANTI), which was potent and effective after systemic treatment.  The behavioral effects of the κ-antagonists resembled those of tricyclic antidepressants (desipramine) and selective serotonin reuptake inhibitors (fluoxetine and citalopram).  Conversely, systemic administration of the κ-agonist [5α,7α,8β]-N-methyl-N-[7-[1-pyrrolidinyl]-1-oxaspiro[4.5]dec-8-yl]-benzenacetamide (U-69593) dose dependently increased immobility in the FST, consistent with prodepressant-like effects.  The effects of the κ-ligands in the FST were not correlated with nonspecific effects on locomotor activity.  Furthermore, the most potent and effective κ-antagonist (ANTI) did not affect the rewarding impact of lateral hypothalamic brain stimulation at a dose with strong antidepressant-like effects.  These findings are consistent with the hypothesis that CREB-mediated induction of dynorphin in the NAc "triggers" immobility behavior in the FST.  Furthermore, they raise the possibility that κ-antagonists may have efficacy as antidepressants, but lack stimulant or reward-related effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGRihMkz2i9LVg90H21EOLACvtfcHk0lhfaUbiKqzndA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1amsr8%253D&md5=86513c1a7f214720f5b1920a44a6ee49</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.046433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.046433%26sid%3Dliteratum%253Aachs%26aulast%3DMague%26aufirst%3DS.%2BD.%26aulast%3DPliakas%26aufirst%3DA.%2BM.%26aulast%3DTodtenkopf%26aufirst%3DM.%2BS.%26aulast%3DTomasiewicz%26aufirst%3DH.%2BC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DStevens%26aufirst%3DW.%2BC.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26aulast%3DCarlezon%26aufirst%3DW.%2BA.%26atitle%3DAntidepressant-like%2520effects%2520of%2520kappa-opioid%2520receptor%2520antagonists%2520in%2520the%2520forced%2520swim%2520test%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D305%26spage%3D323%26epage%3D330%26doi%3D10.1124%2Fjpet.102.046433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnakenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skosnik, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Souza, D. C.</span></span> <span> </span><span class="NLM_article-title">Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist salvinorin A in humans</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">879</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2012.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2Fj.biopsych.2012.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=22817868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVyksLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=871-879&author=M.+Ranganathanauthor=A.+Schnakenbergauthor=P.+D.+Skosnikauthor=B.+M.+Cohenauthor=B.+Pittmanauthor=R.+A.+Sewellauthor=D.+C.+D%E2%80%99Souza&title=Dose-related+behavioral%2C+subjective%2C+endocrine%2C+and+psychophysiological+effects+of+the+%CE%BA+opioid+agonist+salvinorin+A+in+humans&doi=10.1016%2Fj.biopsych.2012.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the κ Opioid Agonist Salvinorin A in Humans</span></div><div class="casAuthors">Ranganathan, Mohini; Schnakenberg, Ashley; Skosnik, Patrick D.; Cohen, Bruce M.; Pittman, Brian; Sewell, R. Andrew; D'Souza, Deepak Cyril</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">871-879</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Salvia divinorum (Salvia) is an increasingly popular recreational drug amongst adolescents and young adults.  Its primary active ingredient, Salvinorin A (SA)-a highly selective agonist at the κ opiate receptor-is believed to be one of the most potent naturally occurring hallucinogens.  However, there is little exptl. data on the effects of SA in humans.  In a 3-day, double-blind, randomized, crossover, counterbalanced study, the behavioral, subjective, cognitive, psychophysiol., and endocrine effects of 0 mg, 8 mg, and 12 mg of inhaled SA were characterized in 10 healthy individuals who had previously used Salvia.  SA produced psychotomimetic effects and perceptual alterations, including dissociative and somaesthetic effects, increased plasma cortisol and prolactin, and reduced resting EEG spectral power.  The SA administration was assocd. with a rapid increase of its levels in the blood.  SA did not produce euphoria, cognitive deficits, or changes in vital signs.  The effects were transient and not dose-related.  SA administration was very well-tolerated without acute or delayed adverse effects.  SA produced a wide range of transient effects in healthy subjects.  The perceptual altering effects and lack of euphoric effects would explain its intermittent use pattern.  Such a profile would also suggest a low addictive potential similar to other hallucinogens and consistent with κ opiate receptor agonism.  Further work is warranted to carefully characterize a full spectrum of its effects in humans, to elucidate the underlying mechanisms involved, and to explore the basis for individual variability in its effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8pvfFW2Ay-7Vg90H21EOLACvtfcHk0lhfaUbiKqzndA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVyksLbJ&md5=af0dfe15a1762702d95562692c65a1cc</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2012.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2012.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DRanganathan%26aufirst%3DM.%26aulast%3DSchnakenberg%26aufirst%3DA.%26aulast%3DSkosnik%26aufirst%3DP.%2BD.%26aulast%3DCohen%26aufirst%3DB.%2BM.%26aulast%3DPittman%26aufirst%3DB.%26aulast%3DSewell%26aufirst%3DR.%2BA.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DD.%2BC.%26atitle%3DDose-related%2520behavioral%252C%2520subjective%252C%2520endocrine%252C%2520and%2520psychophysiological%2520effects%2520of%2520the%2520%25CE%25BA%2520opioid%2520agonist%2520salvinorin%2520A%2520in%2520humans%26jtitle%3DBiol.%2520Psychiatry%26date%3D2012%26volume%3D72%26spage%3D871%26epage%3D879%26doi%3D10.1016%2Fj.biopsych.2012.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Lanerolle, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meredith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuteau, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brines, M. L.</span></span> <span> </span><span class="NLM_article-title">Dynorphin and the kappa 1 ligand [3H]u69,593 binding in the human epileptogenic hippocampus</span>. <i>Epilepsy Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/S0920-1211(97)00044-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2FS0920-1211%2897%2900044-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=9332884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaK2sXlvVKlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1997&pages=189-205&author=N.+C.+de%0ALanerolleauthor=A.+Williamsonauthor=C.+Meredithauthor=J.+H.+Kimauthor=H.+Tabuteauauthor=D.+D.+Spencerauthor=M.+L.+Brines&title=Dynorphin+and+the+kappa+1+ligand+%5B3H%5Du69%2C593+binding+in+the+human+epileptogenic+hippocampus&doi=10.1016%2FS0920-1211%2897%2900044-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Dynorphin and the kappa 1 ligand [3H]U69,593 binding in the human epileptogenic hippocampus</span></div><div class="casAuthors">de Lanerolle, N. C.; Williamson, A.; Meredith, C.; Kim, J. H.; Tabuteau, H.; Spencer, D. D.; Brines, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsy Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">189-205</span>CODEN:
                <span class="NLM_cas:coden">EPIRE8</span>;
        ISSN:<span class="NLM_cas:issn">0920-1211</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The distribution of dynorphin (DYN), one of its binding sites (κ1 receptor) and their relationship to neuronal loss and granule cell hyperexcitability was examd. in hippocampi from patients with temporal lobe epilepsy (TLE).  In hippocampi that were not the seizure focus (mass assocd. temporal lobe epilepsy, MaTLE; and paradoxical temporal lobe epilepsy, PTLE) DYN-like immunoreactivity was localized in the dentate granule cells and their mossy fiber terminals within the hilus and area CA3.  In hippocampi that were the seizure focus (MTLE), 89% showed an addnl. band of immunoreactivity confined to the inner mol. layer (IML) of the dentate gyrus, representing recurrent mossy fiber collaterals.  In 11% of MTLE patients no staining was found in the IML (MTLE/DYN-).  The MTLE/DYN- hippocampi were also characterized by a significantly lower degree of cell loss than in MTLE hippocampi in the dentate granule cell layer, the hilus and CA3.  Both MTLE and MTLE/DYN- hippocampi showed evoked epileptiform bursting in granule cells while MTLE showed greater polysynaptic EPSPs and spontaneous excitatory activity.  Thus, granule cell recurrent collateral sprouting may account for only some aspects of hyperexcitability.  In 30% of the MTLE group, hilar neurons of a variety of morphol. types expressed DYN immunoreactivity in their somata and dendrites.  The d. of [3H]U 69593 binding sites in MaTLE and PTLE patients was highest in areas CA1 and the subiculum-regions having little or no DYN-staining.  In the dentate mol. layer, hilus and CA3-regions with the most DYN immunoreactivity-there was a low d. of ligand binding.  The significance of this transmitter/receptor mismatch is yet unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrofAFgOMQqjrVg90H21EOLACvtfcHk0lhfaUbiKqzndA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvVKlu7o%253D&md5=fc3470183fd9d083ce588031c4d6ee48</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0920-1211%2897%2900044-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0920-1211%252897%252900044-2%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLanerolle%26aufirst%3DN.%2BC.%26aulast%3DWilliamson%26aufirst%3DA.%26aulast%3DMeredith%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DTabuteau%26aufirst%3DH.%26aulast%3DSpencer%26aufirst%3DD.%2BD.%26aulast%3DBrines%26aufirst%3DM.%2BL.%26atitle%3DDynorphin%2520and%2520the%2520kappa%25201%2520ligand%2520%255B3H%255Du69%252C593%2520binding%2520in%2520the%2520human%2520epileptogenic%2520hippocampus%26jtitle%3DEpilepsy%2520Res.%26date%3D1997%26volume%3D28%26spage%3D189%26epage%3D205%26doi%3D10.1016%2FS0920-1211%2897%2900044-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loacker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayyah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzer, C.</span></span> <span> </span><span class="NLM_article-title">Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1093/brain/awl384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1093%2Fbrain%2Fawl384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=17347252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A280%3ADC%252BD2s3islGitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2007&pages=1017-1028&author=S.+Loackerauthor=M.+Sayyahauthor=W.+Wittmannauthor=H.+Herzogauthor=C.+Schwarzer&title=Endogenous+dynorphin+in+epileptogenesis+and+epilepsy%3A+anticonvulsant+net+effect+via+kappa+opioid+receptors&doi=10.1093%2Fbrain%2Fawl384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors</span></div><div class="casAuthors">Loacker Stephan; Sayyah Mohammad; Wittmann Walter; Herzog Herbert; Schwarzer Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">Pt 4</span>),
    <span class="NLM_cas:pages">1017-28</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neuropsychiatric disorders are one of the main challenges of human medicine with epilepsy being one of the most common serious disorders of the brain.  Increasing evidence suggest neuropeptides, particularly the opioids, play an important role in epilepsy.  However, little is known about the mechanisms of the endogenous opioid system in epileptogenesis and epilepsy.  Therefore, we investigated the role of endogenous prodynorphin-derived peptides in epileptogenesis, acute seizure behaviour and epilepsy in prodynorphin-deficient mice.  Compared with wild-type littermates, prodynorphin knockout mice displayed a significantly reduced seizure threshold as assessed by tail-vein infusion of the GABA(A) antagonist pentylenetetrazole.  This phenotype could be entirely rescued by the kappa receptor-specific agonist U-50488, but not by the mu receptor-specific agonist DAMGO.  The delta-specific agonist SNC80 decreased seizure threshold in both genotypes, wild-type and knockout.  Pre-treatment with the kappa selective antagonist GNTI completely blocked the rescue effect of U-50488.  Consistent with the reduced seizure threshold, prodynorphin knockout mice showed faster seizure onset and a prolonged time of seizure activity after intracisternal injection of kainic acid.  Three weeks after local injection of kainic acid into the stratum radiatum CA1 of the dorsal hippocampus, prodynorphin knockout mice displayed an increased extent of granule cell layer dispersion and neuronal loss along the rostrocaudal axis of the ipsi- and partially also of the contralateral hippocampus.  In the classical pentylenetetrazole kindling model, dynorphin-deficient mice showed significantly faster kindling progression with six out of eight animals displaying clonic seizures, while none of the nine wild-types exceeded rating 3 (forelimb clonus).  Taken together, our data strongly support a critical role for dynorphin in the regulation of hippocampal excitability, indicating an anticonvulsant role of kappa opioid receptors, thereby providing a potential target for antiepileptic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuUgwosTcJCrZpSb_XWfMrfW6udTcc2eavRv1TxmxY4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3islGitg%253D%253D&md5=ef104d0c31b29eba19695d4234b53c41</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawl384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawl384%26sid%3Dliteratum%253Aachs%26aulast%3DLoacker%26aufirst%3DS.%26aulast%3DSayyah%26aufirst%3DM.%26aulast%3DWittmann%26aufirst%3DW.%26aulast%3DHerzog%26aufirst%3DH.%26aulast%3DSchwarzer%26aufirst%3DC.%26atitle%3DEndogenous%2520dynorphin%2520in%2520epileptogenesis%2520and%2520epilepsy%253A%2520anticonvulsant%2520net%2520effect%2520via%2520kappa%2520opioid%2520receptors%26jtitle%3DBrain%26date%3D2007%26volume%3D130%26spage%3D1017%26epage%3D1028%26doi%3D10.1093%2Fbrain%2Fawl384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu-Kia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreek, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiller, J. M.</span></span> <span> </span><span class="NLM_article-title">Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer’s disease patients</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>893</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/S0006-8993(00)03302-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2FS0006-8993%2800%2903302-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=11223000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD3MXht12nt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=893&publication_year=2001&pages=121-134&author=A.+M.+Mathieu-Kiaauthor=L.+Q.+Fanauthor=M.+J.+Kreekauthor=E.+J.+Simonauthor=J.+M.+Hiller&title=Mu-%2C+delta-+and+kappa-opioid+receptor+populations+are+differentially+altered+in+distinct+areas+of+postmortem+brains+of+Alzheimer%E2%80%99s+disease+patients&doi=10.1016%2FS0006-8993%2800%2903302-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">μ-, δ- and κ-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients</span></div><div class="casAuthors">Mathieu-Kia, A.-M.; Fan, L.-Q.; Kreek, M. J.; Simon, E. J.; Hiller, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">893</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">121-134</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The putative role of the opioid system in cognitive and memory functions prompted the authors to search for possible changes in the cohort of the major opioid receptors, μ, δ and κ, in Alzheimer's disease.  The present study examines alterations in opioid receptor levels by quant. autoradiog.  These expts. were carried out on coronal sections of postmortem brains from Alzheimer's disease patients and from age-matched, dementia-free individuals.  Brain sections were labeled with the tritiated forms of μ-, δ- and κ-opioid ligands; DAMGO ([d-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin), DPDPE ([d-Pen2,5]-enkephalin) and bremazocine (in the presence of μ- and δ-ligands), resp.  Nonspecific binding was detd. in the presence of naloxone (10 μM).  Brain areas analyzed were caudate, putamen, amygdaloid complex, hippocampal formation and various cerebral and cerebellar cortices.  Image analyses of autoradiographs show, that in comparison to the same areas in control brain, statistically significant redns. in μ-opioid receptor binding occur in the subiculum and hippocampus of Alzheimer's disease brains.  Binding of δ-opioid receptors is also decreased in the amygdaloid complex and ventral putamen of Alzheimer's disease brains.  In contrast, large increases of κ-opioid receptor binding are found in the dorsal and ventral putamen as well as in the cerebellar cortex of Alzheimer's disease brains.  Levels of μ-, δ- and κ-opioid receptor binding are unaltered in the caudate, parahippocampal gyrus and occipito-temporal gyrus.  These results may suggest an involvement of the endogenous opioid system in some of the multitude of effects that accompany this dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJG37xhb0VXLVg90H21EOLACvtfcHk0li6e_bPQfTybQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXht12nt70%253D&md5=a0c1a9cf3c59d3df3e8d84d273e2840d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0006-8993%2800%2903302-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-8993%252800%252903302-3%26sid%3Dliteratum%253Aachs%26aulast%3DMathieu-Kia%26aufirst%3DA.%2BM.%26aulast%3DFan%26aufirst%3DL.%2BQ.%26aulast%3DKreek%26aufirst%3DM.%2BJ.%26aulast%3DSimon%26aufirst%3DE.%2BJ.%26aulast%3DHiller%26aufirst%3DJ.%2BM.%26atitle%3DMu-%252C%2520delta-%2520and%2520kappa-opioid%2520receptor%2520populations%2520are%2520differentially%2520altered%2520in%2520distinct%2520areas%2520of%2520postmortem%2520brains%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520patients%26jtitle%3DBrain%2520Res.%26date%3D2001%26volume%3D893%26spage%3D121%26epage%3D134%26doi%3D10.1016%2FS0006-8993%2800%2903302-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreason, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doudet, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunderland, T.</span></span> <span> </span><span class="NLM_article-title">Opiate receptor avidity and cerebral blood flow in Alzheimer’s disease</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1016/S0022-510X(96)05315-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2FS0022-510X%2896%2905315-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=9129113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaK2sXislentLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=1997&pages=171-180&author=R.+M.+Cohenauthor=P.+J.+Andreasonauthor=D.+J.+Doudetauthor=R.+E.+Carsonauthor=T.+Sunderland&title=Opiate+receptor+avidity+and+cerebral+blood+flow+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS0022-510X%2896%2905315-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Opiate receptor avidity and cerebral blood flow in Alzheimer's disease</span></div><div class="casAuthors">Cohen, Robert M.; Andreason, Paul J.; Doudet, Doris J.; Carson, Richard E.; Sunderland, Trey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Neurological Sciences</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-180</span>CODEN:
                <span class="NLM_cas:coden">JNSCAG</span>;
        ISSN:<span class="NLM_cas:issn">0022-510X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Positron emission tomog. was performed on 12 Alzheimer's patients and 12 age-matched normal controls following the administration of the opiate receptor antagonist 6-deoxy-6-β-[18F]fluoronaltrexone (cyclofoxy, CF).  Tracer kinetic anal. was used to det. the vol. of distribution of CF, a measure of unoccupied μ and κ receptor d., i.e. opiate receptor avidity in 34 brain regions.  Regional cerebral blood flow rates (CBF) were detd. on the same day with H2[15O].  Global gray CF avidity and global gray CBF were lower in the Alzheimer's patients and correlated (r = 0.73).  Regional CBF differences were superimposed on global CBF changes in the Alzheimer's patients, with the subcortex relatively spared.  Multivariate statistical analyses, however, failed to demonstrate regional specificity for the CF avidity changes.  Furthermore, percent changes in regional CF avidity were not correlated with percent changes in regional CBF (r = 0.12, P = NS).  These findings demonstrate involvement of the opiate system in Alzheimer's disease.  Although, neurodegeneration is the likely underlying process responsible for both the changes in CF avidity and CBF in Alzheimer's disease, the differences with respect to the patterns of these losses suggest that the intermediate mechanisms leading from neurodegeneration to loss are distinct.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuh20_aw3bWLVg90H21EOLACvtfcHk0li6e_bPQfTybQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislentLY%253D&md5=f8fc78c88922ba421cb2300ea543c806</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0022-510X%2896%2905315-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-510X%252896%252905315-4%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DR.%2BM.%26aulast%3DAndreason%26aufirst%3DP.%2BJ.%26aulast%3DDoudet%26aufirst%3DD.%2BJ.%26aulast%3DCarson%26aufirst%3DR.%2BE.%26aulast%3DSunderland%26aufirst%3DT.%26atitle%3DOpiate%2520receptor%2520avidity%2520and%2520cerebral%2520blood%2520flow%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D1997%26volume%3D148%26spage%3D171%26epage%3D180%26doi%3D10.1016%2FS0022-510X%2896%2905315-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shippenberg, T. S.</span></span> <span> </span><span class="NLM_article-title">The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">247</span>, <span class="refDoi"> DOI: 10.1038/npp.2008.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1038%2Fnpp.2008.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=19079072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVyru7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=247&author=T.+S.+Shippenberg&title=The+dynorphin%2Fkappa+opioid+receptor+system%3A+a+new+target+for+the+treatment+of+addiction+and+affective+disorders%3F&doi=10.1038%2Fnpp.2008.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?</span></div><div class="casAuthors">Shippenberg, Toni S.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">247</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Studies in exptl. animals suggest that manipulations that decrease the activity of kappa-opioid receptor (KOPr) systems may be effective in the treatment of depression and drug addiction.  The KOPr and the endogenous KOPr ligand dynorphin are enriched in the ventral tegmental area, nucleus accumbens, and prefrontal cortex; brain regions that regulate mood and motivation.  Neurochem. and electrophysiol. data have shown that KOPr activation in these regions decreases dopamine (DA) transmission.  Decreased mesoaccumbal DA transmission is implicated in certain symptoms of depression and several medications with proven antidepressant efficacy in humans are selective DA uptake inhibitors.  Rodent studies have shown that KOPr antagonists attenuate stress-induced reinstatement of cocaine-seeking and stress-induced potentiation of the conditioned rewarding of cocaine.  These findings have prompted the phase I testing of KOPr antagonists for the treatment of addiction.  However, further studies are needed to better understand KOPr system plasticity and the role of opioid peptides systems in normal brain function and various psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoypu1mYJnip7Vg90H21EOLACvtfcHk0lhCrHeVyZgZBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVyru7rM&md5=79f02d1419022782387893e7befff137</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2008.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2008.165%26sid%3Dliteratum%253Aachs%26aulast%3DShippenberg%26aufirst%3DT.%2BS.%26atitle%3DThe%2520dynorphin%252Fkappa%2520opioid%2520receptor%2520system%253A%2520a%2520new%2520target%2520for%2520the%2520treatment%2520of%2520addiction%2520and%2520affective%2520disorders%253F%26jtitle%3DNeuropsychopharmacology%26date%3D2009%26volume%3D34%26spage%3D247%26doi%3D10.1038%2Fnpp.2008.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mash, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staley, J. K.</span></span> <span> </span><span class="NLM_article-title">D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>877</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1999.tb09286.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1111%2Fj.1749-6632.1999.tb09286.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=877&publication_year=1999&pages=507-522&author=D.+C.+Mashauthor=J.+K.+Staley&title=D3+dopamine+and+kappa+opioid+receptor+alterations+in+human+brain+of+cocaine-overdose+victims&doi=10.1111%2Fj.1749-6632.1999.tb09286.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1999.tb09286.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1999.tb09286.x%26sid%3Dliteratum%253Aachs%26aulast%3DMash%26aufirst%3DD.%2BC.%26aulast%3DStaley%26aufirst%3DJ.%2BK.%26atitle%3DD3%2520dopamine%2520and%2520kappa%2520opioid%2520receptor%2520alterations%2520in%2520human%2520brain%2520of%2520cocaine-overdose%2520victims%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1999%26volume%3D877%26spage%3D507%26epage%3D522%26doi%3D10.1111%2Fj.1749-6632.1999.tb09286.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van’t
Veer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlezon, W. A.</span></span> <span> </span><span class="NLM_article-title">Role of kappa-opioid receptors in stress and anxiety-related behavior</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>229</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1007/s00213-013-3195-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1007%2Fs00213-013-3195-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=23836029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOjurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=2013&pages=435-452&author=A.+Van%E2%80%99t%0AVeerauthor=W.+A.+Carlezon&title=Role+of+kappa-opioid+receptors+in+stress+and+anxiety-related+behavior&doi=10.1007%2Fs00213-013-3195-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Role of kappa-opioid receptors in stress and anxiety-related behavior</span></div><div class="casAuthors">Van't Veer, Ashlee; Carlezon, William A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">435-452</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence indicates that brain kappa-opioid receptors (KORs) and dynorphin, the endogenous ligand that binds at these receptors, are involved in regulating states of motivation and emotion.  These findings have stimulated interest in the development of KOR-targeted ligands as therapeutic agents.  As one example, it was suggested that KOR antagonists might have a wide range of indications, including the treatment of depressive, anxiety, and addictive disorders, as well as conditions characterized by co-morbidity of these disorders (e.g., post-traumatic stress disorder).  A general effect of reducing the impact of stress may explain how KOR antagonists can have efficacy in such a variety of animal models that would appear to represent different disease states.  Here, the authors review evidence that disruption of KOR function attenuates prominent effects of stress.  We will describe behavioral and mol. endpoints including those from studies that characterize the effects of KOR antagonists and KOR ablation on the effects of stress itself, as well as on the effects of exogenously delivered corticotropin-releasing factor, a brain peptide that mediates key effects of stress.  Collectively, available data suggest that KOR disruption produces anti-stress effects and under some conditions can prevent the development of stress-induced adaptations.  As such, KOR antagonists may have unique potential as therapeutic agents for the treatment and even prevention of stress-related psychiatric illness, a therapeutic niche that is currently unfilled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV6ByDO8OPqrVg90H21EOLACvtfcHk0lhCrHeVyZgZBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOjurjO&md5=c5174c0ad904bacdb228f1a4982edca1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00213-013-3195-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-013-3195-5%26sid%3Dliteratum%253Aachs%26aulast%3DVan%25E2%2580%2599t%2BVeer%26aufirst%3DA.%26aulast%3DCarlezon%26aufirst%3DW.%2BA.%26atitle%3DRole%2520of%2520kappa-opioid%2520receptors%2520in%2520stress%2520and%2520anxiety-related%2520behavior%26jtitle%3DPsychopharmacology%26date%3D2013%26volume%3D229%26spage%3D435%26epage%3D452%26doi%3D10.1007%2Fs00213-013-3195-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pietrzak, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsi-Travali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ropchan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumeister, A.</span></span> <span> </span><span class="NLM_article-title">Association of in vivo κ-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology</span>. <i>JAMA Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1262</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1001/jamapsychiatry.2014.1221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1001%2Fjamapsychiatry.2014.1221" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=1262-1270&author=R.+H.+Pietrzakauthor=M.+Naganawaauthor=Y.+Huangauthor=S.+Corsi-Travaliauthor=M.+Q.+Zhengauthor=M.+B.+Steinauthor=S.+Henryauthor=K.+Limauthor=J.+Ropchanauthor=S.+F.+Linauthor=R.+E.+Carsonauthor=A.+Neumeister&title=Association+of+in+vivo+%CE%BA-opioid+receptor+availability+and+the+transdiagnostic+dimensional+expression+of+trauma-related+psychopathology&doi=10.1001%2Fjamapsychiatry.2014.1221"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1001%2Fjamapsychiatry.2014.1221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamapsychiatry.2014.1221%26sid%3Dliteratum%253Aachs%26aulast%3DPietrzak%26aufirst%3DR.%2BH.%26aulast%3DNaganawa%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCorsi-Travali%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DM.%2BQ.%26aulast%3DStein%26aufirst%3DM.%2BB.%26aulast%3DHenry%26aufirst%3DS.%26aulast%3DLim%26aufirst%3DK.%26aulast%3DRopchan%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DS.%2BF.%26aulast%3DCarson%26aufirst%3DR.%2BE.%26aulast%3DNeumeister%26aufirst%3DA.%26atitle%3DAssociation%2520of%2520in%2520vivo%2520%25CE%25BA-opioid%2520receptor%2520availability%2520and%2520the%2520transdiagnostic%2520dimensional%2520expression%2520of%2520trauma-related%2520psychopathology%26jtitle%3DJAMA%2520Psychiatry%26date%3D2014%26volume%3D71%26spage%3D1262%26epage%3D1270%26doi%3D10.1001%2Fjamapsychiatry.2014.1221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span> </span><span class="NLM_article-title">Kappa Opioid Receptor Imaging in Post-traumatic
Stress Disorder (PTSD)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>. <span class="NLM_year">2014</span>; <a href="https://clinicaltrials.gov/ct2/show/NCT02237703" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02237703</a> (accessed Aug 15, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kappa+Opioid+Receptor+Imaging+in+Post-traumatic%0AStress+Disorder+%28PTSD%29.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%3A+Bethesda%2C+MD.+2014%3B+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02237703+%28accessed+Aug+15%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DKappa%2520Opioid%2520Receptor%2520Imaging%2520in%2520Post-traumatic%250AStress%2520Disorder%2520%2528PTSD%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Felice, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopruszinski, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaVigne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remeniuk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goshima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ossipov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navratilova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porreca, F.</span></span> <span> </span><span class="NLM_article-title">Kappa opioid receptor antagonists: a possible new class of therapeutics for migraine prevention</span>. <i>Cephalalgia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">780</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1177/0333102417702120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1177%2F0333102417702120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=28376659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A280%3ADC%252BC1cvksFCrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=780-794&author=J.+Y.+Xieauthor=M.+De+Feliceauthor=C.+M.+Kopruszinskiauthor=N.+Eydeauthor=J.+LaVigneauthor=B.+Remeniukauthor=P.+Hernandezauthor=X.+Yueauthor=N.+Goshimaauthor=M.+Ossipovauthor=T.+Kingauthor=J.+M.+Streicherauthor=E.+Navratilovaauthor=D.+Dodickauthor=H.+Rosenauthor=E.+Robertsauthor=F.+Porreca&title=Kappa+opioid+receptor+antagonists%3A+a+possible+new+class+of+therapeutics+for+migraine+prevention&doi=10.1177%2F0333102417702120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention</span></div><div class="casAuthors">Xie Jennifer Y; Eyde Nathan; LaVigne Justin; Remeniuk Bethany; Hernandez Pablo; Yue Xu; Goshima Naomi; Ossipov Michael; Streicher John M; Navratilova Edita; Porreca Frank; De Felice Milena; Kopruszinski Caroline M; King Tamara; Dodick David; Porreca Frank; Rosen Hugh; Roberts Ed</div><div class="citationInfo"><span class="NLM_cas:title">Cephalalgia : an international journal of headache</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">780-794</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background Stress is the most commonly reported migraine trigger.  Dynorphin, an endogenous opioid peptide acting preferentially at kappa opioid receptors (KORs), is a key mediator of stress responses.  The aim of this study was to use an injury-free rat model of functional cephalic pain with features of migraine and medication overuse headache (MOH) to test the possible preventive benefit of KOR blockade on stress-induced cephalic pain.  Methods Following sumatriptan priming to model MOH, rats were hyper-responsive to environmental stress, demonstrating delayed cephalic and extracephalic allodynia and increased levels of CGRP in the jugular blood, consistent with commonly observed clinical outcomes during migraine.  Nor-binaltorphimine (nor-BNI), a long-acting KOR antagonist or CYM51317, a novel short-acting KOR antagonist, were given systemically either during sumatriptan priming or immediately before environmental stress challenge.  The effects of KOR blockade in the amygdala on stress-induced allodynia was determined by administration of nor-BNI into the right or left central nucleus of the amygdala (CeA).  Results KOR blockade prevented both stress-induced allodynia and increased plasma CGRP.  Stress increased dynorphin content and phosphorylated KOR in both the left and right CeA in sumatriptan-primed rats.  However, KOR blockade only in the right CeA prevented stress-induced cephalic allodynia as well as extracephalic allodynia, measured in either the right or left hindpaws.  U69,593, a KOR agonist, given into the right, but not the left, CeA, produced allodynia selectively in sumatriptan-primed rats.  Both stress and U69,593-induced allodynia were prevented by right CeA U0126, a mitogen-activated protein kinase inhibitor, presumably acting downstream of KOR.  Conclusions Our data reveal a novel lateralized KOR circuit that mediated stress-induced cutaneous allodynia and increased plasma CGRP in an injury-free model of functional cephalic pain with features of migraine and medication overuse headache.  Selective, small molecule, orally available, and reversible KOR antagonists are currently in development and may represent a novel class of preventive therapeutics for migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmKA3CiFExd_9pSBfyDvp7fW6udTcc2ebcAsKkghktFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvksFCrtA%253D%253D&md5=b694df1e805eecac04d511c11d3fb5bc</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1177%2F0333102417702120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0333102417702120%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DJ.%2BY.%26aulast%3DDe%2BFelice%26aufirst%3DM.%26aulast%3DKopruszinski%26aufirst%3DC.%2BM.%26aulast%3DEyde%26aufirst%3DN.%26aulast%3DLaVigne%26aufirst%3DJ.%26aulast%3DRemeniuk%26aufirst%3DB.%26aulast%3DHernandez%26aufirst%3DP.%26aulast%3DYue%26aufirst%3DX.%26aulast%3DGoshima%26aufirst%3DN.%26aulast%3DOssipov%26aufirst%3DM.%26aulast%3DKing%26aufirst%3DT.%26aulast%3DStreicher%26aufirst%3DJ.%2BM.%26aulast%3DNavratilova%26aufirst%3DE.%26aulast%3DDodick%26aufirst%3DD.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DE.%26aulast%3DPorreca%26aufirst%3DF.%26atitle%3DKappa%2520opioid%2520receptor%2520antagonists%253A%2520a%2520possible%2520new%2520class%2520of%2520therapeutics%2520for%2520migraine%2520prevention%26jtitle%3DCephalalgia%26date%3D2017%26volume%3D37%26spage%3D780%26epage%3D794%26doi%3D10.1177%2F0333102417702120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munro, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van’t
Veer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Béguin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlezon, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, B. M.</span></span> <span> </span><span class="NLM_article-title">Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity</span>. <i>BMC Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">5</span>, <span class="refDoi"> DOI: 10.1186/1471-2210-12-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1186%2F1471-2210-12-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=22642416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVyrsLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=5&author=T.+A.+Munroauthor=L.+M.+Berryauthor=A.+Van%E2%80%99t%0AVeerauthor=C.+B%C3%A9guinauthor=F.+I.+Carrollauthor=Z.+Zhaoauthor=W.+A.+Carlezonauthor=B.+M.+Cohen&title=Long-acting+%CE%BA+opioid+antagonists+nor-BNI%2C+GNTI+and+JDTic%3A+pharmacokinetics+in+mice+and+lipophilicity&doi=10.1186%2F1471-2210-12-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity</span></div><div class="casAuthors">Munro, Thomas A.; Berry, Loren M.; Van't Veer, Ashlee; Beguin, Cecile; Carroll, F. Ivy; Zhao, Zhiyang; Carlezon, William A., Jr.; Cohen, Bruce M.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5</span>CODEN:
                <span class="NLM_cas:coden">BPMHBU</span>;
        ISSN:<span class="NLM_cas:issn">1471-2210</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Nor-BNI, GNTI and JDTic induce κ opioid antagonism that is delayed by hours and can persist for months.  Other effects are transient.  It has been proposed that these drugs may be slowly absorbed or distributed, and may dissolve in cell membranes, thus slowing elimination and prolonging their effects.  Recent evidence suggests, instead, that they induce prolonged desensitization of the κ opioid receptor.  Methods: To evaluate these hypotheses, we measured relevant physicochem. properties of nor-BNI, GNTI and JDTic, and the timecourse of brain and plasma concns. in mice after i.p. administration (using LC-MS-MS).  Results: In each case, plasma levels were maximal within 30 min and declined by >80% within four hours, correlating well with previously reported transient effects.  A strong neg. correlation was obsd. between plasma levels and the delayed, prolonged timecourse of κ antagonism.  Brain levels of nor-BNI and JDTic peaked within 30 min, but while nor-BNI was largely eliminated within hours, JDTic declined gradually over a week.  Brain uptake of GNTI was too low to measure accurately, and higher doses proved lethal.  None of the drugs were highly lipophilic, showing high water soly. and low-to-moderate distribution into octanol.  Brain homogenate binding was within the range of many shorter-acting drugs.  JDTic showed P-gp-mediated efflux; nor-BNI and GNTI did not, but their low unbound brain uptake suggests efflux by another mechanism.  Conclusions: The neg. plasma concn.-effect relationship we obsd. is difficult to reconcile with simple competitive antagonism, but is consistent with desensitization.  The very slow elimination of JDTic from brain is surprising given that it undergoes active efflux, has modest affinity for homogenate, and has a shorter duration of action than nor-BNI under these conditions.  We propose that this may result from entrapment in cellular compartments such as lysosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq--VqUQhImY7Vg90H21EOLACvtfcHk0liif10LjPuWSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVyrsLbK&md5=01a4ed657ce55dd08f7e8e05ab1f2f7c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1186%2F1471-2210-12-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2210-12-5%26sid%3Dliteratum%253Aachs%26aulast%3DMunro%26aufirst%3DT.%2BA.%26aulast%3DBerry%26aufirst%3DL.%2BM.%26aulast%3DVan%25E2%2580%2599t%2BVeer%26aufirst%3DA.%26aulast%3DB%25C3%25A9guin%26aufirst%3DC.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCarlezon%26aufirst%3DW.%2BA.%26aulast%3DCohen%26aufirst%3DB.%2BM.%26atitle%3DLong-acting%2520%25CE%25BA%2520opioid%2520antagonists%2520nor-BNI%252C%2520GNTI%2520and%2520JDTic%253A%2520pharmacokinetics%2520in%2520mice%2520and%2520lipophilicity%26jtitle%3DBMC%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D5%26doi%3D10.1186%2F1471-2210-12-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urbano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E.</span></span> <span> </span><span class="NLM_article-title">Antagonists of the kappa opioid receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2021</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.03.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2Fj.bmcl.2014.03.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=24690494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2021-2032&author=M.+Urbanoauthor=M.+Guerreroauthor=H.+Rosenauthor=E.+Roberts&title=Antagonists+of+the+kappa+opioid+receptor&doi=10.1016%2Fj.bmcl.2014.03.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists of the kappa opioid receptor</span></div><div class="casAuthors">Urbano, Mariangela; Guerrero, Miguel; Rosen, Hugh; Roberts, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2021-2032</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The research community has increasingly focused on the development of OPRK antagonists as pharmacotherapies for the treatment of depression, anxiety, addictive disorders and other psychiatric conditions produced or exacerbated by stress.  Short-acting OPRK antagonists have been recently developed as a potential improvement over long-acting prototypic ligands including nor-BNI and JDTic.  Remarkably the short-acting LY2456302 is undergoing phase II clin. trials for the augmentation of the antidepressant therapy in treatment-resistant depression.  This Letter reviews relevant chem. and pharmacol. advances in the identification and development of OPRK antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg7WYoVfNnM7Vg90H21EOLACvtfcHk0lg-woBTKuqSMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOjt7o%253D&md5=d278400da78ccdfe6efef74259c964a5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.03.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.03.040%26sid%3Dliteratum%253Aachs%26aulast%3DUrbano%26aufirst%3DM.%26aulast%3DGuerrero%26aufirst%3DM.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DE.%26atitle%3DAntagonists%2520of%2520the%2520kappa%2520opioid%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2021%26epage%3D2032%26doi%3D10.1016%2Fj.bmcl.2014.03.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHardy, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Deusen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, S.</span></span> <span> </span><span class="NLM_article-title">Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2’-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5868</span>– <span class="NLM_lpage">5877</span>, <span class="refDoi"> DOI: 10.1021/jm2006035</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5868-5877&author=P.+R.+Verhoestauthor=A.+Sawant+Basakauthor=V.+Parikhauthor=M.+Haywardauthor=G.+W.+Kauffmanauthor=V.+Paradisauthor=S.+F.+McHardyauthor=S.+McLeanauthor=S.+Grimwoodauthor=A.+W.+Schmidtauthor=M.+Vanase-Frawleyauthor=J.+Freemanauthor=J.+Van+Deusenauthor=L.+Coxauthor=D.+Wongauthor=S.+Liras&title=Design+and+discovery+of+a+selective+small+molecule+%CE%BA+opioid+antagonist+%282-methyl-N-%28%282%E2%80%99-%28pyrrolidin-1-ylsulfonyl%29biphenyl-4-yl%29methyl%29propan-1-amine%2C+PF-4455242%29&doi=10.1021%2Fjm2006035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm2006035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006035%26sid%3Dliteratum%253Aachs%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DSawant%2BBasak%26aufirst%3DA.%26aulast%3DParikh%26aufirst%3DV.%26aulast%3DHayward%26aufirst%3DM.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DParadis%26aufirst%3DV.%26aulast%3DMcHardy%26aufirst%3DS.%2BF.%26aulast%3DMcLean%26aufirst%3DS.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DVanase-Frawley%26aufirst%3DM.%26aulast%3DFreeman%26aufirst%3DJ.%26aulast%3DVan%2BDeusen%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DD.%26aulast%3DLiras%26aufirst%3DS.%26atitle%3DDesign%2520and%2520discovery%2520of%2520a%2520selective%2520small%2520molecule%2520%25CE%25BA%2520opioid%2520antagonist%2520%25282-methyl-N-%2528%25282%25E2%2580%2599-%2528pyrrolidin-1-ylsulfonyl%2529biphenyl-4-yl%2529methyl%2529propan-1-amine%252C%2520PF-4455242%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5868%26epage%3D5877%26doi%3D10.1021%2Fjm2006035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span> </span><span class="NLM_article-title">A Study Of Kappa Opioid Receptor Occupancy
Of PF-04455242, Using
PET (Positron Emission Tomography)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>, <span class="NLM_year">2009</span>; <a href="https://clinicaltrials.gov/ct2/show/study/NCT00939887" class="extLink">https://clinicaltrials.gov/ct2/show/study/NCT00939887</a> (accessed Aug 15, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+Of+Kappa+Opioid+Receptor+Occupancy%0AOf+PF-04455242%2C+Using%0APET+%28Positron+Emission+Tomography%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%2C+2009%3B+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Fstudy%2FNCT00939887+%28accessed+Aug+15%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520Of%2520Kappa%2520Opioid%2520Receptor%2520Occupancy%250AOf%2520PF-04455242%252C%2520Using%250APET%2520%2528Positron%2520Emission%2520Tomography%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitch, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quimby, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedregal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Torre, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canada, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statnick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinzie, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benesh, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rash, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, V. N.</span></span> <span> </span><span class="NLM_article-title">Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8000</span>– <span class="NLM_lpage">8012</span>, <span class="refDoi"> DOI: 10.1021/jm200789r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200789r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOgu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8000-8012&author=C.+H.+Mitchauthor=S.+J.+Quimbyauthor=N.+Diazauthor=C.+Pedregalauthor=M.+G.+de+la+Torreauthor=A.+Jimenezauthor=Q.+Shiauthor=E.+J.+Canadaauthor=S.+D.+Kahlauthor=M.+A.+Statnickauthor=D.+L.+McKinzieauthor=D.+R.+Beneshauthor=K.+S.+Rashauthor=V.+N.+Barth&title=Discovery+of+aminobenzyloxyarylamides+as+%CE%BA+opioid+receptor+selective+antagonists%3A+application+to+preclinical+development+of+a+%CE%BA+opioid+receptor+antagonist+receptor+occupancy+tracer&doi=10.1021%2Fjm200789r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Aminobenzyloxyarylamides as κ Opioid Receptor Selective Antagonists: Application to Preclinical Development of a κ Opioid Receptor Antagonist Receptor Occupancy Tracer</span></div><div class="casAuthors">Mitch, Charles H.; Quimby, Steven J.; Diaz, Nuria; Pedregal, Concepcion; de la Torre, Marta G.; Jimenez, Alma; Shi, Qing; Canada, Emily J.; Kahl, Steven D.; Statnick, Michael A.; McKinzie, David L.; Benesh, Dana R.; Rash, Karen S.; Barth, Vanessa N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8000-8012</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Arylphenylpyrrolidinylmethylphenoxybenzamides were found to have high affinity and selectivity for κ opioid receptors.  On the basis of receptor binding assays in Chinese hamster ovary (CHO) cells expressing cloned human opioid receptors, (S)-3-fluoro-4-(4-((2-(3-fluorophenyl)pyrrolidin-1-yl)methyl)phenoxy)benzamide (25) had a Ki = 0.565 nM for κ opioid receptor binding while having a Ki = 35.8 nM for μ opioid receptors and a Ki = 211 nM for δ opioid receptor binding.  Compd. 25 was also a potent antagonist of κ opioid receptors when tested in vitro using a [35S]-guanosine 5'O-[3-thiotriphosphate] ([35S]GTP-γ-S) functional assay in CHO cells expressing cloned human opioid receptors.  Compds. were also evaluated for potential use as receptor occupancy tracers.  Tracer evaluation was done in vivo, using liq. chromatog.-tandem mass spectrometry (LC/MS/MS) methods, precluding the need for radiolabeling.  (S)-3-Chloro-4-(4-((2-(pyridine-3-yl)pyrrolidin-1-yl)methyl)phenoxy)benzamide (18) was found to have favorable properties for a tracer for receptor occupancy, including good specific vs. nonspecific binding and good brain uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUKlIPCr34grVg90H21EOLACvtfcHk0lgnJiAdYi1sKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOgu73N&md5=a17d3133182c2c33b78a85bf153c56fd</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm200789r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200789r%26sid%3Dliteratum%253Aachs%26aulast%3DMitch%26aufirst%3DC.%2BH.%26aulast%3DQuimby%26aufirst%3DS.%2BJ.%26aulast%3DDiaz%26aufirst%3DN.%26aulast%3DPedregal%26aufirst%3DC.%26aulast%3Dde%2Bla%2BTorre%26aufirst%3DM.%2BG.%26aulast%3DJimenez%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DCanada%26aufirst%3DE.%2BJ.%26aulast%3DKahl%26aufirst%3DS.%2BD.%26aulast%3DStatnick%26aufirst%3DM.%2BA.%26aulast%3DMcKinzie%26aufirst%3DD.%2BL.%26aulast%3DBenesh%26aufirst%3DD.%2BR.%26aulast%3DRash%26aufirst%3DK.%2BS.%26aulast%3DBarth%26aufirst%3DV.%2BN.%26atitle%3DDiscovery%2520of%2520aminobenzyloxyarylamides%2520as%2520%25CE%25BA%2520opioid%2520receptor%2520selective%2520antagonists%253A%2520application%2520to%2520preclinical%2520development%2520of%2520a%2520%25CE%25BA%2520opioid%2520receptor%2520antagonist%2520receptor%2520occupancy%2520tracer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8000%26epage%3D8012%26doi%3D10.1021%2Fjm200789r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehlert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barchiesi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilig, M.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1805</span>– <span class="NLM_lpage">1812</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0015-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1038%2Fs41386-018-0015-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=29463912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Cgt7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=1805-1812&author=E.+Domiauthor=E.+Barbierauthor=E.+Augierauthor=G.+Augierauthor=D.+Gehlertauthor=R.+Barchiesiauthor=A.+Thorsellauthor=L.+Holmauthor=M.+Heilig&title=Preclinical+evaluation+of+the+kappa-opioid+receptor+antagonist+CERC-501+as+a+candidate+therapeutic+for+alcohol+use+disorders&doi=10.1038%2Fs41386-018-0015-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders</span></div><div class="casAuthors">Domi, E.; Barbier, E.; Augier, E.; Augier, G.; Gehlert, D.; Barchiesi, R.; Thorsell, A.; Holm, L.; Heilig, M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1805-1812</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Prior work suggests a role of kappa-opioid signaling in the control of alc. drinking, in particular when drinking is escalated due to alc.-induced long-term neuroadaptations.  Here, we examd. the small mol. selective kappa antagonist CERC-501 in rat models of alc.-related behaviors, with the objective to evaluate its potential as a candidate therapeutic for alc. use disorders.  We first tested the effect of CERC-501 on acute alc. withdrawal-induced anxiety-like behavior.  CERC-501 was then tested on basal as well as escalated alc. self-administration induced by 20% alc. intermittent access.  Finally, we detd. the effects of CERC-501 on relapse to alc. seeking triggered by both stress and alc.-assocd. cues.  Control expts. were performed to confirm the specificity of CERC-501 effects on alc.-related behaviors.  CERC-501 reversed anxiety-like behavior induced by alc. withdrawal.  It did not affect basal alc. self-administration but did dose-dependently suppress self-administration that had escalated following long-term intermittent access to alc.  CERC-501 blocked relapse to alc. seeking induced by stress, but not when relapse-like behavior was triggered by alc.-assocd. cues.  The effects of CERC-501 were obsd. in the absence of sedative side effects and were not due to effects on alc. metab.  Thus, in a broad battery of preclin. alc. models, CERC-501 has an activity profile characteristic of anti-stress compds.  Combined with its demonstrated preclin. and clin. safety profile, these data support clin. development of CERC-501 for alc. use disorders, in particular for patients with neg. reinforced, stress-driven alc. seeking and use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIW1OsMfhf-7Vg90H21EOLACvtfcHk0lgnJiAdYi1sKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Cgt7zE&md5=853aae19858b58ea4568614bd502c900</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0015-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0015-y%26sid%3Dliteratum%253Aachs%26aulast%3DDomi%26aufirst%3DE.%26aulast%3DBarbier%26aufirst%3DE.%26aulast%3DAugier%26aufirst%3DE.%26aulast%3DAugier%26aufirst%3DG.%26aulast%3DGehlert%26aufirst%3DD.%26aulast%3DBarchiesi%26aufirst%3DR.%26aulast%3DThorsell%26aufirst%3DA.%26aulast%3DHolm%26aufirst%3DL.%26aulast%3DHeilig%26aufirst%3DM.%26atitle%3DPreclinical%2520evaluation%2520of%2520the%2520kappa-opioid%2520receptor%2520antagonist%2520CERC-501%2520as%2520a%2520candidate%2520therapeutic%2520for%2520alcohol%2520use%2520disorders%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26spage%3D1805%26epage%3D1812%26doi%3D10.1038%2Fs41386-018-0015-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damaj, M. I.</span></span> <span> </span><span class="NLM_article-title">Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2015.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2Fj.neuropharm.2015.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=26044637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWgtrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=270-274&author=K.+J.+Jacksonauthor=A.+Jacksonauthor=F.+I.+Carrollauthor=M.+I.+Damaj&title=Effects+of+orally-bioavailable+short-acting+kappa+opioid+receptor-selective+antagonist+LY2456302+on+nicotine+withdrawal+in+mice&doi=10.1016%2Fj.neuropharm.2015.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice</span></div><div class="casAuthors">Jackson, Kia J.; Jackson, Asti; Carroll, F. Ivy; Damaj, M. Imad</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">270-274</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Kappa opioid receptor (KOR) signaling has been implicated in mediating behavioral and biochem. effects assocd. with drug dependence.  The most commonly used KOR antagonists, norbinaltorphimine (norBNI) and (3R)-7-Hydroxy-N{(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl}-1,2,3,4-tetrahydro-3-isoquinoline-carboxamide (JDTic), have provided a wealth of information in this area; however, the delayed onset and long-lasting effects of these antagonists complicate exptl. design and interpretation of results, and make them less than ideal for clin. studies.  Initial studies with the recently developed KOR antagonist, LY2456302, show that the compd. is a short acting, high-affinity, selective KOR antagonist with therapeutic potential for mood disorders and ethanol use in animal models, and is well tolerated in humans.  The goal of the current study was to evaluate the effectiveness of LY2456302 in alleviating the nicotine withdrawal syndrome in mice.  Mice were chronically treated with nicotine for 14 days and phys. and affective nicotine withdrawal signs were measured using a spontaneous nicotine withdrawal model and conditioned place aversion (CPA) following pre-treatment with LY2456302, administered orally.  Vehicle treated nicotine withdrawn mice displayed significant anxiety-related behavior, somatic signs, hyperalgesia, and CPA.  Similar to previous studies with norBNI and JDTic, LY2456302 alleviated the nicotine withdrawal syndrome, as evidenced by decreased expression of nicotine withdrawal induced anxiety-related behavior, somatic signs, and CPA, and increased hotplate latency in nicotine withdrawn mice following pre-treatment.  Given the current results, and with its favorable pharmacokinetic and pharmacodynamic profile, LY2456302 may be a useful therapeutic agent for treatment of multiple aspects of the nicotine withdrawal syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTUmNoy6lBT7Vg90H21EOLACvtfcHk0lgnJiAdYi1sKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWgtrjN&md5=8c3acdf063502f5fa80553970bd63677</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2015.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2015.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DK.%2BJ.%26aulast%3DJackson%26aufirst%3DA.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DDamaj%26aufirst%3DM.%2BI.%26atitle%3DEffects%2520of%2520orally-bioavailable%2520short-acting%2520kappa%2520opioid%2520receptor-selective%2520antagonist%2520LY2456302%2520on%2520nicotine%2520withdrawal%2520in%2520mice%26jtitle%3DNeuropharmacology%26date%3D2015%26volume%3D97%26spage%3D270%26epage%3D274%26doi%3D10.1016%2Fj.neuropharm.2015.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witcher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorick-Kehn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royalty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauscher-Wisniewski, S.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">968</span>– <span class="NLM_lpage">978</span>, <span class="refDoi"> DOI: 10.1002/jcph.286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1002%2Fjcph.286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=24619932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlWgurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=968-978&author=S.+L.+Loweauthor=C.+J.+Wongauthor=J.+Witcherauthor=C.+R.+Gonzalesauthor=G.+L.+Dickinsonauthor=R.+L.+Bellauthor=L.+Rorick-Kehnauthor=M.+Wellerauthor=R.+R.+Stoltzauthor=J.+Royaltyauthor=S.+Tauscher-Wisniewski&title=Safety%2C+tolerability%2C+and+pharmacokinetic+evaluation+of+single-+and+multiple-ascending+doses+of+a+novel+kappa+opioid+receptor+antagonist+LY2456302+and+drug+interaction+with+ethanol+in+healthy+subjects&doi=10.1002%2Fjcph.286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects</span></div><div class="casAuthors">Lowe, Stephen L.; Wong, Conrad J.; Witcher, Jennifer; Gonzales, Celedon R.; Dickinson, Gemma L.; Bell, Robert L.; Rorick-Kehn, Linda; Weller, MaryAnn; Stoltz, Randall R.; Royalty, Jane; Tauscher-Wisniewski, Sitra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">968-978</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Accumulating evidence indicates that selective antagonism of kappa opioid receptors may provide therapeutic benefit in the treatment of major depressive disorder, anxiety disorders, and substance use disorders.  LY2456302 is a high-affinity, selective kappa opioid antagonist that demonstrates >30-fold functional selectivity over mu and delta opioid receptors.  The safety, tolerability, and pharmacokinetics (PK) of LY2456302 were investigated following single oral doses (2-60 mg), multiple oral doses (2, 10, and 35 mg), and when co-administered with ethanol.  Plasma concns. of LY2456302 were measured by liq. chromatog.-tandem mass spectrometry method.  Safety analyses were conducted on all enrolled subjects.  LY2456302 doses were well-tolerated with no clin. significant findings.  No safety concerns were seen on co-administration with ethanol.  No evidence for an interaction between LY2456302 and ethanol on cognitive-motor performance was detected.  LY2456302 displayed rapid oral absorption and a terminal half-life of approx. 30-40 h.  Plasma exposure of LY2456302 increased proportionally with increasing doses and reached steady state after 6-8 days of once-daily dosing.  Steady-state PK of LY2456302 were not affected by coadministration of a single dose of ethanol.  No clin. important changes in max. concn. (Cmax) or AUC of ethanol (in the presence of LY2456302) were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzd5qDiMDLq7Vg90H21EOLACvtfcHk0lgBrfYByhIneA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlWgurzO&md5=dbc065f8c96e002460269bb31bfbab0a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fjcph.286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.286%26sid%3Dliteratum%253Aachs%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DWong%26aufirst%3DC.%2BJ.%26aulast%3DWitcher%26aufirst%3DJ.%26aulast%3DGonzales%26aufirst%3DC.%2BR.%26aulast%3DDickinson%26aufirst%3DG.%2BL.%26aulast%3DBell%26aufirst%3DR.%2BL.%26aulast%3DRorick-Kehn%26aufirst%3DL.%26aulast%3DWeller%26aufirst%3DM.%26aulast%3DStoltz%26aufirst%3DR.%2BR.%26aulast%3DRoyalty%26aufirst%3DJ.%26aulast%3DTauscher-Wisniewski%26aufirst%3DS.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520pharmacokinetic%2520evaluation%2520of%2520single-%2520and%2520multiple-ascending%2520doses%2520of%2520a%2520novel%2520kappa%2520opioid%2520receptor%2520antagonist%2520LY2456302%2520and%2520drug%2520interaction%2520with%2520ethanol%2520in%2520healthy%2520subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2014%26volume%3D54%26spage%3D968%26epage%3D978%26doi%3D10.1002%2Fjcph.286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reed, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butelman, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreek, M. J.</span></span> <span> </span><span class="NLM_article-title">Repeated administration of opra kappa (LY2456302), a novel, short-acting, selective kop-r antagonist, in persons with and without cocaine dependence</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1038%2Fnpp.2017.205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=28857070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFKisbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=739-750&author=B.+Reedauthor=E.+R.+Butelmanauthor=R.+S.+Fryauthor=R.+Kimaniauthor=M.+J.+Kreek&title=Repeated+administration+of+opra+kappa+%28LY2456302%29%2C+a+novel%2C+short-acting%2C+selective+kop-r+antagonist%2C+in+persons+with+and+without+cocaine+dependence&doi=10.1038%2Fnpp.2017.205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence</span></div><div class="casAuthors">Reed, Brian; Butelman, Eduardo R.; Fry, Rebecca S.; Kimani, Rachel; Kreek, Mary Jeanne</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">739-750</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The κ-opioid receptor (KOP-r) system and its endogenous ligands, the dynorphins, are involved in the neurobiol. regulation of addictive states, and of mood.  There are limited data on the impact of selective KOP-r antagonism in humans on basic biobehavioral functions, or on addictive diseases and mood disorders.  Previously studied selective KOP-r antagonists have unusual pharmacodynamic and pharmacokinetic properties (slow development of KOP-r selectivity, extremely long duration of action) that limit translation to human studies.  A recently developed selective KOP-r-antagonist, Opra Kappa (LY2456302; CERC-501), has medication-like duration of action, oral bioavailability, and target engagement.  The current study is the first investigation of the effects of a KOP-r-antagonist in cocaine-dependent persons in comparison with normal volunteers.  In a stress-minimized inpatient setting, we detd. the neuroendocrine and neurobehavioral effects of repeated administration of an active dose of Opra Kappa (10 mg p.o. daily, four consecutive days in comparison with an initial baseline day).  Healthy volunteers (n=40), persons diagnosed with cocaine dependence in early abstinence (<2 mo, EACD) (n=23), and drug-free former cocaine-dependent persons (7-mo to 25-yr abstinence, DFFCD) (n=7) were studied, with measurements including circulating neuroendocrine hormones, affect, and, in cocaine-dependent persons, cocaine craving.  Modest adverse events related to Opra Kappa included pruritus, obsd. in a subset of individuals.  No significant change was obsd. in serum prolactin levels following Opra Kappa administration, but modest increases in circulating adrenocorticotropic hormone and cortisol were obsd.  No significant changes were noted in measures of depression or cocaine craving in this stress-minimized setting.  Overall, these studies demonstrate that effects of 10 mg Opra Kappa are largely consistent with those predicted for a selective KOP-r antagonist.  This medication regimen was tolerable, and is therefore feasible for further studies in cocaine-dependent persons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbkzD6bb5ZX7Vg90H21EOLACvtfcHk0lgBrfYByhIneA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFKisbzJ&md5=87651bc8d9479deb92bcda719a0f6a1a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.205%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DB.%26aulast%3DButelman%26aufirst%3DE.%2BR.%26aulast%3DFry%26aufirst%3DR.%2BS.%26aulast%3DKimani%26aufirst%3DR.%26aulast%3DKreek%26aufirst%3DM.%2BJ.%26atitle%3DRepeated%2520administration%2520of%2520opra%2520kappa%2520%2528LY2456302%2529%252C%2520a%2520novel%252C%2520short-acting%252C%2520selective%2520kop-r%2520antagonist%252C%2520in%2520persons%2520with%2520and%2520without%2520cocaine%2520dependence%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26spage%3D739%26epage%3D750%26doi%3D10.1038%2Fnpp.2017.205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span> <i>Cerecor Reports Encouraging Topline Data from a NIH Sponsored Proof-of-Concept
Trial of CERC-501 in Treatment-Resistant Depression</i>; <span class="NLM_publisher-name">Cerecor</span>, May 1, <span class="NLM_year">2017</span>; <a href="https://ir.cerecor.com/press-releases/detail/36" class="extLink">https://ir.cerecor.com/press-releases/detail/36</a> (accessed Sept 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Cerecor+Reports+Encouraging+Topline+Data+from+a+NIH+Sponsored+Proof-of-Concept%0ATrial+of+CERC-501+in+Treatment-Resistant+Depression%3B+Cerecor%2C+May+1%2C+2017%3B+https%3A%2F%2Fir.cerecor.com%2Fpress-releases%2Fdetail%2F36+%28accessed+Sept+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCerecor%2520Reports%2520Encouraging%2520Topline%2520Data%2520from%2520a%2520NIH%2520Sponsored%2520Proof-of-Concept%250ATrial%2520of%2520CERC-501%2520in%2520Treatment-Resistant%2520Depression%26pub%3DCerecor%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rorick-Kehn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witcher, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Need, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinzie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statnick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suico, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinzie, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauscher-Wisniewski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitch, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C. J.</span></span> <span> </span><span class="NLM_article-title">Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">pyu036</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyu036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1093%2Fijnp%2Fpyu036" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=pyu036&author=L.+M.+Rorick-Kehnauthor=J.+W.+Witcherauthor=S.+L.+Loweauthor=C.+R.+Gonzalesauthor=M.+A.+Wellerauthor=R.+L.+Bellauthor=J.+C.+Hartauthor=A.+B.+Needauthor=J.+H.+McKinzieauthor=M.+A.+Statnickauthor=J.+G.+Suicoauthor=D.+L.+McKinzieauthor=S.+Tauscher-Wisniewskiauthor=C.+H.+Mitchauthor=R.+R.+Stoltzauthor=C.+J.+Wong&title=Determining+pharmacological+selectivity+of+the+kappa+opioid+receptor+antagonist+LY2456302+using+pupillometry+as+a+translational+biomarker+in+rat+and+human&doi=10.1093%2Fijnp%2Fpyu036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyu036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyu036%26sid%3Dliteratum%253Aachs%26aulast%3DRorick-Kehn%26aufirst%3DL.%2BM.%26aulast%3DWitcher%26aufirst%3DJ.%2BW.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DGonzales%26aufirst%3DC.%2BR.%26aulast%3DWeller%26aufirst%3DM.%2BA.%26aulast%3DBell%26aufirst%3DR.%2BL.%26aulast%3DHart%26aufirst%3DJ.%2BC.%26aulast%3DNeed%26aufirst%3DA.%2BB.%26aulast%3DMcKinzie%26aufirst%3DJ.%2BH.%26aulast%3DStatnick%26aufirst%3DM.%2BA.%26aulast%3DSuico%26aufirst%3DJ.%2BG.%26aulast%3DMcKinzie%26aufirst%3DD.%2BL.%26aulast%3DTauscher-Wisniewski%26aufirst%3DS.%26aulast%3DMitch%26aufirst%3DC.%2BH.%26aulast%3DStoltz%26aufirst%3DR.%2BR.%26aulast%3DWong%26aufirst%3DC.%2BJ.%26atitle%3DDetermining%2520pharmacological%2520selectivity%2520of%2520the%2520kappa%2520opioid%2520receptor%2520antagonist%2520LY2456302%2520using%2520pupillometry%2520as%2520a%2520translational%2520biomarker%2520in%2520rat%2520and%2520human%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2015%26volume%3D18%26spage%3Dpyu036%26doi%3D10.1093%2Fijnp%2Fpyu036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ragguett, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblat, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, R. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1080/17425255.2018.1459564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1080%2F17425255.2018.1459564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=29621905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A280%3ADC%252BC1MnptlOlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=475-482&author=R.+M.+Ragguettauthor=C.+Rongauthor=J.+D.+Rosenblatauthor=R.+C.+Hoauthor=R.+S.+McIntyre&title=Pharmacodynamic+and+pharmacokinetic+evaluation+of+buprenorphine+%2B+samidorphan+for+the+treatment+of+major+depressive+disorder&doi=10.1080%2F17425255.2018.1459564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder</span></div><div class="casAuthors">Ragguett Renee-Marie; Rong Carola; Rosenblat Joshua D; McIntyre Roger S; Rosenblat Joshua D; McIntyre Roger S; Ho Roger C; McIntyre Roger S</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug metabolism & toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">475-482</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Treatment resistant depression (TRD) represents approximately 20% of all individuals receiving care for major depressive disorder.  The opioidergic system is identified as a novel target which hitherto has not been sufficiently investigated in adults with TRD.  The combination product buprenorphine + samidorphan is an opioid modulatory agent which has demonstrated replicated evidence of efficacy in TRD without abuse liability.  Areas covered: Databases Pubmed, Google Scholar and clinicaltrials.gov were searched from inception through December 2017 for clinical trial information, pharmacokinetics, and pharmacodynamics of buprenorphine + samidorphan.  Herein we provide a summary of the available information.  Eight clinical trials were identified for inclusion, of the eight trials, five trials had available results and are included in detail in our review.  Expert opinion: Buprenorphine + samidorphan has demonstrated efficacy in TRD.  Extant evidence surrounding the safety and tolerability profile of buprenorphine + samidorphan does not identify any significant safety concerns.  Additional studies are needed in order to assess the long-term safety and efficacy of this product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3FOlIyvxQqhBrI9DTGjC0fW6udTcc2eYdHU_lQtGTzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnptlOlsg%253D%253D&md5=a0a8c669ef96dc9c2d43910a2c45c33d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1080%2F17425255.2018.1459564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17425255.2018.1459564%26sid%3Dliteratum%253Aachs%26aulast%3DRagguett%26aufirst%3DR.%2BM.%26aulast%3DRong%26aufirst%3DC.%26aulast%3DRosenblat%26aufirst%3DJ.%2BD.%26aulast%3DHo%26aufirst%3DR.%2BC.%26aulast%3DMcIntyre%26aufirst%3DR.%2BS.%26atitle%3DPharmacodynamic%2520and%2520pharmacokinetic%2520evaluation%2520of%2520buprenorphine%2520%252B%2520samidorphan%2520for%2520the%2520treatment%2520of%2520major%2520depressive%2520disorder%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2018%26volume%3D14%26spage%3D475%26epage%3D482%26doi%3D10.1080%2F17425255.2018.1459564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memisoglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodkin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Somer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leigh-Pemberton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPetrillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrich, E.</span></span> <span> </span><span class="NLM_article-title">Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2015.15070921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1176%2Fappi.ajp.2015.15070921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=26869247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A280%3ADC%252BC28npvFeqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=499-508&author=M.+Favaauthor=A.+Memisogluauthor=M.+E.+Thaseauthor=J.+A.+Bodkinauthor=M.+H.+Trivediauthor=M.+de+Somerauthor=Y.+Duauthor=R.+Leigh-Pembertonauthor=L.+DiPetrilloauthor=B.+Silvermanauthor=E.+Ehrich&title=Opioid+modulation+with+buprenorphine%2Fsamidorphan+as+adjunctive+treatment+for+inadequate+response+to+antidepressants%3A+a+randomized+double-blind+placebo-controlled+trial&doi=10.1176%2Fappi.ajp.2015.15070921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial</span></div><div class="casAuthors">Fava Maurizio; Memisoglu Asli; Thase Michael E; Bodkin J Alexander; Trivedi Madhukar H; de Somer Marc; Du Yangchun; Leigh-Pemberton Richard; DiPetrillo Lauren; Silverman Bernard; Ehrich Elliot</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">499-508</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Major depressive disorder has been associated with dysregulation of the endogenous opioid system.  The authors sought to determine whether opioid modulation achieved through administration of ALKS 5461, a combination of a μ- and κ-opioid partial agonist, buprenorphine, and a μ-opioid antagonist, samidorphan, would exhibit antidepressant activity in patients with major depression.  METHOD:  A multicenter, randomized, double-blind, placebo-controlled, two-stage sequential parallel comparison design study was conducted in adults with major depression who had an inadequate response to one or two courses of antidepressant treatment.  Participants were randomly assigned to receive adjunctive treatment with 2 mg/2 mg of buprenorphine/samidorphan (the 2/2 dosage group), 8 mg/8 mg of buprenorphine/samidorphan (the 8/8 dosage group), or placebo.  Antidepressant effect was measured based on change from baseline to the end of 4 weeks of treatment on the 17-item Hamilton Depression Rating Scale (HAM-D), the Montgomery-ÅAsberg Depression Rating Scale (MADRS), and the Clinical Global Impressions severity scale (CGI-S).  RESULTS:  Compared with the placebo group, there were significantly greater improvements in the 2/2 dosage group across the three depression outcome measures (HAM-D: -2.8, 95% CI=-5.1, -0.6; MADRS: -4.9, 95% CI=-8.2, -1.6; CGI-S: -0.5, 95% CI=-0.9, -0.1).  There was also evidence of improvement in the 8/8 dosage group, although it did not achieve statistical significance.  Overall, the buprenorphine/samidorphan combinations were well tolerated, and there was no evidence of opioid withdrawal on treatment discontinuation.  CONCLUSIONS:  The buprenorphine/samidorphan combination is a novel and promising candidate for treatment of major depressive disorder in patients who have an inadequate response to standard antidepressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAVonKfnT36_x2phytoz6_fW6udTcc2eYdHU_lQtGTzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28npvFeqtw%253D%253D&md5=50faaf07f582ccee6749d8e4937806d1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2015.15070921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2015.15070921%26sid%3Dliteratum%253Aachs%26aulast%3DFava%26aufirst%3DM.%26aulast%3DMemisoglu%26aufirst%3DA.%26aulast%3DThase%26aufirst%3DM.%2BE.%26aulast%3DBodkin%26aufirst%3DJ.%2BA.%26aulast%3DTrivedi%26aufirst%3DM.%2BH.%26aulast%3Dde%2BSomer%26aufirst%3DM.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DLeigh-Pemberton%26aufirst%3DR.%26aulast%3DDiPetrillo%26aufirst%3DL.%26aulast%3DSilverman%26aufirst%3DB.%26aulast%3DEhrich%26aufirst%3DE.%26atitle%3DOpioid%2520modulation%2520with%2520buprenorphine%252Fsamidorphan%2520as%2520adjunctive%2520treatment%2520for%2520inadequate%2520response%2520to%2520antidepressants%253A%2520a%2520randomized%2520double-blind%2520placebo-controlled%2520trial%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2016%26volume%3D173%26spage%3D499%26epage%3D508%26doi%3D10.1176%2Fappi.ajp.2015.15070921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span> <i>Alkermes Announces FDA Acceptance for Review of
New Drug Application
for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder</i>; <span class="NLM_publisher-name">Alkermes</span>, April 16, <span class="NLM_year">2018</span>; <a href="http://phx.corporate-ir.net/phoenix.zhtml?c=92211&amp;p=irol-corporateNewsArticle&amp;ID=2342624" class="extLink">http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-corporateNewsArticle&ID=2342624</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Alkermes+Announces+FDA+Acceptance+for+Review+of%0ANew+Drug+Application%0Afor+ALKS+5461+for+the+Adjunctive+Treatment+of+Major+Depressive+Disorder%3B+Alkermes%2C+April+16%2C+2018%3B+http%3A%2F%2Fphx.corporate-ir.net%2Fphoenix.zhtml%3Fc%3D92211%26p%3Dirol-corporateNewsArticle%26ID%3D2342624."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DAlkermes%2520Announces%2520FDA%2520Acceptance%2520for%2520Review%2520of%250ANew%2520Drug%2520Application%250Afor%2520ALKS%25205461%2520for%2520the%2520Adjunctive%2520Treatment%2520of%2520Major%2520Depressive%2520Disorder%26pub%3DAlkermes%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, M.</span>; <span class="NLM_string-name">Urbano, M.</span>; <span class="NLM_string-name">Brown, S.
J.</span>; <span class="NLM_string-name">Cayanan, C.</span>; <span class="NLM_string-name">Ferguson, J.</span>; <span class="NLM_string-name">Cameron, M.</span>; <span class="NLM_string-name">Devi, L.
A.</span>; <span class="NLM_string-name">Roberts, E.</span>; <span class="NLM_string-name">Rosen, H.</span></span> <span> </span><span class="NLM_article-title">Optimization and characterization of an opioid kappa receptor (OPRK1) antagonist</span>. In  <i>Probe Reports from the NIH Molecular Libraries Program [Internet]</i>; <span class="NLM_publisher-name">National Center for Biotechnology Information</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2013</span>; <a href="https://www.ncbi.nlm.nih.gov/books/NBK179827/" class="extLink">https://www.ncbi.nlm.nih.gov/books/NBK179827/</a> (accessed Dec 14, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Guerrero&author=M.+Urbano&author=S.%0AJ.+Brown&author=C.+Cayanan&author=J.+Ferguson&author=M.+Cameron&author=L.%0AA.+Devi&author=E.+Roberts&author=H.+Rosen&title=Optimization+and+characterization+of+an+opioid+kappa+receptor+%28OPRK1%29+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DGuerrero%26aufirst%3DM.%26atitle%3DOptimization%2520and%2520characterization%2520of%2520an%2520opioid%2520kappa%2520receptor%2520%2528OPRK1%2529%2520antagonist%26jtitle%3DProbe%2520Reports%2520from%2520the%2520NIH%2520Molecular%2520Libraries%2520Program%2520%255BInternet%255D%26pub%3DNational%2520Center%2520for%2520Biotechnology%2520Information%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbertz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudkins, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallamo, J. P.</span></span> <span> </span><span class="NLM_article-title">Knowledge-Based, Central nervous system (CNS) lead selection and lead optimization for CNS drug discovery</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1021/cn200100h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn200100h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=50-68&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=R.+L.+Hudkinsauthor=B.+D.+Dorseyauthor=J.+P.+Mallamo&title=Knowledge-Based%2C+Central+nervous+system+%28CNS%29+lead+selection+and+lead+optimization+for+CNS+drug+discovery&doi=10.1021%2Fcn200100h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Hudkins, Robert L.; Dorsey, Bruce D.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-68</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The central nervous system (CNS) is the major area that is affected by aging.  Alzheimer's disease (AD), Parkinson's disease (PD), brain cancer, and stroke are the CNS diseases that will cost trillions of dollars for their treatment.  Achievement of appropriate blood-brain barrier (BBB) penetration is often considered a significant hurdle in the CNS drug discovery process.  On the other hand, BBB penetration may be a liability for many of the non-CNS drug targets, and a clear understanding of the physicochem. and structural differences between CNS and non-CNS drugs may assist both research areas.  Because of the numerous and challenging issues in CNS drug discovery and the low success rates, pharmaceutical companies are beginning to deprioritize their drug discovery efforts in the CNS arena.  Prompted by these challenges and to aid in the design of high-quality, efficacious CNS compds., we analyzed the physicochem. property and the chem. structural profiles of 317 CNS and 626 non-CNS oral drugs.  The conclusions derived provide an ideal property profile for lead selection and the property modification strategy during the lead optimization process.  A list of substructural units that may be useful for CNS drug design was also provided here.  A classification tree was also developed to differentiate between CNS drugs and non-CNS oral drugs.  The combined anal. provided the following guidelines for designing high-quality CNS drugs: (i) topol. mol. polar surface area of <76 Å2 (25-60 Å2), (ii) at least one (one or two, including one aliph. amine) nitrogen, (iii) fewer than seven (two to four) linear chains outside of rings, (iv) fewer than three (zero or one) polar hydrogen atoms, (v) vol. of 740-970 Å3, (vi) solvent accessible surface area of 460-580 Å2, and (vii) pos. QikProp parameter CNS.  The ranges within parentheses may be used during lead optimization.  One violation to this proposed profile may be acceptable.  The chemoinformatics approaches for graphically analyzing multiple properties efficiently are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozqfO0vq2i5bVg90H21EOLACvtfcHk0lgG6PyyVoE6yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO&md5=4c20ba34c3d5397170b50242975ce25d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcn200100h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn200100h%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge-Based%252C%2520Central%2520nervous%2520system%2520%2528CNS%2529%2520lead%2520selection%2520and%2520lead%2520optimization%2520for%2520CNS%2520drug%2520discovery%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D50%26epage%3D68%26doi%3D10.1021%2Fcn200100h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benigni, R.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship studies of chemical mutagens and carcinogens: mechanistic investigations and prediction approaches</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1021/cr030049y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr030049y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=1767-1800&author=R.+Benigni&title=Structure-activity+relationship+studies+of+chemical+mutagens+and+carcinogens%3A+mechanistic+investigations+and+prediction+approaches&doi=10.1021%2Fcr030049y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fcr030049y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr030049y%26sid%3Dliteratum%253Aachs%26aulast%3DBenigni%26aufirst%3DR.%26atitle%3DStructure-activity%2520relationship%2520studies%2520of%2520chemical%2520mutagens%2520and%2520carcinogens%253A%2520mechanistic%2520investigations%2520and%2520prediction%2520approaches%26jtitle%3DChem.%2520Rev.%26date%3D2005%26volume%3D105%26spage%3D1767%26epage%3D1800%26doi%3D10.1021%2Fcr030049y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Mayoral, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreiras, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, E.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the Friedländer reaction</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2652</span>– <span class="NLM_lpage">2671</span>, <span class="refDoi"> DOI: 10.1021/cr800482c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr800482c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVSltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2652-2671&author=J.+Marco-Contellesauthor=E.+P%C3%A9rez-Mayoralauthor=A.+Samadiauthor=M.+C.+Carreirasauthor=E.+Soriano&title=Recent+advances+in+the+Friedl%C3%A4nder+reaction&doi=10.1021%2Fcr800482c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Friedlander Reaction</span></div><div class="casAuthors">Marco-Contelles, Jose; Perez-Mayoral, Elena; Samadi, Abdelouahid; Carreiras, Maria do Carmo; Soriano, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2652-2671</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This review is an update of the Friedlander reaction from the most significant literature from 1981 to the present.  A particular emphasis is on the development of novel catalysts, exptl. conditions as well as an application toward natural products synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8jFyV0XzFYLVg90H21EOLACvtfcHk0lgG6PyyVoE6yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVSltrY%253D&md5=247618f98000f1a747a443a1648854bc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fcr800482c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr800482c%26sid%3Dliteratum%253Aachs%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DP%25C3%25A9rez-Mayoral%26aufirst%3DE.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DCarreiras%26aufirst%3DM.%2BC.%26aulast%3DSoriano%26aufirst%3DE.%26atitle%3DRecent%2520advances%2520in%2520the%2520Friedl%25C3%25A4nder%2520reaction%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D2652%26epage%3D2671%26doi%3D10.1021%2Fcr800482c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arvela, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span> <span> </span><span class="NLM_article-title">Highly regioselective internal heck arylation of hydroxyalkyl vinyl ethers by aryl halides in water</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">6390</span>– <span class="NLM_lpage">6396</span>, <span class="refDoi"> DOI: 10.1021/jo0705768</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0705768" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFGntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=6390-6396&author=R.+K.+Arvelaauthor=S.+Pasquiniauthor=M.+Larhed&title=Highly+regioselective+internal+heck+arylation+of+hydroxyalkyl+vinyl+ethers+by+aryl+halides+in+water&doi=10.1021%2Fjo0705768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Regioselective Internal Heck Arylation of Hydroxyalkyl Vinyl Ethers by Aryl Halides in Water</span></div><div class="casAuthors">Arvela, Riina K.; Pasquini, Serena; Larhed, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6390-6396</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Highly regioselective and fast Pd(0)-catalyzed internal α-arylation of ethylene glycol vinyl ether with aryl halides was shown to be possible in water without the need for any halide scavengers or ionic liq. additives.  This presents the first case of water being utilized in the selective arylation of electron-rich olefins.  Resulting α-products, e.g. I, were hydrolyzed and isolated as corresponding acetophenones, e.g. II, in good to excellent yields when using aryl bromides and with good to moderate yields in the case of aryl iodides.  Microwave irradn. was shown to be beneficial in activation of aryl chlorides toward the internal Heck arylation.  The scope of the protocol was further increased to include different hydroxyalkyl vinyl ethers, these all giving selectively only branched α-products.  The active role of the hydroxy group in directing the regioselectivity toward internal arylation of electron-rich olefins, even in nonpolar toluene, was revealed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosc1YtaLz2C7Vg90H21EOLACvtfcHk0lijCSGcyzdXXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFGntLg%253D&md5=e869d07bf33fcbc89264604b636cc46a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjo0705768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0705768%26sid%3Dliteratum%253Aachs%26aulast%3DArvela%26aufirst%3DR.%2BK.%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DLarhed%26aufirst%3DM.%26atitle%3DHighly%2520regioselective%2520internal%2520heck%2520arylation%2520of%2520hydroxyalkyl%2520vinyl%2520ethers%2520by%2520aryl%2520halides%2520in%2520water%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D6390%26epage%3D6396%26doi%3D10.1021%2Fjo0705768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torner, L.</span></span> <span> </span><span class="NLM_article-title">Actions of prolactin in the brain: from physiological adaptations to stress and neurogenesis to psychopathology</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi"> DOI: 10.3389/fendo.2016.00025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.3389%2Ffendo.2016.00025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=27065946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A280%3ADC%252BC28fovFahsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=25&author=L.+Torner&title=Actions+of+prolactin+in+the+brain%3A+from+physiological+adaptations+to+stress+and+neurogenesis+to+psychopathology&doi=10.3389%2Ffendo.2016.00025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Actions of Prolactin in the Brain: From Physiological Adaptations to Stress and Neurogenesis to Psychopathology</span></div><div class="casAuthors">Torner Luz</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">Prolactin (PRL) is one of the most versatile hormones known.  It is considered an adaptive hormone due to the key roles it plays in the modulation of the stress response and during pregnancy and lactation.  Within the brain, PRL acts as a neuropeptide to promote physiological responses related to reproduction, stress adaptation, neurogenesis, and neuroprotection.  The action of PRL on the nervous system contributes to the wide array of changes that occur in the female brain during pregnancy and result in the attenuation of the hypothalamic-pituitary-adrenal axis.  Together, all these changes promote behavioral and physiological adaptations of the new mother to enable reproductive success.  Brain adaptations driven by PRL are also important for the regulation of maternal emotionality and well-being.  PRL also affects the male brain during the stress response, but its effects have been less studied.  PRL regulates neurogenesis both in the subventricular zone and in the hippocampus.  Therefore, alterations in the PRL system due to stress or exposure to substances that reduce neurogenesis or other conditions, could contribute to maladaptive responses and pathological behavioral outcomes.  Here, we review the PRL system and the role it plays in the modulation of stress response and emotion regulation.  We discuss the effects of PRL on neurogenesis and neuroprotection, the putative neuronal mechanisms underlying these effects, and their contribution to the onset of psychopathological states such as depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcNoUq-9QkGmlSCSgBhwJFfW6udTcc2ebU1EwSFZ_Vibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fovFahsg%253D%253D&md5=3eac529f37a92cece83076a58c5f3f85</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2016.00025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2016.00025%26sid%3Dliteratum%253Aachs%26aulast%3DTorner%26aufirst%3DL.%26atitle%3DActions%2520of%2520prolactin%2520in%2520the%2520brain%253A%2520from%2520physiological%2520adaptations%2520to%2520stress%2520and%2520neurogenesis%2520to%2520psychopathology%26jtitle%3DFront.%2520Endocrinol.%26date%3D2016%26volume%3D7%26spage%3D25%26doi%3D10.3389%2Ffendo.2016.00025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binart, N.</span></span> <span> </span><span class="NLM_article-title">New insights in prolactin: pathological implications</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2015.36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1038%2Fnrendo.2015.36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=25781857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVyiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=265-275&author=V.+Bernardauthor=J.+Youngauthor=P.+Chansonauthor=N.+Binart&title=New+insights+in+prolactin%3A+pathological+implications&doi=10.1038%2Fnrendo.2015.36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">New insights in prolactin: pathological implications</span></div><div class="casAuthors">Bernard, Valerie; Young, Jacques; Chanson, Philippe; Binart, Nadine</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">265-275</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Prolactin is a hormone that is mainly secreted by lactotroph cells of the anterior pituitary gland, and is involved in many biol. processes including lactation and reprodn.  Animal models have provided insights into the biol. of prolactin proteins and offer compelling evidence that the different prolactin isoforms each have independent biol. functions.  The major isoform, 23 kDa prolactin, acts via its membrane receptor, the prolactin receptor (PRL-R), which is a member of the hematopoietic cytokine superfamily and for which the mechanism of activation has been deciphered.  The 16 kDa prolactin isoform is a cleavage product derived from native prolactin, which has received particular attention as a result of its newly described inhibitory effects on angiogenesis and tumorigenesis.  The discovery of multiple extrapituitary sites of prolactin secretion also increases the range of known functions of this hormone.  This Review summarizes current knowledge of the biol. of prolactin and its receptor, as well as its physiol. and pathol. roles.  We focus on the role of prolactin in human pathophysiol., particularly the discovery of the mechanism underlying infertility assocd. with hyperprolactinemia and the identification of the first mutation in human PRLR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo90HVf0LrwVbVg90H21EOLACvtfcHk0lijCSGcyzdXXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVyiurc%253D&md5=55b45b43b5628dd70f25ea5a175ff045</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2015.36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2015.36%26sid%3Dliteratum%253Aachs%26aulast%3DBernard%26aufirst%3DV.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DChanson%26aufirst%3DP.%26aulast%3DBinart%26aufirst%3DN.%26atitle%3DNew%2520insights%2520in%2520prolactin%253A%2520pathological%2520implications%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2015%26volume%3D11%26spage%3D265%26epage%3D275%26doi%3D10.1038%2Fnrendo.2015.36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schluger, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidlack, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreek, M. J.</span></span> <span> </span><span class="NLM_article-title">Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2254</span>– <span class="NLM_lpage">2262</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1300811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1038%2Fsj.npp.1300811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=15988468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WqurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2005&pages=2254-2262&author=G.+Bartauthor=J.+H.+Schlugerauthor=L.+Borgauthor=A.+Hoauthor=J.+M.+Bidlackauthor=M.+J.+Kreek&title=Nalmefene+induced+elevation+in+serum+prolactin+in+normal+human+volunteers%3A+partial+kappa+opioid+agonist+activity%3F&doi=10.1038%2Fsj.npp.1300811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Nalmefene Induced Elevation in Serum Prolactin in Normal Human Volunteers: Partial Kappa Opioid Agonist Activity?</span></div><div class="casAuthors">Bart, Gavin; Schluger, James H.; Borg, Lisa; Ho, Ann; Bidlack, Jean M.; Kreek, Mary Jeanne</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2254-2262</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In humans, mu- and kappa-opioid receptor agonists lower tuberoinfundibular dopamine, which tonically inhibits prolactin release.  Serum prolactin is, therefore, a useful biomarker for tuberoinfundibular dopamine.  The current study evaluated the unexpected finding that the relative mu- and kappa-opioid receptor selective antagonist nalmefene increases serum prolactin, indicating possible kappa-opioid receptor agonist activity.  In all, 33 healthy human volunteers (14 female) with no history of psychiatric or substance use disorders received placebo, nalmefene 3 mg, and nalmefene 10 mg in a double-blind manner.  Drugs were administered between 0900 and 1000 on sep. days via 2-min i.v. infusion.  Serial blood specimens were analyzed for serum levels of prolactin.  Addnl. in vitro studies of nalmefene binding to cloned human kappa-opioid receptors transfected into Chinese hamster ovary cells were performed.  Compared to placebo, both doses of nalmefene caused significant elevations in serum prolactin (p<0.002 for nalmefene 3 mg and p<0.0005 for nalmefene 10 mg).  There was no difference in prolactin response between the 3 and 10 mg doses.  Binding assays confirmed nalmefene's affinity at kappa-opioid receptors and antagonism of mu-opioid receptors. [35S]GTPγS binding studies demonstrated that nalmefene is a full antagonist at mu-opioid receptors and has partial agonist properties at kappa-opioid receptors.  Elevations in serum prolactin following nalmefene are consistent with this partial agonist effect at kappa-opioid receptors.  As kappa-opioid receptor activation can lower dopamine in brain regions important to the persistence of alc. and cocaine dependence, the partial kappa agonist effect of nalmefene may enhance its therapeutic efficacy in selected addictive diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNyaQ97u9HsbVg90H21EOLACvtfcHk0lh2_mPtT_NyWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WqurvN&md5=791e1e9c10f9c18157662e02d0d0ce2c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300811%26sid%3Dliteratum%253Aachs%26aulast%3DBart%26aufirst%3DG.%26aulast%3DSchluger%26aufirst%3DJ.%2BH.%26aulast%3DBorg%26aufirst%3DL.%26aulast%3DHo%26aufirst%3DA.%26aulast%3DBidlack%26aufirst%3DJ.%2BM.%26aulast%3DKreek%26aufirst%3DM.%2BJ.%26atitle%3DNalmefene%2520induced%2520elevation%2520in%2520serum%2520prolactin%2520in%2520normal%2520human%2520volunteers%253A%2520partial%2520kappa%2520opioid%2520agonist%2520activity%253F%26jtitle%3DNeuropsychopharmacology%26date%3D2005%26volume%3D30%26spage%3D2254%26epage%3D2262%26doi%3D10.1038%2Fsj.npp.1300811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Jonathan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hnasko, R.</span></span> <span> </span><span class="NLM_article-title">Dopamine as a prolactin (PRL) inhibitor</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">724</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1210/edrv.22.6.0451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1210%2Fedrv.22.6.0451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=11739329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlOhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=724-763&author=N.+Ben-Jonathanauthor=R.+Hnasko&title=Dopamine+as+a+prolactin+%28PRL%29+inhibitor&doi=10.1210%2Fedrv.22.6.0451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine as a prolactin (PRL) inhibitor</span></div><div class="casAuthors">Ben-Jonathan, Nira; Hnasko, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">724-763</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  Dopamine is a small and relatively simple mol. that fulfills diverse functions.  Within the brain, it acts as a classical neurotransmitter whose attenuation or overactivity can result in disorders such as Parkinson's disease and schizophrenia.  Major advances in the cloning and characterization of biosynthetic enzymes, transporters, and receptors have increased our knowledge regarding the metab., release, reuptake, and mechanism of action of dopamine.  Dopamine reaches the pituitary via hypophysial portal blood from several hypothalamic nerve tracts that are regulated by PRL itself, estrogens, and several neuropeptides and neurotransmitters.  Dopamine binds to type-2 dopamine receptors that are functionally linked to membrane channels and G proteins and suppresses the high intrinsic secretory activity of the pituitary lactotrophs.  In addn. to inhibiting PRL release by controlling calcium fluxes, dopamine activates several interacting intracellular signaling pathways and suppresses PRL gene expression and lactotroph proliferation.  Thus, PRL homeostasis should be viewed in the context of a fine balance between the action of dopamine as an inhibitor and the many hypothalamic, systemic, and local factors acting as stimulators, none of which has yet emerged as a primary PRL releasing factor.  The generation of transgenic animals with overexpressed or mutated genes expanded our understanding of dopamine-PRL interactions and the physiol. consequences of their perturbations.  PRL release in humans, which differs in many respects from that in lab. animals, is affected by several drugs used in clin. practice.  Hyperprolactinemia is a major neuroendocrine-related cause of reproductive disturbances in both men and women.  The treatment of hyperprolactinemia has greatly benefited from the generation of progressively more effective and selective dopaminergic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRaf7Hlnxaa7Vg90H21EOLACvtfcHk0lh2_mPtT_NyWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlOhug%253D%253D&md5=5cbdcf9f307d93da02763f5f9666b5f6</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1210%2Fedrv.22.6.0451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fedrv.22.6.0451%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Jonathan%26aufirst%3DN.%26aulast%3DHnasko%26aufirst%3DR.%26atitle%3DDopamine%2520as%2520a%2520prolactin%2520%2528PRL%2529%2520inhibitor%26jtitle%3DEndocr.%2520Rev.%26date%3D2001%26volume%3D22%26spage%3D724%26epage%3D763%26doi%3D10.1210%2Fedrv.22.6.0451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butelman, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreek, M. J.</span></span> <span> </span><span class="NLM_article-title">Kappa-opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D(2)-like receptor agonists</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(01)01121-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2FS0014-2999%2801%2901121-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=11448491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltVGjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2001&pages=243-249&author=E.+R.+Butelmanauthor=M.+J.+Kreek&title=Kappa-opioid+receptor+agonist-induced+prolactin+release+in+primates+is+blocked+by+dopamine+D%282%29-like+receptor+agonists&doi=10.1016%2FS0014-2999%2801%2901121-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">κ-Opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D2-like receptor agonists</span></div><div class="casAuthors">Butelman, E. R.; Kreek, M.-J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">243-249</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Kappa (κ)-opioid receptor agonists may have pharmacotherapeutic potential in the management of psychostimulant abuse, due to their ability to modulate dopamine receptor systems involved in drug reinforcement.  κ-Opioid receptor agonists also modulate dopamine receptor function in the hypothalamic tuberoinfundibular system, which has inhibitory control over an anterior pituitary hormone, prolactin.  Prolactin levels may thus be a "biomarker" for the ability of κ-opioid receptor agonists (e.g., (+)-(5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide (U69,593)) to modulate a dopamine receptor system in vivo in primates.  The effectiveness of dopamine D2-like receptor agonists (quinpirole and (±)-7-hydroxy-dipropylaminotetralin (7-OH-DPAT); 0.0032-0.1 mg/kg) in preventing U69,593-induced prolactin release was studied in intact female rhesus monkeys.  Quinpirole and 7-OH-DPAT inhibited U69,593-induced prolactin release (ID50 values: 0.013 and 0.0072 mg/kg, resp.).  However, the dopamine D1-receptor agonist (±)-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazapine (SKF 82958; 1 mg/kg) did not inhibit U69,593-induced prolactin release under the same conditions.  In contrast, the largest doses of quinpirole or 7-OH-DPAT presently studied (0.1 mg/kg), did not decrease sedation caused by U69,593 (0.01, 0.032 mg/kg), a prominent effect of centrally penetrating κ-opioid receptor agonists.  The sedative effect of U69,593 (0.032 mg/kg) was prevented by naltrexone (0.32 mg/kg), consistent with κ-opioid receptor mediation of this effect.  These studies suggest that prolactin release is a valid biomarker for the ability of κ-opioid receptor agonists to modulate dopamine D2-like receptor function, and may also be used to quantify dopamine D2-like receptor agonist potency in primates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre_zNIfsWlh7Vg90H21EOLACvtfcHk0lh2_mPtT_NyWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltVGjsLo%253D&md5=957d00d5eef7a3580e49960cb67f0bc6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2801%2901121-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252801%252901121-9%26sid%3Dliteratum%253Aachs%26aulast%3DButelman%26aufirst%3DE.%2BR.%26aulast%3DKreek%26aufirst%3DM.%2BJ.%26atitle%3DKappa-opioid%2520receptor%2520agonist-induced%2520prolactin%2520release%2520in%2520primates%2520is%2520blocked%2520by%2520dopamine%2520D%25282%2529-like%2520receptor%2520agonists%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D423%26spage%3D243%26epage%3D249%26doi%3D10.1016%2FS0014-2999%2801%2901121-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of 2-methyl-N-((2’-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.185108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1124%2Fjpet.111.185108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=21821697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFehtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2011&pages=555-566&author=S.+Grimwoodauthor=Y.+Luauthor=A.+W.+Schmidtauthor=M.+A.+Vanase-Frawleyauthor=A.+Sawant-Basakauthor=E.+Millerauthor=S.+McLeanauthor=J.+Freemanauthor=S.+Wongauthor=J.+P.+McLaughlinauthor=P.+R.+Verhoest&title=Pharmacological+characterization+of+2-methyl-N-%28%282%E2%80%99-%28pyrrolidin-1-ylsulfonyl%29biphenyl-4-yl%29methyl%29propan-1-amine+%28PF-04455242%29%2C+a+high-affinity+antagonist+selective+for+%CE%BA-opioid+receptors&doi=10.1124%2Fjpet.111.185108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors</span></div><div class="casAuthors">Grimwood, S.; Lu, Y.; Schmidt, A. W.; Vanase-Frawley, M. A.; Sawant-Basak, A.; Miller, E.; McLean, S.; Freeman, J.; Wong, S.; McLaughlin, J. P.; Verhoest, P. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">555-566</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">2-Methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242) is a novel κ-opioid receptor (KOR) antagonist with high affinity for human (3 nM), rat (21 nM), and mouse (22 nM) KOR, a ∼20-fold reduced affinity for human μ-opioid receptors (MORs; Ki = 64 nM), and negligible affinity for δ-opioid receptors (Ki > 4 μM).  PF-04455242 also showed selectivity for KORs in vivo.  In rats, PF-04455242 blocked KOR and MOR agonist-induced analgesia with ID50 values of 1.5 and 9.8 mg/kg, resp., and inhibited ex vivo [3H](2-(benzofuran-4-yl)-N-methyl-N-((5S,7R,8R)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-yl)acetamide ([3H]CI977) and [3H](2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl) propanoyl]amino]propanoyl]amino]acetyl]-methylamino]-N-(2-hydroxyethyl)-3-phenylpropanamide ([3H]DAMGO) binding to KOR and MOR receptors with ID50 values of 2.0 and 8.6 mg/kg, resp.  An in vivo binding assay was developed using (-)-4-[3H]methoxycarbonyl-2-[(1-pyrrolidinylmethyl]-1-[(3,4-dichlorophenyl)acetyl]-piperidine ([3H]PF-04767135), a tritiated version of the KOR positron emission tomog. ligand (-)-4-[11C]methoxycarbonyl-2-[(1-pyrrolidinylmethyl]-1-[(3,4-dichlorophenyl)acetyl]-piperidine ([11C]GR103545) in which PF-04455242 had an ID50 of 5.2 mg/kg.  PF-04455242 demonstrated antidepressant-like efficacy (mouse forced-swim test), attenuated the behavioral effects of stress (mouse social defeat stress assay), and showed therapeutic potential in treating reinstatement of extinguished cocaine-seeking behavior (mouse conditioned place preference).  KOR agonist-induced plasma prolactin was investigated as a translatable mechanism biomarker.  Spiradoline (0.32 mg/kg) significantly increased rat plasma prolactin levels from 1.9 ± 0.4 to 41.9 ± 4.9 ng/mL.  PF-04455242 dose-dependently reduced the elevation of spiradoline-induced plasma prolactin with an ID50 of 2.3 ± 0.1 mg/kg, which aligned well with the ED50 values obtained from the rat in vivo binding and efficacy assays.  These data provide further evidence that KOR antagonists have potential for the treatment of depression and addiction disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6o0AfESL4erVg90H21EOLACvtfcHk0liDPisVuFhchg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFehtbrI&md5=23093593fd3960da26ec89ea25123001</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.185108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.185108%26sid%3Dliteratum%253Aachs%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DVanase-Frawley%26aufirst%3DM.%2BA.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DE.%26aulast%3DMcLean%26aufirst%3DS.%26aulast%3DFreeman%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DMcLaughlin%26aufirst%3DJ.%2BP.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26atitle%3DPharmacological%2520characterization%2520of%25202-methyl-N-%2528%25282%25E2%2580%2599-%2528pyrrolidin-1-ylsulfonyl%2529biphenyl-4-yl%2529methyl%2529propan-1-amine%2520%2528PF-04455242%2529%252C%2520a%2520high-affinity%2520antagonist%2520selective%2520for%2520%25CE%25BA-opioid%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D339%26spage%3D555%26epage%3D566%26doi%3D10.1124%2Fjpet.111.185108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byon, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badura, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span> <span> </span><span class="NLM_article-title">Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1208/s12248-011-9296-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1208%2Fs12248-011-9296-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=565-575&author=C.+Changauthor=W.+Byonauthor=Y.+Luauthor=L.+K.+Jacobsenauthor=L.+L.+Baduraauthor=A.+Sawant-Basakauthor=E.+Millerauthor=J.+Liuauthor=S.+Grimwoodauthor=E.+Q.+Wangauthor=T.+S.+Maurer&title=Quantitative+PK-PD+model-based+translational+pharmacology+of+a+novel+kappa+opioid+receptor+antagonist+between+rats+and+humans&doi=10.1208%2Fs12248-011-9296-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1208%2Fs12248-011-9296-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-011-9296-3%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DC.%26aulast%3DByon%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DJacobsen%26aufirst%3DL.%2BK.%26aulast%3DBadura%26aufirst%3DL.%2BL.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DE.%2BQ.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26atitle%3DQuantitative%2520PK-PD%2520model-based%2520translational%2520pharmacology%2520of%2520a%2520novel%2520kappa%2520opioid%2520receptor%2520antagonist%2520between%2520rats%2520and%2520humans%26jtitle%3DAAPS%2520J.%26date%3D2011%26volume%3D13%26spage%3D565%26epage%3D575%26doi%3D10.1208%2Fs12248-011-9296-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span> <i>BlackThorn Therapeutics Initiates Phase 1 Study
of BTRX-335140, an
Investigational Kappa Opioid Receptor (KOR) Antagonist</i>; <span class="NLM_publisher-name">BlackThorn Therapeutics</span>: <span class="NLM_publisher-loc">San Francisco,
CA</span>, Jun 6, <span class="NLM_year">2018</span>; <a href="http://www.blackthornrx.com/blackthorn-therapeutics-initiates-phase-1-study-of-btrx-335140-an-investigational-kappa-opioid-receptor-kor-antagonist/" class="extLink">http://www.blackthornrx.com/blackthorn-therapeutics-initiates-phase-1-study-of-btrx-335140-an-investigational-kappa-opioid-receptor-kor-antagonist/</a> (accessed Dec 14, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+BlackThorn+Therapeutics+Initiates+Phase+1+Study%0Aof+BTRX-335140%2C+an%0AInvestigational+Kappa+Opioid+Receptor+%28KOR%29+Antagonist%3B+BlackThorn+Therapeutics%3A+San+Francisco%2C%0ACA%2C+Jun+6%2C+2018%3B+http%3A%2F%2Fwww.blackthornrx.com%2Fblackthorn-therapeutics-initiates-phase-1-study-of-btrx-335140-an-investigational-kappa-opioid-receptor-kor-antagonist%2F+%28accessed+Dec+14%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DBlackThorn%2520Therapeutics%2520Initiates%2520Phase%25201%2520Study%250Aof%2520BTRX-335140%252C%2520an%250AInvestigational%2520Kappa%2520Opioid%2520Receptor%2520%2528KOR%2529%2520Antagonist%26pub%3DBlackThorn%2520Therapeutics%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="note"><p class="first last">cLogP and tPSA calculated with Chembiodraw Ultra 12.0.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span>Cp<i>K</i><sub>a</sub> calculated with Marvin 5.7.1, 2012; <a href="http://www.chemaxon.com" class="extLink">http://www.chemaxon.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CpKa+calculated+with+Marvin+5.7.1%2C+2012%3B+http%3A%2F%2Fwww.chemaxon.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':[],'ref51':['cit51']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard J.  Bodnar</span>. </span><span class="cited-content_cbyCitation_article-title">Endogenous opiates and behavior: 2019. </span><span class="cited-content_cbyCitation_journal-name">Peptides</span><span> <strong>2021,</strong> <em>141 </em>, 170547. <a href="https://doi.org/10.1016/j.peptides.2021.170547" title="DOI URL">https://doi.org/10.1016/j.peptides.2021.170547</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.peptides.2021.170547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.peptides.2021.170547%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptides%26atitle%3DEndogenous%252Bopiates%252Band%252Bbehavior%25253A%252B2019%26aulast%3DBodnar%26aufirst%3DRichard%2BJ.%26date%3D2021%26volume%3D141%26spage%3D170547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei-Jie  Fang</span>, <span class="hlFld-ContribAuthor ">Thomas F.  Murray</span>, <span class="hlFld-ContribAuthor ">Jane V.  Aldrich</span>. </span><span class="cited-content_cbyCitation_article-title">Analogs of the κ opioid receptor antagonist arodyn cyclized by ring-closing metathesis retain κ opioid receptor affinity, selectivity and κ opioid receptor antagonism. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2021,</strong> <em>30 </em>
                                    (7)
                                     , 1397-1407. <a href="https://doi.org/10.1007/s00044-021-02758-x" title="DOI URL">https://doi.org/10.1007/s00044-021-02758-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-021-02758-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-021-02758-x%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DAnalogs%252Bof%252Bthe%252B%2525CE%2525BA%252Bopioid%252Breceptor%252Bantagonist%252Barodyn%252Bcyclized%252Bby%252Bring-closing%252Bmetathesis%252Bretain%252B%2525CE%2525BA%252Bopioid%252Breceptor%252Baffinity%25252C%252Bselectivity%252Band%252B%2525CE%2525BA%252Bopioid%252Breceptor%252Bantagonism%26aulast%3DFang%26aufirst%3DWei-Jie%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D7%26spage%3D1397%26epage%3D1407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Wang</span>, <span class="hlFld-ContribAuthor ">Xiyan  Rui</span>, <span class="hlFld-ContribAuthor ">Dongjuan  Si</span>, <span class="hlFld-ContribAuthor ">Rupeng  Dai</span>, <span class="hlFld-ContribAuthor ">Yueyue  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongmei  Wen</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Jian  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Copper‐Catalyzed Three‐Component Cascade Reaction of Benzaldehyde with Benzylamine and Hydroxylamine or Aniline: Synthesis of 1,2,4‐Oxadiazoles and Quinazolines. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>363 </em>
                                    (11)
                                     , 2825-2833. <a href="https://doi.org/10.1002/adsc.202001535" title="DOI URL">https://doi.org/10.1002/adsc.202001535</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202001535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202001535%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DCopper%2525E2%252580%252590Catalyzed%252BThree%2525E2%252580%252590Component%252BCascade%252BReaction%252Bof%252BBenzaldehyde%252Bwith%252BBenzylamine%252Band%252BHydroxylamine%252Bor%252BAniline%25253A%252BSynthesis%252Bof%252B1%25252C2%25252C4%2525E2%252580%252590Oxadiazoles%252Band%252BQuinazolines%26aulast%3DWang%26aufirst%3DChao%26date%3D2021%26date%3D2021%26volume%3D363%26issue%3D11%26spage%3D2825%26epage%3D2833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eduardo R  Butelman</span>, <span class="hlFld-ContribAuthor ">Caroline  Baynard</span>, <span class="hlFld-ContribAuthor ">Bryan D  McElroy</span>, <span class="hlFld-ContribAuthor ">Thomas E  Prisinzano</span>, <span class="hlFld-ContribAuthor ">Mary Jeanne  Kreek</span>. </span><span class="cited-content_cbyCitation_article-title">Profile of a short-acting κ-antagonist, LY2795050, on self-grooming behaviors, forced swim test and locomotor activity: sex comparison in mice. </span><span class="cited-content_cbyCitation_journal-name">Journal of Psychopharmacology</span><span> <strong>2021,</strong> <em>35 </em>
                                    (5)
                                     , 579-590. <a href="https://doi.org/10.1177/0269881121996883" title="DOI URL">https://doi.org/10.1177/0269881121996883</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/0269881121996883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F0269881121996883%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Psychopharmacology%26atitle%3DProfile%252Bof%252Ba%252Bshort-acting%252B%2525CE%2525BA-antagonist%25252C%252BLY2795050%25252C%252Bon%252Bself-grooming%252Bbehaviors%25252C%252Bforced%252Bswim%252Btest%252Band%252Blocomotor%252Bactivity%25253A%252Bsex%252Bcomparison%252Bin%252Bmice%26aulast%3DButelman%26aufirst%3DEduardo%2BR%26date%3D2021%26date%3D2021%26volume%3D35%26issue%3D5%26spage%3D579%26epage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caroline M  Kopruszinski</span>, <span class="hlFld-ContribAuthor ">Edita  Navratilova</span>, <span class="hlFld-ContribAuthor ">Juliana  Swiokla</span>, <span class="hlFld-ContribAuthor ">David W  Dodick</span>, <span class="hlFld-ContribAuthor ">Iain P  Chessell</span>, <span class="hlFld-ContribAuthor ">Frank  Porreca</span>. </span><span class="cited-content_cbyCitation_article-title">A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. </span><span class="cited-content_cbyCitation_journal-name">Cephalalgia</span><span> <strong>2021,</strong> <em>41 </em>
                                    (3)
                                     , 305-317. <a href="https://doi.org/10.1177/0333102420959794" title="DOI URL">https://doi.org/10.1177/0333102420959794</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/0333102420959794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F0333102420959794%26sid%3Dliteratum%253Aachs%26jtitle%3DCephalalgia%26atitle%3DA%252Bnovel%25252C%252Binjury-free%252Brodent%252Bmodel%252Bof%252Bvulnerability%252Bfor%252Bassessment%252Bof%252Bacute%252Band%252Bpreventive%252Btherapies%252Breveals%252Btemporal%252Bcontributions%252Bof%252BCGRP-receptor%252Bactivation%252Bin%252Bmigraine-like%252Bpain%26aulast%3DKopruszinski%26aufirst%3DCaroline%2BM%26date%3D2021%26date%3D2020%26volume%3D41%26issue%3D3%26spage%3D305%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miao-Jin  Ji</span>, <span class="hlFld-ContribAuthor ">Jiao  Yang</span>, <span class="hlFld-ContribAuthor ">Zhi-Qiang  Gao</span>, <span class="hlFld-ContribAuthor ">Liang  Zhang</span>, <span class="hlFld-ContribAuthor ">Chao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of the Kappa Opioid System in Comorbid Pain and Psychiatric Disorders: Function and Implications. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Neuroscience</span><span> <strong>2021,</strong> <em>15 </em><a href="https://doi.org/10.3389/fnins.2021.642493" title="DOI URL">https://doi.org/10.3389/fnins.2021.642493</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnins.2021.642493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnins.2021.642493%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Neuroscience%26atitle%3DThe%252BRole%252Bof%252Bthe%252BKappa%252BOpioid%252BSystem%252Bin%252BComorbid%252BPain%252Band%252BPsychiatric%252BDisorders%25253A%252BFunction%252Band%252BImplications%26aulast%3DJi%26aufirst%3DMiao-Jin%26date%3D2021%26date%3D2021%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicolas  Massaly</span>, <span class="hlFld-ContribAuthor ">Tamara  Markovic</span>, <span class="hlFld-ContribAuthor ">Meaghan  Creed</span>, <span class="hlFld-ContribAuthor ">Ream  Al-Hasani</span>, <span class="hlFld-ContribAuthor ">Catherine M.  Cahill</span>, <span class="hlFld-ContribAuthor ">Jose A.  Moron</span>. </span><span class="cited-content_cbyCitation_article-title">Pain, negative affective states and opioid-based analgesics: Safer pain therapies to dampen addiction. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 31-68. <a href="https://doi.org/10.1016/bs.irn.2020.09.002" title="DOI URL">https://doi.org/10.1016/bs.irn.2020.09.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.irn.2020.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.irn.2020.09.002%26sid%3Dliteratum%253Aachs%26atitle%3DPain%25252C%252Bnegative%252Baffective%252Bstates%252Band%252Bopioid-based%252Banalgesics%25253A%252BSafer%252Bpain%252Btherapies%252Bto%252Bdampen%252Baddiction%26aulast%3DMassaly%26aufirst%3DNicolas%26date%3D2021%26spage%3D31%26epage%3D68%26pub%3DElsevier%26atitle%3DNeurobiology%252Bof%252BAddiction%252Band%252BCo-Morbid%252BDisorders%26date%3D2021%26volume%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai-Min  Shen</span>, <span class="hlFld-ContribAuthor ">Xiong  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Ning</span>, <span class="hlFld-ContribAuthor ">A-Bing  Guo</span>, <span class="hlFld-ContribAuthor ">Jin-Hui  Deng</span>, <span class="hlFld-ContribAuthor ">Yuan-Bin  She</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient oxidation of cycloalkanes with simultaneously increased conversion and selectivity using O2 catalyzed by metalloporphyrins and boosted by Zn(AcO)2: A practical strategy to inhibit the formation of aliphatic diacids. </span><span class="cited-content_cbyCitation_journal-name">Applied Catalysis A: General</span><span> <strong>2021,</strong> <em>609 </em>, 117904. <a href="https://doi.org/10.1016/j.apcata.2020.117904" title="DOI URL">https://doi.org/10.1016/j.apcata.2020.117904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apcata.2020.117904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apcata.2020.117904%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Catalysis%2520A%253A%2520General%26atitle%3DEfficient%252Boxidation%252Bof%252Bcycloalkanes%252Bwith%252Bsimultaneously%252Bincreased%252Bconversion%252Band%252Bselectivity%252Busing%252BO2%252Bcatalyzed%252Bby%252Bmetalloporphyrins%252Band%252Bboosted%252Bby%252BZn%252528AcO%2525292%25253A%252BA%252Bpractical%252Bstrategy%252Bto%252Binhibit%252Bthe%252Bformation%252Bof%252Baliphatic%252Bdiacids%26aulast%3DShen%26aufirst%3DHai-Min%26date%3D2021%26volume%3D609%26spage%3D117904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elyssa B.  Margolis</span>, <span class="hlFld-ContribAuthor ">Tanya L.  Wallace</span>, <span class="hlFld-ContribAuthor ">Lori Jean  Van Orden</span>, <span class="hlFld-ContribAuthor ">William J.  Martin</span>, . </span><span class="cited-content_cbyCitation_article-title">Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2020,</strong> <em>15 </em>
                                    (12)
                                     , e0232864. <a href="https://doi.org/10.1371/journal.pone.0232864" title="DOI URL">https://doi.org/10.1371/journal.pone.0232864</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0232864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0232864%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DDifferential%252Beffects%252Bof%252Bnovel%252Bkappa%252Bopioid%252Breceptor%252Bantagonists%252Bon%252Bdopamine%252Bneurons%252Busing%252Bacute%252Bbrain%252Bslice%252Belectrophysiology%26aulast%3DMargolis%26aufirst%3DElyssa%2BB.%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D12%26spage%3De0232864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kathryn L.  Reichard</span>, <span class="hlFld-ContribAuthor ">Keionna A.  Newton</span>, <span class="hlFld-ContribAuthor ">Zeena M.G.  Rivera</span>, <span class="hlFld-ContribAuthor ">Paulo M.  Sotero de Menezes</span>, <span class="hlFld-ContribAuthor ">Selena S.  Schattauer</span>, <span class="hlFld-ContribAuthor ">Benjamin B.  Land</span>, <span class="hlFld-ContribAuthor ">Charles  Chavkin</span>. </span><span class="cited-content_cbyCitation_article-title">Regulation of Kappa Opioid Receptor Inactivation Depends on Sex and Cellular Site of Antagonist Action. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmacology</span><span> <strong>2020,</strong> <em>98 </em>
                                    (5)
                                     , 548-558. <a href="https://doi.org/10.1124/molpharm.120.000124" title="DOI URL">https://doi.org/10.1124/molpharm.120.000124</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/molpharm.120.000124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fmolpharm.120.000124%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmacology%26atitle%3DRegulation%252Bof%252BKappa%252BOpioid%252BReceptor%252BInactivation%252BDepends%252Bon%252BSex%252Band%252BCellular%252BSite%252Bof%252BAntagonist%252BAction%26aulast%3DReichard%26aufirst%3DKathryn%2BL.%26date%3D2020%26date%3D2020%26volume%3D98%26issue%3D5%26spage%3D548%26epage%3D558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karol  Biernacki</span>, <span class="hlFld-ContribAuthor ">Mateusz  Daśko</span>, <span class="hlFld-ContribAuthor ">Olga  Ciupak</span>, <span class="hlFld-ContribAuthor ">Konrad  Kubiński</span>, <span class="hlFld-ContribAuthor ">Janusz  Rachon</span>, <span class="hlFld-ContribAuthor ">Sebastian  Demkowicz</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 1,2,4-Oxadiazole Derivatives in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (6)
                                     , 111. <a href="https://doi.org/10.3390/ph13060111" title="DOI URL">https://doi.org/10.3390/ph13060111</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13060111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13060111%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DNovel%252B1%25252C2%25252C4-Oxadiazole%252BDerivatives%252Bin%252BDrug%252BDiscovery%26aulast%3DBiernacki%26aufirst%3DKarol%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D6%26spage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian  Reed</span>, <span class="hlFld-ContribAuthor ">Eduardo R.  Butelman</span>, <span class="hlFld-ContribAuthor ">Mary Jeanne  Kreek</span>. </span><span class="cited-content_cbyCitation_article-title">Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1007/164_2020_401" title="DOI URL">https://doi.org/10.1007/164_2020_401</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/164_2020_401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F164_2020_401%26sid%3Dliteratum%253Aachs%26atitle%3DKappa%252BOpioid%252BReceptor%252BAntagonists%252Bas%252BPotential%252BTherapeutics%252Bfor%252BMood%252Band%252BSubstance%252BUse%252BDisorders%26aulast%3DReed%26aufirst%3DBrian%26date%3D2020%26date%3D2020%26pub%3DSpringer%2520Berlin%2520Heidelberg%26date%3D2020%26date%3D2020%26volume%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mei-Chuan  Ko</span>, <span class="hlFld-ContribAuthor ">Stephen M.  Husbands</span>. </span><span class="cited-content_cbyCitation_article-title">Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1007/164_2020_419" title="DOI URL">https://doi.org/10.1007/164_2020_419</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/164_2020_419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F164_2020_419%26sid%3Dliteratum%253Aachs%26atitle%3DPleiotropic%252BEffects%252Bof%252BKappa%252BOpioid%252BReceptor-Related%252BLigands%252Bin%252BNon-human%252BPrimates%26aulast%3DKo%26aufirst%3DMei-Chuan%26date%3D2020%26date%3D2020%26pub%3DSpringer%2520Berlin%2520Heidelberg%26date%3D2020%26date%3D2020%26volume%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammed Noorladeen  Al–Qattan</span>, <span class="hlFld-ContribAuthor ">Nirupam  Das</span>, <span class="hlFld-ContribAuthor ">Rati Kailash Prasad  Tripathi</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacology of Endogenous Opioids, Opiates and Their Receptors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 381-414. <a href="https://doi.org/10.1007/978-981-15-3556-7_12" title="DOI URL">https://doi.org/10.1007/978-981-15-3556-7_12</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-15-3556-7_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-15-3556-7_12%26sid%3Dliteratum%253Aachs%26atitle%3DPharmacology%252Bof%252BEndogenous%252BOpioids%25252C%252BOpiates%252Band%252BTheir%252BReceptors%26aulast%3DAl%25E2%2580%2593Qattan%26aufirst%3DMohammed%2BNoorladeen%26date%3D2020%26date%3D2020%26spage%3D381%26epage%3D414%26pub%3DSpringer%2520Singapore%26atitle%3DFrontiers%252Bin%252BPharmacology%252Bof%252BNeurotransmitters%26aulast%3DKumar%26aufirst%3DPuneet%26date%3D2020%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah  Page</span>, <span class="hlFld-ContribAuthor ">Maria M  Mavrikaki</span>, <span class="hlFld-ContribAuthor ">Tania  Lintz</span>, <span class="hlFld-ContribAuthor ">Daniel  Puttick</span>, <span class="hlFld-ContribAuthor ">Edward  Roberts</span>, <span class="hlFld-ContribAuthor ">Hugh  Rosen</span>, <span class="hlFld-ContribAuthor ">F Ivy  Carroll</span>, <span class="hlFld-ContribAuthor ">William A  Carlezon</span>, <span class="hlFld-ContribAuthor ">Elena H  Chartoff</span>. </span><span class="cited-content_cbyCitation_article-title">Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Neuropsychopharmacology</span><span> <strong>2019,</strong> <em>160 </em><a href="https://doi.org/10.1093/ijnp/pyz054" title="DOI URL">https://doi.org/10.1093/ijnp/pyz054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ijnp/pyz054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fijnp%2Fpyz054%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Neuropsychopharmacology%26atitle%3DBehavioral%252BPharmacology%252Bof%252BNovel%252BKappa%252BOpioid%252BReceptor%252BAntagonists%252Bin%252BRats%26aulast%3DPage%26aufirst%3DSarah%26date%3D2019%26date%3D2019%26volume%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Prototypical and clinical stage KOR antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Early KOR antagonist HTS hit <b>8</b> and <b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <b>10</b> (1.0 equiv), <b>11</b> (1.0 equiv), NaBH(OAc)<sub>3</sub> (1.5 equiv), AcOH (1.5 equiv), 1,2-dichloroethane, rt, 24 h, 76%; (ii) Pd/c 10%, EtOH, 2 h, rt, 97%; (iii) <b>13</b> (1.0 equiv), <b>14</b> (1.1 equiv), EDCI (1.3 equiv), HOBt (1.3 equiv), DMF, 110 °C, mw, 1 h, 71%; (iv) <b>15</b> (1.0 equiv), <b>12</b> (2.0 equiv), DIPEA (2.0 equiv), EtOH, mw, 135 °C, 4 h, 62%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>27</b>–<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) (a) <b>17</b> or <b>18</b> (1.0 equiv), SOCl<sub>2</sub> (3.0 equiv), DMF (cat.), CH<sub>2</sub>Cl<sub>2</sub>, 60 °C, 2 h, (b) <b>14</b> (1.3 equiv), DIPEA (2.0 equiv), 1,4-dioxane, 110 °C, 3 h, 39–42%; (ii) <b>19</b> or <b>20</b> (1.0 equiv), <b>21</b> (2.0 equiv), DIPEA (2.0 equiv), EtOH, mw, 130 °C, 3 h, 82–86%; (iii) 10% aq H<sub>2</sub>SO<sub>4</sub>, THF, rt, 3 h, 87–91%; (iv) <b>24</b> or <b>25</b> (1.0 equiv), <b>26</b> (1.1–2.0 equiv), NaBH(OAc)<sub>3</sub> (2.0 equiv), AcOH (2.0 equiv), 1,2-dichloroethane, rt, overnight, 75–92%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>46</b>–<b>50</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <b>40</b> (1.0 equiv), BH<sub>3</sub>–THF (3.0 equiv), THF, 0 °C to rt, 18 h, 76%; (ii) MnO<sub>2</sub> (6.0 equiv), CH<sub>2</sub>Cl<sub>2,</sub> rt, 8 h, quantitative; (iii) <b>41</b> (1.0 equiv), POCl<sub>3,</sub> 80 °C, 1 h, 14%; (iv) <b>43</b> (1.0 equiv), <b>21</b> (1.5 equiv), DIPEA (1.5 equiv), EtOH, 130 °C, mw, 2 h, 45%; (v) (a) <b>44</b> (1.0 equiv), Cs<sub>2</sub>CO<sub>3</sub> (3.0 equiv), Pd(dppf)Cl<sub>2</sub>·DCM (0.1 equiv), THF, 70 °C, 1 h, 74%, (b) 10% aq H<sub>2</sub>SO<sub>4</sub>, 45 °C, 2h, 94%; (vi) <b>45</b> (1.0 equiv), 26 (2.0 equiv), NaBH(OAc)<sub>3</sub> (3.0 equiv), AcOH (3.0 equiv), DIPEA (2.0 equiv), 1,2-dichloroethane, rt, overnight, 77–87%.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>58</b>–<b>62</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <b>51</b> (1.0 equiv), NIS (1.05 equiv), AcOH, rt, 1 h, 94%; (ii) <b>52</b> (1.0 equiv), <b>53</b> (6.0 equiv), K<sub>2</sub>CO<sub>3</sub> (1.2 equiv), DPPP (0.05 equiv), <b>42</b> (1.1 equiv), POCl<sub>3</sub>, 80 °C, 1 h, 40%; (iv) <b>55</b> (1.0 equiv), <b>21</b> (1.3 equiv), DIPEA (2.0 equiv), EtOH, 110 °C, overnight, 93%; (v) <b>56</b> (1.0 equiv), 10% aq H<sub>2</sub>SO<sub>4</sub>, THF, 45 °C, 2 h, 84%; (vi) <b>57</b> (1.0 equiv), <b>26</b> (2.0 equiv), NaBH(OAc)<sub>3</sub> (2.0 equiv), AcOH (2.0 equiv), 1,2-dicholoroethane, rt, overnight, 73–84%.</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of KOR agonist stimulated prolactin via po administration of <b>47</b>, <b>49</b>, and <b>62</b>. KOR antagonists were dosed as the monotartrate salts. Three mice per dose group where two samples were collected per mouse.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibition of KOR agonist stimulated prolactin via po administration of <b>58</b>. <b>58</b> was dosed as the monotartrate salt. Four mice per dose group where two samples were collected per mouse.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/medium/jm-2018-01679y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0005.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. KOR nlockade of antinociceptive response by <b>58</b> in the mouse tail-flick assay. (A,B) Systemic injection of U50488 (15 mg kg<sup>–1</sup>, ip) induced robust antinociception within 30 min in the mouse tail-flick test (50 °C water bath), which was blocked by <b>58</b> (1 mg kg<sup>–1</sup>, ip) given at 1 h prior to U50488. (C,D) <b>58</b> (1 mg kg<sup>–1</sup>, ip) given at 24 h prior to U50488 (15 mg kg<sup>–1</sup>, ip) failed to block U50488-induced antinociception assessed at 30 min post-U50,488. (E,F) <b>58</b> (1 mg kg<sup>–1</sup>, ip) alone did not alter tail flick latency at 60 min postdose. (G,H) Oral <b>58</b> (3, 10, 30 mg kg<sup>–1</sup>, po) given at 1 h prior to U50488 (15 mg kg<sup>–1</sup>, ip) dose-dependently blocked U50488-induced antinociception assessed at 30 min post-U50488. Data represent mean ± SEM %maximum possible effect (MPE) = (post-dose latency – pre-dose latency)/(cutoff – pre-dose latency) × 100. Cutoff = 15 s to prevent tissue damage. Statistics performed using two-way ANOVA followed by Sidak’s multiple comparisons posthoc test (A–F) or linear regression (G,H). *<i>P</i> < 0.05 vs baseline (BL) of the corresponding treatment group. Group sizes are shown in the figure. <b>58</b> was dosed as the monotartrate salt.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b01679/20190221/images/large/jm-2018-01679y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01679&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74257" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74257" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagerström, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundin, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiöth, H. B.</span></span> <span> </span><span class="NLM_article-title">The G-protein-coupled receptors in the human genome form five main families. phylogenetic analysis, paralogon groups, and fingerprints</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1272</span>, <span class="refDoi"> DOI: 10.1124/mol.63.6.1256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1124%2Fmol.63.6.1256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=12761335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Shu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=1256-1272&author=R.+Fredrikssonauthor=M.+C.+Lagerstr%C3%B6mauthor=L.+G.+Lundinauthor=H.+B.+Schi%C3%B6th&title=The+G-protein-coupled+receptors+in+the+human+genome+form+five+main+families.+phylogenetic+analysis%2C+paralogon+groups%2C+and+fingerprints&doi=10.1124%2Fmol.63.6.1256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints</span></div><div class="casAuthors">Fredriksson, Robert; Lagerstrom, Malin C.; Lundin, Lars-Gustav; Schioth, Helgi B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1256-1272</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The superfamily of G-protein-coupled receptors (GPCRs) is very diverse in structure and function and its members are among the most pursued targets for drug development.  We identified more than 800 human GPCR sequences and simultaneously analyzed 342 unique functional nonolfactory human GPCR sequences with phylogenetic analyses.  Our results show, with high bootstrap support, five main families, named glutamate, rhodopsin, adhesion, frizzled/taste2, and secretin, forming the GRAFS classification system.  The rhodopsin family is the largest and forms four main groups with 13 subbranches.  Positions of the GPCRs in chromosomal paralogons regions indicate the importance of tetraploidizations or local gene duplication events for their creation.  We also searched for "fingerprint" motifs using Hidden Markov Models delineating the putative inter-relationship of the GRAFS families.  We show several common structural features indicating that the human GPCRs in the GRAFS families share a common ancestor.  This study represents the first overall map of the GPCRs in a single mammalian genome.  Our novel approach of analyzing such large and diverse sequence sets may be useful for studies on GPCRs in other genomes and divergent protein families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdX4VhTsaDzrVg90H21EOLACvtfcHk0ljk66Ok1h_cBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Shu7k%253D&md5=504ea873ee8469cd0b6016bc94943836</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fmol.63.6.1256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.63.6.1256%26sid%3Dliteratum%253Aachs%26aulast%3DFredriksson%26aufirst%3DR.%26aulast%3DLagerstr%25C3%25B6m%26aufirst%3DM.%2BC.%26aulast%3DLundin%26aufirst%3DL.%2BG.%26aulast%3DSchi%25C3%25B6th%26aufirst%3DH.%2BB.%26atitle%3DThe%2520G-protein-coupled%2520receptors%2520in%2520the%2520human%2520genome%2520form%2520five%2520main%2520families.%2520phylogenetic%2520analysis%252C%2520paralogon%2520groups%252C%2520and%2520fingerprints%26jtitle%3DMol.%2520Pharmacol.%26date%3D2003%26volume%3D63%26spage%3D1256%26epage%3D1272%26doi%3D10.1124%2Fmol.63.6.1256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldhoer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whistler, J. L.</span></span> <span> </span><span class="NLM_article-title">Opioid receptors</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">990</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.73.011303.073940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1146%2Fannurev.biochem.73.011303.073940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=15189164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslagsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2004&pages=953-990&author=M.+Waldhoerauthor=S.+E.+Bartlettauthor=J.+L.+Whistler&title=Opioid+receptors&doi=10.1146%2Fannurev.biochem.73.011303.073940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid receptors</span></div><div class="casAuthors">Waldhoer, Maria; Bartlett, Selena E.; Whistler, Jennifer L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">953-990</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Opioid receptors belong to the large superfamily of 7 transmembrane-spanning (7TM) G protein-coupled receptors (GPCRs).  As a class, GPCRs are of fundamental physiol. importance mediating the actions of the majority of known neurotransmitters and hormones.  Opioid receptors are particularly intriguing members of this receptor family.  They are activated both by endogenously produced opioid peptides and by exogenously administered opiate compds., some of which are not only among the most effective analgesics known but also highly addictive drugs of abuse.  A fundamental question in addiction biol. is why exogenous opioid drugs, such as morphine and heroin, have a high liability for inducing tolerance, dependence, and addiction.  This review focuses on many aspects of opioid receptors with the aim of gaining a greater insight into mechanisms of opioid tolerance and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSV3Nl3WDHrVg90H21EOLACvtfcHk0ljk66Ok1h_cBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslagsbs%253D&md5=9f865544116a6dac76c80432587180a3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.73.011303.073940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.73.011303.073940%26sid%3Dliteratum%253Aachs%26aulast%3DWaldhoer%26aufirst%3DM.%26aulast%3DBartlett%26aufirst%3DS.%2BE.%26aulast%3DWhistler%26aufirst%3DJ.%2BL.%26atitle%3DOpioid%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2004%26volume%3D73%26spage%3D953%26epage%3D990%26doi%3D10.1146%2Fannurev.biochem.73.011303.073940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, A.</span></span> <span> </span><span class="NLM_article-title">Dynorphin is a specific endogenous ligand of the kappa opioid receptor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1126/science.6120570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1126%2Fscience.6120570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=6120570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaL38XhtFKntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=1982&pages=413-415&author=C.+Chavkinauthor=I.+F.+Jamesauthor=A.+Goldstein&title=Dynorphin+is+a+specific+endogenous+ligand+of+the+kappa+opioid+receptor&doi=10.1126%2Fscience.6120570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Dynorphin is a specific endogenous ligand of the κ opioid receptor</span></div><div class="casAuthors">Chavkin, Charles; James, Iain F.; Goldstein, Avram</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue">4531</span>),
    <span class="NLM_cas:pages">413-15</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">In the guinea pig ileum myenteric plexus-longitudinal muscle prepn., dynorphin-(1-13)  [72957-38-1] and the prototypical κ agonist ethylketocyclazocine had equally poor sensitivity to naloxone antagonism and showed selective cross protection in receptor inactivation expts. with the alkylating antagonist β-chlornaltrexamine.  In binding assays with membranes from guinea pig brain, ethylketocyclazocine and dynorphin-(1-13) amide  [79515-34-7] were more potent in displacing tritium labeled ethylketocyclazocine than in displacing typical μ and δ opioid receptor ligands.  In the two prepns. studied, the dynorphin receptor appears to be the same as the κ opioid receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0CJdDpQ9ourVg90H21EOLACvtfcHk0lj42ZmFiy19HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XhtFKntbc%253D&md5=90f2695917a67dba88463f0673eb16c5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.6120570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.6120570%26sid%3Dliteratum%253Aachs%26aulast%3DChavkin%26aufirst%3DC.%26aulast%3DJames%26aufirst%3DI.%2BF.%26aulast%3DGoldstein%26aufirst%3DA.%26atitle%3DDynorphin%2520is%2520a%2520specific%2520endogenous%2520ligand%2520of%2520the%2520kappa%2520opioid%2520receptor%26jtitle%3DScience%26date%3D1982%26volume%3D215%26spage%3D413%26epage%3D415%26doi%3D10.1126%2Fscience.6120570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruchas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Land, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span> <span> </span><span class="NLM_article-title">The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1314</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2009.08.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2Fj.brainres.2009.08.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=19716811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlelsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1314&publication_year=2010&pages=44-55&author=M.+R.+Bruchasauthor=B.+B.+Landauthor=C.+Chavkin&title=The+dynorphin%2Fkappa+opioid+system+as+a+modulator+of+stress-induced+and+pro-addictive+behaviors&doi=10.1016%2Fj.brainres.2009.08.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors</span></div><div class="casAuthors">Bruchas, M. R.; Land, B. B.; Chavkin, C.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1314</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">44-55</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Stress is a complex experience that carries both aversive and motivating properties.  Chronic stress causes an increase in the risk of depression, is well known to increase relapse of drug seeking behavior, and can adversely impact health.  Several brain systems have been demonstrated to be crit. in mediating the neg. affect assocd. with stress, and recent evidence directly links the actions of the endogenous opioid neuropeptide dynorphin in modulating mood and increasing the rewarding effects of abused drugs.  These results suggest that activation of the dynorphin/kappa opioid receptor (KOR) system is likely to play a major role in the pro-addictive effects of stress.  This review explores the relationship between dynorphin and corticotropin-releasing factor (CRF) in the induction of dysphoria, the potentiation of drug seeking, and stress-induced reinstatement.  We also provide an overview of the signal transduction events responsible for CRF and dynorphin/KOR-dependent behaviors.  Understanding the recent work linking activation of CRF and dynorphin/KOR systems and their specific roles in brain stress systems and behavioral models of addiction provides novel insight to neuropeptide systems that regulate affective state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWddx4_zzq3LVg90H21EOLACvtfcHk0lj42ZmFiy19HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlelsL8%253D&md5=bfe759208b7a72a43fe30ddc806758a1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2009.08.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2009.08.062%26sid%3Dliteratum%253Aachs%26aulast%3DBruchas%26aufirst%3DM.%2BR.%26aulast%3DLand%26aufirst%3DB.%2BB.%26aulast%3DChavkin%26aufirst%3DC.%26atitle%3DThe%2520dynorphin%252Fkappa%2520opioid%2520system%2520as%2520a%2520modulator%2520of%2520stress-induced%2520and%2520pro-addictive%2520behaviors%26jtitle%3DBrain%2520Res.%26date%3D2010%26volume%3D1314%26spage%3D44%26epage%3D55%26doi%3D10.1016%2Fj.brainres.2009.08.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simonin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavériaux-Ruff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Befort, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micheletti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattéi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, B.</span></span> <span> </span><span class="NLM_article-title">Kappa-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">7006</span>– <span class="NLM_lpage">7010</span>, <span class="refDoi"> DOI: 10.1073/pnas.92.15.7006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1073%2Fpnas.92.15.7006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=7006-7010&author=F.+Simoninauthor=C.+Gav%C3%A9riaux-Ruffauthor=K.+Befortauthor=H.+Matthesauthor=B.+Lannesauthor=G.+Michelettiauthor=M.+G.+Matt%C3%A9iauthor=G.+Charronauthor=B.+Blochauthor=B.+Kieffer&title=Kappa-opioid+receptor+in+humans%3A+cDNA+and+genomic+cloning%2C+chromosomal+assignment%2C+functional+expression%2C+pharmacology%2C+and+expression+pattern+in+the+central+nervous+system&doi=10.1073%2Fpnas.92.15.7006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1073%2Fpnas.92.15.7006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.92.15.7006%26sid%3Dliteratum%253Aachs%26aulast%3DSimonin%26aufirst%3DF.%26aulast%3DGav%25C3%25A9riaux-Ruff%26aufirst%3DC.%26aulast%3DBefort%26aufirst%3DK.%26aulast%3DMatthes%26aufirst%3DH.%26aulast%3DLannes%26aufirst%3DB.%26aulast%3DMicheletti%26aufirst%3DG.%26aulast%3DMatt%25C3%25A9i%26aufirst%3DM.%2BG.%26aulast%3DCharron%26aufirst%3DG.%26aulast%3DBloch%26aufirst%3DB.%26aulast%3DKieffer%26aufirst%3DB.%26atitle%3DKappa-opioid%2520receptor%2520in%2520humans%253A%2520cDNA%2520and%2520genomic%2520cloning%252C%2520chromosomal%2520assignment%252C%2520functional%2520expression%252C%2520pharmacology%252C%2520and%2520expression%2520pattern%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1995%26volume%3D92%26spage%3D7006%26epage%3D7010%26doi%3D10.1073%2Fpnas.92.15.7006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hille, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, P.</span></span> <span> </span><span class="NLM_article-title">Subtraction autoradiography of opiate receptor subtypes in human brain</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>418</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(87)90101-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2F0006-8993%2887%2990101-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=2823963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaL2sXlt1Omtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=418&publication_year=1987&pages=343-348&author=A.+J.+Crossauthor=C.+Hilleauthor=P.+Slater&title=Subtraction+autoradiography+of+opiate+receptor+subtypes+in+human+brain&doi=10.1016%2F0006-8993%2887%2990101-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Subtraction autoradiography of opiate receptor subtypes in human brain</span></div><div class="casAuthors">Cross, Alan J.; Hille, Christopher; Slater, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">418</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">343-8</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">Opiate-binding sites in sections of human brain were labeled with [3H]etorphine.  Many brain areas contained high levels of [3H]etorphine-binding sites, although the globus pallidus was an exception.  Subtraction autoradiog. was performed using selective displacement of [3H]etorphine with opioid agonists to visualize μ-, δ-, and κ-opiate receptor subtypes.  μ-Receptors were most abundant the thalamus, caudate nucleus, putamen, and the superficial layers of the cerebral cortex.  Kappa receptors were concd. in the high concns. of endogenous opioid peptides have many receptors, but in other areas, for example the globus pallidus, there is a mismatch between peptide concn. and receptor d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSK2XSEJMouLVg90H21EOLACvtfcHk0lgZNxlCLofBaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXlt1Omtbw%253D&md5=befc9ea332b946f9eb3754c30116f85f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2887%2990101-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252887%252990101-6%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DA.%2BJ.%26aulast%3DHille%26aufirst%3DC.%26aulast%3DSlater%26aufirst%3DP.%26atitle%3DSubtraction%2520autoradiography%2520of%2520opiate%2520receptor%2520subtypes%2520in%2520human%2520brain%26jtitle%3DBrain%2520Res.%26date%3D1987%26volume%3D418%26spage%3D343%26epage%3D348%26doi%3D10.1016%2F0006-8993%2887%2990101-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belcheva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coscia, C. J.</span></span> <span> </span><span class="NLM_article-title">Opioid receptor density changes in Alzheimer amygdala and putamen</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>632</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(93)91155-L</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2F0006-8993%2893%2991155-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=8149229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVeru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=632&publication_year=1993&pages=209-215&author=J.+Bargauthor=M.+Belchevaauthor=J.+Rowinskiauthor=A.+Hoauthor=W.+J.+Burkeauthor=H.+D.+Chungauthor=C.+A.+Schmidtauthor=C.+J.+Coscia&title=Opioid+receptor+density+changes+in+Alzheimer+amygdala+and+putamen&doi=10.1016%2F0006-8993%2893%2991155-L"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid receptor density changes in Alzheimer amygdala and putamen</span></div><div class="casAuthors">Barg, Jacob; Belcheva, Mariana; Rowinski, Jan; Ho, Andrew; Burke, William J.; Chung, Hyung. D.; Schmidt, Catherine A.; Coscia, Carmine J.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">632</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">209-15</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">Since opioids can influence the release of acetylcholine, substance P and a no. of other neurotransmitters that have been implicated in the pathogenesis of Alzheimer's disease (AD), it is of interest to assess opioid receptor levels in AD.  The authors have examd. μ, δ and κ opioid receptor binding parameters, binding sensitivity to a GTP analog and distribution in amygdala, frontal cortex and putamen of AD brain.  Control brains were matched according to age, sex, post-mortem interval and storage time.  Kd values and GTP analog binding sensitivity did not differ in AD and control brains.  Bmax values for μ ([3H]DAMGE) sites also appeared unaffected by in vitro binding assays.  In contrast, κ ([3H]U69593) and δ ([3H]DSLET) opioid receptor levels, were significantly changed.  In AD amygdala κ Bmax values increased from control levels of 123±12 to 168±13 fmol/mg protein, whereas densities of κ and δ sites were decreased from 94±8 to 48±8 and 102±3.6 to 69±8.5 fmol/mg protein, resp., in putamen.  Autoradiog. revealed corresponding differences in the distribution of κ opioid receptors.  The findings indicate that the κ binding site, which is quant. the major opioid receptor class in human brain, undergoes marked changes in AD amygdala and putamen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXJPEM61tjN7Vg90H21EOLACvtfcHk0lgZNxlCLofBaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVeru7g%253D&md5=27e37d823057e6ddb57d440d326f4e89</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2893%2991155-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252893%252991155-L%26sid%3Dliteratum%253Aachs%26aulast%3DBarg%26aufirst%3DJ.%26aulast%3DBelcheva%26aufirst%3DM.%26aulast%3DRowinski%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DW.%2BJ.%26aulast%3DChung%26aufirst%3DH.%2BD.%26aulast%3DSchmidt%26aufirst%3DC.%2BA.%26aulast%3DCoscia%26aufirst%3DC.%2BJ.%26atitle%3DOpioid%2520receptor%2520density%2520changes%2520in%2520Alzheimer%2520amygdala%2520and%2520putamen%26jtitle%3DBrain%2520Res.%26date%3D1993%26volume%3D632%26spage%3D209%26epage%3D215%26doi%3D10.1016%2F0006-8993%2893%2991155-L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehraein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herz, A.</span></span> <span> </span><span class="NLM_article-title">Opiate receptor binding sites in human brain</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>248</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(82)91150-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2F0006-8993%2882%2991150-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=6289997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaL38XlsFOht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1982&pages=87-96&author=A.+Pfeifferauthor=A.+Pasiauthor=P.+Mehraeinauthor=A.+Herz&title=Opiate+receptor+binding+sites+in+human+brain&doi=10.1016%2F0006-8993%2882%2991150-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Opiate receptor binding sites in human brain</span></div><div class="casAuthors">Pfeiffer, Andreas; Pasi, Aurelio; Mehraein, Parviz; Herz, Albert</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">248</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-96</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">Subclasses of opiate receptor binding sites in human brain membranes were investigated by means of competitive binding techniques.  The exptl. data were analyzed by use of a computerized nonlinear regression curve fitting program.  The μ-, δ-, and κ-types of opiate binding were found in 5 different regions of the brain.  A more extensive anal. of the regional distribution of subclasses of opiate-binding sites was performed using a simple sequential inhibition technique.  This method gave results which were comparable with those obtained by computer anal. of multiple tracer displacement curves.  The κ- and μ-sites represented the major component of binding in most brain areas, whereas δ-sites were fewer in no.  The 3 types of binding showed different distribution patterns, suggesting that they are independent from each other.  The distribution pattern obsd. in human brain resembled the one obsd. in rat brain, although κ-sites appear to represent a more important, and δ-sites appear to represent a less important, fraction of binding in human as compared with rat brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiBdlykH_Ad7Vg90H21EOLACvtfcHk0lgZNxlCLofBaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlsFOht7s%253D&md5=35bb4a70a626234c46fb1df25b07e273</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2882%2991150-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252882%252991150-7%26sid%3Dliteratum%253Aachs%26aulast%3DPfeiffer%26aufirst%3DA.%26aulast%3DPasi%26aufirst%3DA.%26aulast%3DMehraein%26aufirst%3DP.%26aulast%3DHerz%26aufirst%3DA.%26atitle%3DOpiate%2520receptor%2520binding%2520sites%2520in%2520human%2520brain%26jtitle%3DBrain%2520Res.%26date%3D1982%26volume%3D248%26spage%3D87%26epage%3D96%26doi%3D10.1016%2F0006-8993%2882%2991150-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delay-Goyet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javoy-Agid, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agid, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span> <span> </span><span class="NLM_article-title">Regional distribution of μ, δ and κ opioid receptors in human brains from controls and parkinsonian subjects</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>414</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(87)91321-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2F0006-8993%2887%2991321-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=3040166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaL2sXltFeltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=1987&pages=8-14&author=P.+Delay-Goyetauthor=J.+M.+Zajacauthor=F.+Javoy-Agidauthor=Y.+Agidauthor=B.+P.+Roques&title=Regional+distribution+of+%CE%BC%2C+%CE%B4+and+%CE%BA+opioid+receptors+in+human+brains+from+controls+and+parkinsonian+subjects&doi=10.1016%2F0006-8993%2887%2991321-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Regional distribution of μ, δ and κ opioid receptors in human brains from controls and parkinsonian subjects</span></div><div class="casAuthors">Delay-Goyet, P.; Zajac, J. M.; Javoy-Agid, F.; Roques, B. P.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-14</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">The binding properties of μ and δ opioid receptors were investigated in several areas of human brain by using [3H]Tyr-D-Ala-Gly(Me)Phe-Gly-ol and [3H]Tyr-D-Thr-Gly-Phe-Leu-Thr as resp. selective ligands, while the totality of opioid receptors was measured by using [3H]etorphine as a non-selective agonist.  Receptor densities were highest in cerebral cortex, amygdala and striatum, and lowest in the substantia nigra (pars compacta).  In the different brain areas of patients with Parkinson's disease, the d. and the proportion of the various opioid receptors were not significantly different from control subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU5K19hx_b_rVg90H21EOLACvtfcHk0liZbGTPP3-jJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXltFeltb4%253D&md5=0eaa9db177a7cd18996ce0d4efe3d4b0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2887%2991321-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252887%252991321-7%26sid%3Dliteratum%253Aachs%26aulast%3DDelay-Goyet%26aufirst%3DP.%26aulast%3DZajac%26aufirst%3DJ.%2BM.%26aulast%3DJavoy-Agid%26aufirst%3DF.%26aulast%3DAgid%26aufirst%3DY.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26atitle%3DRegional%2520distribution%2520of%2520%25CE%25BC%252C%2520%25CE%25B4%2520and%2520%25CE%25BA%2520opioid%2520receptors%2520in%2520human%2520brains%2520from%2520controls%2520and%2520parkinsonian%2520subjects%26jtitle%3DBrain%2520Res.%26date%3D1987%26volume%3D414%26spage%3D8%26epage%3D14%26doi%3D10.1016%2F0006-8993%2887%2991321-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlezon, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Béguin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNieri, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todtenkopf, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, B. M.</span></span> <span> </span><span class="NLM_article-title">Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">440</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.092304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1124%2Fjpet.105.092304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=16223871" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2005&pages=440-447&author=W.+A.+Carlezonauthor=C.+B%C3%A9guinauthor=J.+A.+DiNieriauthor=M.+H.+Baumannauthor=M.+R.+Richardsauthor=M.+S.+Todtenkopfauthor=R.+B.+Rothmanauthor=Z.+Maauthor=D.+Y.+Leeauthor=B.+M.+Cohen&title=Depressive-like+effects+of+the+kappa-opioid+receptor+agonist+salvinorin+A+on+behavior+and+neurochemistry+in+rats&doi=10.1124%2Fjpet.105.092304"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.092304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.092304%26sid%3Dliteratum%253Aachs%26aulast%3DCarlezon%26aufirst%3DW.%2BA.%26aulast%3DB%25C3%25A9guin%26aufirst%3DC.%26aulast%3DDiNieri%26aufirst%3DJ.%2BA.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DRichards%26aufirst%3DM.%2BR.%26aulast%3DTodtenkopf%26aufirst%3DM.%2BS.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DD.%2BY.%26aulast%3DCohen%26aufirst%3DB.%2BM.%26atitle%3DDepressive-like%2520effects%2520of%2520the%2520kappa-opioid%2520receptor%2520agonist%2520salvinorin%2520A%2520on%2520behavior%2520and%2520neurochemistry%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D316%26spage%3D440%26epage%3D447%26doi%3D10.1124%2Fjpet.105.092304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mague, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pliakas, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todtenkopf, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasiewicz, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlezon, W. A.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>305</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1124/jpet.102.046433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1124%2Fjpet.102.046433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=12649385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1amsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2003&pages=323-330&author=S.+D.+Magueauthor=A.+M.+Pliakasauthor=M.+S.+Todtenkopfauthor=H.+C.+Tomasiewiczauthor=Y.+Zhangauthor=W.+C.+Stevensauthor=R.+M.+Jonesauthor=P.+S.+Portogheseauthor=W.+A.+Carlezon&title=Antidepressant-like+effects+of+kappa-opioid+receptor+antagonists+in+the+forced+swim+test+in+rats&doi=10.1124%2Fjpet.102.046433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats</span></div><div class="casAuthors">Mague, Stephen D.; Pliakas, Andrea M.; Todtenkopf, Mark S.; Tomasiewicz, Hilarie C.; Zhang, Yan; Stevens, William C., Jr.; Jones, Robert M.; Portoghese, Philip S.; Carlezon, William A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">323-330</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We showed previously that cAMP response element-binding protein (CREB) within the nucleus accumbens (NAc) of rats regulates immobility in the forced swim test (FST), an assay used to study depression.  Because CREB regulates expression of dynorphin (which acts at κ-opioid receptors) in NAc neurons, these findings raised the possibility that κ-receptors mediate immobility behaviors in the FST.  Here, we report that i.c.v. administration of the κ-antagonist nor-binaltorphimine dose dependently decreased immobility in the FST, suggesting that it has antidepressant-like effects.  VImplicating a specific effect at κ-receptors, similar antidepressant-like effects were seen after treatment with either of two novel, structurally dissimilar κ-antagonists: 5'-guanidinonaltrindole, which was effective after i.c.v. but not systemic treatment, and 5'-acetamidinoethylnaltrindole (ANTI), which was potent and effective after systemic treatment.  The behavioral effects of the κ-antagonists resembled those of tricyclic antidepressants (desipramine) and selective serotonin reuptake inhibitors (fluoxetine and citalopram).  Conversely, systemic administration of the κ-agonist [5α,7α,8β]-N-methyl-N-[7-[1-pyrrolidinyl]-1-oxaspiro[4.5]dec-8-yl]-benzenacetamide (U-69593) dose dependently increased immobility in the FST, consistent with prodepressant-like effects.  The effects of the κ-ligands in the FST were not correlated with nonspecific effects on locomotor activity.  Furthermore, the most potent and effective κ-antagonist (ANTI) did not affect the rewarding impact of lateral hypothalamic brain stimulation at a dose with strong antidepressant-like effects.  These findings are consistent with the hypothesis that CREB-mediated induction of dynorphin in the NAc "triggers" immobility behavior in the FST.  Furthermore, they raise the possibility that κ-antagonists may have efficacy as antidepressants, but lack stimulant or reward-related effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGRihMkz2i9LVg90H21EOLACvtfcHk0liNuC8nS9OzuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1amsr8%253D&md5=86513c1a7f214720f5b1920a44a6ee49</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.046433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.046433%26sid%3Dliteratum%253Aachs%26aulast%3DMague%26aufirst%3DS.%2BD.%26aulast%3DPliakas%26aufirst%3DA.%2BM.%26aulast%3DTodtenkopf%26aufirst%3DM.%2BS.%26aulast%3DTomasiewicz%26aufirst%3DH.%2BC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DStevens%26aufirst%3DW.%2BC.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26aulast%3DCarlezon%26aufirst%3DW.%2BA.%26atitle%3DAntidepressant-like%2520effects%2520of%2520kappa-opioid%2520receptor%2520antagonists%2520in%2520the%2520forced%2520swim%2520test%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D305%26spage%3D323%26epage%3D330%26doi%3D10.1124%2Fjpet.102.046433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnakenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skosnik, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Souza, D. C.</span></span> <span> </span><span class="NLM_article-title">Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist salvinorin A in humans</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">879</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2012.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2Fj.biopsych.2012.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=22817868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVyksLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=871-879&author=M.+Ranganathanauthor=A.+Schnakenbergauthor=P.+D.+Skosnikauthor=B.+M.+Cohenauthor=B.+Pittmanauthor=R.+A.+Sewellauthor=D.+C.+D%E2%80%99Souza&title=Dose-related+behavioral%2C+subjective%2C+endocrine%2C+and+psychophysiological+effects+of+the+%CE%BA+opioid+agonist+salvinorin+A+in+humans&doi=10.1016%2Fj.biopsych.2012.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the κ Opioid Agonist Salvinorin A in Humans</span></div><div class="casAuthors">Ranganathan, Mohini; Schnakenberg, Ashley; Skosnik, Patrick D.; Cohen, Bruce M.; Pittman, Brian; Sewell, R. Andrew; D'Souza, Deepak Cyril</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">871-879</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Salvia divinorum (Salvia) is an increasingly popular recreational drug amongst adolescents and young adults.  Its primary active ingredient, Salvinorin A (SA)-a highly selective agonist at the κ opiate receptor-is believed to be one of the most potent naturally occurring hallucinogens.  However, there is little exptl. data on the effects of SA in humans.  In a 3-day, double-blind, randomized, crossover, counterbalanced study, the behavioral, subjective, cognitive, psychophysiol., and endocrine effects of 0 mg, 8 mg, and 12 mg of inhaled SA were characterized in 10 healthy individuals who had previously used Salvia.  SA produced psychotomimetic effects and perceptual alterations, including dissociative and somaesthetic effects, increased plasma cortisol and prolactin, and reduced resting EEG spectral power.  The SA administration was assocd. with a rapid increase of its levels in the blood.  SA did not produce euphoria, cognitive deficits, or changes in vital signs.  The effects were transient and not dose-related.  SA administration was very well-tolerated without acute or delayed adverse effects.  SA produced a wide range of transient effects in healthy subjects.  The perceptual altering effects and lack of euphoric effects would explain its intermittent use pattern.  Such a profile would also suggest a low addictive potential similar to other hallucinogens and consistent with κ opiate receptor agonism.  Further work is warranted to carefully characterize a full spectrum of its effects in humans, to elucidate the underlying mechanisms involved, and to explore the basis for individual variability in its effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8pvfFW2Ay-7Vg90H21EOLACvtfcHk0liNuC8nS9OzuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVyksLbJ&md5=af0dfe15a1762702d95562692c65a1cc</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2012.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2012.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DRanganathan%26aufirst%3DM.%26aulast%3DSchnakenberg%26aufirst%3DA.%26aulast%3DSkosnik%26aufirst%3DP.%2BD.%26aulast%3DCohen%26aufirst%3DB.%2BM.%26aulast%3DPittman%26aufirst%3DB.%26aulast%3DSewell%26aufirst%3DR.%2BA.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DD.%2BC.%26atitle%3DDose-related%2520behavioral%252C%2520subjective%252C%2520endocrine%252C%2520and%2520psychophysiological%2520effects%2520of%2520the%2520%25CE%25BA%2520opioid%2520agonist%2520salvinorin%2520A%2520in%2520humans%26jtitle%3DBiol.%2520Psychiatry%26date%3D2012%26volume%3D72%26spage%3D871%26epage%3D879%26doi%3D10.1016%2Fj.biopsych.2012.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Lanerolle, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meredith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuteau, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brines, M. L.</span></span> <span> </span><span class="NLM_article-title">Dynorphin and the kappa 1 ligand [3H]u69,593 binding in the human epileptogenic hippocampus</span>. <i>Epilepsy Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/S0920-1211(97)00044-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2FS0920-1211%2897%2900044-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=9332884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaK2sXlvVKlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1997&pages=189-205&author=N.+C.+de%0ALanerolleauthor=A.+Williamsonauthor=C.+Meredithauthor=J.+H.+Kimauthor=H.+Tabuteauauthor=D.+D.+Spencerauthor=M.+L.+Brines&title=Dynorphin+and+the+kappa+1+ligand+%5B3H%5Du69%2C593+binding+in+the+human+epileptogenic+hippocampus&doi=10.1016%2FS0920-1211%2897%2900044-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Dynorphin and the kappa 1 ligand [3H]U69,593 binding in the human epileptogenic hippocampus</span></div><div class="casAuthors">de Lanerolle, N. C.; Williamson, A.; Meredith, C.; Kim, J. H.; Tabuteau, H.; Spencer, D. D.; Brines, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsy Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">189-205</span>CODEN:
                <span class="NLM_cas:coden">EPIRE8</span>;
        ISSN:<span class="NLM_cas:issn">0920-1211</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The distribution of dynorphin (DYN), one of its binding sites (κ1 receptor) and their relationship to neuronal loss and granule cell hyperexcitability was examd. in hippocampi from patients with temporal lobe epilepsy (TLE).  In hippocampi that were not the seizure focus (mass assocd. temporal lobe epilepsy, MaTLE; and paradoxical temporal lobe epilepsy, PTLE) DYN-like immunoreactivity was localized in the dentate granule cells and their mossy fiber terminals within the hilus and area CA3.  In hippocampi that were the seizure focus (MTLE), 89% showed an addnl. band of immunoreactivity confined to the inner mol. layer (IML) of the dentate gyrus, representing recurrent mossy fiber collaterals.  In 11% of MTLE patients no staining was found in the IML (MTLE/DYN-).  The MTLE/DYN- hippocampi were also characterized by a significantly lower degree of cell loss than in MTLE hippocampi in the dentate granule cell layer, the hilus and CA3.  Both MTLE and MTLE/DYN- hippocampi showed evoked epileptiform bursting in granule cells while MTLE showed greater polysynaptic EPSPs and spontaneous excitatory activity.  Thus, granule cell recurrent collateral sprouting may account for only some aspects of hyperexcitability.  In 30% of the MTLE group, hilar neurons of a variety of morphol. types expressed DYN immunoreactivity in their somata and dendrites.  The d. of [3H]U 69593 binding sites in MaTLE and PTLE patients was highest in areas CA1 and the subiculum-regions having little or no DYN-staining.  In the dentate mol. layer, hilus and CA3-regions with the most DYN immunoreactivity-there was a low d. of ligand binding.  The significance of this transmitter/receptor mismatch is yet unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrofAFgOMQqjrVg90H21EOLACvtfcHk0livMPjk9BfVQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvVKlu7o%253D&md5=fc3470183fd9d083ce588031c4d6ee48</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0920-1211%2897%2900044-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0920-1211%252897%252900044-2%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLanerolle%26aufirst%3DN.%2BC.%26aulast%3DWilliamson%26aufirst%3DA.%26aulast%3DMeredith%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DTabuteau%26aufirst%3DH.%26aulast%3DSpencer%26aufirst%3DD.%2BD.%26aulast%3DBrines%26aufirst%3DM.%2BL.%26atitle%3DDynorphin%2520and%2520the%2520kappa%25201%2520ligand%2520%255B3H%255Du69%252C593%2520binding%2520in%2520the%2520human%2520epileptogenic%2520hippocampus%26jtitle%3DEpilepsy%2520Res.%26date%3D1997%26volume%3D28%26spage%3D189%26epage%3D205%26doi%3D10.1016%2FS0920-1211%2897%2900044-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loacker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayyah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzer, C.</span></span> <span> </span><span class="NLM_article-title">Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1093/brain/awl384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1093%2Fbrain%2Fawl384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=17347252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A280%3ADC%252BD2s3islGitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2007&pages=1017-1028&author=S.+Loackerauthor=M.+Sayyahauthor=W.+Wittmannauthor=H.+Herzogauthor=C.+Schwarzer&title=Endogenous+dynorphin+in+epileptogenesis+and+epilepsy%3A+anticonvulsant+net+effect+via+kappa+opioid+receptors&doi=10.1093%2Fbrain%2Fawl384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors</span></div><div class="casAuthors">Loacker Stephan; Sayyah Mohammad; Wittmann Walter; Herzog Herbert; Schwarzer Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">Pt 4</span>),
    <span class="NLM_cas:pages">1017-28</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neuropsychiatric disorders are one of the main challenges of human medicine with epilepsy being one of the most common serious disorders of the brain.  Increasing evidence suggest neuropeptides, particularly the opioids, play an important role in epilepsy.  However, little is known about the mechanisms of the endogenous opioid system in epileptogenesis and epilepsy.  Therefore, we investigated the role of endogenous prodynorphin-derived peptides in epileptogenesis, acute seizure behaviour and epilepsy in prodynorphin-deficient mice.  Compared with wild-type littermates, prodynorphin knockout mice displayed a significantly reduced seizure threshold as assessed by tail-vein infusion of the GABA(A) antagonist pentylenetetrazole.  This phenotype could be entirely rescued by the kappa receptor-specific agonist U-50488, but not by the mu receptor-specific agonist DAMGO.  The delta-specific agonist SNC80 decreased seizure threshold in both genotypes, wild-type and knockout.  Pre-treatment with the kappa selective antagonist GNTI completely blocked the rescue effect of U-50488.  Consistent with the reduced seizure threshold, prodynorphin knockout mice showed faster seizure onset and a prolonged time of seizure activity after intracisternal injection of kainic acid.  Three weeks after local injection of kainic acid into the stratum radiatum CA1 of the dorsal hippocampus, prodynorphin knockout mice displayed an increased extent of granule cell layer dispersion and neuronal loss along the rostrocaudal axis of the ipsi- and partially also of the contralateral hippocampus.  In the classical pentylenetetrazole kindling model, dynorphin-deficient mice showed significantly faster kindling progression with six out of eight animals displaying clonic seizures, while none of the nine wild-types exceeded rating 3 (forelimb clonus).  Taken together, our data strongly support a critical role for dynorphin in the regulation of hippocampal excitability, indicating an anticonvulsant role of kappa opioid receptors, thereby providing a potential target for antiepileptic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuUgwosTcJCrZpSb_XWfMrfW6udTcc2eZweOtWCWvDpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3islGitg%253D%253D&md5=ef104d0c31b29eba19695d4234b53c41</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawl384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawl384%26sid%3Dliteratum%253Aachs%26aulast%3DLoacker%26aufirst%3DS.%26aulast%3DSayyah%26aufirst%3DM.%26aulast%3DWittmann%26aufirst%3DW.%26aulast%3DHerzog%26aufirst%3DH.%26aulast%3DSchwarzer%26aufirst%3DC.%26atitle%3DEndogenous%2520dynorphin%2520in%2520epileptogenesis%2520and%2520epilepsy%253A%2520anticonvulsant%2520net%2520effect%2520via%2520kappa%2520opioid%2520receptors%26jtitle%3DBrain%26date%3D2007%26volume%3D130%26spage%3D1017%26epage%3D1028%26doi%3D10.1093%2Fbrain%2Fawl384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu-Kia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreek, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiller, J. M.</span></span> <span> </span><span class="NLM_article-title">Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer’s disease patients</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>893</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/S0006-8993(00)03302-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2FS0006-8993%2800%2903302-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=11223000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD3MXht12nt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=893&publication_year=2001&pages=121-134&author=A.+M.+Mathieu-Kiaauthor=L.+Q.+Fanauthor=M.+J.+Kreekauthor=E.+J.+Simonauthor=J.+M.+Hiller&title=Mu-%2C+delta-+and+kappa-opioid+receptor+populations+are+differentially+altered+in+distinct+areas+of+postmortem+brains+of+Alzheimer%E2%80%99s+disease+patients&doi=10.1016%2FS0006-8993%2800%2903302-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">μ-, δ- and κ-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients</span></div><div class="casAuthors">Mathieu-Kia, A.-M.; Fan, L.-Q.; Kreek, M. J.; Simon, E. J.; Hiller, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">893</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">121-134</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The putative role of the opioid system in cognitive and memory functions prompted the authors to search for possible changes in the cohort of the major opioid receptors, μ, δ and κ, in Alzheimer's disease.  The present study examines alterations in opioid receptor levels by quant. autoradiog.  These expts. were carried out on coronal sections of postmortem brains from Alzheimer's disease patients and from age-matched, dementia-free individuals.  Brain sections were labeled with the tritiated forms of μ-, δ- and κ-opioid ligands; DAMGO ([d-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin), DPDPE ([d-Pen2,5]-enkephalin) and bremazocine (in the presence of μ- and δ-ligands), resp.  Nonspecific binding was detd. in the presence of naloxone (10 μM).  Brain areas analyzed were caudate, putamen, amygdaloid complex, hippocampal formation and various cerebral and cerebellar cortices.  Image analyses of autoradiographs show, that in comparison to the same areas in control brain, statistically significant redns. in μ-opioid receptor binding occur in the subiculum and hippocampus of Alzheimer's disease brains.  Binding of δ-opioid receptors is also decreased in the amygdaloid complex and ventral putamen of Alzheimer's disease brains.  In contrast, large increases of κ-opioid receptor binding are found in the dorsal and ventral putamen as well as in the cerebellar cortex of Alzheimer's disease brains.  Levels of μ-, δ- and κ-opioid receptor binding are unaltered in the caudate, parahippocampal gyrus and occipito-temporal gyrus.  These results may suggest an involvement of the endogenous opioid system in some of the multitude of effects that accompany this dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJG37xhb0VXLVg90H21EOLACvtfcHk0livMPjk9BfVQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXht12nt70%253D&md5=a0c1a9cf3c59d3df3e8d84d273e2840d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0006-8993%2800%2903302-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-8993%252800%252903302-3%26sid%3Dliteratum%253Aachs%26aulast%3DMathieu-Kia%26aufirst%3DA.%2BM.%26aulast%3DFan%26aufirst%3DL.%2BQ.%26aulast%3DKreek%26aufirst%3DM.%2BJ.%26aulast%3DSimon%26aufirst%3DE.%2BJ.%26aulast%3DHiller%26aufirst%3DJ.%2BM.%26atitle%3DMu-%252C%2520delta-%2520and%2520kappa-opioid%2520receptor%2520populations%2520are%2520differentially%2520altered%2520in%2520distinct%2520areas%2520of%2520postmortem%2520brains%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520patients%26jtitle%3DBrain%2520Res.%26date%3D2001%26volume%3D893%26spage%3D121%26epage%3D134%26doi%3D10.1016%2FS0006-8993%2800%2903302-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreason, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doudet, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunderland, T.</span></span> <span> </span><span class="NLM_article-title">Opiate receptor avidity and cerebral blood flow in Alzheimer’s disease</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1016/S0022-510X(96)05315-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2FS0022-510X%2896%2905315-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=9129113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADyaK2sXislentLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=1997&pages=171-180&author=R.+M.+Cohenauthor=P.+J.+Andreasonauthor=D.+J.+Doudetauthor=R.+E.+Carsonauthor=T.+Sunderland&title=Opiate+receptor+avidity+and+cerebral+blood+flow+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS0022-510X%2896%2905315-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Opiate receptor avidity and cerebral blood flow in Alzheimer's disease</span></div><div class="casAuthors">Cohen, Robert M.; Andreason, Paul J.; Doudet, Doris J.; Carson, Richard E.; Sunderland, Trey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Neurological Sciences</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-180</span>CODEN:
                <span class="NLM_cas:coden">JNSCAG</span>;
        ISSN:<span class="NLM_cas:issn">0022-510X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Positron emission tomog. was performed on 12 Alzheimer's patients and 12 age-matched normal controls following the administration of the opiate receptor antagonist 6-deoxy-6-β-[18F]fluoronaltrexone (cyclofoxy, CF).  Tracer kinetic anal. was used to det. the vol. of distribution of CF, a measure of unoccupied μ and κ receptor d., i.e. opiate receptor avidity in 34 brain regions.  Regional cerebral blood flow rates (CBF) were detd. on the same day with H2[15O].  Global gray CF avidity and global gray CBF were lower in the Alzheimer's patients and correlated (r = 0.73).  Regional CBF differences were superimposed on global CBF changes in the Alzheimer's patients, with the subcortex relatively spared.  Multivariate statistical analyses, however, failed to demonstrate regional specificity for the CF avidity changes.  Furthermore, percent changes in regional CF avidity were not correlated with percent changes in regional CBF (r = 0.12, P = NS).  These findings demonstrate involvement of the opiate system in Alzheimer's disease.  Although, neurodegeneration is the likely underlying process responsible for both the changes in CF avidity and CBF in Alzheimer's disease, the differences with respect to the patterns of these losses suggest that the intermediate mechanisms leading from neurodegeneration to loss are distinct.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuh20_aw3bWLVg90H21EOLACvtfcHk0ljjSM0Y9GCYBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislentLY%253D&md5=f8fc78c88922ba421cb2300ea543c806</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0022-510X%2896%2905315-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-510X%252896%252905315-4%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DR.%2BM.%26aulast%3DAndreason%26aufirst%3DP.%2BJ.%26aulast%3DDoudet%26aufirst%3DD.%2BJ.%26aulast%3DCarson%26aufirst%3DR.%2BE.%26aulast%3DSunderland%26aufirst%3DT.%26atitle%3DOpiate%2520receptor%2520avidity%2520and%2520cerebral%2520blood%2520flow%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D1997%26volume%3D148%26spage%3D171%26epage%3D180%26doi%3D10.1016%2FS0022-510X%2896%2905315-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shippenberg, T. S.</span></span> <span> </span><span class="NLM_article-title">The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">247</span>, <span class="refDoi"> DOI: 10.1038/npp.2008.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1038%2Fnpp.2008.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=19079072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVyru7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=247&author=T.+S.+Shippenberg&title=The+dynorphin%2Fkappa+opioid+receptor+system%3A+a+new+target+for+the+treatment+of+addiction+and+affective+disorders%3F&doi=10.1038%2Fnpp.2008.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?</span></div><div class="casAuthors">Shippenberg, Toni S.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">247</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Studies in exptl. animals suggest that manipulations that decrease the activity of kappa-opioid receptor (KOPr) systems may be effective in the treatment of depression and drug addiction.  The KOPr and the endogenous KOPr ligand dynorphin are enriched in the ventral tegmental area, nucleus accumbens, and prefrontal cortex; brain regions that regulate mood and motivation.  Neurochem. and electrophysiol. data have shown that KOPr activation in these regions decreases dopamine (DA) transmission.  Decreased mesoaccumbal DA transmission is implicated in certain symptoms of depression and several medications with proven antidepressant efficacy in humans are selective DA uptake inhibitors.  Rodent studies have shown that KOPr antagonists attenuate stress-induced reinstatement of cocaine-seeking and stress-induced potentiation of the conditioned rewarding of cocaine.  These findings have prompted the phase I testing of KOPr antagonists for the treatment of addiction.  However, further studies are needed to better understand KOPr system plasticity and the role of opioid peptides systems in normal brain function and various psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoypu1mYJnip7Vg90H21EOLACvtfcHk0ljjSM0Y9GCYBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVyru7rM&md5=79f02d1419022782387893e7befff137</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2008.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2008.165%26sid%3Dliteratum%253Aachs%26aulast%3DShippenberg%26aufirst%3DT.%2BS.%26atitle%3DThe%2520dynorphin%252Fkappa%2520opioid%2520receptor%2520system%253A%2520a%2520new%2520target%2520for%2520the%2520treatment%2520of%2520addiction%2520and%2520affective%2520disorders%253F%26jtitle%3DNeuropsychopharmacology%26date%3D2009%26volume%3D34%26spage%3D247%26doi%3D10.1038%2Fnpp.2008.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mash, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staley, J. K.</span></span> <span> </span><span class="NLM_article-title">D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>877</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1999.tb09286.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1111%2Fj.1749-6632.1999.tb09286.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=877&publication_year=1999&pages=507-522&author=D.+C.+Mashauthor=J.+K.+Staley&title=D3+dopamine+and+kappa+opioid+receptor+alterations+in+human+brain+of+cocaine-overdose+victims&doi=10.1111%2Fj.1749-6632.1999.tb09286.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1999.tb09286.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1999.tb09286.x%26sid%3Dliteratum%253Aachs%26aulast%3DMash%26aufirst%3DD.%2BC.%26aulast%3DStaley%26aufirst%3DJ.%2BK.%26atitle%3DD3%2520dopamine%2520and%2520kappa%2520opioid%2520receptor%2520alterations%2520in%2520human%2520brain%2520of%2520cocaine-overdose%2520victims%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1999%26volume%3D877%26spage%3D507%26epage%3D522%26doi%3D10.1111%2Fj.1749-6632.1999.tb09286.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van’t
Veer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlezon, W. A.</span></span> <span> </span><span class="NLM_article-title">Role of kappa-opioid receptors in stress and anxiety-related behavior</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>229</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1007/s00213-013-3195-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1007%2Fs00213-013-3195-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=23836029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOjurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=2013&pages=435-452&author=A.+Van%E2%80%99t%0AVeerauthor=W.+A.+Carlezon&title=Role+of+kappa-opioid+receptors+in+stress+and+anxiety-related+behavior&doi=10.1007%2Fs00213-013-3195-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Role of kappa-opioid receptors in stress and anxiety-related behavior</span></div><div class="casAuthors">Van't Veer, Ashlee; Carlezon, William A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">435-452</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence indicates that brain kappa-opioid receptors (KORs) and dynorphin, the endogenous ligand that binds at these receptors, are involved in regulating states of motivation and emotion.  These findings have stimulated interest in the development of KOR-targeted ligands as therapeutic agents.  As one example, it was suggested that KOR antagonists might have a wide range of indications, including the treatment of depressive, anxiety, and addictive disorders, as well as conditions characterized by co-morbidity of these disorders (e.g., post-traumatic stress disorder).  A general effect of reducing the impact of stress may explain how KOR antagonists can have efficacy in such a variety of animal models that would appear to represent different disease states.  Here, the authors review evidence that disruption of KOR function attenuates prominent effects of stress.  We will describe behavioral and mol. endpoints including those from studies that characterize the effects of KOR antagonists and KOR ablation on the effects of stress itself, as well as on the effects of exogenously delivered corticotropin-releasing factor, a brain peptide that mediates key effects of stress.  Collectively, available data suggest that KOR disruption produces anti-stress effects and under some conditions can prevent the development of stress-induced adaptations.  As such, KOR antagonists may have unique potential as therapeutic agents for the treatment and even prevention of stress-related psychiatric illness, a therapeutic niche that is currently unfilled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV6ByDO8OPqrVg90H21EOLACvtfcHk0liaiv5SDjyg8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOjurjO&md5=c5174c0ad904bacdb228f1a4982edca1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00213-013-3195-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-013-3195-5%26sid%3Dliteratum%253Aachs%26aulast%3DVan%25E2%2580%2599t%2BVeer%26aufirst%3DA.%26aulast%3DCarlezon%26aufirst%3DW.%2BA.%26atitle%3DRole%2520of%2520kappa-opioid%2520receptors%2520in%2520stress%2520and%2520anxiety-related%2520behavior%26jtitle%3DPsychopharmacology%26date%3D2013%26volume%3D229%26spage%3D435%26epage%3D452%26doi%3D10.1007%2Fs00213-013-3195-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pietrzak, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsi-Travali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ropchan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumeister, A.</span></span> <span> </span><span class="NLM_article-title">Association of in vivo κ-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology</span>. <i>JAMA Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1262</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1001/jamapsychiatry.2014.1221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1001%2Fjamapsychiatry.2014.1221" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=1262-1270&author=R.+H.+Pietrzakauthor=M.+Naganawaauthor=Y.+Huangauthor=S.+Corsi-Travaliauthor=M.+Q.+Zhengauthor=M.+B.+Steinauthor=S.+Henryauthor=K.+Limauthor=J.+Ropchanauthor=S.+F.+Linauthor=R.+E.+Carsonauthor=A.+Neumeister&title=Association+of+in+vivo+%CE%BA-opioid+receptor+availability+and+the+transdiagnostic+dimensional+expression+of+trauma-related+psychopathology&doi=10.1001%2Fjamapsychiatry.2014.1221"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1001%2Fjamapsychiatry.2014.1221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamapsychiatry.2014.1221%26sid%3Dliteratum%253Aachs%26aulast%3DPietrzak%26aufirst%3DR.%2BH.%26aulast%3DNaganawa%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCorsi-Travali%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DM.%2BQ.%26aulast%3DStein%26aufirst%3DM.%2BB.%26aulast%3DHenry%26aufirst%3DS.%26aulast%3DLim%26aufirst%3DK.%26aulast%3DRopchan%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DS.%2BF.%26aulast%3DCarson%26aufirst%3DR.%2BE.%26aulast%3DNeumeister%26aufirst%3DA.%26atitle%3DAssociation%2520of%2520in%2520vivo%2520%25CE%25BA-opioid%2520receptor%2520availability%2520and%2520the%2520transdiagnostic%2520dimensional%2520expression%2520of%2520trauma-related%2520psychopathology%26jtitle%3DJAMA%2520Psychiatry%26date%3D2014%26volume%3D71%26spage%3D1262%26epage%3D1270%26doi%3D10.1001%2Fjamapsychiatry.2014.1221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span> </span><span class="NLM_article-title">Kappa Opioid Receptor Imaging in Post-traumatic
Stress Disorder (PTSD)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>. <span class="NLM_year">2014</span>; <a href="https://clinicaltrials.gov/ct2/show/NCT02237703" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02237703</a> (accessed Aug 15, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kappa+Opioid+Receptor+Imaging+in+Post-traumatic%0AStress+Disorder+%28PTSD%29.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%3A+Bethesda%2C+MD.+2014%3B+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02237703+%28accessed+Aug+15%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DKappa%2520Opioid%2520Receptor%2520Imaging%2520in%2520Post-traumatic%250AStress%2520Disorder%2520%2528PTSD%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Felice, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopruszinski, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaVigne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remeniuk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goshima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ossipov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navratilova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porreca, F.</span></span> <span> </span><span class="NLM_article-title">Kappa opioid receptor antagonists: a possible new class of therapeutics for migraine prevention</span>. <i>Cephalalgia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">780</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1177/0333102417702120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1177%2F0333102417702120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=28376659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A280%3ADC%252BC1cvksFCrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=780-794&author=J.+Y.+Xieauthor=M.+De+Feliceauthor=C.+M.+Kopruszinskiauthor=N.+Eydeauthor=J.+LaVigneauthor=B.+Remeniukauthor=P.+Hernandezauthor=X.+Yueauthor=N.+Goshimaauthor=M.+Ossipovauthor=T.+Kingauthor=J.+M.+Streicherauthor=E.+Navratilovaauthor=D.+Dodickauthor=H.+Rosenauthor=E.+Robertsauthor=F.+Porreca&title=Kappa+opioid+receptor+antagonists%3A+a+possible+new+class+of+therapeutics+for+migraine+prevention&doi=10.1177%2F0333102417702120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention</span></div><div class="casAuthors">Xie Jennifer Y; Eyde Nathan; LaVigne Justin; Remeniuk Bethany; Hernandez Pablo; Yue Xu; Goshima Naomi; Ossipov Michael; Streicher John M; Navratilova Edita; Porreca Frank; De Felice Milena; Kopruszinski Caroline M; King Tamara; Dodick David; Porreca Frank; Rosen Hugh; Roberts Ed</div><div class="citationInfo"><span class="NLM_cas:title">Cephalalgia : an international journal of headache</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">780-794</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background Stress is the most commonly reported migraine trigger.  Dynorphin, an endogenous opioid peptide acting preferentially at kappa opioid receptors (KORs), is a key mediator of stress responses.  The aim of this study was to use an injury-free rat model of functional cephalic pain with features of migraine and medication overuse headache (MOH) to test the possible preventive benefit of KOR blockade on stress-induced cephalic pain.  Methods Following sumatriptan priming to model MOH, rats were hyper-responsive to environmental stress, demonstrating delayed cephalic and extracephalic allodynia and increased levels of CGRP in the jugular blood, consistent with commonly observed clinical outcomes during migraine.  Nor-binaltorphimine (nor-BNI), a long-acting KOR antagonist or CYM51317, a novel short-acting KOR antagonist, were given systemically either during sumatriptan priming or immediately before environmental stress challenge.  The effects of KOR blockade in the amygdala on stress-induced allodynia was determined by administration of nor-BNI into the right or left central nucleus of the amygdala (CeA).  Results KOR blockade prevented both stress-induced allodynia and increased plasma CGRP.  Stress increased dynorphin content and phosphorylated KOR in both the left and right CeA in sumatriptan-primed rats.  However, KOR blockade only in the right CeA prevented stress-induced cephalic allodynia as well as extracephalic allodynia, measured in either the right or left hindpaws.  U69,593, a KOR agonist, given into the right, but not the left, CeA, produced allodynia selectively in sumatriptan-primed rats.  Both stress and U69,593-induced allodynia were prevented by right CeA U0126, a mitogen-activated protein kinase inhibitor, presumably acting downstream of KOR.  Conclusions Our data reveal a novel lateralized KOR circuit that mediated stress-induced cutaneous allodynia and increased plasma CGRP in an injury-free model of functional cephalic pain with features of migraine and medication overuse headache.  Selective, small molecule, orally available, and reversible KOR antagonists are currently in development and may represent a novel class of preventive therapeutics for migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmKA3CiFExd_9pSBfyDvp7fW6udTcc2eZgDWbn3gDaz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvksFCrtA%253D%253D&md5=b694df1e805eecac04d511c11d3fb5bc</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1177%2F0333102417702120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0333102417702120%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DJ.%2BY.%26aulast%3DDe%2BFelice%26aufirst%3DM.%26aulast%3DKopruszinski%26aufirst%3DC.%2BM.%26aulast%3DEyde%26aufirst%3DN.%26aulast%3DLaVigne%26aufirst%3DJ.%26aulast%3DRemeniuk%26aufirst%3DB.%26aulast%3DHernandez%26aufirst%3DP.%26aulast%3DYue%26aufirst%3DX.%26aulast%3DGoshima%26aufirst%3DN.%26aulast%3DOssipov%26aufirst%3DM.%26aulast%3DKing%26aufirst%3DT.%26aulast%3DStreicher%26aufirst%3DJ.%2BM.%26aulast%3DNavratilova%26aufirst%3DE.%26aulast%3DDodick%26aufirst%3DD.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DE.%26aulast%3DPorreca%26aufirst%3DF.%26atitle%3DKappa%2520opioid%2520receptor%2520antagonists%253A%2520a%2520possible%2520new%2520class%2520of%2520therapeutics%2520for%2520migraine%2520prevention%26jtitle%3DCephalalgia%26date%3D2017%26volume%3D37%26spage%3D780%26epage%3D794%26doi%3D10.1177%2F0333102417702120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munro, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van’t
Veer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Béguin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlezon, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, B. M.</span></span> <span> </span><span class="NLM_article-title">Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity</span>. <i>BMC Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">5</span>, <span class="refDoi"> DOI: 10.1186/1471-2210-12-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1186%2F1471-2210-12-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=22642416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVyrsLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=5&author=T.+A.+Munroauthor=L.+M.+Berryauthor=A.+Van%E2%80%99t%0AVeerauthor=C.+B%C3%A9guinauthor=F.+I.+Carrollauthor=Z.+Zhaoauthor=W.+A.+Carlezonauthor=B.+M.+Cohen&title=Long-acting+%CE%BA+opioid+antagonists+nor-BNI%2C+GNTI+and+JDTic%3A+pharmacokinetics+in+mice+and+lipophilicity&doi=10.1186%2F1471-2210-12-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity</span></div><div class="casAuthors">Munro, Thomas A.; Berry, Loren M.; Van't Veer, Ashlee; Beguin, Cecile; Carroll, F. Ivy; Zhao, Zhiyang; Carlezon, William A., Jr.; Cohen, Bruce M.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5</span>CODEN:
                <span class="NLM_cas:coden">BPMHBU</span>;
        ISSN:<span class="NLM_cas:issn">1471-2210</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Nor-BNI, GNTI and JDTic induce κ opioid antagonism that is delayed by hours and can persist for months.  Other effects are transient.  It has been proposed that these drugs may be slowly absorbed or distributed, and may dissolve in cell membranes, thus slowing elimination and prolonging their effects.  Recent evidence suggests, instead, that they induce prolonged desensitization of the κ opioid receptor.  Methods: To evaluate these hypotheses, we measured relevant physicochem. properties of nor-BNI, GNTI and JDTic, and the timecourse of brain and plasma concns. in mice after i.p. administration (using LC-MS-MS).  Results: In each case, plasma levels were maximal within 30 min and declined by >80% within four hours, correlating well with previously reported transient effects.  A strong neg. correlation was obsd. between plasma levels and the delayed, prolonged timecourse of κ antagonism.  Brain levels of nor-BNI and JDTic peaked within 30 min, but while nor-BNI was largely eliminated within hours, JDTic declined gradually over a week.  Brain uptake of GNTI was too low to measure accurately, and higher doses proved lethal.  None of the drugs were highly lipophilic, showing high water soly. and low-to-moderate distribution into octanol.  Brain homogenate binding was within the range of many shorter-acting drugs.  JDTic showed P-gp-mediated efflux; nor-BNI and GNTI did not, but their low unbound brain uptake suggests efflux by another mechanism.  Conclusions: The neg. plasma concn.-effect relationship we obsd. is difficult to reconcile with simple competitive antagonism, but is consistent with desensitization.  The very slow elimination of JDTic from brain is surprising given that it undergoes active efflux, has modest affinity for homogenate, and has a shorter duration of action than nor-BNI under these conditions.  We propose that this may result from entrapment in cellular compartments such as lysosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq--VqUQhImY7Vg90H21EOLACvtfcHk0lhv2-Y8BgLnsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVyrsLbK&md5=01a4ed657ce55dd08f7e8e05ab1f2f7c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1186%2F1471-2210-12-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2210-12-5%26sid%3Dliteratum%253Aachs%26aulast%3DMunro%26aufirst%3DT.%2BA.%26aulast%3DBerry%26aufirst%3DL.%2BM.%26aulast%3DVan%25E2%2580%2599t%2BVeer%26aufirst%3DA.%26aulast%3DB%25C3%25A9guin%26aufirst%3DC.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCarlezon%26aufirst%3DW.%2BA.%26aulast%3DCohen%26aufirst%3DB.%2BM.%26atitle%3DLong-acting%2520%25CE%25BA%2520opioid%2520antagonists%2520nor-BNI%252C%2520GNTI%2520and%2520JDTic%253A%2520pharmacokinetics%2520in%2520mice%2520and%2520lipophilicity%26jtitle%3DBMC%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D5%26doi%3D10.1186%2F1471-2210-12-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urbano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E.</span></span> <span> </span><span class="NLM_article-title">Antagonists of the kappa opioid receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2021</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.03.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2Fj.bmcl.2014.03.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=24690494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2021-2032&author=M.+Urbanoauthor=M.+Guerreroauthor=H.+Rosenauthor=E.+Roberts&title=Antagonists+of+the+kappa+opioid+receptor&doi=10.1016%2Fj.bmcl.2014.03.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists of the kappa opioid receptor</span></div><div class="casAuthors">Urbano, Mariangela; Guerrero, Miguel; Rosen, Hugh; Roberts, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2021-2032</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The research community has increasingly focused on the development of OPRK antagonists as pharmacotherapies for the treatment of depression, anxiety, addictive disorders and other psychiatric conditions produced or exacerbated by stress.  Short-acting OPRK antagonists have been recently developed as a potential improvement over long-acting prototypic ligands including nor-BNI and JDTic.  Remarkably the short-acting LY2456302 is undergoing phase II clin. trials for the augmentation of the antidepressant therapy in treatment-resistant depression.  This Letter reviews relevant chem. and pharmacol. advances in the identification and development of OPRK antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg7WYoVfNnM7Vg90H21EOLACvtfcHk0lhv2-Y8BgLnsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOjt7o%253D&md5=d278400da78ccdfe6efef74259c964a5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.03.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.03.040%26sid%3Dliteratum%253Aachs%26aulast%3DUrbano%26aufirst%3DM.%26aulast%3DGuerrero%26aufirst%3DM.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DE.%26atitle%3DAntagonists%2520of%2520the%2520kappa%2520opioid%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2021%26epage%3D2032%26doi%3D10.1016%2Fj.bmcl.2014.03.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHardy, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Deusen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, S.</span></span> <span> </span><span class="NLM_article-title">Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2’-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5868</span>– <span class="NLM_lpage">5877</span>, <span class="refDoi"> DOI: 10.1021/jm2006035</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5868-5877&author=P.+R.+Verhoestauthor=A.+Sawant+Basakauthor=V.+Parikhauthor=M.+Haywardauthor=G.+W.+Kauffmanauthor=V.+Paradisauthor=S.+F.+McHardyauthor=S.+McLeanauthor=S.+Grimwoodauthor=A.+W.+Schmidtauthor=M.+Vanase-Frawleyauthor=J.+Freemanauthor=J.+Van+Deusenauthor=L.+Coxauthor=D.+Wongauthor=S.+Liras&title=Design+and+discovery+of+a+selective+small+molecule+%CE%BA+opioid+antagonist+%282-methyl-N-%28%282%E2%80%99-%28pyrrolidin-1-ylsulfonyl%29biphenyl-4-yl%29methyl%29propan-1-amine%2C+PF-4455242%29&doi=10.1021%2Fjm2006035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm2006035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006035%26sid%3Dliteratum%253Aachs%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DSawant%2BBasak%26aufirst%3DA.%26aulast%3DParikh%26aufirst%3DV.%26aulast%3DHayward%26aufirst%3DM.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DParadis%26aufirst%3DV.%26aulast%3DMcHardy%26aufirst%3DS.%2BF.%26aulast%3DMcLean%26aufirst%3DS.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DVanase-Frawley%26aufirst%3DM.%26aulast%3DFreeman%26aufirst%3DJ.%26aulast%3DVan%2BDeusen%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DD.%26aulast%3DLiras%26aufirst%3DS.%26atitle%3DDesign%2520and%2520discovery%2520of%2520a%2520selective%2520small%2520molecule%2520%25CE%25BA%2520opioid%2520antagonist%2520%25282-methyl-N-%2528%25282%25E2%2580%2599-%2528pyrrolidin-1-ylsulfonyl%2529biphenyl-4-yl%2529methyl%2529propan-1-amine%252C%2520PF-4455242%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5868%26epage%3D5877%26doi%3D10.1021%2Fjm2006035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span> </span><span class="NLM_article-title">A Study Of Kappa Opioid Receptor Occupancy
Of PF-04455242, Using
PET (Positron Emission Tomography)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>, <span class="NLM_year">2009</span>; <a href="https://clinicaltrials.gov/ct2/show/study/NCT00939887" class="extLink">https://clinicaltrials.gov/ct2/show/study/NCT00939887</a> (accessed Aug 15, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+Of+Kappa+Opioid+Receptor+Occupancy%0AOf+PF-04455242%2C+Using%0APET+%28Positron+Emission+Tomography%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%2C+2009%3B+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Fstudy%2FNCT00939887+%28accessed+Aug+15%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520Of%2520Kappa%2520Opioid%2520Receptor%2520Occupancy%250AOf%2520PF-04455242%252C%2520Using%250APET%2520%2528Positron%2520Emission%2520Tomography%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitch, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quimby, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedregal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Torre, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canada, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statnick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinzie, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benesh, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rash, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, V. N.</span></span> <span> </span><span class="NLM_article-title">Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8000</span>– <span class="NLM_lpage">8012</span>, <span class="refDoi"> DOI: 10.1021/jm200789r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200789r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOgu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8000-8012&author=C.+H.+Mitchauthor=S.+J.+Quimbyauthor=N.+Diazauthor=C.+Pedregalauthor=M.+G.+de+la+Torreauthor=A.+Jimenezauthor=Q.+Shiauthor=E.+J.+Canadaauthor=S.+D.+Kahlauthor=M.+A.+Statnickauthor=D.+L.+McKinzieauthor=D.+R.+Beneshauthor=K.+S.+Rashauthor=V.+N.+Barth&title=Discovery+of+aminobenzyloxyarylamides+as+%CE%BA+opioid+receptor+selective+antagonists%3A+application+to+preclinical+development+of+a+%CE%BA+opioid+receptor+antagonist+receptor+occupancy+tracer&doi=10.1021%2Fjm200789r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Aminobenzyloxyarylamides as κ Opioid Receptor Selective Antagonists: Application to Preclinical Development of a κ Opioid Receptor Antagonist Receptor Occupancy Tracer</span></div><div class="casAuthors">Mitch, Charles H.; Quimby, Steven J.; Diaz, Nuria; Pedregal, Concepcion; de la Torre, Marta G.; Jimenez, Alma; Shi, Qing; Canada, Emily J.; Kahl, Steven D.; Statnick, Michael A.; McKinzie, David L.; Benesh, Dana R.; Rash, Karen S.; Barth, Vanessa N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8000-8012</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Arylphenylpyrrolidinylmethylphenoxybenzamides were found to have high affinity and selectivity for κ opioid receptors.  On the basis of receptor binding assays in Chinese hamster ovary (CHO) cells expressing cloned human opioid receptors, (S)-3-fluoro-4-(4-((2-(3-fluorophenyl)pyrrolidin-1-yl)methyl)phenoxy)benzamide (25) had a Ki = 0.565 nM for κ opioid receptor binding while having a Ki = 35.8 nM for μ opioid receptors and a Ki = 211 nM for δ opioid receptor binding.  Compd. 25 was also a potent antagonist of κ opioid receptors when tested in vitro using a [35S]-guanosine 5'O-[3-thiotriphosphate] ([35S]GTP-γ-S) functional assay in CHO cells expressing cloned human opioid receptors.  Compds. were also evaluated for potential use as receptor occupancy tracers.  Tracer evaluation was done in vivo, using liq. chromatog.-tandem mass spectrometry (LC/MS/MS) methods, precluding the need for radiolabeling.  (S)-3-Chloro-4-(4-((2-(pyridine-3-yl)pyrrolidin-1-yl)methyl)phenoxy)benzamide (18) was found to have favorable properties for a tracer for receptor occupancy, including good specific vs. nonspecific binding and good brain uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUKlIPCr34grVg90H21EOLACvtfcHk0lgdb9KDEZnxuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOgu73N&md5=a17d3133182c2c33b78a85bf153c56fd</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm200789r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200789r%26sid%3Dliteratum%253Aachs%26aulast%3DMitch%26aufirst%3DC.%2BH.%26aulast%3DQuimby%26aufirst%3DS.%2BJ.%26aulast%3DDiaz%26aufirst%3DN.%26aulast%3DPedregal%26aufirst%3DC.%26aulast%3Dde%2Bla%2BTorre%26aufirst%3DM.%2BG.%26aulast%3DJimenez%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DCanada%26aufirst%3DE.%2BJ.%26aulast%3DKahl%26aufirst%3DS.%2BD.%26aulast%3DStatnick%26aufirst%3DM.%2BA.%26aulast%3DMcKinzie%26aufirst%3DD.%2BL.%26aulast%3DBenesh%26aufirst%3DD.%2BR.%26aulast%3DRash%26aufirst%3DK.%2BS.%26aulast%3DBarth%26aufirst%3DV.%2BN.%26atitle%3DDiscovery%2520of%2520aminobenzyloxyarylamides%2520as%2520%25CE%25BA%2520opioid%2520receptor%2520selective%2520antagonists%253A%2520application%2520to%2520preclinical%2520development%2520of%2520a%2520%25CE%25BA%2520opioid%2520receptor%2520antagonist%2520receptor%2520occupancy%2520tracer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8000%26epage%3D8012%26doi%3D10.1021%2Fjm200789r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehlert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barchiesi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilig, M.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1805</span>– <span class="NLM_lpage">1812</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0015-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1038%2Fs41386-018-0015-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=29463912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Cgt7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=1805-1812&author=E.+Domiauthor=E.+Barbierauthor=E.+Augierauthor=G.+Augierauthor=D.+Gehlertauthor=R.+Barchiesiauthor=A.+Thorsellauthor=L.+Holmauthor=M.+Heilig&title=Preclinical+evaluation+of+the+kappa-opioid+receptor+antagonist+CERC-501+as+a+candidate+therapeutic+for+alcohol+use+disorders&doi=10.1038%2Fs41386-018-0015-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders</span></div><div class="casAuthors">Domi, E.; Barbier, E.; Augier, E.; Augier, G.; Gehlert, D.; Barchiesi, R.; Thorsell, A.; Holm, L.; Heilig, M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1805-1812</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Prior work suggests a role of kappa-opioid signaling in the control of alc. drinking, in particular when drinking is escalated due to alc.-induced long-term neuroadaptations.  Here, we examd. the small mol. selective kappa antagonist CERC-501 in rat models of alc.-related behaviors, with the objective to evaluate its potential as a candidate therapeutic for alc. use disorders.  We first tested the effect of CERC-501 on acute alc. withdrawal-induced anxiety-like behavior.  CERC-501 was then tested on basal as well as escalated alc. self-administration induced by 20% alc. intermittent access.  Finally, we detd. the effects of CERC-501 on relapse to alc. seeking triggered by both stress and alc.-assocd. cues.  Control expts. were performed to confirm the specificity of CERC-501 effects on alc.-related behaviors.  CERC-501 reversed anxiety-like behavior induced by alc. withdrawal.  It did not affect basal alc. self-administration but did dose-dependently suppress self-administration that had escalated following long-term intermittent access to alc.  CERC-501 blocked relapse to alc. seeking induced by stress, but not when relapse-like behavior was triggered by alc.-assocd. cues.  The effects of CERC-501 were obsd. in the absence of sedative side effects and were not due to effects on alc. metab.  Thus, in a broad battery of preclin. alc. models, CERC-501 has an activity profile characteristic of anti-stress compds.  Combined with its demonstrated preclin. and clin. safety profile, these data support clin. development of CERC-501 for alc. use disorders, in particular for patients with neg. reinforced, stress-driven alc. seeking and use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIW1OsMfhf-7Vg90H21EOLACvtfcHk0lgdb9KDEZnxuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Cgt7zE&md5=853aae19858b58ea4568614bd502c900</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0015-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0015-y%26sid%3Dliteratum%253Aachs%26aulast%3DDomi%26aufirst%3DE.%26aulast%3DBarbier%26aufirst%3DE.%26aulast%3DAugier%26aufirst%3DE.%26aulast%3DAugier%26aufirst%3DG.%26aulast%3DGehlert%26aufirst%3DD.%26aulast%3DBarchiesi%26aufirst%3DR.%26aulast%3DThorsell%26aufirst%3DA.%26aulast%3DHolm%26aufirst%3DL.%26aulast%3DHeilig%26aufirst%3DM.%26atitle%3DPreclinical%2520evaluation%2520of%2520the%2520kappa-opioid%2520receptor%2520antagonist%2520CERC-501%2520as%2520a%2520candidate%2520therapeutic%2520for%2520alcohol%2520use%2520disorders%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26spage%3D1805%26epage%3D1812%26doi%3D10.1038%2Fs41386-018-0015-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damaj, M. I.</span></span> <span> </span><span class="NLM_article-title">Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2015.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2Fj.neuropharm.2015.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=26044637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWgtrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=270-274&author=K.+J.+Jacksonauthor=A.+Jacksonauthor=F.+I.+Carrollauthor=M.+I.+Damaj&title=Effects+of+orally-bioavailable+short-acting+kappa+opioid+receptor-selective+antagonist+LY2456302+on+nicotine+withdrawal+in+mice&doi=10.1016%2Fj.neuropharm.2015.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice</span></div><div class="casAuthors">Jackson, Kia J.; Jackson, Asti; Carroll, F. Ivy; Damaj, M. Imad</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">270-274</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Kappa opioid receptor (KOR) signaling has been implicated in mediating behavioral and biochem. effects assocd. with drug dependence.  The most commonly used KOR antagonists, norbinaltorphimine (norBNI) and (3R)-7-Hydroxy-N{(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl}-1,2,3,4-tetrahydro-3-isoquinoline-carboxamide (JDTic), have provided a wealth of information in this area; however, the delayed onset and long-lasting effects of these antagonists complicate exptl. design and interpretation of results, and make them less than ideal for clin. studies.  Initial studies with the recently developed KOR antagonist, LY2456302, show that the compd. is a short acting, high-affinity, selective KOR antagonist with therapeutic potential for mood disorders and ethanol use in animal models, and is well tolerated in humans.  The goal of the current study was to evaluate the effectiveness of LY2456302 in alleviating the nicotine withdrawal syndrome in mice.  Mice were chronically treated with nicotine for 14 days and phys. and affective nicotine withdrawal signs were measured using a spontaneous nicotine withdrawal model and conditioned place aversion (CPA) following pre-treatment with LY2456302, administered orally.  Vehicle treated nicotine withdrawn mice displayed significant anxiety-related behavior, somatic signs, hyperalgesia, and CPA.  Similar to previous studies with norBNI and JDTic, LY2456302 alleviated the nicotine withdrawal syndrome, as evidenced by decreased expression of nicotine withdrawal induced anxiety-related behavior, somatic signs, and CPA, and increased hotplate latency in nicotine withdrawn mice following pre-treatment.  Given the current results, and with its favorable pharmacokinetic and pharmacodynamic profile, LY2456302 may be a useful therapeutic agent for treatment of multiple aspects of the nicotine withdrawal syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTUmNoy6lBT7Vg90H21EOLACvtfcHk0ljZVfh2YBAUlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWgtrjN&md5=8c3acdf063502f5fa80553970bd63677</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2015.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2015.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DK.%2BJ.%26aulast%3DJackson%26aufirst%3DA.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DDamaj%26aufirst%3DM.%2BI.%26atitle%3DEffects%2520of%2520orally-bioavailable%2520short-acting%2520kappa%2520opioid%2520receptor-selective%2520antagonist%2520LY2456302%2520on%2520nicotine%2520withdrawal%2520in%2520mice%26jtitle%3DNeuropharmacology%26date%3D2015%26volume%3D97%26spage%3D270%26epage%3D274%26doi%3D10.1016%2Fj.neuropharm.2015.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witcher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorick-Kehn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royalty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauscher-Wisniewski, S.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">968</span>– <span class="NLM_lpage">978</span>, <span class="refDoi"> DOI: 10.1002/jcph.286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1002%2Fjcph.286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=24619932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlWgurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=968-978&author=S.+L.+Loweauthor=C.+J.+Wongauthor=J.+Witcherauthor=C.+R.+Gonzalesauthor=G.+L.+Dickinsonauthor=R.+L.+Bellauthor=L.+Rorick-Kehnauthor=M.+Wellerauthor=R.+R.+Stoltzauthor=J.+Royaltyauthor=S.+Tauscher-Wisniewski&title=Safety%2C+tolerability%2C+and+pharmacokinetic+evaluation+of+single-+and+multiple-ascending+doses+of+a+novel+kappa+opioid+receptor+antagonist+LY2456302+and+drug+interaction+with+ethanol+in+healthy+subjects&doi=10.1002%2Fjcph.286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects</span></div><div class="casAuthors">Lowe, Stephen L.; Wong, Conrad J.; Witcher, Jennifer; Gonzales, Celedon R.; Dickinson, Gemma L.; Bell, Robert L.; Rorick-Kehn, Linda; Weller, MaryAnn; Stoltz, Randall R.; Royalty, Jane; Tauscher-Wisniewski, Sitra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">968-978</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Accumulating evidence indicates that selective antagonism of kappa opioid receptors may provide therapeutic benefit in the treatment of major depressive disorder, anxiety disorders, and substance use disorders.  LY2456302 is a high-affinity, selective kappa opioid antagonist that demonstrates >30-fold functional selectivity over mu and delta opioid receptors.  The safety, tolerability, and pharmacokinetics (PK) of LY2456302 were investigated following single oral doses (2-60 mg), multiple oral doses (2, 10, and 35 mg), and when co-administered with ethanol.  Plasma concns. of LY2456302 were measured by liq. chromatog.-tandem mass spectrometry method.  Safety analyses were conducted on all enrolled subjects.  LY2456302 doses were well-tolerated with no clin. significant findings.  No safety concerns were seen on co-administration with ethanol.  No evidence for an interaction between LY2456302 and ethanol on cognitive-motor performance was detected.  LY2456302 displayed rapid oral absorption and a terminal half-life of approx. 30-40 h.  Plasma exposure of LY2456302 increased proportionally with increasing doses and reached steady state after 6-8 days of once-daily dosing.  Steady-state PK of LY2456302 were not affected by coadministration of a single dose of ethanol.  No clin. important changes in max. concn. (Cmax) or AUC of ethanol (in the presence of LY2456302) were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzd5qDiMDLq7Vg90H21EOLACvtfcHk0ljZVfh2YBAUlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlWgurzO&md5=dbc065f8c96e002460269bb31bfbab0a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fjcph.286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.286%26sid%3Dliteratum%253Aachs%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DWong%26aufirst%3DC.%2BJ.%26aulast%3DWitcher%26aufirst%3DJ.%26aulast%3DGonzales%26aufirst%3DC.%2BR.%26aulast%3DDickinson%26aufirst%3DG.%2BL.%26aulast%3DBell%26aufirst%3DR.%2BL.%26aulast%3DRorick-Kehn%26aufirst%3DL.%26aulast%3DWeller%26aufirst%3DM.%26aulast%3DStoltz%26aufirst%3DR.%2BR.%26aulast%3DRoyalty%26aufirst%3DJ.%26aulast%3DTauscher-Wisniewski%26aufirst%3DS.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520pharmacokinetic%2520evaluation%2520of%2520single-%2520and%2520multiple-ascending%2520doses%2520of%2520a%2520novel%2520kappa%2520opioid%2520receptor%2520antagonist%2520LY2456302%2520and%2520drug%2520interaction%2520with%2520ethanol%2520in%2520healthy%2520subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2014%26volume%3D54%26spage%3D968%26epage%3D978%26doi%3D10.1002%2Fjcph.286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reed, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butelman, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreek, M. J.</span></span> <span> </span><span class="NLM_article-title">Repeated administration of opra kappa (LY2456302), a novel, short-acting, selective kop-r antagonist, in persons with and without cocaine dependence</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1038%2Fnpp.2017.205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=28857070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFKisbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=739-750&author=B.+Reedauthor=E.+R.+Butelmanauthor=R.+S.+Fryauthor=R.+Kimaniauthor=M.+J.+Kreek&title=Repeated+administration+of+opra+kappa+%28LY2456302%29%2C+a+novel%2C+short-acting%2C+selective+kop-r+antagonist%2C+in+persons+with+and+without+cocaine+dependence&doi=10.1038%2Fnpp.2017.205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence</span></div><div class="casAuthors">Reed, Brian; Butelman, Eduardo R.; Fry, Rebecca S.; Kimani, Rachel; Kreek, Mary Jeanne</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">739-750</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The κ-opioid receptor (KOP-r) system and its endogenous ligands, the dynorphins, are involved in the neurobiol. regulation of addictive states, and of mood.  There are limited data on the impact of selective KOP-r antagonism in humans on basic biobehavioral functions, or on addictive diseases and mood disorders.  Previously studied selective KOP-r antagonists have unusual pharmacodynamic and pharmacokinetic properties (slow development of KOP-r selectivity, extremely long duration of action) that limit translation to human studies.  A recently developed selective KOP-r-antagonist, Opra Kappa (LY2456302; CERC-501), has medication-like duration of action, oral bioavailability, and target engagement.  The current study is the first investigation of the effects of a KOP-r-antagonist in cocaine-dependent persons in comparison with normal volunteers.  In a stress-minimized inpatient setting, we detd. the neuroendocrine and neurobehavioral effects of repeated administration of an active dose of Opra Kappa (10 mg p.o. daily, four consecutive days in comparison with an initial baseline day).  Healthy volunteers (n=40), persons diagnosed with cocaine dependence in early abstinence (<2 mo, EACD) (n=23), and drug-free former cocaine-dependent persons (7-mo to 25-yr abstinence, DFFCD) (n=7) were studied, with measurements including circulating neuroendocrine hormones, affect, and, in cocaine-dependent persons, cocaine craving.  Modest adverse events related to Opra Kappa included pruritus, obsd. in a subset of individuals.  No significant change was obsd. in serum prolactin levels following Opra Kappa administration, but modest increases in circulating adrenocorticotropic hormone and cortisol were obsd.  No significant changes were noted in measures of depression or cocaine craving in this stress-minimized setting.  Overall, these studies demonstrate that effects of 10 mg Opra Kappa are largely consistent with those predicted for a selective KOP-r antagonist.  This medication regimen was tolerable, and is therefore feasible for further studies in cocaine-dependent persons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbkzD6bb5ZX7Vg90H21EOLACvtfcHk0lhtCcknExAgtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFKisbzJ&md5=87651bc8d9479deb92bcda719a0f6a1a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.205%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DB.%26aulast%3DButelman%26aufirst%3DE.%2BR.%26aulast%3DFry%26aufirst%3DR.%2BS.%26aulast%3DKimani%26aufirst%3DR.%26aulast%3DKreek%26aufirst%3DM.%2BJ.%26atitle%3DRepeated%2520administration%2520of%2520opra%2520kappa%2520%2528LY2456302%2529%252C%2520a%2520novel%252C%2520short-acting%252C%2520selective%2520kop-r%2520antagonist%252C%2520in%2520persons%2520with%2520and%2520without%2520cocaine%2520dependence%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26spage%3D739%26epage%3D750%26doi%3D10.1038%2Fnpp.2017.205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span> <i>Cerecor Reports Encouraging Topline Data from a NIH Sponsored Proof-of-Concept
Trial of CERC-501 in Treatment-Resistant Depression</i>; <span class="NLM_publisher-name">Cerecor</span>, May 1, <span class="NLM_year">2017</span>; <a href="https://ir.cerecor.com/press-releases/detail/36" class="extLink">https://ir.cerecor.com/press-releases/detail/36</a> (accessed Sept 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Cerecor+Reports+Encouraging+Topline+Data+from+a+NIH+Sponsored+Proof-of-Concept%0ATrial+of+CERC-501+in+Treatment-Resistant+Depression%3B+Cerecor%2C+May+1%2C+2017%3B+https%3A%2F%2Fir.cerecor.com%2Fpress-releases%2Fdetail%2F36+%28accessed+Sept+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCerecor%2520Reports%2520Encouraging%2520Topline%2520Data%2520from%2520a%2520NIH%2520Sponsored%2520Proof-of-Concept%250ATrial%2520of%2520CERC-501%2520in%2520Treatment-Resistant%2520Depression%26pub%3DCerecor%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rorick-Kehn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witcher, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Need, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinzie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statnick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suico, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinzie, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauscher-Wisniewski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitch, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C. J.</span></span> <span> </span><span class="NLM_article-title">Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">pyu036</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyu036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1093%2Fijnp%2Fpyu036" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=pyu036&author=L.+M.+Rorick-Kehnauthor=J.+W.+Witcherauthor=S.+L.+Loweauthor=C.+R.+Gonzalesauthor=M.+A.+Wellerauthor=R.+L.+Bellauthor=J.+C.+Hartauthor=A.+B.+Needauthor=J.+H.+McKinzieauthor=M.+A.+Statnickauthor=J.+G.+Suicoauthor=D.+L.+McKinzieauthor=S.+Tauscher-Wisniewskiauthor=C.+H.+Mitchauthor=R.+R.+Stoltzauthor=C.+J.+Wong&title=Determining+pharmacological+selectivity+of+the+kappa+opioid+receptor+antagonist+LY2456302+using+pupillometry+as+a+translational+biomarker+in+rat+and+human&doi=10.1093%2Fijnp%2Fpyu036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyu036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyu036%26sid%3Dliteratum%253Aachs%26aulast%3DRorick-Kehn%26aufirst%3DL.%2BM.%26aulast%3DWitcher%26aufirst%3DJ.%2BW.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DGonzales%26aufirst%3DC.%2BR.%26aulast%3DWeller%26aufirst%3DM.%2BA.%26aulast%3DBell%26aufirst%3DR.%2BL.%26aulast%3DHart%26aufirst%3DJ.%2BC.%26aulast%3DNeed%26aufirst%3DA.%2BB.%26aulast%3DMcKinzie%26aufirst%3DJ.%2BH.%26aulast%3DStatnick%26aufirst%3DM.%2BA.%26aulast%3DSuico%26aufirst%3DJ.%2BG.%26aulast%3DMcKinzie%26aufirst%3DD.%2BL.%26aulast%3DTauscher-Wisniewski%26aufirst%3DS.%26aulast%3DMitch%26aufirst%3DC.%2BH.%26aulast%3DStoltz%26aufirst%3DR.%2BR.%26aulast%3DWong%26aufirst%3DC.%2BJ.%26atitle%3DDetermining%2520pharmacological%2520selectivity%2520of%2520the%2520kappa%2520opioid%2520receptor%2520antagonist%2520LY2456302%2520using%2520pupillometry%2520as%2520a%2520translational%2520biomarker%2520in%2520rat%2520and%2520human%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2015%26volume%3D18%26spage%3Dpyu036%26doi%3D10.1093%2Fijnp%2Fpyu036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ragguett, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblat, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, R. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1080/17425255.2018.1459564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1080%2F17425255.2018.1459564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=29621905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A280%3ADC%252BC1MnptlOlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=475-482&author=R.+M.+Ragguettauthor=C.+Rongauthor=J.+D.+Rosenblatauthor=R.+C.+Hoauthor=R.+S.+McIntyre&title=Pharmacodynamic+and+pharmacokinetic+evaluation+of+buprenorphine+%2B+samidorphan+for+the+treatment+of+major+depressive+disorder&doi=10.1080%2F17425255.2018.1459564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder</span></div><div class="casAuthors">Ragguett Renee-Marie; Rong Carola; Rosenblat Joshua D; McIntyre Roger S; Rosenblat Joshua D; McIntyre Roger S; Ho Roger C; McIntyre Roger S</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug metabolism & toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">475-482</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Treatment resistant depression (TRD) represents approximately 20% of all individuals receiving care for major depressive disorder.  The opioidergic system is identified as a novel target which hitherto has not been sufficiently investigated in adults with TRD.  The combination product buprenorphine + samidorphan is an opioid modulatory agent which has demonstrated replicated evidence of efficacy in TRD without abuse liability.  Areas covered: Databases Pubmed, Google Scholar and clinicaltrials.gov were searched from inception through December 2017 for clinical trial information, pharmacokinetics, and pharmacodynamics of buprenorphine + samidorphan.  Herein we provide a summary of the available information.  Eight clinical trials were identified for inclusion, of the eight trials, five trials had available results and are included in detail in our review.  Expert opinion: Buprenorphine + samidorphan has demonstrated efficacy in TRD.  Extant evidence surrounding the safety and tolerability profile of buprenorphine + samidorphan does not identify any significant safety concerns.  Additional studies are needed in order to assess the long-term safety and efficacy of this product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3FOlIyvxQqhBrI9DTGjC0fW6udTcc2easztrGd78C0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnptlOlsg%253D%253D&md5=a0a8c669ef96dc9c2d43910a2c45c33d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1080%2F17425255.2018.1459564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17425255.2018.1459564%26sid%3Dliteratum%253Aachs%26aulast%3DRagguett%26aufirst%3DR.%2BM.%26aulast%3DRong%26aufirst%3DC.%26aulast%3DRosenblat%26aufirst%3DJ.%2BD.%26aulast%3DHo%26aufirst%3DR.%2BC.%26aulast%3DMcIntyre%26aufirst%3DR.%2BS.%26atitle%3DPharmacodynamic%2520and%2520pharmacokinetic%2520evaluation%2520of%2520buprenorphine%2520%252B%2520samidorphan%2520for%2520the%2520treatment%2520of%2520major%2520depressive%2520disorder%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2018%26volume%3D14%26spage%3D475%26epage%3D482%26doi%3D10.1080%2F17425255.2018.1459564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memisoglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodkin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Somer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leigh-Pemberton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPetrillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrich, E.</span></span> <span> </span><span class="NLM_article-title">Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2015.15070921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1176%2Fappi.ajp.2015.15070921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=26869247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A280%3ADC%252BC28npvFeqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=499-508&author=M.+Favaauthor=A.+Memisogluauthor=M.+E.+Thaseauthor=J.+A.+Bodkinauthor=M.+H.+Trivediauthor=M.+de+Somerauthor=Y.+Duauthor=R.+Leigh-Pembertonauthor=L.+DiPetrilloauthor=B.+Silvermanauthor=E.+Ehrich&title=Opioid+modulation+with+buprenorphine%2Fsamidorphan+as+adjunctive+treatment+for+inadequate+response+to+antidepressants%3A+a+randomized+double-blind+placebo-controlled+trial&doi=10.1176%2Fappi.ajp.2015.15070921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial</span></div><div class="casAuthors">Fava Maurizio; Memisoglu Asli; Thase Michael E; Bodkin J Alexander; Trivedi Madhukar H; de Somer Marc; Du Yangchun; Leigh-Pemberton Richard; DiPetrillo Lauren; Silverman Bernard; Ehrich Elliot</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">499-508</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Major depressive disorder has been associated with dysregulation of the endogenous opioid system.  The authors sought to determine whether opioid modulation achieved through administration of ALKS 5461, a combination of a μ- and κ-opioid partial agonist, buprenorphine, and a μ-opioid antagonist, samidorphan, would exhibit antidepressant activity in patients with major depression.  METHOD:  A multicenter, randomized, double-blind, placebo-controlled, two-stage sequential parallel comparison design study was conducted in adults with major depression who had an inadequate response to one or two courses of antidepressant treatment.  Participants were randomly assigned to receive adjunctive treatment with 2 mg/2 mg of buprenorphine/samidorphan (the 2/2 dosage group), 8 mg/8 mg of buprenorphine/samidorphan (the 8/8 dosage group), or placebo.  Antidepressant effect was measured based on change from baseline to the end of 4 weeks of treatment on the 17-item Hamilton Depression Rating Scale (HAM-D), the Montgomery-ÅAsberg Depression Rating Scale (MADRS), and the Clinical Global Impressions severity scale (CGI-S).  RESULTS:  Compared with the placebo group, there were significantly greater improvements in the 2/2 dosage group across the three depression outcome measures (HAM-D: -2.8, 95% CI=-5.1, -0.6; MADRS: -4.9, 95% CI=-8.2, -1.6; CGI-S: -0.5, 95% CI=-0.9, -0.1).  There was also evidence of improvement in the 8/8 dosage group, although it did not achieve statistical significance.  Overall, the buprenorphine/samidorphan combinations were well tolerated, and there was no evidence of opioid withdrawal on treatment discontinuation.  CONCLUSIONS:  The buprenorphine/samidorphan combination is a novel and promising candidate for treatment of major depressive disorder in patients who have an inadequate response to standard antidepressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAVonKfnT36_x2phytoz6_fW6udTcc2easztrGd78C0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28npvFeqtw%253D%253D&md5=50faaf07f582ccee6749d8e4937806d1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2015.15070921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2015.15070921%26sid%3Dliteratum%253Aachs%26aulast%3DFava%26aufirst%3DM.%26aulast%3DMemisoglu%26aufirst%3DA.%26aulast%3DThase%26aufirst%3DM.%2BE.%26aulast%3DBodkin%26aufirst%3DJ.%2BA.%26aulast%3DTrivedi%26aufirst%3DM.%2BH.%26aulast%3Dde%2BSomer%26aufirst%3DM.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DLeigh-Pemberton%26aufirst%3DR.%26aulast%3DDiPetrillo%26aufirst%3DL.%26aulast%3DSilverman%26aufirst%3DB.%26aulast%3DEhrich%26aufirst%3DE.%26atitle%3DOpioid%2520modulation%2520with%2520buprenorphine%252Fsamidorphan%2520as%2520adjunctive%2520treatment%2520for%2520inadequate%2520response%2520to%2520antidepressants%253A%2520a%2520randomized%2520double-blind%2520placebo-controlled%2520trial%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2016%26volume%3D173%26spage%3D499%26epage%3D508%26doi%3D10.1176%2Fappi.ajp.2015.15070921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span> <i>Alkermes Announces FDA Acceptance for Review of
New Drug Application
for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder</i>; <span class="NLM_publisher-name">Alkermes</span>, April 16, <span class="NLM_year">2018</span>; <a href="http://phx.corporate-ir.net/phoenix.zhtml?c=92211&amp;p=irol-corporateNewsArticle&amp;ID=2342624" class="extLink">http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-corporateNewsArticle&ID=2342624</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Alkermes+Announces+FDA+Acceptance+for+Review+of%0ANew+Drug+Application%0Afor+ALKS+5461+for+the+Adjunctive+Treatment+of+Major+Depressive+Disorder%3B+Alkermes%2C+April+16%2C+2018%3B+http%3A%2F%2Fphx.corporate-ir.net%2Fphoenix.zhtml%3Fc%3D92211%26p%3Dirol-corporateNewsArticle%26ID%3D2342624."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DAlkermes%2520Announces%2520FDA%2520Acceptance%2520for%2520Review%2520of%250ANew%2520Drug%2520Application%250Afor%2520ALKS%25205461%2520for%2520the%2520Adjunctive%2520Treatment%2520of%2520Major%2520Depressive%2520Disorder%26pub%3DAlkermes%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, M.</span>; <span class="NLM_string-name">Urbano, M.</span>; <span class="NLM_string-name">Brown, S.
J.</span>; <span class="NLM_string-name">Cayanan, C.</span>; <span class="NLM_string-name">Ferguson, J.</span>; <span class="NLM_string-name">Cameron, M.</span>; <span class="NLM_string-name">Devi, L.
A.</span>; <span class="NLM_string-name">Roberts, E.</span>; <span class="NLM_string-name">Rosen, H.</span></span> <span> </span><span class="NLM_article-title">Optimization and characterization of an opioid kappa receptor (OPRK1) antagonist</span>. In  <i>Probe Reports from the NIH Molecular Libraries Program [Internet]</i>; <span class="NLM_publisher-name">National Center for Biotechnology Information</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2013</span>; <a href="https://www.ncbi.nlm.nih.gov/books/NBK179827/" class="extLink">https://www.ncbi.nlm.nih.gov/books/NBK179827/</a> (accessed Dec 14, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Guerrero&author=M.+Urbano&author=S.%0AJ.+Brown&author=C.+Cayanan&author=J.+Ferguson&author=M.+Cameron&author=L.%0AA.+Devi&author=E.+Roberts&author=H.+Rosen&title=Optimization+and+characterization+of+an+opioid+kappa+receptor+%28OPRK1%29+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DGuerrero%26aufirst%3DM.%26atitle%3DOptimization%2520and%2520characterization%2520of%2520an%2520opioid%2520kappa%2520receptor%2520%2528OPRK1%2529%2520antagonist%26jtitle%3DProbe%2520Reports%2520from%2520the%2520NIH%2520Molecular%2520Libraries%2520Program%2520%255BInternet%255D%26pub%3DNational%2520Center%2520for%2520Biotechnology%2520Information%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbertz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudkins, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallamo, J. P.</span></span> <span> </span><span class="NLM_article-title">Knowledge-Based, Central nervous system (CNS) lead selection and lead optimization for CNS drug discovery</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1021/cn200100h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn200100h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=50-68&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=R.+L.+Hudkinsauthor=B.+D.+Dorseyauthor=J.+P.+Mallamo&title=Knowledge-Based%2C+Central+nervous+system+%28CNS%29+lead+selection+and+lead+optimization+for+CNS+drug+discovery&doi=10.1021%2Fcn200100h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Hudkins, Robert L.; Dorsey, Bruce D.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-68</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The central nervous system (CNS) is the major area that is affected by aging.  Alzheimer's disease (AD), Parkinson's disease (PD), brain cancer, and stroke are the CNS diseases that will cost trillions of dollars for their treatment.  Achievement of appropriate blood-brain barrier (BBB) penetration is often considered a significant hurdle in the CNS drug discovery process.  On the other hand, BBB penetration may be a liability for many of the non-CNS drug targets, and a clear understanding of the physicochem. and structural differences between CNS and non-CNS drugs may assist both research areas.  Because of the numerous and challenging issues in CNS drug discovery and the low success rates, pharmaceutical companies are beginning to deprioritize their drug discovery efforts in the CNS arena.  Prompted by these challenges and to aid in the design of high-quality, efficacious CNS compds., we analyzed the physicochem. property and the chem. structural profiles of 317 CNS and 626 non-CNS oral drugs.  The conclusions derived provide an ideal property profile for lead selection and the property modification strategy during the lead optimization process.  A list of substructural units that may be useful for CNS drug design was also provided here.  A classification tree was also developed to differentiate between CNS drugs and non-CNS oral drugs.  The combined anal. provided the following guidelines for designing high-quality CNS drugs: (i) topol. mol. polar surface area of <76 Å2 (25-60 Å2), (ii) at least one (one or two, including one aliph. amine) nitrogen, (iii) fewer than seven (two to four) linear chains outside of rings, (iv) fewer than three (zero or one) polar hydrogen atoms, (v) vol. of 740-970 Å3, (vi) solvent accessible surface area of 460-580 Å2, and (vii) pos. QikProp parameter CNS.  The ranges within parentheses may be used during lead optimization.  One violation to this proposed profile may be acceptable.  The chemoinformatics approaches for graphically analyzing multiple properties efficiently are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozqfO0vq2i5bVg90H21EOLACvtfcHk0lhesn1OyOt_uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO&md5=4c20ba34c3d5397170b50242975ce25d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcn200100h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn200100h%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge-Based%252C%2520Central%2520nervous%2520system%2520%2528CNS%2529%2520lead%2520selection%2520and%2520lead%2520optimization%2520for%2520CNS%2520drug%2520discovery%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D50%26epage%3D68%26doi%3D10.1021%2Fcn200100h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benigni, R.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship studies of chemical mutagens and carcinogens: mechanistic investigations and prediction approaches</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1021/cr030049y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr030049y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=1767-1800&author=R.+Benigni&title=Structure-activity+relationship+studies+of+chemical+mutagens+and+carcinogens%3A+mechanistic+investigations+and+prediction+approaches&doi=10.1021%2Fcr030049y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fcr030049y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr030049y%26sid%3Dliteratum%253Aachs%26aulast%3DBenigni%26aufirst%3DR.%26atitle%3DStructure-activity%2520relationship%2520studies%2520of%2520chemical%2520mutagens%2520and%2520carcinogens%253A%2520mechanistic%2520investigations%2520and%2520prediction%2520approaches%26jtitle%3DChem.%2520Rev.%26date%3D2005%26volume%3D105%26spage%3D1767%26epage%3D1800%26doi%3D10.1021%2Fcr030049y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Mayoral, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreiras, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, E.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the Friedländer reaction</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2652</span>– <span class="NLM_lpage">2671</span>, <span class="refDoi"> DOI: 10.1021/cr800482c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr800482c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVSltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2652-2671&author=J.+Marco-Contellesauthor=E.+P%C3%A9rez-Mayoralauthor=A.+Samadiauthor=M.+C.+Carreirasauthor=E.+Soriano&title=Recent+advances+in+the+Friedl%C3%A4nder+reaction&doi=10.1021%2Fcr800482c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Friedlander Reaction</span></div><div class="casAuthors">Marco-Contelles, Jose; Perez-Mayoral, Elena; Samadi, Abdelouahid; Carreiras, Maria do Carmo; Soriano, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2652-2671</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This review is an update of the Friedlander reaction from the most significant literature from 1981 to the present.  A particular emphasis is on the development of novel catalysts, exptl. conditions as well as an application toward natural products synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8jFyV0XzFYLVg90H21EOLACvtfcHk0lhesn1OyOt_uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVSltrY%253D&md5=247618f98000f1a747a443a1648854bc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fcr800482c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr800482c%26sid%3Dliteratum%253Aachs%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DP%25C3%25A9rez-Mayoral%26aufirst%3DE.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DCarreiras%26aufirst%3DM.%2BC.%26aulast%3DSoriano%26aufirst%3DE.%26atitle%3DRecent%2520advances%2520in%2520the%2520Friedl%25C3%25A4nder%2520reaction%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D2652%26epage%3D2671%26doi%3D10.1021%2Fcr800482c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arvela, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span> <span> </span><span class="NLM_article-title">Highly regioselective internal heck arylation of hydroxyalkyl vinyl ethers by aryl halides in water</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">6390</span>– <span class="NLM_lpage">6396</span>, <span class="refDoi"> DOI: 10.1021/jo0705768</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0705768" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFGntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=6390-6396&author=R.+K.+Arvelaauthor=S.+Pasquiniauthor=M.+Larhed&title=Highly+regioselective+internal+heck+arylation+of+hydroxyalkyl+vinyl+ethers+by+aryl+halides+in+water&doi=10.1021%2Fjo0705768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Regioselective Internal Heck Arylation of Hydroxyalkyl Vinyl Ethers by Aryl Halides in Water</span></div><div class="casAuthors">Arvela, Riina K.; Pasquini, Serena; Larhed, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6390-6396</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Highly regioselective and fast Pd(0)-catalyzed internal α-arylation of ethylene glycol vinyl ether with aryl halides was shown to be possible in water without the need for any halide scavengers or ionic liq. additives.  This presents the first case of water being utilized in the selective arylation of electron-rich olefins.  Resulting α-products, e.g. I, were hydrolyzed and isolated as corresponding acetophenones, e.g. II, in good to excellent yields when using aryl bromides and with good to moderate yields in the case of aryl iodides.  Microwave irradn. was shown to be beneficial in activation of aryl chlorides toward the internal Heck arylation.  The scope of the protocol was further increased to include different hydroxyalkyl vinyl ethers, these all giving selectively only branched α-products.  The active role of the hydroxy group in directing the regioselectivity toward internal arylation of electron-rich olefins, even in nonpolar toluene, was revealed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosc1YtaLz2C7Vg90H21EOLACvtfcHk0lhesn1OyOt_uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFGntLg%253D&md5=e869d07bf33fcbc89264604b636cc46a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjo0705768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0705768%26sid%3Dliteratum%253Aachs%26aulast%3DArvela%26aufirst%3DR.%2BK.%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DLarhed%26aufirst%3DM.%26atitle%3DHighly%2520regioselective%2520internal%2520heck%2520arylation%2520of%2520hydroxyalkyl%2520vinyl%2520ethers%2520by%2520aryl%2520halides%2520in%2520water%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D6390%26epage%3D6396%26doi%3D10.1021%2Fjo0705768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torner, L.</span></span> <span> </span><span class="NLM_article-title">Actions of prolactin in the brain: from physiological adaptations to stress and neurogenesis to psychopathology</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi"> DOI: 10.3389/fendo.2016.00025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.3389%2Ffendo.2016.00025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=27065946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A280%3ADC%252BC28fovFahsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=25&author=L.+Torner&title=Actions+of+prolactin+in+the+brain%3A+from+physiological+adaptations+to+stress+and+neurogenesis+to+psychopathology&doi=10.3389%2Ffendo.2016.00025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Actions of Prolactin in the Brain: From Physiological Adaptations to Stress and Neurogenesis to Psychopathology</span></div><div class="casAuthors">Torner Luz</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">Prolactin (PRL) is one of the most versatile hormones known.  It is considered an adaptive hormone due to the key roles it plays in the modulation of the stress response and during pregnancy and lactation.  Within the brain, PRL acts as a neuropeptide to promote physiological responses related to reproduction, stress adaptation, neurogenesis, and neuroprotection.  The action of PRL on the nervous system contributes to the wide array of changes that occur in the female brain during pregnancy and result in the attenuation of the hypothalamic-pituitary-adrenal axis.  Together, all these changes promote behavioral and physiological adaptations of the new mother to enable reproductive success.  Brain adaptations driven by PRL are also important for the regulation of maternal emotionality and well-being.  PRL also affects the male brain during the stress response, but its effects have been less studied.  PRL regulates neurogenesis both in the subventricular zone and in the hippocampus.  Therefore, alterations in the PRL system due to stress or exposure to substances that reduce neurogenesis or other conditions, could contribute to maladaptive responses and pathological behavioral outcomes.  Here, we review the PRL system and the role it plays in the modulation of stress response and emotion regulation.  We discuss the effects of PRL on neurogenesis and neuroprotection, the putative neuronal mechanisms underlying these effects, and their contribution to the onset of psychopathological states such as depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcNoUq-9QkGmlSCSgBhwJFfW6udTcc2eYViiVtIjpEA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fovFahsg%253D%253D&md5=3eac529f37a92cece83076a58c5f3f85</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2016.00025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2016.00025%26sid%3Dliteratum%253Aachs%26aulast%3DTorner%26aufirst%3DL.%26atitle%3DActions%2520of%2520prolactin%2520in%2520the%2520brain%253A%2520from%2520physiological%2520adaptations%2520to%2520stress%2520and%2520neurogenesis%2520to%2520psychopathology%26jtitle%3DFront.%2520Endocrinol.%26date%3D2016%26volume%3D7%26spage%3D25%26doi%3D10.3389%2Ffendo.2016.00025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binart, N.</span></span> <span> </span><span class="NLM_article-title">New insights in prolactin: pathological implications</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2015.36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1038%2Fnrendo.2015.36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=25781857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVyiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=265-275&author=V.+Bernardauthor=J.+Youngauthor=P.+Chansonauthor=N.+Binart&title=New+insights+in+prolactin%3A+pathological+implications&doi=10.1038%2Fnrendo.2015.36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">New insights in prolactin: pathological implications</span></div><div class="casAuthors">Bernard, Valerie; Young, Jacques; Chanson, Philippe; Binart, Nadine</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">265-275</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Prolactin is a hormone that is mainly secreted by lactotroph cells of the anterior pituitary gland, and is involved in many biol. processes including lactation and reprodn.  Animal models have provided insights into the biol. of prolactin proteins and offer compelling evidence that the different prolactin isoforms each have independent biol. functions.  The major isoform, 23 kDa prolactin, acts via its membrane receptor, the prolactin receptor (PRL-R), which is a member of the hematopoietic cytokine superfamily and for which the mechanism of activation has been deciphered.  The 16 kDa prolactin isoform is a cleavage product derived from native prolactin, which has received particular attention as a result of its newly described inhibitory effects on angiogenesis and tumorigenesis.  The discovery of multiple extrapituitary sites of prolactin secretion also increases the range of known functions of this hormone.  This Review summarizes current knowledge of the biol. of prolactin and its receptor, as well as its physiol. and pathol. roles.  We focus on the role of prolactin in human pathophysiol., particularly the discovery of the mechanism underlying infertility assocd. with hyperprolactinemia and the identification of the first mutation in human PRLR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo90HVf0LrwVbVg90H21EOLACvtfcHk0lhCgt7pybPsKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVyiurc%253D&md5=55b45b43b5628dd70f25ea5a175ff045</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2015.36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2015.36%26sid%3Dliteratum%253Aachs%26aulast%3DBernard%26aufirst%3DV.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DChanson%26aufirst%3DP.%26aulast%3DBinart%26aufirst%3DN.%26atitle%3DNew%2520insights%2520in%2520prolactin%253A%2520pathological%2520implications%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2015%26volume%3D11%26spage%3D265%26epage%3D275%26doi%3D10.1038%2Fnrendo.2015.36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schluger, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidlack, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreek, M. J.</span></span> <span> </span><span class="NLM_article-title">Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2254</span>– <span class="NLM_lpage">2262</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1300811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1038%2Fsj.npp.1300811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=15988468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WqurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2005&pages=2254-2262&author=G.+Bartauthor=J.+H.+Schlugerauthor=L.+Borgauthor=A.+Hoauthor=J.+M.+Bidlackauthor=M.+J.+Kreek&title=Nalmefene+induced+elevation+in+serum+prolactin+in+normal+human+volunteers%3A+partial+kappa+opioid+agonist+activity%3F&doi=10.1038%2Fsj.npp.1300811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Nalmefene Induced Elevation in Serum Prolactin in Normal Human Volunteers: Partial Kappa Opioid Agonist Activity?</span></div><div class="casAuthors">Bart, Gavin; Schluger, James H.; Borg, Lisa; Ho, Ann; Bidlack, Jean M.; Kreek, Mary Jeanne</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2254-2262</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In humans, mu- and kappa-opioid receptor agonists lower tuberoinfundibular dopamine, which tonically inhibits prolactin release.  Serum prolactin is, therefore, a useful biomarker for tuberoinfundibular dopamine.  The current study evaluated the unexpected finding that the relative mu- and kappa-opioid receptor selective antagonist nalmefene increases serum prolactin, indicating possible kappa-opioid receptor agonist activity.  In all, 33 healthy human volunteers (14 female) with no history of psychiatric or substance use disorders received placebo, nalmefene 3 mg, and nalmefene 10 mg in a double-blind manner.  Drugs were administered between 0900 and 1000 on sep. days via 2-min i.v. infusion.  Serial blood specimens were analyzed for serum levels of prolactin.  Addnl. in vitro studies of nalmefene binding to cloned human kappa-opioid receptors transfected into Chinese hamster ovary cells were performed.  Compared to placebo, both doses of nalmefene caused significant elevations in serum prolactin (p<0.002 for nalmefene 3 mg and p<0.0005 for nalmefene 10 mg).  There was no difference in prolactin response between the 3 and 10 mg doses.  Binding assays confirmed nalmefene's affinity at kappa-opioid receptors and antagonism of mu-opioid receptors. [35S]GTPγS binding studies demonstrated that nalmefene is a full antagonist at mu-opioid receptors and has partial agonist properties at kappa-opioid receptors.  Elevations in serum prolactin following nalmefene are consistent with this partial agonist effect at kappa-opioid receptors.  As kappa-opioid receptor activation can lower dopamine in brain regions important to the persistence of alc. and cocaine dependence, the partial kappa agonist effect of nalmefene may enhance its therapeutic efficacy in selected addictive diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNyaQ97u9HsbVg90H21EOLACvtfcHk0lhCgt7pybPsKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WqurvN&md5=791e1e9c10f9c18157662e02d0d0ce2c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300811%26sid%3Dliteratum%253Aachs%26aulast%3DBart%26aufirst%3DG.%26aulast%3DSchluger%26aufirst%3DJ.%2BH.%26aulast%3DBorg%26aufirst%3DL.%26aulast%3DHo%26aufirst%3DA.%26aulast%3DBidlack%26aufirst%3DJ.%2BM.%26aulast%3DKreek%26aufirst%3DM.%2BJ.%26atitle%3DNalmefene%2520induced%2520elevation%2520in%2520serum%2520prolactin%2520in%2520normal%2520human%2520volunteers%253A%2520partial%2520kappa%2520opioid%2520agonist%2520activity%253F%26jtitle%3DNeuropsychopharmacology%26date%3D2005%26volume%3D30%26spage%3D2254%26epage%3D2262%26doi%3D10.1038%2Fsj.npp.1300811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Jonathan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hnasko, R.</span></span> <span> </span><span class="NLM_article-title">Dopamine as a prolactin (PRL) inhibitor</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">724</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1210/edrv.22.6.0451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1210%2Fedrv.22.6.0451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=11739329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlOhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=724-763&author=N.+Ben-Jonathanauthor=R.+Hnasko&title=Dopamine+as+a+prolactin+%28PRL%29+inhibitor&doi=10.1210%2Fedrv.22.6.0451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine as a prolactin (PRL) inhibitor</span></div><div class="casAuthors">Ben-Jonathan, Nira; Hnasko, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">724-763</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  Dopamine is a small and relatively simple mol. that fulfills diverse functions.  Within the brain, it acts as a classical neurotransmitter whose attenuation or overactivity can result in disorders such as Parkinson's disease and schizophrenia.  Major advances in the cloning and characterization of biosynthetic enzymes, transporters, and receptors have increased our knowledge regarding the metab., release, reuptake, and mechanism of action of dopamine.  Dopamine reaches the pituitary via hypophysial portal blood from several hypothalamic nerve tracts that are regulated by PRL itself, estrogens, and several neuropeptides and neurotransmitters.  Dopamine binds to type-2 dopamine receptors that are functionally linked to membrane channels and G proteins and suppresses the high intrinsic secretory activity of the pituitary lactotrophs.  In addn. to inhibiting PRL release by controlling calcium fluxes, dopamine activates several interacting intracellular signaling pathways and suppresses PRL gene expression and lactotroph proliferation.  Thus, PRL homeostasis should be viewed in the context of a fine balance between the action of dopamine as an inhibitor and the many hypothalamic, systemic, and local factors acting as stimulators, none of which has yet emerged as a primary PRL releasing factor.  The generation of transgenic animals with overexpressed or mutated genes expanded our understanding of dopamine-PRL interactions and the physiol. consequences of their perturbations.  PRL release in humans, which differs in many respects from that in lab. animals, is affected by several drugs used in clin. practice.  Hyperprolactinemia is a major neuroendocrine-related cause of reproductive disturbances in both men and women.  The treatment of hyperprolactinemia has greatly benefited from the generation of progressively more effective and selective dopaminergic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRaf7Hlnxaa7Vg90H21EOLACvtfcHk0lgETIBkd1cpYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlOhug%253D%253D&md5=5cbdcf9f307d93da02763f5f9666b5f6</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1210%2Fedrv.22.6.0451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fedrv.22.6.0451%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Jonathan%26aufirst%3DN.%26aulast%3DHnasko%26aufirst%3DR.%26atitle%3DDopamine%2520as%2520a%2520prolactin%2520%2528PRL%2529%2520inhibitor%26jtitle%3DEndocr.%2520Rev.%26date%3D2001%26volume%3D22%26spage%3D724%26epage%3D763%26doi%3D10.1210%2Fedrv.22.6.0451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butelman, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreek, M. J.</span></span> <span> </span><span class="NLM_article-title">Kappa-opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D(2)-like receptor agonists</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(01)01121-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1016%2FS0014-2999%2801%2901121-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=11448491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltVGjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2001&pages=243-249&author=E.+R.+Butelmanauthor=M.+J.+Kreek&title=Kappa-opioid+receptor+agonist-induced+prolactin+release+in+primates+is+blocked+by+dopamine+D%282%29-like+receptor+agonists&doi=10.1016%2FS0014-2999%2801%2901121-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">κ-Opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D2-like receptor agonists</span></div><div class="casAuthors">Butelman, E. R.; Kreek, M.-J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">243-249</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Kappa (κ)-opioid receptor agonists may have pharmacotherapeutic potential in the management of psychostimulant abuse, due to their ability to modulate dopamine receptor systems involved in drug reinforcement.  κ-Opioid receptor agonists also modulate dopamine receptor function in the hypothalamic tuberoinfundibular system, which has inhibitory control over an anterior pituitary hormone, prolactin.  Prolactin levels may thus be a "biomarker" for the ability of κ-opioid receptor agonists (e.g., (+)-(5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide (U69,593)) to modulate a dopamine receptor system in vivo in primates.  The effectiveness of dopamine D2-like receptor agonists (quinpirole and (±)-7-hydroxy-dipropylaminotetralin (7-OH-DPAT); 0.0032-0.1 mg/kg) in preventing U69,593-induced prolactin release was studied in intact female rhesus monkeys.  Quinpirole and 7-OH-DPAT inhibited U69,593-induced prolactin release (ID50 values: 0.013 and 0.0072 mg/kg, resp.).  However, the dopamine D1-receptor agonist (±)-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazapine (SKF 82958; 1 mg/kg) did not inhibit U69,593-induced prolactin release under the same conditions.  In contrast, the largest doses of quinpirole or 7-OH-DPAT presently studied (0.1 mg/kg), did not decrease sedation caused by U69,593 (0.01, 0.032 mg/kg), a prominent effect of centrally penetrating κ-opioid receptor agonists.  The sedative effect of U69,593 (0.032 mg/kg) was prevented by naltrexone (0.32 mg/kg), consistent with κ-opioid receptor mediation of this effect.  These studies suggest that prolactin release is a valid biomarker for the ability of κ-opioid receptor agonists to modulate dopamine D2-like receptor function, and may also be used to quantify dopamine D2-like receptor agonist potency in primates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre_zNIfsWlh7Vg90H21EOLACvtfcHk0lgETIBkd1cpYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltVGjsLo%253D&md5=957d00d5eef7a3580e49960cb67f0bc6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2801%2901121-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252801%252901121-9%26sid%3Dliteratum%253Aachs%26aulast%3DButelman%26aufirst%3DE.%2BR.%26aulast%3DKreek%26aufirst%3DM.%2BJ.%26atitle%3DKappa-opioid%2520receptor%2520agonist-induced%2520prolactin%2520release%2520in%2520primates%2520is%2520blocked%2520by%2520dopamine%2520D%25282%2529-like%2520receptor%2520agonists%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D423%26spage%3D243%26epage%3D249%26doi%3D10.1016%2FS0014-2999%2801%2901121-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of 2-methyl-N-((2’-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.185108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1124%2Fjpet.111.185108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=21821697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFehtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2011&pages=555-566&author=S.+Grimwoodauthor=Y.+Luauthor=A.+W.+Schmidtauthor=M.+A.+Vanase-Frawleyauthor=A.+Sawant-Basakauthor=E.+Millerauthor=S.+McLeanauthor=J.+Freemanauthor=S.+Wongauthor=J.+P.+McLaughlinauthor=P.+R.+Verhoest&title=Pharmacological+characterization+of+2-methyl-N-%28%282%E2%80%99-%28pyrrolidin-1-ylsulfonyl%29biphenyl-4-yl%29methyl%29propan-1-amine+%28PF-04455242%29%2C+a+high-affinity+antagonist+selective+for+%CE%BA-opioid+receptors&doi=10.1124%2Fjpet.111.185108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors</span></div><div class="casAuthors">Grimwood, S.; Lu, Y.; Schmidt, A. W.; Vanase-Frawley, M. A.; Sawant-Basak, A.; Miller, E.; McLean, S.; Freeman, J.; Wong, S.; McLaughlin, J. P.; Verhoest, P. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">555-566</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">2-Methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242) is a novel κ-opioid receptor (KOR) antagonist with high affinity for human (3 nM), rat (21 nM), and mouse (22 nM) KOR, a ∼20-fold reduced affinity for human μ-opioid receptors (MORs; Ki = 64 nM), and negligible affinity for δ-opioid receptors (Ki > 4 μM).  PF-04455242 also showed selectivity for KORs in vivo.  In rats, PF-04455242 blocked KOR and MOR agonist-induced analgesia with ID50 values of 1.5 and 9.8 mg/kg, resp., and inhibited ex vivo [3H](2-(benzofuran-4-yl)-N-methyl-N-((5S,7R,8R)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-yl)acetamide ([3H]CI977) and [3H](2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl) propanoyl]amino]propanoyl]amino]acetyl]-methylamino]-N-(2-hydroxyethyl)-3-phenylpropanamide ([3H]DAMGO) binding to KOR and MOR receptors with ID50 values of 2.0 and 8.6 mg/kg, resp.  An in vivo binding assay was developed using (-)-4-[3H]methoxycarbonyl-2-[(1-pyrrolidinylmethyl]-1-[(3,4-dichlorophenyl)acetyl]-piperidine ([3H]PF-04767135), a tritiated version of the KOR positron emission tomog. ligand (-)-4-[11C]methoxycarbonyl-2-[(1-pyrrolidinylmethyl]-1-[(3,4-dichlorophenyl)acetyl]-piperidine ([11C]GR103545) in which PF-04455242 had an ID50 of 5.2 mg/kg.  PF-04455242 demonstrated antidepressant-like efficacy (mouse forced-swim test), attenuated the behavioral effects of stress (mouse social defeat stress assay), and showed therapeutic potential in treating reinstatement of extinguished cocaine-seeking behavior (mouse conditioned place preference).  KOR agonist-induced plasma prolactin was investigated as a translatable mechanism biomarker.  Spiradoline (0.32 mg/kg) significantly increased rat plasma prolactin levels from 1.9 ± 0.4 to 41.9 ± 4.9 ng/mL.  PF-04455242 dose-dependently reduced the elevation of spiradoline-induced plasma prolactin with an ID50 of 2.3 ± 0.1 mg/kg, which aligned well with the ED50 values obtained from the rat in vivo binding and efficacy assays.  These data provide further evidence that KOR antagonists have potential for the treatment of depression and addiction disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6o0AfESL4erVg90H21EOLACvtfcHk0lhFzIRzwhscGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFehtbrI&md5=23093593fd3960da26ec89ea25123001</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.185108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.185108%26sid%3Dliteratum%253Aachs%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DVanase-Frawley%26aufirst%3DM.%2BA.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DE.%26aulast%3DMcLean%26aufirst%3DS.%26aulast%3DFreeman%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DMcLaughlin%26aufirst%3DJ.%2BP.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26atitle%3DPharmacological%2520characterization%2520of%25202-methyl-N-%2528%25282%25E2%2580%2599-%2528pyrrolidin-1-ylsulfonyl%2529biphenyl-4-yl%2529methyl%2529propan-1-amine%2520%2528PF-04455242%2529%252C%2520a%2520high-affinity%2520antagonist%2520selective%2520for%2520%25CE%25BA-opioid%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D339%26spage%3D555%26epage%3D566%26doi%3D10.1124%2Fjpet.111.185108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byon, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badura, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span> <span> </span><span class="NLM_article-title">Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1208/s12248-011-9296-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;key=10.1208%2Fs12248-011-9296-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=565-575&author=C.+Changauthor=W.+Byonauthor=Y.+Luauthor=L.+K.+Jacobsenauthor=L.+L.+Baduraauthor=A.+Sawant-Basakauthor=E.+Millerauthor=J.+Liuauthor=S.+Grimwoodauthor=E.+Q.+Wangauthor=T.+S.+Maurer&title=Quantitative+PK-PD+model-based+translational+pharmacology+of+a+novel+kappa+opioid+receptor+antagonist+between+rats+and+humans&doi=10.1208%2Fs12248-011-9296-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1208%2Fs12248-011-9296-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-011-9296-3%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DC.%26aulast%3DByon%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DJacobsen%26aufirst%3DL.%2BK.%26aulast%3DBadura%26aufirst%3DL.%2BL.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DE.%2BQ.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26atitle%3DQuantitative%2520PK-PD%2520model-based%2520translational%2520pharmacology%2520of%2520a%2520novel%2520kappa%2520opioid%2520receptor%2520antagonist%2520between%2520rats%2520and%2520humans%26jtitle%3DAAPS%2520J.%26date%3D2011%26volume%3D13%26spage%3D565%26epage%3D575%26doi%3D10.1208%2Fs12248-011-9296-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span> <i>BlackThorn Therapeutics Initiates Phase 1 Study
of BTRX-335140, an
Investigational Kappa Opioid Receptor (KOR) Antagonist</i>; <span class="NLM_publisher-name">BlackThorn Therapeutics</span>: <span class="NLM_publisher-loc">San Francisco,
CA</span>, Jun 6, <span class="NLM_year">2018</span>; <a href="http://www.blackthornrx.com/blackthorn-therapeutics-initiates-phase-1-study-of-btrx-335140-an-investigational-kappa-opioid-receptor-kor-antagonist/" class="extLink">http://www.blackthornrx.com/blackthorn-therapeutics-initiates-phase-1-study-of-btrx-335140-an-investigational-kappa-opioid-receptor-kor-antagonist/</a> (accessed Dec 14, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+BlackThorn+Therapeutics+Initiates+Phase+1+Study%0Aof+BTRX-335140%2C+an%0AInvestigational+Kappa+Opioid+Receptor+%28KOR%29+Antagonist%3B+BlackThorn+Therapeutics%3A+San+Francisco%2C%0ACA%2C+Jun+6%2C+2018%3B+http%3A%2F%2Fwww.blackthornrx.com%2Fblackthorn-therapeutics-initiates-phase-1-study-of-btrx-335140-an-investigational-kappa-opioid-receptor-kor-antagonist%2F+%28accessed+Dec+14%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DBlackThorn%2520Therapeutics%2520Initiates%2520Phase%25201%2520Study%250Aof%2520BTRX-335140%252C%2520an%250AInvestigational%2520Kappa%2520Opioid%2520Receptor%2520%2528KOR%2529%2520Antagonist%26pub%3DBlackThorn%2520Therapeutics%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="note"><p class="first last">cLogP and tPSA calculated with Chembiodraw Ultra 12.0.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span>Cp<i>K</i><sub>a</sub> calculated with Marvin 5.7.1, 2012; <a href="http://www.chemaxon.com" class="extLink">http://www.chemaxon.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CpKa+calculated+with+Marvin+5.7.1%2C+2012%3B+http%3A%2F%2Fwww.chemaxon.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i76"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01679">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_75708"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01679">10.1021/acs.jmedchem.8b01679</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental details of the ADME/PK and off-target studies; plasma protein and brain tissue binding; microsomal stability; hepatocyte stability; MDCK-MDR1 or Caco-2 cell permeability and efflux assay; kinetic solubility; off-target selectivity; safety off-target panels; ion channel inhibition and functional hERG; cytochrome P450 (Cyp) inhibition; screening bacterial reverse mutation tests in <i>Salmonella typhimurium</i> and <i>Escherichia coli</i> (Ames); pharmacokinetic analysis (brain and plasma) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_001.pdf">jm8b01679_si_001.pdf (165.97 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01679/suppl_file/jm8b01679_si_002.csv">jm8b01679_si_002.csv (2.77 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01679&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01679%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-4%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01679" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799604fbae42374","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
